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Abstract 
Factor VIII (FVIII) is a co-factor in the haemostatic system required for fibrin-rich clot 
formation. Inherited F8 gene defects result in haemophilia A (HA), one of the commonest 
inherited bleeding disorders. Acquired FVIII defects (acquired haemophilia A, AHA) occur 
through auto-antibody formation. FVIII antibodies (allo and auto-antibodies) are the greatest 
challenges facing the haemophilia treating physician. Prediction of risk of antibody formation 
is based on genetic and environmental factors. There is incomplete understanding of the 
total immune response to FVIII due to limitations in current laboratory methodology used for 
FVIII antibody testing.  
The aim of this this work was to assess clinical practices, laboratory methodology and high-
throughput approaches to further characterise the immune response to FVIII. The key 
findings are as follows: 
1) Sub-optimal compliance with targeted inhibitor screening following FVIII treatment 
was seen in non-severe HA in London haemophilia centres. 
2) A national survey of AHA demonstrated heterogeneity in the management of 
immunosuppression and testing.  
3) A FVIII ELISA was specific with a high negative predictive values for FVIII antibody 
detection in routine practice. 
4) Pre-analytical heat treatment prior to antibody testing, improved sensitivity for auto-
antibody detection and a systematic evaluation optimised incubation conditions for 
this modification.  
5) A novel re-usable high-throughput peptide microarray, characterised B-cell epitopes 
of monoclonal and polyclonal FVIII antibodies, demonstrating immunodominant 
epitopes in regions of functional or structural importance.  
6) A modified low volume RNA sample tube demonstrated feasibility for transcriptome 
analysis in patients with severe haemophilia A, providing a repository of 
transcriptome data for developing understanding of the allo-immune response to 
FVIII.  
Heterogeneity in clinical and laboratory practices limits interpretation of data from 
observational studies of FVIII antibodies. Improvements in detection and characterisation of 
FVIII antibodies, may further advance understanding of the total immune response to FVIII 
identifying biomarkers for risk stratification.  
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Chapter 1: Introduction  
1.1 Factor VIII Structure and Function 
1.1.1 Cell Based Model of Haemostasis 
The process of haemostasis is a tightly regulated chain of events that results in clot formation 
at the site of vascular injury. This system restricts clot formation to these sites and prevents 
inappropriate clot formation (thrombosis). Haemostasis has traditionally been divided into 
two distinct (primary and secondary), but overlapping phases. Primary haemostasis, results 
in vasoconstriction and formation of a platelet rich plug with platelet binding to exposed 
collagen. Secondary haemostasis occurs through a series of proteolytic reactions at the 
surface of tissue-factor (TF) bearing cells and activated platelets, resulting in formation of a 
stable fibrin rich clot. This process is currently summarised in a cell-based model 1, occurring 
over three phases: initiation, amplification and propagation (Figure 1.1). This series of 
proteolytic reactions results in the formation of a thrombin (Factor IIa) burst, which cleaves 
fibrinogen to fibrin 1. Fibrin forms a mesh-like network allowing stable clot formation, which 
is further mediated by Factor XIII (FXIII). Inherited or acquired deficiencies of these pro-
coagulant constituents (factors), result in the development of a bleeding phenotype.  
 
Figure 1.1: Cell Based Model of Haemostasis, consisting of three phases: initiation, 
amplification and propagation. This involves a series of proteolytic reactions occurring on 
the surface of TF expressing cells and platelets. The result of activation of this pathway is 
the production of thrombin (Factor IIa), which causes cleavage of fibrinogen to fibrin. 
Image reproduced from Woodruff et al. with the permission of the publisher 2. 
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Factor VIII (FVIII) is an important co-factor in this system, which upon activation increases the 
catalytic activity of activated Factor IXa (FIXa) in activating Factor X (FX), as part of the tenase 
complex (Figure 1.1). Understanding of the structure and function of this co-factor has 
progressed greatly since it was first characterised in 1984 3;4, through study of natural and 
artificial mutations and more recently through crystalline structures 5-9. Advances in 
understanding of structural and functional properties of FVIII have resulted directly in 
improvements in the care of patients with inherited defects (haemophilia A) in FVIII function.  
1.1.2 Factor VIII Gene (F8) and Sites of Synthesis 
The FVIII gene (F8) is located on the distal part of the long arm of the X chromosome (Xq28) 
from base pair (bp) positions 154835788 to 155026940, covering 191153 base pairs (bp). The 
F8 gene consists of 26 exons (69-3106bp) with a coding sequence of approximately 9000bp 
3. Although expression of FVIII has been demonstrated in many tissues including the spleen, 
placenta, kidney and lymph nodes 10-12, the liver represents the principal site of FVIII 
synthesis. This was identified, firstly through studies looking at mRNA expression and 
subsequently though animal model perfusion and transplantation studies 13. This was 
confirmed in-vivo in patients with haemophilia A following liver transplantation resulting in 
normalisation of FVIII levels 14. There has been controversy surrounding the predominant 
hepatic cellular source of FVIII with studies demonstrated mRNA expression in both 
hepatocytes and liver sinusoidal endothelial cells 15. Recent data from a murine knockout 
model 16 and from purified human liver sinusoidal endothelial cells 17  has demonstrated that 
hepatic sinusoidal endothelial cells are the primary source of FVIII biosynthesis.  
1.1.3 Factor VIII Structure and Domain Organisation 
The F8 gene encodes a multi-domain protein of 2351 amino acids (aa) (267kDa), comprising 
of a mature protein of 2332aa and signal protein of 19aa 3;4. The mature FVIII protein consists 
of 3 A domains (~370aa), 2 C domains (~160aa) and a B domain (908aa). These six domains 
are ordered as follows, A1-A2-B-A3-C1-C2 (Figure 1.2), forming a heavy (A1-A2-B) and light 
chain (A3-C1-C2) (Table 1.1). Sub-domains containing negatively charged amino acid residues 
are located at the carboxy-terminal ends of the A1 and A2 domains (a1 and a2) and the 
amino-terminus of the A3 domain (a3) (Figure 1.2 & Table 1.1). These regions also contain 
multiple sulphated tyrosine residues and are thought to play key roles in the function of FVIII.  
Within FVIII structure there is inter-domain homology. The A domains share 31% homology 
with each other and with the A domains of hephaestin, ceruloplasmin and Factor V 3;18.  The 
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C domains, share approximately 40% homology with each other and the C domains of Factor 
V. Sequence homology is also seen between the C domains of FVIII and those in milk fat 
globule-EGF factor 8 (MFGE8) and discoidin I 3;19;20. 
Domain Legacy Position 
(aa) 
HGVS Position 
(aa) 
Length Exons 
Signal -18 – 0 1 – 19 19 1 
A1 1 – 336 20 – 355 336 1 – 8 
a1 337 – 372 356 – 391 36 
A2 373 – 710 392 – 729 338 8 – 14 
a2 711 – 740 730 – 759 30 
B 741 – 1648 760 – 1667 908 14 
a3 1649 – 1689 1668 – 1708 41 14 – 19  
A3 1690 – 2019 1709 – 2038 330 
C1 2020 – 2172 2039 – 2191 153 20 – 23 
C2 2173 – 2332 2192 – 2351 160 24 – 26 
Table 1.1: FVIII domain organisation, indicating start and finish positions within the 
mature in-active protein 6;15.    
The B domain shares no substantial homology with other known protein sequences or with 
the FVIII B domains found in other species 3. This domain, despite its length, is encoded by a 
single un-interrupted exon (exon 14). The B domain plays no significant role in the 
haemostatic function of FVIII and is cleaved upon activation of FVIII 21. This domain plays 
important intracellular roles (processing / trafficking) and protecting FVIII from premature 
activation or clearance from the circulation 22. 
FVIII requires a number of co-ordinating metal ions to maintain its structural integrity and 
function 23, which have been further characterised within the crystal structures of B domain 
deleted FVIII molecules. The first of these structure (resolution 3.98 Å) consists of heavy chain 
residues 1-740, a short linker sequence 741-754 and light chain 1649-2332 6. The structure is 
poorly ordered in the heavy chain residues 17-43, 211-223, 334-376, 714-754 and light chain 
residues 1649-1690 and 1714-1724. The second (resolution 3.70 Å), presents a fully active (B 
domain deleted) hetero-dimeric structure of FVIII. This is poorly ordered over sequence 
positions 34-38, 213-227, 335-336 and a 155 long residue sequence spanning the end of the 
A2/a2 domain through the truncated B domain and the final three residues of the C2 domain 
7. These models contain predicted copper (2 ions) and calcium (1-2 ions) ions 6;7. The first 
copper ion position is modelled within the A3 domain, co-ordinated by His1954, His2005 and 
Cys2000. The second lies within the A1 domain, co-ordinated by His267, His315 and Cys310. 
The first calcium ion observed in both structures is modelled in the A1 domain, co-ordinated 
26 
 
by Glu110, Asp116, Asp125, Asp126, Lys107 and Glu122 6;7. The second is seen in the A2 
domain co-ordinated by Asp538 and Asp542 in the first model only 7. 
1.1.4 Intra-Cellular Processing and Post Translational Modification 
Prior to secretion into the circulation, the newly synthesised single chain FVIII polypeptide 
undergoes a number of post-translational modifications (Figure 1.2B) 15;22;23. Following 
synthesis, FVIII is translocated to the Endoplasmic Reticulum (ER) where the signal peptide 
(19aa) is cleaved. Glycosylation (N-linked) of asparagine residues occurs at consensus 
sequences (Asn-Xxx-Ser/Thr). Twenty five, potential N-linked glycosylation sites have been 
identified, of which 21 have been identified as carrying oligosaccharides. The majority of 
these (n=17) are located within the B domain, with additional sites seen in the A1 (n=2), A3 
(n=1) and C1 domains (n=1) 15;22;24. For those seen in the A1 and C1 domains, high mannose 
glycans have been characterised at positions, Asn239 and Asn2118 respectively. Within the 
ER, disulphide bond formation occurs, with eight disulphide bonds being present; two in each 
A domain and one in each C domain 15. Within the ER, the N-glycosylated FVIII undergoes 
folding, a process facilitated by a number of intercellular chaperones, including calnexin and 
calreticulin. If properly folded, FVIII leaves the ER in coated vesicles, which when uncoated 
form the Endoplasmic Reticulum-Golgi intermediate compartment (ERGIC). This process 
requires the trans-membrane mannose-binding lectin 1 (LMAN) and the luminal multiple 
coagulation factor deficiency protein 2 (MCFD2). This pathway is involved in transportation 
of both FV and FVIII from the ER to the Golgi, with mutations in LMAN resulting in combined 
deficiency in FV and FVIII 25. In the Golgi, further modifications occur which includes 
sulphation of tyrosine residues at six positions (346, 664, 719, 721, 723 and 1680), O-linked 
glycosylation (≥7 B domain sites) 26  and further modification of the N-linked oligosaccharides. 
Finally, prior to secretion, variable cleavage of the heavy chain occurs at the B-a3 domain 
junction (Arg1648) and within the B domain (Arg1313). This cleavage process is thought to 
occur through the action of an unknown protease from the protease furin/PACE (paired basic 
amino acid cleavage enzyme) family, based on an Arg-Xxx-Xxx-Arg motif seen at these 
cleavage points 23. 
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Figure 1.2: Factor VIII Structure and Domain Organisation. A: Two dimensional 
representation of FVIII demonstrating sites of activation and inactivation. B: Two 
dimensional representation of FVIII with domain related post-translational modification. 
C: Three dimensional crystal structure of B-domain depleted Factor VIII (2R7E) 7 showing 
domain organisation, created using the PyMOL Molecular Graphics System.  
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 1.1.5 Extra-Cellular Interaction with von Willebrand Factor 
FVIII is then secreted into the circulation as a hetero-dimer consisting of a variably processed 
heavy chain (~90-200kDa) and light chain (~80kDa). These two chains are non-covalently 
bound with metal-ion dependent linkage between the A1 and A3 domains. Once in the 
circulation, FVIII rapidly associates with high affinity (kd~0.3nM) to a chaperone molecule, 
von Willebrand factor (VWF), with one molecule of FVIII binding to one monomer of the VWF 
multimer. VWF is a large multimeric glycoprotein (250kDa) secreted from the Weibel-Palade 
bodies of vascular endothelial cells (ECs). This interaction occurs through non-covalent 
binding between the a , C  and C  domains of FVIII with the D’D  domains of VWF 27;28, with 
the a3-VWF interaction demonstrating 8 fold greater binding affinity 29. The sequence 
positions of the interaction between FVIII and VWF have previously been mapped to 
positions 1649-1689 (a3), 2181-2243 (C2) and 2248-2312 (C2) 27. This interaction has recently 
been further characterised by electron microscopy and hydrogen-deuterium mass 
spectrometry in a recombinant FVIII-Fc fusion protein complexed to the VWF D’D  domain. 
This demonstrated binding of VWF to the a3 (Val1670-Asp1678), A3 (Val1857-Asn1861 and 
Glu1875), C1 (Trp2062-Ser2069; Thr2086-Ser2095 and Ser2157-Leu2166) and C2 domains 
(Gln2235-Thr2244) of FVIII 30. Formation of the VWF-FVIII complex, directs FVIII to sites of 
vascular injury through the involvement of VWF in primary haemostasis 31. The presence of 
VWF, increases the stability of the interaction between the FVIII heavy and light chains, 
increases FVIII half-life (t½) and prevents premature tenase complex involvement and 
inactivation by activated Factor Xa (FXa) and activated Protein C (APC) 32-36. This complex 
formation is thought to play a role in one of the mechanisms of FVIII cellular uptake 26.  
1.1.6 Activation of Factor VIII 
FVIII requires proteolytic activation to fulfil its co-factor role of enhancing the activity of FIXa 
within the tenase complex 37. This process occurs via cleavage of FVIII at residues Arg372, 
Arg740 and Arg1689 which are located at the junctions of the a1-A2, a2-B and a3-A3 domains 
respectively 38. This proteolysis has been shown in-vitro to be mediated by thrombin and FXa 
37. There is sequential cleavage occurring firstly at Arg740, followed by cleavage at Arg372, 
with the catalytic activity being approximately 20 fold higher for the first cleavage site. The 
presence of VWF increases cleavage efficiency at Arg372 by 8 fold, although the mechanism 
via which this is mediated is not clear. This is followed by cleavage at Arg1689 resulting in 
dissociation of FVIII from VWF. Although thrombin and FXa share cleavage points on FVIII, 
the mechanism behind these events appear different. Sulphation of tyrosine residues close 
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to these cleavage sites appears to be important for this process when mediated by thrombin, 
but not for FXa. Point mutation converting Tyrosine to Phenylalanine at positions 346 and 
1664 suggest that sulphation at these points accelerates thrombin but not FXa mediated 
cleavage 39. Experiments using thromboplastin activated plasma in-vitro in the presence of a 
thrombin specific inhibitor (hirudin) have demonstrated that thrombin and not FXa is 
responsible for FVIII activation 40. Alongside this, FXa requires the presence of an anionic 
phospholipid surface for efficient cleavage of FVIII, which is blocked when FVIII is associated 
to VWF 38. 
1.1.7 Role of Activated FVIII Within the Tenase Complex  
Thrombin cleavage at these three positions (Arg372, Arg740 and Arg1689) results in the 
removal of the a3 and B domains and formation of activated FVIII (FVIIIa). Removal of the a3 
domain causes conformational change within the C2 domain, which is relatively flexible 
within the light chain 6;7. This facilitates release of VWF, increasing the affinity of FVIIIa for 
phospholipid membranes (e.g. activated platelet) and increases the activity of FVIII via a 
further unknown mechanism 37. Following extrusion of these regions, FVIIIa forms a hetero-
trimer comprised of the A1, A2 and A3-C1-C2 regions. FVIIIa is then able to act as a tri-
directional magnet for formation of the tenase complex 41. The first stage of this process 
occurs through high affinity binding of FVIIIa to the phospholipid membrane via hydrophobic 
and electrostatic interactions between residues in the C2 domain and the phospholipid 
membrane 37. These hydrophobic interactions are mediated by residues Met2199, Phe2200, 
Val2223 and Lys2252 which penetrate the lipid bi-layer and electrostatic interactions by 
Arg2215, Arg2220, Lys2227 and Lys2249, respectively 42. Thrombin cleavage within the heavy 
chain at positions 372 and 740 results in the exposing of cryptic sites allowing interaction 
between FVIIIa with FIXa. These sites of interaction with FIXa have been modelled to residues 
within the A2/a2 (484-509, 558-565 and 707-714) 43 and A3 domain (1811-1819) 6;44. Finally, 
interaction between FVIIIa and FX is mediated by residues within the a1 domain (positions 
337-372) 45.  
1.1.8 Factor VIII Inactivation and Clearance 
Following activation of FVIII, there is rapid loss of activity.  This process of inactivation is both 
active (proteinase mediated) and passively mediated. Passive inactivation occurs though 
spontaneous dissociation of the A2 domain 46;47. Proteinase mediated inactivation occurs via 
the action of APC, FXa, and thrombin, with APC likely representing the key enzyme in this 
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process (Figure 1.2A). APC cleaves the A1 domain at Arg336 and the A2 domain at Arg562 48. 
Factor Xa has a dual role in the lifecycle of FVIII, firstly in the activation of FVIII and 
subsequent inactivation of FVIIIa. Cleavage points for Factor Xa have been identified within 
the A1 domain at Lys36 and Arg336, the latter a position shared with APC (Figure 1.2A) 38;49.  
The mechanism and location for clearance of the inactive and breakdown products of FVIII is 
poorly understood. It has recently been proposed that FVIII, may be cleared in the presence 
of VWF or via uptake of free FVIII by Kuppfer cells and hepatocytes respectively 50. A number 
of scavenger receptors have been implicated in this process including the low-density 
lipoprotein receptor related protein-1 (LRP1) 35, low-density lipoprotein receptor (LRP), 
asialoglycoprotein receptor (ASGRP), macrophage-mannose receptor type 1 (MMR/CD206), 
heparin sulphate proteoglycans (HSPG), sialic acid binding IgG-like lectin 5 (Siglec5), 
scavenger receptor class A member 5 (SCARA5), stabilin-2 (STAB2) and the C-type lectin 
domain family 4 member M (CLEC4M) 51.  
1.2: Congenital Defects of Factor VIII Function (Haemophilia A) 
1.2.1 History of Haemophilia 
The term haemophilia (love of blood), was first attributed to Friedrich Hopff in his 
dissertation of  8 8: “Haemophilie oder Über die Hämophilie oder die erbliche Anlage zu 
tödlichen Blutungen” (On haemophilia or hereditary predisposition to fatal bleeding) 52. 
Haemophilia has been used to describe two X-linked recessive inherited bleeding disorders, 
haemophilia A and B, which occur through defects in the F8 and F9 genes respectively. There 
have been descriptions of inherited bleeding disorders thought to represent haemophilia 
within the classical literature (Talmud) since the 2nd century AD 53;54. These reports recognised 
familial inheritance, stating some families had “loose blood” whereas others had blood that 
is “held fast” 52. The first clear genealogical descriptions likely to be due to haemophilia 
appeared in the medical literature at the turn of the 19th century 52. One of the first of these 
was presented by John Conrad Otto in 1803, describing a family with a hereditary 
haemorrhagic disposition spanning three generations in New Hampshire, USA 52;55. The 
extensive genealogy text (The Treasury of Human Inheritance) by Bulloch and Fildes in 1911, 
collated published (and unpublished) cases from the late 19th and early 20th century 56. This 
important early descriptive text provided details on clinical presentation and inheritance of 
this disorder prior to the availability of more advanced diagnostic techniques. Haemophilia 
is commonly referred to as the Royal Disease, with Queen Victoria being a carrier of 
31 
 
haemophilia. This resulted in male descendants being affected with haemophilia in the 
Russian, Spanish and German royal families 57. Perhaps the most well described of these 
descendants is the Tsarevich Alexei, the son of the Russian Tsar Nicholas II and his consort 
Alexandra, who was cared for by the mystic Grigori Rasputin. Genotype analysis of historical 
samples of members of the Romanov family has recently revealed a mutation in the F9 gene, 
showing that Victoria’s kindred were affected by the less common haemophilia B 58. 
1.2.2 Prevalence of Haemophilia A 
Haemophilia A represents one of the commonest inherited bleeding disorders affecting 
males of all countries and race, forming the focus of this thesis 59;60. Survey data collected by 
the World Federation of Haemophilia (WFH) has reported a mean prevalence of 8.4 per 
100,000 males worldwide, with higher prevalence seen in higher income countries compared 
to the rest of the world (12.8 versus 6.6 per 100,000 males) 59. Differences were also seen 
between countries of similar financial status. Lower prevalence was seen for lower income 
countries which is likely to result from impaired access to effective diagnostic and treatment 
regimens, meaning patients with milder phenotypes are not diagnosed and those with more 
severe phenotypes die at a younger age. In the United Kingdom (UK) there are 5686 patients 
registered with haemophilia A, of whom 3077 (54.1%) received treatment between 2013-
2014 (Table 1.2) 61.  
1.2.3 Diagnosis and Classification of Haemophilia A 
International guidelines classify severity of haemophilia A as being either mild, moderate or 
severe based on the residual functional FVIII protein detected by a clotting based assay of 
FVIII activity (FVIII:C) (Table 1.2) 62;63.  
Severity FVIII:C 
(IU/dL) 
Registered 
patients 
(UK) 
Age at 
diagnosis 
(range) 
Age at first 
joint bleed 
(range) 
Phenotype 
Severe <1 2002 0.8 (0-5) 1.9 
(1.2-3.0) 
Spontaneous joint 
and muscle bleeds 
Moderate 1-5 512 1.8 (0-27) 6.7 
(3.7-23.9) 
Occasional 
spontaneous 
bleeding 
Mild 5-40 3172 2.3 (0-36) 14.2 
(7.3-28.2) 
Spontaneous 
bleeding rare 
Table 1.2: Classification of haemophilia A and associated clinical features. FVIII:C levels in 
bold indicate the international diagnostic criteria as set out by the Scientific and 
Standardization Committee of the International Society on Thrombosis and Haemostasis 
63-68. 
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These laboratory cut-offs for defining severity are based on cohort studies from the late 
1950s 62;69, with bleeding severity generally relating to the level of residual FVIII:C 66. Patients 
with severe haemophilia A have undetectable residual FVIII:C (<1IU/dL) 70. Without 
treatment patients with severe haemophilia A experience spontaneous bleeding into the 
joints and soft tissues, which progresses to a chronic disabling arthropathy by the second 
decade 69. Patients with non-severe (mild and moderate) haemophilia A generally bleed only 
following trauma or surgery (Table 1.2) 65. As the FVIII:C increases there is a reduction in the 
annual number of joint bleeds with distinctions seen between severe and non-severe 
haemophilia A. In a study of 377 patients with haemophilia A, the percentage of patients who 
had never suffered a joint bleed was 54%, 20% and 6% for mild, moderate and severe 
haemophilia respectively. In this study, in patients with FVIII:C levels >12IU/dL, the number 
of joint bleeds per year was approximately 0 (Figure 1.3) 66. There is however heterogeneity 
in the laboratory cut-offs used to define severity within the published literature, with some 
reports (particularly those from the UK) using a FVIII:C <2IU/dL and <50IU/dL to classify 
severe and mild haemophilia A, respectively 64. These variations in classification of mild 
haemophilia A are discussed in more detail later in this work and could directly impact on 
outcomes described in clinical studies.   
 
Figure 1.3: Relationship between baseline FVIII:C level and annual number of joint bleeds. 
Dotted lines represent divides between severe and moderate (FVIII:C 1IU/dL) and 
moderate and mild (FVIII:C 5IU/dL) haemophilia A. Clear distinctions in annual joint bleed 
rates are seen between severe and non-severe haemophilia A patients. Figure reproduced 
from Den Uijl et al. 2011 with the permission of the publisher 66. 
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1.2.4 Genetics of Haemophilia A  
Haemophilia A results from an inherited mutation in the F8 gene resulting in deficiency in 
functional FVIII. Further sub-classification can also be made based on whether the FVIII 
antigen (FVIII:Ag) is detectable or not. Patients can then be classified as being either cross 
reactive material (CRM) positive, where there is considerable amounts of FVIII:Ag present 
but this is dysfunctional, or CRM negative where the FVIII:Ag is not detectable. FVIII:Ag does 
not currently form part of routine laboratory testing and reporting of this is subsequently 
variable in the international databases 71. Lack of functional FVIII results in impaired thrombin 
generation at platelet surfaces and the inability to a form a stable fibrin clot. There is also a 
reduction in the activation of FXIII and Thrombin Activatable Fibrinolysis Inhibitor (TAFI) 
resulting in impaired clot stability and fibrinolysis 72-75.   
All types of genetic mutations (including missense, non-sense, splice site changes/variants, 
deletions, insertions and inversions) have been described as being haemophilia causative for 
both severe and non-severe haemophilia. There are currently two online, open-access 
reference databanks of F8 mutations, the Factor VIII Variant/Mutation Database (formerly 
the Haemophilia A Mutation, Structure, Test and Resource Site, HAMSTeRS / HADB) and the 
Centers for Disease Control and Prevention Hemophilia A Mutation Project (CHAMP). These 
have collated information regarding reported F8 mutations and associated clinical phenotype 
and list 2107 (HADB) and 2537 (CHAMP) unique F8 mutations 71;76.   
Severe haemophilia A results from a mutation in the F8 gene leading to an absence of 
functional FVIII. The commonest mutation seen in this group is an inversion mutation 
involving intron 22, affecting around half of patients (42-47%) 77-81. This causes translocation 
of exons 1-22 away from exons 23-26, as a result of homologous recombination, with the F8A 
gene within intron 22 and another F8A gene. Interestingly, despite this mutation resulting in 
CRM negativity in the peripheral blood, recent data has demonstrated intracellular FVIII 82;83. 
Mutations resulting in non-severe haemophilia A lead to reduced amounts of secreted 
functional FVIII, with the commonest genetic abnormalities being missense mutations (non-
synonymous single nucleotide polymorphisms, SNPs) 71. Dependent on the location of these 
mutations, these may have a number of potential structural and functional consequences 84. 
FVIII missense mutations form an interesting sub-group of haemophilia-causing mutations, 
forming the commonest mutation seen in the HADB (66.5%; 1341/2015) 71, with some being 
well tolerated resulting in mild haemophilia, whilst others are intolerant resulting in severe 
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haemophilia. Phenotypic variability is described for the same F8 mutation between 
individuals (e.g. Arg593Cys, FVIII:C <1-38%) and for different amino acid substitutions at the 
same residue (e.g. Leu308Val has a FVIII:C 15-34%, whereas Leu308Pro a FVIII:C<1%) 71;85. A 
number of factors could cause variance in FVIII:C seen for the same mutations, including 
inter-laboratory variability (coefficient of variation 20.5-23.3%) 86, discrepancies seen in 
FVIII:C depending on the laboratory testing methodology assay (one stage or chromogenic 
assay)87-91 or be a result of reporting error when using a centralised database. Recent in-silico 
studies have evaluated F8 SNPs which may allow prediction of deleterious, functional and 
phenotypic effects 92-95. Although current classification is based on FVIII:C, with increased 
understanding of effect of F8 mutations on other clinical factors, e.g. severity, response to 
treatment and immunogenicity, further genomic classification may be of use within the clinic. 
1.2.5 Treatment of Haemophilia A 
The aim of treatment in haemophilia A is to restore FVIII:C to a sufficient level to allow stable 
clot formation. Replacement therapy has progressed from early usage of blood transfusions 
96 , through use of fresh frozen plasma (1950s-60s), to cryoprecipitate (1965) 97 and FVIII 
concentrates from the early 1970s 52;98.  In developed countries, the standard of care is the 
intravenous infusion of FVIII concentrate 67, although in countries of more limited resources, 
cryoprecipitate, fresh frozen plasma and even whole blood continue to provide a source of 
FVIII replacement 67. Treatment can be given either “on-demand” to treat or prevent (e.g. 
peri-operatively) bleeding, or as “prophyla is” to pre ent spontaneous joint bleeding. The 
duration and dosage of FVIII treatment required is dependent on the location and severity of 
bleeding or type of surgery. The duration of treatment is often summarised by the number 
of exposure days (ED), defined by a day in which one or more FVIII infusions has been given 
to a patient 99;100.  An intravenous infusion of 1IU/kg of FVIII concentrate elevates plasma 
FVIII:C by approximately 2IU/dL, with infused FVIII having a half-life of 8-12 hours 101.  
Modern FVIII concentrates are derived either from plasma donation (plasma derived, pdFVIII) 
or are cell-line derived (recombinant, rFVIII). In the UK, rFVIII concentrates are recommended 
as the product of choice 102, with national switching from pdFVIII occurring in 1998 for 
children <16 years and in 2003 for all other patients, following concerns regarding prion and 
viral safety 103. Recombinant FVIII concentrates, are derived from non-human cell lines (baby 
hamster kidney, BHK or Chinese Hamster Ovary, CHO) and may vary dependent on whether 
the encoded FVIII protein contains the B domain or not (full-length, FL or B domain deleted, 
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BDD). Differences in the primary cellular sources (animal and tissue) result in differences in 
post-translational modifications of rFVIII compared to human FVIII 104; although the 
significance of this is not clear. Further categorisation of rFVIII is made based on the presence 
of animal/human products stabilisation within the final formulation (first, second and third 
generation rFVIII) 102. Advances in the manufacture of FVIII concentrates, firstly in pdFVIII 
(viral inactivation) and later with the development of rFVIII products has resulted in safe and 
efficacious treatment for persons with haemophilia. The greatest problem currently facing 
haemophilia treating physicians in developed nations is the occurrence of inhibitory 
antibodies (inhibitors) to FVIII.  
An alternative approach, for management of bleeding or surgery in patients with non-severe 
haemophilia A, is the use of a synthetic antidiuretic hormone analogue, desmopressin (1-
deamino-8-d-arginine vasopressin, DDAVP). DDAVP, acts on extra-renal arginine vasopressin 
V2 receptors causing release of VWF from endothelial cells and a subsequent release of FVIII 
from an unknown cellular source. In responsive DDAVP patients this results in a 2-6 fold 105, 
rise in endogenous FVIII:C. This approach can allow avoidance or reduction in exposure to 
FVIII concentrate, which could potentially be protective from the immune complications of 
FVIII treatment.  
1.3: Acquired Defects of Factor VIII Function (Acquired Haemophilia A) 
1.3.1 Introduction 
Acquired Haemophilia A (AHA) is a rare acquired severe bleeding disorder (incidence 1 in 1.48 
million/year) resulting from auto-antibody formation to FVIII 106. AHA mainly affects the 
elderly, with a median age at onset of 73.9 years 107. Incidence appears to increase further 
with age, reaching 14.7 per million/year in people >85 years of age 106-108. A second, smaller 
peak in incidence is seen in younger women (median 34 years), relating to pregnancy 107;109. 
This most frequently presents in the post-partum period (21-120 days post-partum) and is 
estimated to affect 1 in 350,000 births in the UK 106;108;109. The occurrence of AHA in children 
(<16 years) is rare (0.045 per million/year) 106;108;110. Almost half of AHA cases are associated 
with an underlying disorder; including malignancy (11.8%), auto-immune disease (11.6%), 
pregnancy (8.4%), drugs (3.4%), skin disorders (1.4%), infection (3.8%) and blood transfusion 
(0.8%) 107. The pathological mechanisms underlying auto-antibody formation to FVIII are 
poorly understood. It is likely that this results from a loss in tolerance to FVIII (self). Given 
such complex aetiologies and rarity of this disorder there is limited investigation at a cellular 
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level of these immune mechanisms. Genetic associations relating to the underlying HLA 
genotype and a polymorphisms in the cytotoxic T lymphocyte antigen-4 genes (see Section 
1.4.3 and 1.4.4) involved in the immune response have been characterised 111;112.  
Diagnosis is made generally made following a patient presenting with new onset bleeding 
and subsequently being found to have an inhibitory antibody to FVIII on laboratory testing. 
AHA often present to a general physician or surgeon, rather than directly to a haemostasis 
specialist, which may result in a delay in diagnosis or treatment 113. Rarely, AHA may be 
diagnosed on routine blood testing (2/149 patients) 108;110. Even within a haemophilia 
comprehensive care centre the number of cases seen per year may be low 106;110;114;115. A 
single centre experience over 28 years (1970-1998), described only 24 patients (0.9 
cases/year) 114. Similarly, in a recent survey of clinicians in Germany, Austria and Switzerland, 
the median number of patients treated per year was 1.8 (range 0-10). As such, patients with 
AHA may often be managed by clinicians with limited personal experience of treatment of 
this disorder 110;115 Treatment approaches are likely to be influenced by previous experience, 
local protocols or recently published reports. Within the recent literature, there have been a 
number of large observational studies that have provided important new data on the natural 
history of this rare disorder 106;107;116-118. 
1.3.2 Clinical Features of Acquired Haemophilia A 
Bleeding is the presenting feature in the majority (94.6%) of patients with AHA which is often 
spontaneous (77.4%) or following a haemostatic challenge (trauma 8.4%, surgery 8.2% and 
peri-partum 3.6%) 107. Of these episodes, 70.3% were severe and a similar proportion (70.5%) 
required treatment with a haemostatic agent 107. The sites of bleeding seen in AHA differ 
from those seen in congenital haemophilia A, with subcutaneous (53.3%), deep 
muscle/retroperitoneal (50.2%) and mucosal bleeding (respiratory, gastrointestinal, 
urogenital) (31.6%) representing the commonest sites. Joint bleeding (4.9%) and intra-
cerebral bleeding (1.1%) are less common 106. Although most patients have only one episode 
of bleeding at presentation, a third (33.5%, n=159) will have more than one bleeding episode 
(median 28 days) 107. 
1.3.3 Treatment of Acquired Haemophilia A 
The management of AHA involves therapy to treat bleeding followed by immunosuppression 
aimed at inhibitor eradication. Agents used in the treatment of bleeding are similar to those 
used in the treatment of patients with congenital haemophilia A with allo-antibodies to FVIII 
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(discussed in Section 1.5). Given the high mortality and morbidity associated with AHA 
without treatment (see below), there is consensus that all patients should receive 
immunosuppression with the goal of inhibitor eradication 113;119;120. Although spontaneous 
remission has been reported in 25-35.5% patients in two reports from the 1980s, these 
findings have not been confirmed in larger cohorts 110;121. The first of these studies, a case 
series of 215 patients, reported spontaneous disappearance of inhibitory antibodies in 11/31 
patients (35.5%), receiving supportive care only (transfusion or FVIII) after 14 months (range 
1-156 months). Of the remaining patients receiving supportive care alone, 8 died (median 12 
months) and 10 had an inhibitor present at 36 months. Outcomes were better in patients 
who received treatment in comparison to those that did not 110. There is no reporting of 
morbidity in patients who received supportive care or immunosuppression in this study. A 
second single centre ten year experience (1975-1985) reported 16 patients receiving no or 
minimal immunosuppression, reporting spontaneous remission in up to 25% of patients (n=4; 
no treatment=2, minimally treated=2). Within this cohort significant morbidity due to 
bleeding was seen, although interestingly in some patients the bleeding phenotype appeared 
to ameliorate with time even in the presence of residual antibody 121. In more recent reports, 
patients who have not received immunosuppression are limited to those in whom treatment 
was felt inappropriate and poorer outcomes have been described 106;122-124. 
Treatment with immunosuppression leads to improvement in outcomes and remission in a 
substantial proportion of patients, although the optimal first line treatment is not clear 108. 
There have been no adequately powered interventional studies in AHA, with all outcome 
data being derived from observation studies. The largest of these studies, is the recently 
reported European Acquired Haemophilia Registry (EACH2), which presented data on 331 
patients with AHA. In this study, the most commonly used regimens for immunosuppression, 
were a corticosteroid (e.g. prednisolone) in isolation (43%, n=142) or combined with a 
cytotoxic agent (e.g. cyclophosphamide) (15%, n=83) 116. The presenting features of AHA 
including underlying disorder, bleeding and inhibitor titre may influence clinicians’ treatment 
decisions 115. This could result in different immunosuppressive approaches being used in 
different patient groups, such as those presenting in the post-partum period or elderly.    
One small prospective interventional study has been conducted in AHA investigated safety 
and efficacy of steroids (prednisolone) and cyclophosphamide in isolation or in combination 
125. All patients (n=31) were treated initially with single agent prednisolone and after 3 weeks, 
those who had not responded (n=21) were then randomised to either continuing steroids 
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(n=4), single agent cyclophosphamide (n=6) or steroids and cyclophosphamide (n=10). 
Complete response (CR) rates seen in these three groups were 75%, 50% and 50%, 
respectively with no difference between the treatment arms. This study was underpowered 
to demonstrate differences between the treatment arms and managed to accrue only 31 
(target=100) patients over a 5 year period. A recent comparison of 25 clinical studies showed 
similar response rates for steroids (72%) compared to steroids in combination with a 
cytotoxic agent (78%) 108. If only studies that included both treatment arms were considered 
the response rates seen were 76% (68/90) and 78% (109/139), respectively 108. In a meta-
analysis of 20 studies, although higher CR rates were seen for steroids and cyclophosphamide 
compared to steroids alone (89% versus 70%), overall survival was similar between both 
treatment groups, which was attributed to increased mortality from enhanced 
immunosuppression 123. In the EACH2 study, the CR rates (inhibitor undetectable, FVIII:C 
>70IU/dL and immunosuppression stopped) for those treated with steroids alone (n=142) 
compared to steroids and cyclophosphamide (n=83), were 58% and 80% respectively. 
Patients treated with steroids and cyclophosphamide, obtained CR faster (HR=2.36; 95%CI 
1.49-3.74, p<0.001) and were more likely to obtain a stable CR (i.e. no relapse reported) than 
those treated with steroids alone (OR=3.25; 95%CI 1.51-6.69, p<0.003). Of note, the 
occurrence of adverse events was higher in patients treated with steroids and 
cyclophosphamide (41%) compared to those treated with steroids alone (25%). Despite 
improved CR rates in patients treated with steroids and cyclophosphamide, the final 
outcomes (being alive and inhibitor free at final follow-up) were similar in both groups (67% 
steroids alone versus 62% steroids and cyclophosphamide). This suggests that although 
patients treated with steroids and cyclophosphamide achieve higher rates of stable CR this 
is not associated with improved long term outcomes and at the cost of higher iatrogenic 
morbidity 116. Other approaches for inhibitor eradication have been described in smaller 
patient groups, including immune tolerance induction (Section 1.5.7), mycophenolate 
mofetil, ciclosporin and usage of an anti-CD20 monoclonal (rituximab) which are discussed 
in more detail in the context of the data presented in Chapter 5.  
There is less data surrounding response to immunosuppression in patients presenting with 
AHA relating to pregnancy. The EACH2 study presents one of the largest reports to date, with 
42 patients, demonstrating complete response rates of 74% 109. In patients with available 
data, these were treated with steroids, either in isolation (n=27) or combined with another 
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agent (cyclophosphamide=6, intravenous immunoglobulin=4 or rituximab=2). All patients 
were alive at final follow-up and 86% were in complete remission.  
1.3.4 Outcome Measures in Acquired Haemophilia A  
Recent studies in the management of AHA have highlighted some of the difficulties in the 
management of this rare condition. Despite recent improvements in the treatment of this 
disorder, it continues to be associated with significant mortality (27.9% of patients in the 
EACH2 cohort) 107. In this study, equal numbers of patients died as a result of 
immunosuppressive therapy (16%, n=16) as those who died from bleeding (16%, n=16) 107. 
Patients treated with these modalities required substantial periods of time on 
immunosuppression, with the median time to stopping of immunosuppression being 108 
days (IQR 55-208) for steroids alone and 74 days (IQR 52-151) for steroids and 
cyclophosphamide. Immunosuppression resulted in at least one adverse event in 25% and 
41% of patients treated with steroids or steroids and cyclophosphamide, respectively 116. Of 
patients who obtained CR, 18% (steroids alone) and 12% (steroids and cyclophosphamide) 
relapsed. Current recommendations for screening for relapse suggests laboratory testing 
monthly for the first 6 months, then every 2-3 months up to one year and twice yearly after 
one year 119. Greater clarity in terms of the optimal way of testing for early relapse is required 
to reduce morbidity in this group of patients.  
1.3.5 Prediction of Risk in Acquired Haemophilia A 
Given the high morbidity, mortality and associated hospital stay associated with AHA, it 
would be desirable to provide risk stratification to identify patients in whom early escalation 
of immunosuppression may be required or, conversely, who could be treated with a less 
intensive approach to minimise toxicity from treatment. There have been a number of 
reports looking into factors associated with poorer outcomes, with two meta-analyses 
reporting in 2003 123 and 2009 126. The first of these included 20 studies (1985-2002) and a 
case-series from the authors’ centre, comprising     patients (    included) 123. In the 
univariate analysis, failure to achieve CR, age >65 years, related diseases (malignancy v post-
partum), inhibitor titre at diagnosis <10BU/mL, were significantly associated with poorer 
overall and disease specific survival. No significant difference was seen for sex, FVIII:C (2%) 
or choice of immunotherapy. In multivariate analysis, only achievement of CR, was seen to 
affect both overall and disease specific survival. A second meta-analysis (1985-2008), 
assessed 32 studies (359 patients) which included ≥  patients 126. Within the univariate 
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analysis, age, sex, underlying autoimmune disease, peri-partum period and inhibitor titre had 
no significant effect on obtaining CR. Patients with an underlying malignancy were less likely 
to achieve CR. Patient treated with immunosuppression were more likely to obtain a CR 
compared to those that did not receive treatment and those receiving immunosuppression 
were less likely to die. Older patients, those with underlying malignancy and those with a 
persistent inhibitor were more likely to die. The effect of survival from obtaining CR was only 
significant if this was achieved within 150 days. Multivariate analysis demonstrated that 
immunosuppression was associated with increased prediction of CR, with combination 
chemotherapy having the lowest odds of persistent disease.  
More recent evaluation of prognosis has been performed within the EACH2 107 and GTH-AH 
01/2010 118 studies. Within the EACH2 study, multiple step-wise regression demonstrated 
older age, lower presenting haemoglobin, malignancy and failure to clear the auto-antibody 
as being independent predictors of death. Gender, initial FVIII:C and inhibitor titre did not 
affect outcome. Within this cohort, patients with pregnancy related AHA had improved 
survival than other patients included in this study. In the GTH-AH 01/2010 study, patients 
with a presenting FVIII:C <1IU/dL achieved the end point of partial remission (PR) less 
frequently 118. Within this study a subset of patients presenting with FVIII:C >1IU/dL and 
inhibitor titre <20BU/mL, demonstrated faster achievement of a PR in <21 days (OR=11.2; 
p<0.0001). These findings suggest that it may be possible to select intensification of 
treatment early to improve outcomes in those at higher risk of not obtaining remission and 
to use less intensive approaches for those predicted to have better outcomes with the aim 
of minimising toxicity. 
To allow provision of clearer guidance in the management of AHA, there is a need to define 
the optimal first line management, laboratory follow-up and response criteria. These criteria 
also tend to be based on measurement of patient’s FVIII:C for which a patient’s normal 
baseline would not be known and at present rely on usage of a functional clotting based 
inhibitor assay (discussed in Section 1.5 and 1.6). There is a lack of evidence to guide how 
immunosuppression should be reduced and stopped. Studies that could stratify patients into 
high or low risk groups, could allow more personalised approaches to management that 
might improve rates of treatment related morbidity. Finally, no studies to date have looked 
at the impact in terms of quality of life and effects of functional capacity in this group of 
patients.  
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1.4: Factor VIII and the Immune System 
1.4.1 Introduction 
The immune response to infused exogenous FVIII in patients with congenital haemophilia is 
seen as an example of a classical allo-immune response, mediated by CD4+ T-cells. In patients 
with severe haemophilia A, it is perhaps surprising only 30% of patients develop inhibitory 
antibodies in the absence of circulating FVIII to impart pre-existing tolerance. As a monogenic 
disorder, haemophilia offers a good model for the investigation of the immune response to 
an infused protein therapeutic for understanding the process of development of anti-drug 
antibodies. There have been many advances in the understanding of the immune response 
to FVIII over the last decade, the results of which have been elegantly outlined in a number 
of recent reviews 41;127-130. T-cell (CD4+) dependence was first noted in HIV infected 
haemophilia patients with inhibitors, who developed a decline in their inhibitor titre and loss 
of anamnesis as their CD4 count fell, with progression to the acquired immunodeficiency 
syndrome (AIDS)  131. On commencement of anti-retroviral therapy (HAART), with a 
subsequent rise in their CD4 counts, these patients again produced inhibitors. Further 
evidence of T-cell dependence has been derived from studies in murine haemophilia models 
which have demonstrated somatic hypermutation and class switching for inhibitory FVIII 
antibodies 132-135. 
1.4.2 Antigen Presenting Cells and Factor VIII Cellular Uptake 
Following infusion, FVIII must undergo a number of steps prior to being presented to the 
immune system. Antigen presentation to the immune system is mediated by antigen 
presenting cells (APCs) consisting of dendritic cells (DCs), macrophages and B-cells 
(lymphocytes). Cellular uptake of foreign protein by APCs occurs via receptor mediated 
endocytosis, phagocytosis and macropinocytosis 136. Experimental data from haemophilia 
mice (exon 16 deleted) has demonstrated that the main site of FVIII uptake into APC is the 
spleen (marginal zone) 137. Following intravenous injection of FVIII, preferential co-
localisation of FVIII occurred within metallophilic (MOMA-1 +ve) macrophages and to a lesser 
extent in CD11c +ve DCs and marginal zone (MARCO +ve) macrophages. Splenectomy or 
depletion of these cells in-vivo resulted in a reduction in the immune response to FVIII 137. 
The precise nature and mechanisms of receptor mediated cellular uptake of FVIII is 
incompletely understood 130;138. The macrophage mannose receptor (MR) forms one 
mechanism for cellular uptake interacting with mannose ending glycans in the A1 (Asn239) 
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and C1 (Asn2118) domains (Figure 1.2A). Blockade of these mannose mediated interactions, 
results in partial reduction in FVIII endocytosis and resultant T-cell activation in immature 
cultured human DCs 139. Knockdown of MR (small interfering RNA, siRNA), however did not 
affect FVIII endocytosis suggesting the involvement of other mechanisms 140. Other uptake 
mechanisms include the LDL receptor related protein (LRP), which interacts with FVIII via the 
A2, A3 and C1 (Lys2092 and Phe2093) domains. This receptor has, however, not been shown 
to have a role in FVIII uptake by DCs 141. Recently published experiments, using a C1 domain 
anti-FVIII antibody (KM33), which interacts with the C1 domain (Arg2090, Lys2092 and 
Phe2093), demonstrated  inhibition of endocytosis of FVIII by DC (human and murine) in-vitro 
142. Infusion of modified FVIII with alanine substitutions at these positions in a mouse model 
resulted in a reduced immune response. Although KM33 shares an epitope on FVIII with LRP, 
this does not appear to represent a key pathway of FVIII uptake into DCs 143 Other receptors 
(ASGRP, HSPG, Siglec5, SCARA5, STAB2 and CLEC4M) have recently been found to play a role 
in FVIII uptake, although the full mechanism for this process remains to be identified.  
1.4.3 Antigen Presentation and the Major Histocompatibility Complex 
Following internalisation of FVIII into APCs, this undergoes proteolytic cleavage in the 
endosomal compartments. Endogenous and exogenous peptide fragments are then 
presented to the immune system via the major histocompatibility complex (MHC) or human 
leukocyte antigen (HLA). The MHC genes located on chromosome 6, encode the MHC class I 
(HLA-A, -B and -C) and II (HLA-DR, -DP and -DQ) molecules in humans. MHC class I and II 
present peptide fragments to CD8+ and CD4+ T-cells, respectively. Extracellular peptide 
fragments are loaded into the peptide binding groo e of MHC Class II (≥  aa) resulting in 
formation of the MHC-peptide complex. The MHC-peptide complex is then transported to 
the cell membrane for presentation to helper T-cells. Activation of naïve CD4+ depends on a 
number of “signals”, with the first being recognition of peptide antigens within the MHC-
peptide complex by the T-cell receptor (TCR). Increased expression of MHC-peptide 
complexes is induced by maturation of naïve dendritic cells, a process which requires the 
presence of danger signals 144;145. These danger signals may be provided by endogenous (e.g. 
co-stimulatory molecules or cytokines) or exogenous (e.g. pathogen derived products) 
stimuli. The precise nature of danger signals in response to FVIII are however unclear. In-vitro 
data demonstrated that neither FVIII alone (inactive or thrombin activated), nor complexed 
with VWF is able to modulate maturation of human monocyte derived DCs or stimulate 
autologous or allogenic T-cells 146. Although a murine haemophilia model suggested thrombin 
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may provide this danger signal in-vivo 147, equal immunogenicity was seen by other 
investigators for wild type FVIII and two FVIII molecules (Arg372Ala/Arg1689Ala and 
Val634Met) devoid of pro-coagulant activity, suggesting immunogenicity is independent of 
FVIII haemostatic function 148. The environmental context at the time of FVIII infusion could 
potentially provide these danger signals, although data (in-vitro and in-vivo) to support this 
hypothesis is currently lacking 99;100;149.  
1.4.4 Co-Stimulatory Signalling 
Interaction between the MHC-peptide complex and the TCR alone is insufficient to induce 
differentiation of naïve CD4+ T cells. Co-stimulatory signalling is required, which includes 
interaction between CD40 and CD80/86 (B7-1/B7-2) on the surface of APC and CD40 ligand 
(CD40L) and CD28 on the surface of naïve helper T-cells (CD4+). Interaction of the TCR with 
the MHC class II complex causes up-regulation of CD40L, which binds CD40 causing further 
expression of B7, CD40 and MHC Class II. Negative regulation of co-stimulation occurs 
through the CD28 homologue, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, CD152) 
which binds to B7-1 and B7-2 inhibiting signalling via the TCR. The importance of these co-
stimulatory signalling pathways has been demonstrated in murine haemophilia models. 
Targeted disruption of the B7/CD28 co-stimulatory (B7-2-/- knockout) signalling or injection 
of a murine CTLA-4 immunoglobulin blocked the primary immune response in the 
haemophilia mice 150. Blockade of the CD40/CD40L interaction also prevented induction of 
neutralising antibodies on exposure to human FVIII, with suppression of FVIII specific T-cell 
responses 151. The third signal required for maturation of the follicular T-cell is promoted by 
cytokines which results in formation of helper (effector) T-cell (TH1, TH2 or TH17) or regulatory 
T-cells (Treg). Cytokine secretion from both TH1 and TH2 cells then promotes B-cell 
differentiation and anti-FVIII antibody synthesis 152.  
1.4.5 B-Cell Activation and Antibody Secretion  
B-cells form the precursor to antibody secreting plasma cells, a process requiring T-cell help. 
Antigenic epitopes recognised by the B-cell receptor result in antigen internalisation via the 
B-cell receptor complex. These undergo internal processing and are presented in complex 
with MHC Class II to CD4+ effector T-cells. A naïve B-cell can then be activated if the MHC-
class II-peptide complex is recognised by an effector T-cell that responds to the same antigen 
(linked recognition). Secondary signals are also required to promote differentiation of naïve 
B-cells, with interaction between CD40L and CD40 on the B-cell surface as well as various 
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other cytokines (including IL-4, IL-5, IL-6 and IL-10) promoting B-cell activation and 
proliferation. The importance of these co-stimulatory pathways has been seen through 
blockade of these pathways in-vitro and in-vivo. Anti-CD40L, anti-B7-1 or anti-B7-2 
monoclonal antibodies and a CTLA4-Fc have all been shown to prevent re-stimulation and 
differentiation of memory B-cells in-vitro and in-vivo (exon 17 disrupted haemophilia A mice) 
153. In the primary response, activation of B-cells results in differentiation into antibody 
secreting short-lived plasma cells. A proportion of these B-cells then translocate to the spleen 
and lymph nodes. In these organs, proliferation occurs in the germinal centres. Affinity 
maturation occurs in the germinal centres via somatic hypermutation and clonal selection. 
High affinity B-cells presenting a MHC-peptide complex on the surface that can then be 
recognised by CD4+ T-cells in an antigen specific manner by their T-cell receptor, with up-
regulation of CD40L and cytokine secretion (IL-4). This leads to B-cell clonal expansion and 
isotype switching. These cells then go on to form antibody secreting cells or memory cells 
which remain resident in the germinal centres of the secondary lymphoid organs. On re-
exposure to antigen, these memory cells are re-activated. The profile of FVIII antibodies seen 
in haemophilia, although showing physiological profiles of IgG, demonstrated higher 
amounts of the IgG1 and IgG4 subclasses. Class switching to IgG4 is a process seen as further 
evidence of the requirement for T-cell help.  
1.5 Clinical and Laboratory Aspects of Factor VIII Antibodies 
1.5.1 Clinical Aspects of Inhibitory Antibodies to Factor VIII 
Antibody formation to FVIII in patients with congenital haemophilia and acquired 
haemophilia A is one of the greatest clinical challenges facing haemophilia treating 
physicians. These are associated with morbidity, mortality, impairment in quality of life and 
cost. Laboratory testing and quantification of these antibodies is based on a functional 
haemostatic assay (Nijmegen-Bethesda Assay, NBA), detecting antibodies with inhibitory 
capacity (inhibitors). These are sub-classified as being either low-titre (inhibitors titre 
<5BU/mL, despite repeated FVIII challenge and a lack of anamnesis) or high-titre (inhibitor 
titre >5BU/mL at any time) 63. Inhibitory antibodies represent only a proportion of the 
immune response to FVIII, with the total immune response being largely unknown. Much of 
current understanding of mechanism of action, testing methodology and inhibitor risk factors 
are derived from patients with severe haemophilia A. There are however, differences in the 
clinical and immunological contexts in which patients with severe and non-severe 
haemophilia A receive treatment with FVIII (discussed in Chapter 4). Similarly, the immune 
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processes and antibody characteristics seen in patients with acquired haemophilia A differ 
from those seen in congenital haemophilia. Despite commonality of the target antigen (FVIII) 
in these three settings, there are limitations in extrapolation of laboratory and clinical data.  
1.5.2 Severe Haemophilia A 
Patients with severe haemophilia A frequently require FVIII treatment within the first year of 
life (median 9.8 months, IQR 5.3-13.5). Understanding of the epidemiology and 
environmental risk factors for inhibitor formation in severe haemophilia A has progressed 
greatly within the last 8 years through large international cohort studies of previously 
untreated patients (PUPs). The first of these, the CANAL (Concerted Action on Neutralizing 
Antibodies in severe haemophiLia), reported on 366 consecutive patients with moderate-
severe haemophilia (FVIII:C <2IU/dL), born between 1990-2000 100. The second of these, the 
Research Of Determinants of INhibitor development (RODIN) study, evaluated 606 severe 
haemophilia A PUPs born between 2000-2010 149;154. Within the RODIN study, there was a 
cumulative inhibitor incidence of 32.0% (high-titre 22.2%), occurring at median age of 15.5 
months (14.5ED) 149. In patients who developed an inhibitor, 50% had developed this within 
15EDs 99;100, with these findings being similar to previously published observational studies 
99;100. The formation of inhibitors beyond 50EDs is less frequent, with a reported incidence of 
3 per 1000 treatment years (95%CI 1-4) in a recent meta-analysis of 33 studies (4323 patients, 
43 de-novo inhibitors) 155. Data published from a large cohort of UK patients, with severe 
haemophilia A alive and treated between 1990 and 2009, has suggested a bimodal 
distribution in inhibitor incidence 156. An initial peak in incidence was seen in those <5 years 
(64.29/1000 treatment years) and a second peak seen in those ≥   years (  .  /     
treatment years), compared to those aged 10-49 years (5.31/1000 treatment years, p=0.01) 
156. This second peak remained significant even with adjustment for HIV seropositivity. 
Interestingly in this cohort, inhibitor incidence described in previously treated patients (PTPs)  
is higher than has been reported in other studies  155.  
The formation of inhibitors in patients with severe haemophilia A impairs adequate delivery 
of prophylaxis and results in significant morbidity. There are varying reports of the effect of 
inhibitor formation on mortality. Although a UK report (1977-1999) demonstrated no 
significant difference in mortality in inhibitor patients 156, recent data from the US has 
suggested a 70% increased risk (OR=1.7, 95%CI 1.2-2.5) in severe haemophilia A patients with 
a current inhibitor compared to those without (including those who had undergone 
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successful ITI) 157. Inhibitor formation also negatively impacts on quality of life 158, physical 
activity 159,  caregiver burden 160;161 and is associated with significant cost relating to both 
delivery of treatment for bleeding and therapies directed at suppression of inhibitors. 
1.5.3 Non-Severe Haemophilia A 
The cumulative incidence of inhibitors in non-severe haemophilia is lower (3-13%) than is 
seen in patients with severe haemophilia A. Inhibitors in these patients however, still 
represented a substantial proportion (28%) of inhibitors reported in the UK between 1/1990 
and 1/1997 64. Until recently, much of the understanding of inhibitor formation in non-severe 
haemophilia was derived from small cohort studies and case series 64;162-165. Recent reports 
from the “INternational Study on etiology of inhibitors in patients with a moderate or mild 
form of hemophilia A, influences of Immuno Genetic & Hemophilia Treatment factors” 
(INSIGHT) 166-170 and European Haemophilia Safety Surveillance (EUHASS) 171;172 studies are 
starting to provide more data in this area.  
Inhibitor formation in patients with non-severe haemophilia A occurs later in life 64;166;172-175, 
at a median age of 46 years (IQR 18-65) and after 28 ED (IQR 12-71) 166. Although the majority 
of inhibitors occurred within the first 50ED, in the INSIGHT (69.5%, 41/59) 166 and EUHASS 
(72%, 28/39) 172 studies respectively, there was continued inhibitor occurrence beyond 
100EDs. In the EUHASS study, 15% of inhibitors occurred beyond 100ED. Within the INSIGHT 
study the cumulative inhibitor incidence was 3.5% at 20ED; 6.7% at 50ED; rising to 13.3% at 
100ED. Within this study a substantial proportion (517/1112) of patients were minimally 
treated (<20ED), with 68% of patients receiving <50ED, so there was only a small number of 
patients remained under observation by 100ED (297 patients at 75ED reducing to 33 patients 
at 100ED) 166. Given the infrequent nature of exposure over many years there may also be 
limitations in the recall of accurate ED data in non-severe haemophilia A. 
Some of the clinical difficulties specific to inhibitors in non-severe haemophilia A were first 
highlighted in a case-series (n=26) reported in the late 1990s 64. Alongside causing inhibition 
of infused exogenous FVIII, cross-reactivity with endogenous FVIII was seen in 24/36 patients 
which resulted in a fall in baseline FVIII:C (median pre: 8IU/dL to post: 1IU/dL) and change in 
bleeding phenotype (22/26) 64. Similar findings have been reported in the INSIGHT study, 
with a fall in FVIII:C in 58% (n=34) of inhibitor patients and change in bleeding phenotype in 
51% (n=30). Sixteen patients (27%) had a fall in FVIII:C to ≤1%. Only 11 (19%) of inhibitors 
were detected by routine testing. Inhibitor formation is also associated with increased 
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morbidity 64;170 and mortality 64;168. There was a ten-fold increase in annualised bleeding rate 
(pre: 0.095, IQR 0.02-0.42 and post 1.1, IQR 0.1-2.5) following inhibitor formation in the 
INSIGHT cohort 170. The all-cause mortality rate was also five-fold higher (n=16, age-adjusted 
mortality rate ratio 5.6) in inhibitor patients and 7 patients died from inhibitor related 
bleeding 168. 
1.5.4 Risk Factors for Inhibitor Formation in Congenital Haemophilia A  
The ability to predict whether patients with haemophilia will develop an immune response 
to FVIII could help personalise management. Risk factors that have been identified to date 
relate either to the context that FVIII is infused (environmental), are inherited (genetic) or 
the approaches (methodology and timing) to inhibitor testing 176.  
1.5.4.1 Severe Haemophilia A 
Genetic Risk Factors in Severe Haemophilia 
In severe haemophilia A, the strongest predictor of risk of inhibitor formation is the 
underlying F8 gene mutation 177 . Patients with large deletions and nonsense mutations have 
higher risk of inhibitor development than those with inversion mutation, OR=3.6 (95%CI 2.3-
5.7) and OR=1.4 (95%CI 1.1-1.8), respectively. The risk of inhibitor formation is less in patients 
with small deletions/insertions, OR=0.5 (95%CI 0.4-0.6) and missense mutations, OR=0.3 
(95%CI 0.2-0.4) 177. A family history of inhibitor formation is associated with increased risk of 
inhibitor formation, with an inhibitor incidence reported at 48% (95%CI 35-62) in patients 
with a positive family history and 15% (95%CI 11-21%) in those with a negative family history 
(RR=3.2, 95%CI 2.1-4.9) in one large study 178.  
Increased incidence of inhibitor formation has been described in patients of Hispanic and 
African origin compared to those of Caucasian origin in a number of studies, although the 
underlying genetic mechanism for this are not clear 178-180. One mechanism that has been 
proposed is that there is a mismatch between wild type FVIII seen in these patients in 
contrast to that infused as part of replacement therapy. Four nonsynonymous single-
nucleotide polymorphisms (SNPs) were identified in the F8 gene in a study of healthy 
individuals (n=137), resulting in six haplotypes, which have been denoted H1-H6 179;181. These 
vary at four positions in the A2, B and C2 domains, and have the following residues 
represented:  H1 (Arg484, Arg776, Asp1241, Met2238), H2 (Arg484, Arg776, Glu1241, 
Met2238), H3 (Arg484, Arg776, Glu1241, Val2238), H4 (His484, Arg776, Glu1241, Met2238), 
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H5 (Arg484, Arg776, Asp1241, Val2238) and H6 (Arg484, Gly776, Glu1241, Met2238). The H1 
haplotype forms the predominant haplotype in Caucasian individuals, occurring in around 
93% with the remaining 7% having the H2 haplotype. More diversity in wildtype haplotypes 
is seen in black individuals, with the following haplotype frequencies being seen: H1 (35%), 
H2 (37%), H3 (22%), H4 (4%) and H5 (1%). It was proposed, that a mismatch between the 
wild-type FVIII haplotypes (H3-4) seen in black patients and those found in recombinant FVIII 
products (H1-2) resulted in increased inhibitor formation. In this study (n=78) the prevalence 
of inhibitors was higher in black patients with H3-H4 haplotypes in comparison to those with 
F8 H1-H2 haplotypes (OR=3.6; 95%CI 1.1-12.3; p=0.04) 179. These findings are however 
controversial and have not been replicated by other investigators 180;182-185. Further study in 
this area is required and the genetic mechanisms for these differences in inhibitor incidence 
are likely to be far more complex than relating to a single F8 SNP. 
Given the requirement for T-cell (CD4+) help in the process of inhibitor development, one 
might expect MHC class II alleles to be associated with an increased risk of inhibitor formation 
178-180. Studies in patients with severe haemophilia A, with the intron 22 inversion mutation 
have not demonstrated strong associations for any MHC class II haplotype and inhibitor 
formation, although HLA-DQA0102, -DQB0602 and -DR15 have been described to occur more 
frequently in patients with inhibitors 186;187. This potentially only forms a weak determinant 
of risk, given the vast number of potential T-cell epitopes that could be expressed on MHC in 
patients with null mutations. Alternatively, due to presence of intracellular FVIII in patients 
with intron 22 inversion 82, this may allowed development of tolerance. Earlier investigations 
into polymorphisms in genes involved in the immune response showed a modest increase in 
risk for polymorphism in the IL-10 and TNF-α genes and decreased risk for mutations in the 
CTLA-4 gene 188-192. More recent work has identified a SNP within the FCGR2A, which encodes 
the low affinity Fc gamma receptor (FcγR), to be associated with increased risk of inhibitor 
formation (OR per H-allele=1.8; 95%CI 1.1-2.9) 193. 
A recently published large international study (n=833), using a microarray approach to 
investigate 13331 SNPs in 1081 primary immune response / immune modifying genes has 
not confirm these findings, for polymorphisms in the IL-10, TNF-α and CTLA-4 genes 194. This 
study however identified 13 SNPs associated with either increased (n=5) or reduced risk (n=8) 
of inhibitor formation, including mutations the genes for CD44, CSF1R, DOCK2, MAPK9, and 
IQGAP2 183. There has also been one case-control small (n=20) study evaluating gene 
expression profiles (RNA) using a microarray comparing patients with inhibitors (n=9) to 
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controls (n=11) 195. Downregulation of Chemokine (C-C motif) ligand 3-like 1 and 3 (CCL3L1 
and CCL3L3), Pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) PPBP (CXCL7), 
Interleukin-8 (IL8) and upregulation of Chemokine (C-X-C motif) ligand 9 (CXCL9) 
and Chemokine (C-X-C motif) ligand 11 (CXCL11) were seen in patients with inhibitors. These 
have all previously been shown to be involved in the regulation of the immune response 195. 
Although these findings provide interesting preliminary data, this study is severely limited by 
a small sample size, poor case-control matching and lack of clarity in the sampling 
methodology. Further study of changes in mRNA expression in patients with inhibitors may 
provide a dynamic biomarker for prediction of risk, which is discussed in more detail in 
Chapters 9 and 10.   
Environmental Risk Factors in Severe Haemophilia 
FVIII administration alone is insufficient to provide danger signals for the development of an 
immune response. As such environmental factors relating to context of treatment could 
provide differential risk. Characterisation of these factors is important as this could allow 
modification of risk or future alternate treatment strategies in those who are known to have 
high baseline risk due to genetic factors. The main risk factors identified from observation 
studies relate to intensity of early exposure to FVIII. Intensive treatment for bleeding or 
surgery (HR=2.0; 95%CI 1.3-3.0) and high dose FVIII treatment (HR=2.3; 95%CI 1.0-4.8) has 
been associated with increased risk of inhibitor formation at the start of treatment 149. 
Although age at first treatment, in a number of studies, was found to be a risk factor for 
inhibitor formation, data in the CANAL study has found that this directly related to treatment 
intensity 100. No association with inhibitor risk has been seen relating to vaccination 196;197, 
breast-feeding 100;196, inter-current infection 196;198 or treatment for central nervous system 
bleeding. Within both the CANAL (RR=0.4; 95%CI 0.2-0.8) 100 and RODIN (HR=0.6; 95%CI 0.47-
0.99) 149 studies, usage of prophylaxis was associated with a significant reduction in risk of 
inhibitor. The Kaplan-Meier curve of inhibitor incidence within the RODIN study, however, 
demonstrated no significant difference in risk comparing those on prophylaxis and on-
demand during the first 20ED, but after this time point there is a marked reduction in the 
inhibitor incidence in those on prophylaxis 149. Data from a large cohort of severe haemophilia 
patients from the UK has suggested that there is increased inhibitor risk occurring with age 
≥   years (discussed abo e) 199. The underlying reasons for this requires further study, but 
could relate to treatment related factors (e.g. major surgery) or immunosenescence. There 
has been great discussion and controversy, within the recent literature regarding 
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immunogenicity relating to different FVIII concentrates which represents the most (if not 
only) modifiable risk factor in the treatment of patients with severe haemophilia A. There 
have been conflicting reports of inhibitor risk relating firstly to the source of FVIII 
concentrate, whether from a plasma derived or recombinant source 154;176;200-202. There have 
also been reports of differences in immunogenicity within FVIII sources, relating to VWF 
content (pdFVIII) 154;203 and for BDD-FVIII 155;204 and second generation rFL-FVIII concentrates 
(rFVIII) 154;205-208. There is clinical equipoise surrounding immunogenicity relating to FVIII 
concentrates and further study is required. There have also been concerns that switching 
between FVIII concentrates may be associated with increased inhibitor incidence, although 
this was not seen in a recent prospective report from the UK relating to product switching 
from rFL-FVIII concentrates to a recombinant B domain deleted FVIII concentrate (rBDD-FVIII) 
209. 
1.5.4.2 Non-Severe Haemophilia A 
Risk factors for inhibitor formation in non-severe haemophilia A are less clear, due to a 
paucity and difficulty in construction of large studies in these patients.  
Genetic Risk Factors in Non-Severe Haemophilia 
Similar to findings seen in severe haemophilia A, the causative F8 mutation appears to 
influence risk of inhibitor formation 64;166;210;211. Following on from earlier reports of increased 
incidence of inhibitor formation relating to a number of specific F8 point mutations, the 
INSIGHT study has provided an extensive analysis of risk relating to underlying F8 mutation. 
In this study, mutations associated with increased incidence of inhibitor formation (risk at 
50ED) were: Arg593Cys (18.3%), Asn618Ser (2.9%), Asp2074Gly (21.2%), Arg2150His (12.2%), 
Arg2159Cys (39.4%) and Trp2229Cys (41.7%) 166. A study of 1135 patients with missense 
mutations has also recently described significantly increased inhibitor risk where there is a 
substitution of an amino acid belonging to a different physiochemical class (inter-class) 
compared to a switch within the same class (intra-class) 211. In this analysis the most 
significant risk (p=0.048) occurred when the substitution involves a small/hydrophobic (class 
I) amino acid. This study consisted of patients with all severities of haemophilia and of the 
patients with inhibitors, 42% (15/36) had severe haemophilia. A previous in-silico study of 
missense mutations showed a trend towards increased frequency of a switch to different 
group in those with severe 78.2% (240/307) compared to mild haemophilia 71.4% (235/329) 
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(p=0.05) 95, although this effect is small. Whether these inter-class switches result in a change 
in phenotype, which is more marked for changes from a class I amino acid, is not known.  
A small study of mild haemophilia A patients (n=45) with the Arg593Cys mutation did not 
show any statistically significant HLA associations in patients with inhibitors (n=7) compared 
to those without (n=38) 212. There is no data relating to whether ethnicity or F8 haplotype are 
risk factors for inhibitor formation in non-severe haemophilia A. Similar to studies in severe 
haemophilia, this is complicated by low inclusion/recruitment rates of non-Caucasian 
patients in clinical studies. The INSIGHT Study only included 14/1112 (1.3%) African-American 
patients. Similarly, there is no data on the effect of FVIII haplotype, family history or SNPs in 
genes involved within the immune response. These areas are of interest for further research, 
as differences between endogenous and exogenous FVIII or in the immune response could 
be more permissive to presentation of novel T-cell epitopes to the immune system, which is 
discussed in more detail in Chapter 4.   
Environmental Risk Factors in Non-Severe Haemophilia 
Environmental risk factors for inhibitor formation described in patients with non-severe 
haemophilia A include surgery (in patients with a high risk mutation) and intense exposure 
to FVIII 173;174;213. A case-control study performed by the Division of Blood Disorders of the 
Centers for Disease Control and Prevention has recently reported evaluating inhibitor risk in 
98 patients (cases=36, controls=62). There was a strong association with intensive FVIII 
treatment, which was greater in those >30 years (OR 13.54), in comparison to those <30 
years. Within this analysis ethnicity, FVIII:C 1 to <2%, <50ED prior, young age (<5 years) at 
first FVIII treatment and rFVIII usage were not significant. The incidence of the Arg593Cys 
mutation was more common in cases than controls (19.4% v 4.8%, p=0.03), but interestingly 
this lost significance within the multivariate analysis. Preliminary results (307 patients with 
77 inhibitor cases) from the INSIGHT case-control study were presented in abstract format in 
2013 167. After adjusting for potential confounding variables (ethnicity, mild/moderate 
haemophilia, family history and age), neither treatment intensity, for moderate (3-4ED) or 
major (≥ ED) bleeding nor surgery were found to be independently associated with inhibitor 
formation compared to minor bleeding or absence of surgery respectively. Similar to 
observations seen within PTPs in severe haemophilia A, there has been reported increased 
inhibitor incidence occurring with age 174, with a trend towards increasing risk of inhibitor 
development in those >60 years (OR=1.8; 95%CI 0.79-4.17) within this preliminary analysis. 
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Whether this represents changes in the aging immune system or represents more intensive 
FVIII exposure occurring later in life due to factors such as surgery is not clear. The final 
analysis of the INSIGHT case-control study is awaited, which may provide further detail of 
environmental risk in these patients. 
The risk relating to different FVIII concentrates in patients with non-severe haemophilia A 
has recently been evaluated within the first four years of the EUHASS registry 172. This data 
reported on 7,969 patients with non-severe haemophilia A, with a total of 37 inhibitors and 
an inhibitor rate of 0.43/100 treatment years. Inhibitor rates were similar between different 
concentrate brands and classes. The inhibitor rate for pdFVIII concentrates was 0.14/100 
years (95%CI 0.14-0.42) and 0.52/100 years (95%CI 0.36-0.73) for rFVIII concentrates, with 
overlapping confidence intervals.     
1.5.5 Timing of Inhibitor Testing in Haemophilia A 
In severe haemophilia A, as most inhibitors occur early in the course of treatment (50% within 
the first 15ED), the aim of inhibitor testing is to detect emerging inhibitors to allow 
commencement of inhibitor eradication therapy with immune tolerance induction 99. Based 
on clinical trial data, this has allowed the development of guidance suggesting that severe 
haemophilia A patients should be tested every 3EDs (or every 3 months) in the first 20EDs, 
every 3-6 months until 150ED and then 1-2 times/year 214. Alongside this, patients 
undertaking a product switch should be tested prior to and twice in the 6 months following 
switching 214.  ctual, ”real-world” timing of inhibitor testing undertaken in the PUP setting is 
not clear, although recently published data from the CANAL and PedNet studies has provided 
some important descriptive data in this area 215. Within the most recent birth cohort (2005-
2009, n=305) in these studies, there was a median of 5 inhibitor tests (IQR 3-8) performed 
within the first 50ED 215. There was increased intensity of screening seen with time comparing 
the first 1990-1994 (1.9 tests/year) and last 2005-2009 (4.3 tests/year) birth cohorts  215. 
These studies 215, and a previous meta-regression 176, suggest that increased inhibitor testing 
is associated with an increased incidence of inhibitor formation, primarily through detection 
of low-titre inhibitors 215.   
In non-severe haemophilia A, there is a paucity of data to provide evidence-based guidance 
on the timing and frequency of inhibitor testing. Published guidance in the UK advises 
inhibitor screening following episodes of percei ed “high-risk” e posure to FVIII, based on 
consensus opinion and previously published case-series and cohort studies. These suggest all 
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patients treated with FVIII should be tested annually and following intensive exposure 
(≥ ED), surgery or any FVIII e posure in patients with “high-risk” F8 gene mutation 214. There 
is no data, to define current practices for inhibitor screening in non-severe haemophilia A as 
has been described in patients with severe haemophilia 215 .  
1.5.6 Treatment of Bleeding in the Presence of Inhibitory Antibodies 
Treatment options for managing bleeding in haemophilia A patients with inhibitors, include 
usage of FVIII concentrates or “bypassing agents”. FVIII concentrates may be of use in the 
treatment of bleeding in patients with low-titre antibodies, where it may be possible to 
saturate the inhibitor to provide adequate FVIII levels for haemostasis, although this 
approach may risk an amnestic response. Patients with high-titre antibodies, or in whom 
bleeding is unresponsive to high doses of FVIII, are treated with bypassing agents. Bypassing 
agents used in the UK include Factor Eight Inhibitor Bypassing Activity (FEIBA®) and 
recombinant activated factor VII (rFVIIa or NovoSeven®). These two agents appear to have 
similar efficacy for the treatment of bleeding based on data from two randomised studies 
216;217, although further study is required in this area 218. Interestingly, patients with inhibitors 
may display different responses to the two bypassing agents, which may be seen on in-vitro 
spiking experiments, which some groups have used to guide management of patients with 
inhibitors requiring surgery 219. Bypassing agents are recommended as the first line choice 
for the treatment of severe bleeding in AHA 119. Although no direct studies of these two 
agents have been performed to date in AHA, both are thought to similarly efficacious. Within 
the EACH2 study the efficacy of rFVIIa and FEIBA® for control of bleeding events was 91.8%, 
with propensity score matching demonstrating equal efficacy for these approaches (OR=1; 
95%CI 0.23-4.44; p=1) 220.   
1.5.7 Treatment Aimed at Inhibitor Eradication 
The mainstay of treatment aimed at inhibitor eradication in patients with severe haemophilia 
A is through immune tolerance induction (ITI) 214 , although other approaches have been 
described (reviewed in Laros-van Gorkom el al. 221).  ITI involves regular infusion of FVIII either 
alone or in combination with immune modulatory treatment with the aim of restoring 
“tolerance” to FVIII. The three main approaches used have included the Van Creveld (low 
dose FVIII), Bonn (high dose FVIII) and Malmö (high dose FVIII and immune modulation) 
protocols 222.  Despite the usage of this treatment in patients with inhibitors for more than 
30 years, there is still very little information, regarding the cellular mechanism behind this 
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process 223. Proposed mechanisms include development of anti-idiotypic antibodies which 
antagonise the epitope recognition Fab site of the inhibitory antibody and inhibition of 
differentiation of FVIII specific B cells. This does not, however, appear to cause deletion of 
FVIII specific T cells 223. 
Multiple studies have been carried out investigating the response to immune tolerance 
induction in patients with severe haemophilia A, with response rates seen to ITI from national 
and international registry data ranging from 51-76%, using varying ITI dosing protocols 222;224-
228. The International-ITI study has given more insights into the question of dosing in ITI 229. 
This study was a prospective multicentre randomised controlled study comparing a low dose 
(50IU/kg, 3 times a week) to a high dose (200IU/kg daily) ITI regimen in 115 patients with 
severe haemophilia A with inhibitor. Overall, ITI was successful in 69.7% (n=46) of patients 
and a partial response seen in a further 4.5%. Although success rates did not differ between 
the two arms of this study, time taken to reach all criteria for success (inhibitor negativity, 
normal recovery and tolerance) was significantly shorter in patients treated on the high dose 
regimen. Alongside this the rate of bleeding was higher in patients treated with a low dose 
regimen in comparison to a high dose regimen, prompting premature cessation of the study. 
The time to achievement of tolerance on ITI is variable between studies. Usage of protocols 
including immunomodulation such as the Malmö protocol reported median times of 1 
month, although at the expense of inpatient treatment and exposure to cytotoxic agents 230. 
Times to response in the five registry studies reported range from 7.6 to 16.3 months, with 
similar findings seen in the international ITI study (high dose 14.2 months and low dose 16.4 
months) 222;224-229. The undertaking of ITI is a great commitment for patients and their family 
and is associated with significant cost. An estimate of overall costs incurred per patient on 
ITI were between 2.4 (low dose) and 3.4 (high dose) million Euros 231. The international ITI 
study has formed the basis for current guidance in the management of immune tolerance 
induction in patients with inhibitor in the United Kingdom 214. Following on from this guidance 
a national protocol has recently been proposed by the UK Haemophilia Centre Doctors’ 
Organisation (UKHCDO) Inhibitor and Paediatric Working Parties, for guidance for initiation, 
dosing, monitoring and weaning of ITI in patients with severe haemophilia A 232. This now 
advised commencement of ITI immediately, in the presence of an inhibitor detectable by the 
Nijmegen-Bethesda assay on more than one occasion, interfering with prophylaxis or 
treatment of bleeds, with gradation of dosing for initiation dependent on the inhibitor titre.  
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Data in patients with non-severe haemophilia A has suggested that these patients have a 
poorer response to ITI 64;214. In one case-series, describing eight patients treated with various 
different ITI regimens, a complete success was seen in two, partial response in four and no 
response in two patients. In the INSIGHT study, inhibitor disappearance occurred in 70% 
(51/73) of patients who underwent observation and 75% (21/28) of those treated with 
inhibitor eradication therapy (n=28) 169. A variety of eradication therapies were used 
including ITI (n=16), immunosuppression (n=5) or a combination of ITI and 
immunosuppression (n=7). The median time to inhibitor disappearance, in those observed 
and treated with inhibitor eradication therapy was 9 (IQR 3-16) and 15 (IQR 7-38) months 
respectively. Patients were more likely to be treated with inhibitor eradication therapy if 
there was a fall in FVIII to ≤ IU/dL (  %    7%) or when treated in a smaller haemophilia 
treatment centre (53% v 22%). Patients treated with ITI were younger (median 13 years) than 
those that did not receive eradication therapy (median 42 years) and those receiving 
immunosuppression were older (median 69 years) than those receiving other eradication 
therapies. The authors suggest that there has been a change in practice with time, with 
eradication therapy not being administered before 1990, although this only constituted 4 
patients in the study. When looking at the response to treatment (or observation) this will 
be dependent on whether the patient is re-challenged to FVIII (sustained response). The 
sustained response rates were 60% (21/35) and 83% (10/12) in those who were observed 
and treated with inhibitor eradication therapy. Although 65% of the total cohort were re-
challenged with FVIII no details are provided as to the timing and methodology for inhibitor 
testing to confirm sustained response. Although there was no difference in the sustained 
response rate for use of inhibitor eradication therapy for low-titre antibodies (unadjusted 
relative probability=0.8, 95%CI 0.4-1.8), inhibitor eradication was more likely to be associated 
with sustained response for high-titre antibodies (unadjusted relative probability=2.3, 95%CI 
1.3-4.3). A small survey (n=39, response rate 22.9%) of treatment approaches in adult non-
severe haemophilia A patients from the USA demonstrated similar heterogeneity in the 
approaches to immunosuppression depending on the clinical scenario 233. In asymptomatic 
patients with a low-titre inhibitor, 77% (n=30) of respondents opted for observation alone, 
with only 18% (n=7) taking a similar approach in patients with a high-titre inhibitor who was 
bleeding. Although the most common approach for inhibitor eradication in those with a high-
titre inhibitor and bleeding was to commence ITI once the titre was <10BU/mL, there were a 
variety of other approaches selected including use of rituximab and steroids 
(methylprednisolone). Although interpretation of these survey data is limited by a low 
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response rate, differences in approach to management of inhibitors in the non-severe setting 
based on the presenting features have been characterised both in this survey 233 and the 
INSIGHT study 169, which directly affect interpretation of outcomes. There are still many 
questions in the optimal approach to management of inhibitors in patients with non-severe 
haemophilia A and further prospective study is required.   
1.5.8 Classification and Physiology of Factor VIII Antibodies 
Although inhibitors form an important class of clinically relevant FVIII antibodies, these 
represent only a proportion of the true immune response to FVIII, which also includes 
antibodies without direct inhibitory capacity (non-neutralising, NNA). Clinical studies 
investigating FVIII antibodies in congenital and acquired haemophilia have primarily defined 
end-points using a functional haemostatic assay for antibody characterisation, resulting in 
incomplete understanding of the true humoral response to FVIII. The clinical significance 
however of non-neutralising and proteolytic antibodies is not fully understood due to a lack 
of prospective studies studying long term outcomes in patients with these antibodies. Lack 
of characterisation of the complete immune response could impair the significance of clinical 
study findings, resulting in heterogeneity of risk factors and treatment responses described.  
1.5.9 Inhibitory Factor VIII Antibodies (Inhibitors) 
An inhibitor is an antibody directed towards either endogenous (allo-immune) or exogenous 
(allo- or auto-immune) FVIII, detected using a functional clotting based assay. Circulating 
anticoagulants, reducing the effect of early FVIII replacement therapies in haemophilia and 
in previously normal individuals, were first described over 70 years ago 234-237. Inhibitory 
antibodies are time and temperature dependent, which forms the basis of functional 
laboratory assays used in their detection. Inhibitors in congenital and acquired haemophilia 
A, are polyclonal immunoglobulins consisting almost exclusively of the IgG isotype 238;239, 
although rarely, anti-FVIII IgA and IgM has been seen in patients with acquired haemophilia 
A 240. These inhibitors have been shown to be predominantly of the IgG1 and IgG4 subclasses 
135;152;241. Contribution of the IgG2 subclass is variable between reports and IgG3 is rarely seen 
134;241. A recent study has suggested that patients with low-titre antibodies are mainly of the 
IgG1 subclass and those with high-titre antibodies of the IgG4 subclass 241;242. Whether 
differences in outcomes exist in those with IgG1 and IgG4 FVIII antibodies is not clear and 
requires further study. This is currently being evaluated prospectively in patients with severe 
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haemophilia A in the Hemophilia Inhibitor Previously Untreated Patients Study (HIPS, 
ClinicalTrials.gov Identifier: NCT01652027).  
1.5.10 Mechanisms of Factor VIII Inactivation and Inhibitor Epitopes  
The mechanism via which inhibitors act, will be dependent on its epitope (antigenic 
determinant) to FVIII. Dominant domain-based epitopes have been described in patients 
with congenital haemophilia A within the A2 and C2 domains (68%) and a3 region (46%) 
243;244. FVIII auto-antibodies are directed towards the A1, A2 or C2 domains 245;246. One of the 
main mechanism via which inhibitory antibodies act is via steric hindrance. This could result 
in inhibition of the interaction between FVIII and VWF, phospholipid membranes, FVIII 
activation/inactivation by thrombin of FXa, interaction within the tenase complex with FIXa 
and FX and impairment in hetero-trimer formation. Other proposed mechanisms include 
increased clearance and through direct catalytic activity. Given the polyclonal nature of this 
immune response, it is likely that FVIII antibodies may have action via a number of these 
mechanisms. A change in epitope profile with time (epitope spreading) may potentially occur 
in patients with FVIII antibodies 148;247. This results in the development of an immune 
response against distinct and non-cross reactive epitopes from the original epitope, which 
has been seen as part of the normal immune response to infection and in autoimmune 
disease 248. A number of techniques have been applied to investigate the epitope of anti-FVIII 
antibodies from both patients and monoclonal antibodies. These techniques have included 
immuno-precipitation, phage displayed peptides, solid phase peptide synthesis (SPPS) / Spot 
techniques and more recently a immunoassay utilising Luminex® techniques 247 which will be 
discussed in more detail in Chapter 8. The majority of these techniques are not suitable for 
use in routine clinical practice due to labour intensity and sample volume requirements. 
Alongside this, many of these techniques are unable to identify conformational (or 
discontinuous) epitopes for antibodies. There is as yet no high-throughput approach for the 
investigation of amino acid sequence epitopes for use in patients with FVIII antibodies.    
1.5.11 Kinetics of Inhibitor Activity 
Inhibitors can be further classified based on their inactivation kinetics as being type I or II 
inhibitors. Type I inhibitors cause complete (>98%) inactivation of FVIII:C with a linear 
relationship between antibody concentration and log-residual FVIII:C. These antibodies are 
time and concentration dependent and potentially saturable in the presence of sufficient 
FVIII:C 249;250. Type II inhibitors demonstrate an inability to completely inactivate FVIII:C even 
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when undiluted, with a non-linear (complex kinetics) relationship between antibody 
concentration and log-residual FVIII:C. Repeated additions of FVIII, will therefore be required 
before saturation of the antibody is reached 250-252. Patients with severe haemophilia A are 
thought to primarily display type I antibodies 250;253 and those with non-severe and acquired 
haemophilia A to display either type I or II inhibitors 250;253. Although the biological 
mechanism for these differences is not known, two potential hypotheses have been 
proposed 253. The first of these is that the B-cell epitope formed by these different types of 
antibody may be different. It has been suggested that VWF may affect the kinetics of 
inactivation, with one study showing that most type II inhibitors showed partial inactivation 
only in the presence of VWF 250, although more detailed studies of the binding epitopes of 
type I and II inhibitors have not been carried out to date. A second mechanism may relate to 
antibody binding affinity, with type I inhibitors having higher affinity than type II inhibitors 
239. It is interesting to note that clinically the bleeding pattern seen in patients with type I 
inhibitors, which tends to involve bleeding into joint or intra-organ varies from that seen in 
those with type II where bleeding is predominantly involves the soft tissue 239. The 
mechanism for these differences is not apparent and is likely more complex than purely a 
function of the antibodies kinetics. Some studies have suggested that type II inhibitors may 
be more transient and immune tolerance induction may be more likely to be successful 
compared to type I inhibitors 254.  
1.5.12 Non-Neutralising Antibodies 
Antibodies without detectable inhibitory capacity have been seen in patients with 
haemophilia A as well as in haemostatically normal individuals. There has been great 
variability in the reported prevalence (12-54%) of these antibodies within the literature, 
between studies and the assay used for their detection 255-262. In a recent study of 210 
patients with haemophilia A, 18.1% of patients demonstrated non-neutralising antibodies 261. 
Within this study the prevalence of non-neutralising antibodies was not influenced by disease 
severity, age, F8 mutation or FVIII concentrate (pdFVIII v rFVIII or FL-FVIII v BDD-FVIII). The 
majority of antibodies were directed against the heavy chain (73.7%) or both the heavy and 
light chains (13.2%) with only 13.2% being directed against the light chain alone. Of these 
antibodies 7/38 (18.4%) were directed to the B domain of FVIII 261.  
The clinical relevance of this class of FVIII antibody is not clear. It has been hypothesised that 
NNAs may form immune complexes resulting in accelerated clearance of infused FVIII from 
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the circulation 263. This theory might explain abnormal pharmacokinetic responses (impaired 
in-vivo recovery or increased clearance) in the absence of detectable inhibitory antibodies, 
although strong data to support this is lacking. The most widely cited support for this theory 
comes from a small study of severe (n=9) and non-severe haemophilia (n=14) haemophilia A 
patients  256. In this group of patients 39% (9/23) were found to have non-neutralising 
antibodies using an in-house ELISA. The investigators studied the half-life of three patients 
(one with no detectable antibody, one with low-titre and one with high-titre non-neutralising 
antibodies) following an infusion of 30IU/kg of FVIII. The fall to baseline FVIII:C levels was 
seen after 36, 24 and 12 hours in these three patients, respectively. This has been interpreted 
by the investigators of indicating a reduced half-life in the patient with a high-titre non-
neutralising antibody. Although an interesting observation, there are a number of limitations 
to this. Firstly, significant inter-individual variability is seen in FVIII pharmacokinetics in 
patients with haemophilia, making comparison of these variable difficult 264. No historical 
pharmacokinetic data is available for these patients to demonstrate a true reduction in half-
life. Finally, the presence of residual FVIII in the sample of this patient may have masked the 
presence of a low-titre inhibitory antibody (discussed in Section 1.5 and Chapter 7) 256. Other 
studies looking at NNAs have failed to demonstrate an effect of these antibodies on FVIII 
pharmacokinetics 265-267.  
One study has looked at the longitudinal significance of non-neutralising antibodies in 
congenital haemophilia A. This study looked at the occurrence and natural history of non-
neutralising antibodies in 78 patients (severe=74, moderate=4) over a four year period. In 
this cohort, ten patients (12.8%) developed non-neutralising antibodies, which were 
transient and no patients went on to develop inhibitory antibodies 262. Interestingly, the 
incidence of bleeding events was lower in patients that developed non-neutralising 
antibodies compared to those that did not. The study population, however, consisted entirely 
of previously treated patients who were mainly receiving continuous prophylaxis (89.7%). 
Given that dosing of prophylaxis is similar to that seen in low dose immune tolerance 
induction protocols (Van Creveld), these patients may have been tolerised by virtue of being 
on prophylaxis.  
FVIII antibodies have been described in normal individuals as well as in patients with acquired 
or congenital haemophilia. A study of 500 healthy blood donors demonstrated the presence 
of FVIII antibodies (“natural antibodies”) in 17% (85/500) samples that had been heat treated 
(56°C for 60 minutes) prior to being tested with the Bethesda assay 268. In these samples the 
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inhibitory activity ranged from 0.4-2.0BU/mL (low-titre), with an even distribution of 
antibody positivity in male and female donors. The divide between whether an antibody is a 
non-neutralising or “natural antibody” is not clear and clear antibody negativity on testing 
prior to first receiving FVIII treatment would be required to ensure that the measured 
antibody is truly a response to infused FVIII. Whether an antibody is classified as being non-
neutralising or not is also affected by the sensitivity of the assay used to describe its 
functional activity. Differences in the characteristics of non-neutralising antibodies have been 
seen in patients without inhibitor history or healthy controls compared to those with 
inhibitors. Although, IgG1 and IgG4 were characterised in patients with FVIII inhibitors, there 
was a complete absence of IgG4 in those without an inhibitor history or healthy controls 242. 
No correlation was seen between FVIII antibody (IgG1 and IgG3) presence and age or sex in 
the healthy controls. The binding affinity of FVIII antibodies seen in patients with inhibitors 
is substantially higher (100 fold) in comparison to healthy individuals and those without 
inhibitors 269. These findings are in keeping with the process of affinity maturation and class 
switching that has previously been characterised. Whether low affinity, non-neutralising 
antibodies may provide a biomarker for the development of a more established immune 
response, is not clear and requires further study in a well-constructed prospective 
collaborative study, with adequate centralised FVIII antibody testing.  
1.6: Laboratory Detection of Factor VIII Antibodies 
1.6.1 Functional (Haemostatic) Assays for the Detection of FVIII Antibodies 
Recognition of the occurrence of inhibitory antibodies to FVIII has been described in the 
literature in both patients with congenital and acquired haemophilia A for greater than 70 
years 234-237. The gold standard laboratory test for the detection and quantification of FVIII 
antibodies is a functional assay (Nijmegen Bethesda assay, NBA) 270. The principle underlying 
this (and related assays) assay, is that the FVIII antibody presence and inhibitory potency is 
calculated based on the degree of inhibition of FVIII:C when incubated in a known quantity 
of FVIII. These assays are therefore only able to detect FVIII antibodies with direct inhibitory 
capacity. Despite widespread usage of these assays in routine clinical practice, none have 
been systematically evaluated or reported following standard criteria, such as those 
recommended by the “ST ndards for the Reporting of Diagnostic accuracy studies” (ST RD) 
initiative 271. Evaluation of assay performance to assess the presence of FVIII antibodies is 
limited by the lack of a pathological (e.g. histological sample) gold standard for comparison. 
This comparison is also limited by incomplete understanding of the significance of FVIII 
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antibodies with weak or no inhibitory capacity. Further, when evaluating inhibitors, no formal 
evaluation of what defines a positive or negative assay has been performed, with cut-offs 
based on consensus opinion 270. In this section the principles, evolution, clinical utility and 
limitations of these assays will be reviewed.  
1.6.2 Classical Bethesda Assay 
The classical Bethesda assay (CBA) which forms the basis for modern inhibitor testing was 
developed from consensus opinion at a meeting of American Haematologists at the Division 
of Blood Diseases and Resources, National Heart and Lung Institute in Bethesda, Maryland in 
1974 272;273. Prior to this, there was great variation in inhibitor testing methodology and 
quantification, potentially impacting on management if a patient were to be treated at two 
centres 273.  The CBA formed a uniform assay technique using standardised (consensus) units 
to facilitate comparison between centres and clinical studies for use in patients with severe 
haemophilia A 273. This assay involves incubation of test and control samples at 37°C for two 
hours in stoppered tubes (Figure 1.5). The test mixture consisted of one part citrated test 
plasma, with an equal part of normal pooled plasma and the control mixture, one part normal 
pooled plasma with one part imidazole buffer/NaCl (pH 7.4). Following sample incubation 
the FVIII:C is measured and the percentage residual FVIII:C found in the test sample relative 
to the control sample is then used to calculate the inhibitor titre. If no inhibitor is present 
then the expected residual FVIII:C, compared to the control mixture, would be 100%. A FVIII:C 
residual of 50% is equal to One Bethesda Unit / millilitre (1BU/mL) of inhibitor activity. Based 
on the residual FVIII:C, the inhibitor titre can be extrapolated from a reference curve (semi-
logarithmic) of residual factor VIII (log scale) against inhibitor titre (linear scale) 273. A line is 
then drawn between points corresponding to 100% residual / 0 BU/mL and 50% residual / 
1BU/mL (Figure 1.4)274. The inhibitor titre can then be read from this graph, where the FVIII 
residual lies between 25-75%. If the residual FVIII:C is <25% then serial doubling dilutions of 
the patient sample mixed with the incubation mixture are tested until the residual lies within 
this range. If the residual is >75% and there is clinical suspicion of inhibitor presence usage 
of a more sensitive assay is suggested. Calculation of the inhibitor titre can also be made 
using the linear regression equation formed by this curve 275: INH = [(2 - log10R)/0.30103] x D; 
where INH  Inhibitor titre (BU/mL); R=residual FVIII percentage and D=dilution factor. 
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Figure 1.4: Reference Curve for the Bethesda Assay. Reproduced from Kershaw et al. 
2012, with the permission of the publisher 274. 
1.6.3 Modifications to the Bethesda Assay 
Modification 1: Nijmegen-Bethesda Assay 
The CBA, despite bringing about a standardised approach for inhibitor testing in severe 
haemophilia A lacked specificity, particularly around the lower range of inhibitor activity 276. 
Observations of potential false positives arising from the CBA with insufficient buffering or 
variable protein concentrations 277 resulted in the optimisation of this assay to improve 
testing specificity (Nijmegen-Bethesda assay, NBA) (Figure 1.5) 274;276;278 . This included 
buffering of the normal pooled plasma (test and control) with 0.1M imidazole to stabilise the 
pH at 7.4 and replacement of imidazole buffer in the control mixture with FVIII deficient 
plasma to give comparable protein concentrations in both mixtures. A comparison of the two 
assays (CBA and NBA) was performed using samples from patients with and without 
inhibitors. In patients with severe (n=10) or non-severe haemophilia A (n=22) with no 
inhibitor history, the inhibitory activity found was to be 0.0BU/mL compared to 0.5-0.9BU/mL 
using the NBA and CBA, respectively. Similar inhibitor titres were seen comparing the results 
of both assays in patients with an inhibitor history on treatment (n=6) and in those with high-
titre inhibitors (n=7) 276.  
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Modification 2: 4% Bovine Albumin 
Cost issues relating to replacement of the imidazole buffer with FVIII deficient plasma in the 
control mixture have been suggested as one reason for less than universal adoption of the 
NBA 279. The same investigators, who described the NBA have evaluated usage of 4% bovine 
serum albumin (BSA) with or without VWF, in substitution for FVIII deficient plasma in the 
control. This was first evaluated in spiking experiments of purified anti-FVIII:C IgG combined 
with plasma from a single patient with severe haemophilia A, titrated to an inhibitor titre of 
1.5BU/mL with assays performed in quadruplicate 279. This showed good agreement between 
the results of the inhibitor assay using congenital FVIII:C deficiency plasma (F8DP) or 4% BSA, 
with or without the addition of VWF (1.61, 1.59 and 1.63BU/mL, respectively). This 
preliminary analysis was confirmed in samples from 6 patients with known inhibitor presence 
279. A validation of this modification has been recently presented, comparing usage of F8DP 
with 4% BSA, in 59 samples (35 patients) with known FVIII inhibitors, demonstrating good 
agreement between the results of the two assays, especially in those of low-inhibitory 
capacity (<2BU/mL) 280. 
 
Figure 1.5: Comparison of the Classical Bethesda (CBA) and Nijmegen Bethesda assays 
(NBA). Reproduced from Peerschke et al. with permission of the publisher 278. 
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1.6.4 Validation of the Nijmegen-Bethesda Assay 
The CBA and NBA have been compared in an inhibitor surveillance study during switching 
from pdFVIII to rFVIII in Canada in the early 1990s 281. This study included 877 samples tested 
in a single central reference laboratory. In the first year of this study all samples were 
monitored using the CBA and from the second year onwards all samples were tested in 
parallel. A total of 877 samples (233 prior to conversion) were tested using a consensus cut-
off of ≥0.5BU/mL for the assays.  
 CBA +ve CBA -ve 
NBA +ve 34 1 
NBA -ve  13 829 
Table 1.3: Assessment of the classical Bethesda assay (CBA) in comparison to the 
Nijmegen-Bethesda assay (NBA) in a large Canadian population of haemophilia A patients 
on product switching 281. 
There were 35 samples positive by NBA, with all except one of these being positive by the 
CBA. There were 13 samples that were positive by the CBA and negative using the NBA, all of 
which were of low-titre (0.5-0.8BU) (Table 1.3). No significant difference was seen in inhibitor 
titres comparing the CBA and NBA (mean±SD: CBA 15.5±34.6 v 33.4±69.7, p<0.05). All 31 
“grey-zone” samples (> BU/mL to < . BU/mL) detected using the CB  were negati e using 
the NBA.  
1.6.5 Assay Positivity using the Classical and Nijmegen Bethesda Assays 
When the Bethesda assay was first described, no cut-off between positivity and negativity 
was assigned, with this being left to individual laboratories to assign 273;276. Prior to the 
introduction of the NBA the range of cut-offs seen in one report was between 0 and 
0.8BU/mL 276. In the Canadian switching study which compared the CBA and NBA in parallel, 
a survey of centres involved, showed, although approximately 50% (9/19) of centres used a 
cut-off of >0.5BU/mL, there was a wide range from >0BU/mL to >1.9BU/mL 281;282. This study 
also showed the difficulties that arise in samples that they defined as being in a “grey-zone” 
of <0.5BU/mL, with these samples being positive by one assay and negative by another assay. 
A recently published study, using centralised inhibitor testing in 710 samples from patients 
with or without an inhibitor history described a cut-off of ≥ . BU/mL, based on comparative 
data of inhibitor titres seen in both groups 283. There has also been a consensus statement in 
2007, suggesting usage of a threshold of ≥ . BU/mL270. As part of the EUHASS study, data on 
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methodology of inhibitor testing and local assay cut-offs is being collected which will give 
further information into current inhibitor testing practices 171;284.  
1.6.6 Application of Functional Assays in Clinical Practice and Trials  
Functional inhibitor assays give a quantitative description of inhibitory capacity, facilitating 
comparison of results between clinical studies, at least for type I inhibitors. The results from 
these assays have been used to guide treatment and dosing practices in patients with 
inhibitors. For example, patients with low-titre inhibitors (<5BU/mL) are generally treated 
with high dose FVIII treatment as a first line treatment for bleeding 214;285. For type I inhibitors 
the assay result can be used to make a mathematical approximation of the FVIII dose 
required to saturate an inhibitor101;285;286. An example of a formula used for dosing based on 
the inhibitor titre from the Bethesda assays is as follows: FVIII Dose  = (40 X Body Weight (kg) 
x BU) + required therapeutic dose (in absence of an inhibitor)  101. As well as this, various 
studies in congenital and acquired haemophilia A have attempted to risk stratify patients 
based upon their inhibitor titre. Studies of patients undergoing ITI have used the results of 
the Bethesda assay to classify patient as being good or poor risk (i.e. those likely to undergo 
successful ITI) 226;227. All of the large international studies investigating environmental and 
genetic risk factors have only used a functional assay to determine their end-point of 
antibody development to FVIII 99;100;149;154;166;178;183;188-191;194;287. The true incidence of antibody 
formation will be underestimated in these patient groups and this may impair the detection 
of significance of weak risk factors.  
1.6.7 Pre-Analytical Variables and Assay Limitations 
A number of pre-analytical variables may affect the results that are obtained using the 
Bethesda assay. A blinded study of laboratories from the Royal College of Pathologists of 
Australasia Quality Assurance Program looked at the performance of 42 laboratories has 
shown that a number of factors, including heparin, EDTA and lupus anticoagulants may be 
result in false positives using this assay 288;289. The Bethesda assay was developed for 
quantification of type I inhibitory antibodies and will underestimates the inhibitory capacity 
of antibodies with complex kinetics and cannot detect antibodies without direct inhibitory 
capacity. This may have implications if this assay is used in dosing of FVIII replacement 
therapy or for risk stratification based on the inhibitor titre in acquired or non-severe 
haemophilia A. Further study is required to define the optimal strategies for testing for these 
different classes of FVIII antibodies. The commonest pre-analytical variable in routine testing 
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will be presence of FVIII in samples which will be discussed in the following section and 
Chapters 6 and 7. 
1.6.8 Presence of Residual Factor VIII:C in Test Samples  
The principle of the Bethesda assay (CBA and NBA) is based around the presence of equal 
amounts of FVIII:C in both the test and control samples prior to sample incubation. This relies 
on the fact that the patient’s sample does not contain FVIII:C, i.e. a patient with severe 
haemophilia A, who has received no recent treatment. There are however a number of 
circumstances in which inhibitor testing may be required where samples will contain FVIII:C 
including: 
1) Severe haemophilia A patients who have received FVIII treatment (prophylaxis, ITI or 
post-infusion) 
2) Non-severe haemophilia A 
3) Acquired haemophilia A (diagnosis or upon recovery) 
Laboratories may take a number of approaches when performing inhibitor testing in the 
presence of pre-analytical FVIII:C; including testing without adjustment, rejection of samples 
in which FVIII:C is present 290, or usage of a modification to adjust for this. Although a number 
of modifications 291 have previously been described, it is unclear whether these forms part of 
routine testing: 
1) In-vitro correction: FVIII is added to the control sample, providing equal FVIII:C in 
both the control and test samples. This requires testing the FVIII:C of each sample 
prior to performing an inhibitor assay.  
2) In-silico correction: A mathematical correction for residual FVIII:C present in test 
sample prior to testing can be calculated using the formula: REScorr = REStest x [100 + 
(100 x FVIIIpre/D)] 274, where REStest= FVIII:C residual in the test sample, FVIIIpre=FVIII:C 
present within the sample prior to testing and D=dilution factor. This also requires 
knowledge of the FVIII:C present in samples prior to inhibitor testing 
3) Pre-analytical heat treatment: This involves sample incubation (56-58°C) prior to 
inhibitor testing to denature residual FVIII:C 292. This provides a more standardised 
approach to sample preparation and does not require knowledge of FVIII:C in each 
test sample prior to testing. The modification is based on experimental data from the 
early 1970s, prior to standardisation of inhibitor testing 292. Despite increased usage 
of this modification in recent studies 283;290;293-297, varying incubation conditions have 
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been described and these have not been systematically evaluated using current 
laboratory methodology. A detailed discussion of this modification is provided in 
Chapter 7.  
1.6.9 Inter-Laboratory Assay Variability and External Quality Assurance (EQA) 
Similar to other areas of laboratory practice there are a number of national and international 
external quality assurance (EQA) schemes which include modules for the testing of FVIII 
antibodies. These EQA schemes include the UK National Quality External Assessment Scheme 
(UKNEQAS), European Concerted Action on Thrombosis Foundation (ECAT), World 
Federation of Hemophilia (WFH) and North American Specialized Coagulation Laboratory 
Association (NASCOLA).  All of these projects are aimed at standardisation of laboratory 
practices in haemostasis. Functional assays used in the detection of FVIII antibodies have 
shown significant inter-laboratory variability as reported by two EQA exercises 298;299. The first 
of these was carried out over a 13 year period (60-120 centres) by the UKNEQAS scheme, 
which reported a co-efficient of variation of 33-106% in samples from congenital haemophilia 
with an inhibitor 298. The second study carried out over a 3 year period (100-170 laboratories) 
by the ECAT scheme reported variation of 28-52%, with slightly lower variation for the NBA 
(39%) compared to the CBA (45%) 299. In both surveys the variation described would have 
influenced patient management in some centres 298;299. Differences in the assay components, 
for example the source of plasma, were seen to influence the measured inhibitor titre 
between centres 298.  
1.6.10 Immunological Assays for the Detection of Factor VIII Antibodies 
Given the limitations of functional inhibitor assays there is a requirement for more sensitive 
assays to detect FVIII antibody presence. Immunological based assays for antibody detection 
are commonplace within clinical haematology, transfusion and immunology laboratories. 
These approaches could enable description of the totality of the humoral response to FVIII 
and are likely to be less affected by the pre-analytical limitations of functional inhibitor 
assays. A number of techniques have been described in clinical and research settings, 
including enzyme linked immunosorbent assays (ELISA), fluorescence-based immunoassays 
(FLI), and immunoprecipitation (IP) 259-261;266;300-303. The most commonly used immunological 
based technique is the ELISA, developed from radio-immunoassays in the early 1970s 304;305. 
Despite a number of reports of commercial and research laboratory ELISAs for FVIII antibody 
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detection, it is unclear what role this test has in current clinical and laboratory practice 300-
303. 
1.6.11 Laboratory Based ELISA  
Two large studies have compared the use of a research laboratory based FVIII ELISA with the 
Bethesda assay 302;306. The first of these studies used a H1 haplotype rFVIII (Helixate®, CSL 
Behring, Haywards Heath, UK) as the ELISA plate antigen 301. Samples from 312 patients with 
haemophilia A (inhibitor positive=24 and negative=288) were tested in parallel using this 
ELISA and CBA in parallel, demonstrating a sensitivity of 100% and specificity of 97.8% 306. 
The second study also used a H1 haplotype rFVIII (Kogenate®, Bayer Healthcare, Pittsburg, 
USA) as the ELISA plate antigen, with various secondary antibodies to assess Ig subclasses 
and IgG isotypes 302. Samples for 60 patients with severe haemophilia A (inhibitor positive, 
n=30 and inhibitor negative n=30) and healthy controls (n=30) were tested, demonstrating 
significant correlation between the optical density for Ig, IgG and IgG4 and the Bethesda 
assay 302.      
1.6.12 Anti-Factor VIII ELISA Kit (GTI Diagnostics / Immucor) 
A commercially available solid phase indirect ELISA kit has been available for qualitative and 
quantitative detection of FVIII antibodies since the late 1990s. This ELISA utilises a 
recombinant full-length FVIII as its plate antigen, with earlier versions using Recombinate® 
(Baxter Healthcare, Deerfield, USA) and current kits using Kogenate® (Bayer Healthcare, 
Pittsburg, USA) 307 corresponding to H2 and H1 haplotypes of wild type FVIII respectively. Two 
medium sized studies have evaluated usage of the earlier version of this assay 300;303. The first 
of these studies looked at 131 samples (93 patients; 92 congenital HA and 1 acquired 
haemophilia A) over a period of 18 months (inhibitor sample prevalence, 32.8%), testing 
samples in parallel using the ELISA and the New Oxford Assay 300. On the basis of the New 
  ford  ssay being a “gold standard” this study ga e an unadjusted sensiti ity of  7.7%, 
specificity of 78.4%, negative predictive value of 98.6% and positive predictive value of 
68.9%. There were 19 false positives for the ELISA, which were felt to represent non-
neutralising antibodies. Only moderate correlation was seen between the ELISA and 
functional assay (r=0.68). The largest study published to date looking at the use of this FVIII 
ELISA reviewed the results of 246 samples (176 patients) tested over an 18 month period 303. 
This study looked only at samples that had tested positive by the Bethesda (CBA or NBA) 
assay (i.e. 100% prevalence). Of these samples, 235/246 were also positive by the ELISA, 
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corresponding to an unadjusted sensitivity of 95.5%, although with a lack of negative samples 
no further assessment of assay performance is possible. Strong correlation (r=0.82) was seen 
between the ELISA optical density and log-Bethesda titre 303. Data from these studies showing 
high assay sensitivity could be interpreted as suggesting a role for this assay as a confirmatory 
test for FVIII antibody presence, although this has not been evaluated as part of routine 
practice in a large unselected cohort.  
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Chapter 2: Hypotheses and Aims 
There is incomplete understanding of the total immune response to FVIII in both congenital 
and acquired haemophilia A, due to limitations in the current methodology used for FVIII 
antibody testing. Although standardisation of these approaches to testing since the 1970s 
has allowed comparison of results between clinical studies in severe haemophilia A, this has 
skewed assessment of risk of an immune response to FVIII towards antibodies with direct 
function/inhibitor capacity. The prediction of risk of antibody formation to FVIII and the 
response to treatment is based on a triad of genetic, environmental and diagnostic factors. 
An incomplete understanding at all three of these levels impairs the ability to accurately 
predict antibody occurrence or outcomes. Greater understanding of factors underlying FVIII 
formation will allow development of biomarkers of risk offering more personalised 
(stratified) approaches to the management of FVIII antibodies. 
In the first part of this thesis, I will evaluate clinical and laboratory factors in settings where 
FVIII antibody formation is a rare event (i.e. non-severe haemophilia and acquired 
haemophilia). In both settings current clinical and laboratory practices surrounding testing 
for FVIII antibodies and their management is poorly defined. I hypothesise that heterogeneity 
relating to both clinical and laboratory approaches directly impacts on the outcomes 
reported within recent observational studies. In non-severe haemophilia A, I hypothesise 
that a lack of testing for FVIII antibodies by clinicians leads to underestimation of the 
occurrence of an allo-immune response and subsequently biases towards detection of cross-
reacting antibodies to endogenous FVIII. In acquired haemophilia A, I hypothesise that 
heterogeneity in the management of immunosuppression and testing methodology affects 
prediction of response or relapse in patients.  
In the second part of this thesis, I will evaluate laboratory methodologies for the detection 
of FVIII antibodies. This follows on from evaluation of clinical factors, as both non-severe 
haemophilia and acquired haemophilia are settings where there are limitations to using a 
functional inhibitor assays due to the kinetics of FVIII antibodies and the presence of residual 
FVIII prior to testing. There have been no previous diagnostic accuracy studies in haemophilia 
evaluating a new assay in comparison to the gold standard methodology (Nijmegen-Bethesda 
Assay, NBA) following the international recommendations of the Standards for the Reporting 
of Diagnostic Accuracy Studies (STARD) initiative. I hypothesise, that immunological testing 
(ELISA) for FVIII antibodies will provide a screening test capable of detecting both inhibitory 
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and non-neutralising antibodies improving detection of FVIII antibodies where FVIII:C is 
present. Following on from this, I will evaluate a modification to inhibitor testing (pre-
analytical heat treatment), to assess whether this may improve the sensitivity of testing for 
FVIII antibodies, where there is significant FVIII:C present in samples (i.e. acquired 
haemophilia A). There is no data describing the optimal incubation conditions for this 
modification. I hypothesise that different incubation conditions will have a differential effects 
on inactivation of FVIII:C and FVIII antibodies. I will systematically evaluate different 
incubation conditions in a controlled setting with an aim of providing guidance for the 
optimal conditions for routine usage of this modification in clinical laboratory practice.  
Within the third section of this thesis, I will explore the usage of novel high-throughput 
techniques with the aim of developing biomarkers for risk prediction in severe haemophilia 
A. In the first part, developing my prior work in improving detection of FVIII antibodies using 
immunological methodology, I will evaluate a peptide microarray for B-cell epitope mapping 
(amino acid sequence level) of FVIII antibodies. I hypothesise that FVIII antibodies in patients 
with severe haemophilia A fall within immunodominant epitopes on the surface of FVIII. 
Given that a functional assay (NBA) is currently used for detection of inhibitors in clinical 
practice, I hypothesise these antibodies will display epitopes in antigenic regions that have 
direct functional roles in haemostasis. Evaluation of this platform will allow high-throughput 
characterisation of inhibitors in severe haemophilia A to provide biomarkers to predict 
response to treatment such as immune tolerance induction. In the second part of this 
section, I will evaluate the practicalities of sample collection for Next Generation Sequencing 
(NGS) of the transcriptome (RNA-Seq) across first exposure to FVIII concentrate in boys with 
severe haemophilia A. I hypothesise that use of a modified RNA low-volume sample tube 
(prepared within our laboratory) will provide RNA of sufficient quantity and quality to allow 
downstream transcriptome analysis in healthy volunteers and previously untreated patients 
with severe haemophilia A, which will be acceptable to clinicians with an international study. 
Application of NGS techniques, such as RNA-Seq will open up new strategies to contribute to 
further dissecting the immune response to FVIII at a molecular level.
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Chapter 3: Materials and Methods 
Within this section, detail will be provided of the materials and methods that are used in 
multiple parts of this thesis or within one of the core facilities. Within each chapter, specific 
methodology which is salient to the interpretation of the data provided will be described.  
3.1 Factor VIII Antibody Testing 
Materials 
The following sourced reagents were used for testing of FVIII:C, FVIII antibody testing and 
optimisation of the pre-analytical heat treatment conditions: Lyophilised FVIII deficient 
plasma, Dade Standard human plasma, Dade Citrol 1, Owren Veronal Buffer, Control N and 
Control P (Siemens, Germany). Lyophilised Technoclone Factor VIII Inhibitor Plasma (Pathway 
Diagnostics, Dorking, UK). FVIII deficient plasma with inhibitor (George King Bio-Medical, Inc, 
Kansas, USA). Distilled Water (Baxter Healthcare, Deerfield, USA). VWR® Traceable® Water-
Resistant Thermometer (VWR International Ltd, Lutterworth, UK). Solid phase indirect FVIII 
ELISA kit (Lifecodes/Immucor, Norcross, USA). Advate® 500IU (Baxter Healthcare, Deerfield, 
USA) and Wilate® 500IU (Octapharma AG, Lachen, Switzerland) which were kind gifts from 
The Royal London Hospital Haemophilia Centre (London, UK). 
Sample Collection and Preparation 
Blood samples were collected following local venepuncture policy. Following skin cleaning, 
samples were collected directly using a closed vacutainer system into sample tubes 
containing buffered 0.105M sodium citrate, (1 part anticoagulant to 9 parts blood) and mixed 
by gentle inversion. Platelet poor plasma (platelet count <10,000 per µL) was prepared by 
centrifugation at 2000g for 5 minutes. For samples in which batch testing was to be 
performed at a later date a double spin was performed (2000g for 10 minutes) to give platelet 
poor plasma with a platelet count <5,000 per µL and the plasma was transferred to a plastic 
tube and frozen directly at <-70°C. Prior to testing all frozen samples were thawed rapidly at 
37°C for 5 minutes and testing was performed within 2 hours.   
Automated Factor VIII Activity Measurement (One-Stage) 
Lyophilised FVIII deficient plasma (F8DP), Dade Standard human plasma (SHP), Control N and 
Control P, were reconstituted each using 1mL of distilled water and these were allowed to 
equilibrate at room temperature for 15 minutes. Automated calibration was performed prior 
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to batch testing of samples using the Holder Calibration Curve Order. The target value 
(FVIII:C) for the SHP was entered in the assay sheet value box and the calibration curve was 
generated automatically and validated. Internal quality control was performed using Control 
N (normal control) and Control P (abnormal control) plasmas, which following reconstitution 
were transferred into labelled 2mL cups and loaded onto the analyser. Once the internal 
quality control was acceptable, assays were batch tested using an automated work list. 
Within clinical samples, found to have FVIII:C <10IU/dL or >200IU/dL samples were repeated 
using the MDA Low and MDA High settings, respectively. The results of the one stage FVIII:C 
was reported to one decimal point (1DP) between 1-800IU/dL FVIII:C. For FVIII:C outside of 
this range results were reported as either <1IU/dL or >800IU/dL respectively. Within testing 
of routine samples an in-house determined level of imprecision of 6% (normal control: 
Siemens Control N) and 7% (abnormal control: Siemens Control P) samples has previously 
been calculated. 
An automated one stage FVIII:C assay, was performed for clinical samples tested at The Royal 
London Hospital, using a Sysmex CS2100i analyser. Within routine laboratory testing, 
multiple dilutions of platelet poor plasma were performed by the aPTT methodology with 
comparison of the clotting times to a standard curve generated by five dilutions of Standard 
Plasma (SHP) with known FVIII:C in wren’s Buffer added to an equal volume of FVIII deficient 
plasma. Patient samples were performed using three different dilutions (multi dilution 
analysis, MDA) with an average FVIII:C, obtained from these to give a final result. A line is 
plotted with the clotting times for the MDA and compared to the standard curve, to check 
for parallelism.  
Internal and External Quality Control 
Internal quality control (IQA) was performed prior to inhibitor testing.  The negative control 
consisted of Factor VIII deficient plasma was reconstituted in 1mL of distilled water. This was 
mixed gentle and left to equilibrate at room temperature for 15 minutes and then used 
within 8 hours of reconstitution.  A positive control of lyophilised Technoclone Factor VIII 
Inhibitor Plasma was reconstituted in 1 mL of distilled water and left to equilibrate at room 
temperature for 15 minutes prior to use. The laboratory within The Royal London Hospital 
(Barts Health NHS Trust) participates in national and international external quality 
assessment (EQA) schemes. These include the UK NEQAS for Blood Coagulation, European 
Committee for Action on Thrombosis [ECAT] Foundation Quality Assurance Scheme and the 
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World Federation for Hemophilia International External Quality Assurance Scheme. Within 
the ECAT scheme, sample testing is performed twice per year for FVIII inhibitor assays. Within 
the UK NEQAS scheme, FVIII assay evaluation is performed 4 times per year with ad-hoc 
distribution of FVIII inhibitor samples for quantification.  
Nijmegen-Bethesda Assay 
Inhibitor testing following the principles of the NBA was performed as previously described 
308. Briefly, FVIII deficient (control) and patient plasma were incubated at 37°C for 2 hour in 
equal volumes (160µL) of buffered control plasma (lyophilised Control N or Dade Ci-Trol 1, 
Siemens, Germany). In the routine testing of clinical samples with low suspicion for inhibitor 
presence, this assay is performed as an inhibitor screen using neat plasma. For inhibitor 
quantification, serial dilutions (1 in 2, 4, 8, 16 and 32) were performed, with samples diluted 
in FVIII deficient plasma. Residual FVIII:C was measured by a one stage FVIII:C assay, using a 
Sysmex CS2100iv (Sysmex, Milton Keynes, UK) analyser. The percentage residual FVIII:C was 
calculated based on the difference between the FVIII:C within each sample relative to the 
negative control. Quantification of inhibitory activity was based on the principle that 1BU/mL 
represents an inhibitory activity that results in a 50% reduction in FVIII:C. The inhibitor titre 
was then calculated using linear regression equation; INH = [(2 - log10R)/0.30103] x D; where 
INH=Inhibitor titre (BU/mL); R=Percentage Residual FVIII and D=Dilution Factor. Samples with 
inhibitor titres ≥ .  BU/mL were defined as positi e. In-house testing for variability in 
inhibitor testing has previously demonstrated a group imprecision (co-efficient of variability) 
of 38.8% and 28.0%, for testing of a high (8.5BU/mL) and low (0.9BU/mL) titre FVIII inhibitor 
(Platton S., Principal Biomedical Scientist, The Royal London Hospital, London, UK, personal 
communication).   
Factor VIII ELISA Kit 
A commercially available, solid phase indirect FVIII ELISA (Immucor, Norcross, Georgia, USA) 
was used as per the manufacturer’s instruction. This kit contains    microwells pre-coated 
with H1 haplotype rFL-FVIII (Kogenate®, Bayer Corp., Pittsburg, PA, USA) 179;307. Samples and 
controls were initially diluted 1:4 with diluent buffer and added to the microwells. The wells 
were sealed with a plate sealer and incubated at 37°C for 30 minutes in a water-bath. 
Following incubation, the contents of each well were decanted and blotted on absorbent 
towelling. Wells were washed   times with    μL of working wash solution, with this being 
decanted and discarded in-between washes and inverted onto absorbent towelling (washing 
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step).  e t,   μL conjugate (alkaline phosphatase conjugated goat antibody to human IgG, 
0.1% sodium azide diluted 1:100 in specimen diluent) was added to all wells, these were 
sealed with a plate sealer and incubated at 37°C for 30 minutes in a water-bath. The 
microwells washed three times as per the previous washing step.  e t,   μL substrate (P-
nitrophenyl phosphate, reconstituted in de-ionized water and diluted 1:100) was added to 
all wells and the ELISA plate was incubated in the dark at room temperature (22-25°C) for 30 
minutes. The reaction was stopped using   μL Stopping Solution ( M Sodium Hydro ide) to 
each of the sample’s wells and the absorbance was read at    nm using a GE   plate reader 
(BioTek, Winooski, USA). All samples were tested in duplicate and defined as being positive 
if they displayed an OD greater than that of the kit control (KC). The ELISA kit has three 
controls: negative, positive and kit controls, which are run in parallel with the tested samples. 
Within each ELISA the first two wells are left blank allowing.  The negative control is derived 
from a normal (non-haemophilia) human donor, with no demonstrable anti-FVIII antibody 
presence. The positive and kit controls are derived from human serum containing antibodies 
to human FVIII. The KC is lot specific and is tested by the manufacturer to ensure that its use 
results in the expected reportable results (positive/negative) in over 90 test samples. Testing 
of this KC previously within our laboratory has given an inhibitor titre of 0.4BU/mL (Platton 
S., Principal Biomedical Scientist, The Royal London Hospital, London, UK, personal 
communication).   
3.2 Collection and Extraction of Total and miRNA 
Materials 
The following sourced reagents were used for production of the low volume modified 
PAXgene (PG) tubes and for RNA extraction: PAXgene Blood RNA tubes (2.5mL blood, 6.9mL 
PG reagent) (Beckton Dickinson, BD, Franklin Lakes, USA). Ultimate Security 4.5mL cryovials 
and cryoboxes (Alpha Laboratories, Eastleigh, UK); RNaseZap® wipes and UltraPure 
DNAse/RNAse free distilled water (Invitrogen, Carlsbad, USA); Pipetman Classic P1000 
pipette and Diamond® Tips STERILP CK™ (Gilson Scientific, Luton, UK); PAXgene Blood mRNA 
kit and PAXgene Blood miRNA kit (PreAnalytiX, Hombrechtikon, Switzerland); RNeasy mini kit 
(Qiagen, Hilden, Germany) 
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Modified Sample Tube Production Protocol 
Modified PG blood tubes were prepared in RNAse free conditions within a positive pressure 
tissue culture hood. Prior to sample tube production the hood and pipette were cleaned with 
RNaseZAP® followed by RNase/DNase free distilled water. The production of modified PG 
cryovials was performed by two operators using sterile gloves to further reduce risk of RNase 
contamination in sample tubes. The ratio of PG media to blood for the modified tubes was 
maintained as per that in the commercially available tubes (ratio 1mL blood to 2.76mL 
PAXgene reagent). Pipette tips were changed regularly and cryovials were re-sealed inside 
the tissue culture hood. The integrity of the seal for each cryovial was re-tested and sample 
tubes were labelled with the expiry date of source PAXgene media. Any cryovial in which the 
seal was inadequate was disposed of. Sample tubes were stored at ambient temperature in 
a sealed cryobox prior to blood sampling. 
Extraction of Total RNA and miRNA  
Manual purification of RNA was performed within the Genome Centre Core Facility at Queen 
Mary, Uni ersity of London following the manufacturer’s protocols for whole blood 
RNA/miRNA extraction. This included three extraction protocols for extraction of either, total 
RNA (Protocol A) or total RNA and miRNA using either a single (Protocol B) or two tubes 
(Protocol C) methodology. All extractions were performed in RNase free conditions within a 
dedicated laboratory for RNA handling, with surfaces cleaned with RNaseZAP® prior to 
commencement of the extraction. Prior to extraction for all 3 protocols, frozen samples were 
allowed to thaw at room temperature (15-25°C) and incubated for a further 2 hours prior to 
extraction. Following completion of all protocols, samples were frozen at -80°C.   
Total RNA Extraction Protocol (Protocol A) 
PAXgene blood tubes were first centrifuged at 4,000g for 10 minutes in a swing out rotor. 
The supernatant was removed by decanting and the pellet was re-suspended in 4mL RNase-
free water by vortexing and centrifuged at 4,000g for 10 minutes. The supernatant was 
discarded and 350µL of Buffer BR1 was added to the pellet, which was re-suspended by 
vortexing. This was transferred by pipetting into a 1.5mL micro-centrifuge tube and 300 µL 
Buffer BR2 and 40 µL Proteinase K were added, with this being mixed by vortexing. Samples 
were incubated for 10 minutes at 55°C for in a shaker-incubator. The lysate was pipetted into 
a PAXgene shredder spin column in a 2ml processing tubes and centrifuged at maximum 
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speed for 3 minutes. The supernatant from the flow-through fraction was transferred into a 
fresh 1.5ml micro-centrifuge tube and 350 µL of 100% ethanol was added, which was mixed 
by vortexing for 1-2 seconds at 1,000g. 700 µL of each sample was transferred into a new 
spin column within a 2mL processing tube and centrifuged at 14,000g for 1 minute. Following 
centrifuging, the processing tube containing the flow-through was discarded and the spin 
column was transferred to a new 2mL processing tube. The remaining sample was applied to 
this and centrifuged at 14,000g for 1 minute and the flow-through discarded. 350µL Buffer 
BR3 was added to the PAXgene spin column within a new 2mL processing tube and 
centrifuged for 1 minute at 14,000g. The PAXgene spin column was then transferred to 
another new 2mL processing tube and the flow-through discarded. A DNase treatment step 
was performed by adding 10µL of DNAse1 diluted in 70µL DNA digestion buffer to the spin 
column of each sample and left to incubate at room temperature for 15 minutes. 350µL 
Buffer BR3 was then added to the spin column and this was centrifuged for 1 minute at 
14,000g and the flow-through discarded. 500µL of Buffer BR4 (diluted 1 in 4 in 100% ethanol) 
was added to the spin column and centrifuged at 14,000g for 1 minute. This spin column was 
transferred to a new 2mL processing tube and the flow-through discarded and a further 
500µL of Buffer BR4 (diluted 1 in 4 in 100% ethanol) was added and the spin column was 
centrifuged at 14,000g for 3 minutes. The flow-through was discarded and the spin column 
was transferred to a new 2mL processing tube and centrifuged for 1 minute at 14,000g. The 
follow-through was discarded and the PAXgene spin column transferred to a new 1.5mL 
micro-centrifuge tube. Finally an elution step was performed applying 40µL of Buffer BR5 to 
spin column membrane and this was centrifuged at 14,000g for 1 minute. The eluate was 
incubated for 5 minutes at 65°C and the samples were transferred onto ice prior to analysis.  
miRNA Extraction Protocol : Protocol B (Single Tube) 
PAXgene blood tubes were first centrifuged at 4,000g for 10 minutes in a swing-out rotor. 
The supernatant was removed by decanting and the pellet was re-suspended in 4mL RNase-
free water and the tube was closed using a fresh secondary Hemogard closure. The tube was 
vortexed until the pellet had dissolved and this was centrifuged for a further 10 minutes at 
4,000g using a swing-out rotor. The supernatant was discarded by decanting and the pellet 
was re-suspended in 350µL Buffer BM1 and vortexed until this had visibly dissolved. This was 
pipetted into a 1.5mL micro-centrifuge tube and 300µL Buffer BM2 and 40µL proteinase K 
were added. This was vortexed for 5 seconds and then incubated at 55°C for 10 minutes in a 
shaker incubator. The sample was then pipetted into a PAXgene shredder spin column placed 
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in a 2mL processing tube and centrifuged for 3 minutes at maximum speed. The entire 
supernatant was transferred into a new 1.5mL micro-centrifuge without disturbing the pellet 
in the processing tube. 700µL of isopropanol (100% purity grade p.a) was added and mixed 
by vortexing. 700 µL of the sample was pipetted into a PAXgene RNA spin column placed in 
a 2mL processing tube. The lid was closed gently and this was centrifuged at 14,000g and the 
flow through was discarded. The spin column was then placed in a new 2mL processing tube 
and the remaining sample was pipetted into this PAXgene spin column. The lid was closed 
and this was centrifuged for 1 minute at 14,000g and the flow-through discarded. The spin 
column was placed in a new 2mL processing tube and 350µL of Buffer BM3 was added. The 
lid was gently closed and this was centrifuged for 15 seconds at 14,000g and the flow-through 
discarded. The spin column was then placed in a new 2mL processing tube and 80µL of DNase 
I incubation mix (10µL DNase I stock solution diluted in 70µL Buffer RD) was added and this 
was mixed by gentle flicking and incubated at room temperature (20-30°C) for 15 minutes. 
350µL of Buffer BM3 was the added to the PAXgene RNA spin column. The lid was closed 
gently and this was centrifuged for 15 seconds at 14,000g and the flow-through was 
discarded. The spin column was then placed in a new 2mL processing tube and 500µL Buffer 
BM4 was added to the spin column. The lid was closed and this was centrifuged for 15 
seconds at 14,000g and the flow through discarded. The spin column was then placed in a 
new 2mL processing tube and a further 500µL Buffer BM4 was added to the PAXgene RNA 
spin column, the lid was closed and this was centrifuged for 2 minutes at 14,000g. The spin 
column was then placed in a new 2mL processing tube and the old processing tube and flow 
through were discarded. This was then centrifuged at 14,000g for 1 minute. The processing 
tube containing flow-through was discarded and the PAXgene RNA spin column was placed 
in a new 1.5mL micro-centrifuge tube. Finally, 40µL Buffer BR5 was pipetted directly onto the 
spin column membrane. The lid was closed gently and this was centrifuged for 1 minute at 
14,000g. The eluate was incubated for 5 minutes at 65°C and the samples were transferred 
onto ice prior to analysis. 
miRNA Extraction Protocol : Protocol C (Two Tubes) 
PAXgene blood tubes were first centrifuged at 4,000g for 10 minutes. The supernatant was 
removed by decanting and the pellet was re-suspended in 4 ml of RNase-free water and the 
tube was closed using a fresh secondary Hemogard closure. The tube was vortexed until the 
pellet had dissolved and then centrifuged for 10 minutes at 4000g. The supernatant was 
removed and discarded by pipetting. The pellet was then re-suspended in    μL 
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resuspension buffer (BR1) and vortexed until the pellet had visibly dissolved. This sample was 
then pipetted into a 1.5mL micro-centrifuge tube and    μL binding buffer (BR ) and   μL 
proteinase K (PK) were added. This was mixed by vortexing for 5 seconds and incubated for 
10 minutes at 55°C using a shaker-incubator. The lysate (ma imum 7  μL) was pipetted 
directly into a PAXgene shredder spin column in a 2 mL processing tube, and centrifuged for 
3 minutes at maximum speed (but not to exceed 20,000g). The entire supernatant of the 
flow-through fraction was transferred to a fresh 1.5mL micro-centrifuge tube without 
disturbing the pellet in the processing tube.    μL ethanol (   %, purity grade p.a.) was 
added and this was mixed by vortexing. 7  μL sample of the sample was pipetted into the 
spin column in a 2mL processing tube and centrifuged for 1 minute at 14,000g. The spin 
column was placed in a new 2 mL processing tube and the flow though was kept for the later 
stages for miRNA purification. The remaining sample was pipetted into the PAXgene RNA spin 
column and centrifuged for 1 minute at 14,000g. The spin column was placed into a new 2 
ml processing tube (PT). The flow through from each of these steps was kept and added to 
the flow through from the previous step. 350μL BR  buffer was pipetted into the P Xgene 
RNA spin column and these samples were left to one side whilst the flow-through for 
microRNA purification is prepared. miRNA was then prepared using the RNeasy mini kit 
following the manufacturer’s instructions. 7  μL ethanol ( 8%) was added per    μL flow-
through from the PAXgene Blood RNA binding step and mixed carefully by pipetting This was 
applied in 7  μL portions to R easy mini spin column placed in a  mL collection tube and 
centrifuged for 1 minute at 14,000g with the flow-through being discarded following each 
step.    μL Buffer RW  was then added to the R easy spin column and the lid closed. For 
the remainder of the protocol sample preparation for total RNA and miRNA were performed 
in parallel using the PAXgene RNA spin columns and RNeasy spin columns, respectively. The 
spin columns were centrifuged for 1 minute at 14,000g and the flow-through discarded. 8 μL 
of D ase incubation mi ture (  μL D ase I stock solution diluted in 7 μL D   digestion 
buffer) was added to the spin columns and these were incubated at room temperature (20-
30°C) for 15 minutes.   μL wash buffer BR  was pipetted into the P Xgene R   spin column 
and centrifuge for 1 minute at 14,000g, with the flow-through being discarded. The spin 
columns were placed into new  mL processing tube.    μL Buffer RW  was added to the 
R easy spin column and    μL wash BR  buffer into the P Xgene spin column and these 
were centrifuged for 1 minute at 14,000g. The flow-through was discarded and the spin 
columns were placed into new 2mL processing tubes. 500μL Buffer RPE was added to the 
R easy spin column and a further    μL wash buffer BR  to the P Xgene R   spin column 
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and these were centrifuged at 14,000g for 3 minutes. The flow through was discarded and 
the spin columns were transferred to new 2mL processing tubes. 500μL Buffer RPE was 
added to the RNeasy spin column this was centrifuged at 14,000g for 1 minute. The flow-
thorough was discarded and the spin columns were transferred to new 2mL processing tubes 
and centrifuged at 14,000g for 1 minute and the flow through discarded. The PAXgene spin 
column was transferred into a 1.5mL micro-centrifuge tube and   μL elution buffer BR  was 
added directly onto spin column membrane. The RNeasy spin column was transferred into a 
new 1.5mL collection tube and 40μL R ase-free water was added to the spin column 
membrane. These were both centrifuged for 1 minute at 14,000g to elute the RNA. The 
eluate was incubated for 5 minutes at 65°C and the samples were transferred onto ice prior 
to analysis. 
3.3 Nomenclature and Statistical Analyses 
 ll numbering of amino acid positions within this work are stated in “legacy” format for the 
mature FVIII protein (total length 2332aa), lacking in the 19 amino acid signal peptide to allow 
comparability with previously published similar work. 
Specific statistical methodology, is presented prior to the analysis of results within each 
chapter. Evaluation of data distribution was performed, through histograms, Q-Q plots or the 
Kolmogov-Smirnov test. All statistical tests performed were two sided, with a p value of <0.05 
taken as being significant. Statistical analyses were performed and figures presented were 
created using either IBM SPSS version 21 (IBM Corp., Armonk, New York, USA), Stata 
(StataCorp. 2011. Stata Statistical Software: Release 12.1 College Station, TX: StataCorp LP) 
or GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla California USA).  
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Chapter 4: Compliance with Inhibitor Testing in Non-Severe Haemophilia A: 
An Evaluation of Practice in London 
4.1 Introduction 
The cumulative incidence of inhibitory antibodies in patients with non-severe haemophilia A 
within the recently published INSIGHT study was been reported at 5.3% (54/1112) 166, which 
is lower than that seen in severe haemophilia A (32%) 149. Inhibitors in non-severe 
haemophilia A patients however, constitute 20% (109/534) of all previously reported 
inhibitors in the UK within the most recent UKHCDO report (2013-14) 61. These antibodies 
are of concern clinically due to reported cross-reactivity against endogenous FVIII 64;166, 
change in bleeding phenotype 64 and increased mortality 168. In one small study a change in 
bleeding phenotype and fall in baseline FVIII:C (bFVIII:C) was seen in 22/26 and 24/26 of 
patients, respectively 64. More recently in the INSIGHT study a fall in bFVIII:C and a change in 
bleeding phenotype was reported in 34/54 (58%) and 30/54 (51%) of patients 166. In both of 
these reports, inhibitor screening was only performed in the context of clinical suspicion of a 
FVIII inhibitor (change in bleeding phenotype, bFVIII:C or impaired treatment efficacy or FVIII 
recovery) 64;166. Only 11 (19%) asymptomatic patients were diagnosed with an inhibitor on 
routine screening within the INSIGHT study 166. There is also a lack of clarity regarding the 
optimal management of inhibitors in this population 64;169;214, with selection of 
immunosuppression (or observation) being influenced by clinical and laboratory features 233, 
which complicates interpretation of observation study data 169.   
Patients with non-severe haemophilia A receive treatment with FVIII concentrates in a 
different clinical and potentially immunological contexts to those with severe haemophilia A. 
In severe haemophilia A, treatment begins early in life, initially with on-demand treatment 
for bleeding (spontaneous or following minimal trauma) and a transition to prophylaxis. 
Understanding of the timing of inhibitor formation (median 14ED) 100;149, from trial data has 
allowed the development of national guidance for inhibitor monitoring in patients with 
severe haemophilia A 214. These guidelines have focussed on the necessity for close 
monitoring for inhibitors in patients with severe haemophilia A, in the first 50 ED, which has 
resulted in an increase in inhibitor screening in the last two decades 215. Treatment in non-
severe haemophilia A is given less frequently and often in the context of trauma or surgery. 
Although the age at commencement of treatment is variable, this occurs later than in 
patients with severe haemophilia A and many patients will not (or never) receive significant 
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FVIII exposure until later in life. Data from the INSIGHT study has suggested that there is a 
lifelong risk of inhibitor formation in this group of patients 166.  
The optimal approach to when (and how) to test for FVIII antibodies in non-severe 
haemophilia A is not clear and there is a paucity of data to guide these practices. Guidance 
in the UK (published prior to the INSIGHT study) recommends inhibitor screening in situations 
perceived as being of high immunological risk 214. Within these guidelines, the evidence basis 
(grade 1C) for recommendations was made from pooled data from small retrospective 
observational studies or extrapolated from data in severe haemophilia A. Further research is 
required to define optimal inhibitor screening practices in non-severe haemophilia A. There 
is no data describing current inhibitor testing practices in patients with non-severe 
haemophilia A. Despite the publication of consensus guidance for inhibitor testing from 
organisations, such as the UKHCDO, it is unknown whether these impact on clinical practice. 
Within this chapter, a retrospective audit and evaluation of screening practices (inhibitor and 
genetic) from a large cohort of patients with non-severe haemophilia A treated at all 
haemophilia centres in the London region was performed.  
4.2 Hypothesis and Aims  
The hypothesis for this chapter is that the true allo-immune response to FVIII infusions in 
non-severe haemophilia A is underestimated due to inconsistent inhibitor testing following 
FVIII treatment. Despite published national guidance for inhibitor screening, it is 
hypothesised that there is poor compliance with testing for inhibitors in patients treated with 
FVIII. This in turn may result in a bias in the detection of cross-reactive FVIII antibodies. The 
aim of this evaluation was to gain a greater understanding of current practices of inhibitor 
screening, treatment and testing of F8 genotype in patients with non-severe haemophilia A. 
The specific aims of this work were as follows: 
1) To assess treatment patterns of patients with non-severe haemophilia A managed at 
the London haemophilia treatment and comprehensive care centres 
2) To describe occurrence of bleeding and evaluate association between baseline 
FVIII:C and bleeding phenotype 
3) To assess compliance with national (UKHCDO) guidance of genetic screening in 
patients with non-severe haemophilia A 
4) To assess compliance with national (UKHCDO) guidance for inhibitor testing 
following FVIII e posure in patients with “high” and “standard-risk” F8 mutations. 
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4.3 Materials and Methods 
Case and Centre Selection 
A retrospective review was performed of the management and follow-up of all patients with 
non-severe haemophilia A treated at seven active London haemophilia centres (4 
comprehensive care centres, CCCs and 3 haemophilia treatment centres, HTCs). These 
centres included, The Royal London (CCC), Royal Free (CCC), St Thomas’ (CCC), Great rmond 
Street (CCC), St George’s (HTC), Hammersmith (HTC) and Lewisham (HTC) Hospitals. f these 
CCCs, Great Ormond Street Hospital purely manages children and The Royal London Hospital 
and St Thomas’ Hospital manage adults and children. The Royal Free Hospital primarily 
manages adult patients, with a small number of registered adolescent patients (>12 years). 
All sequentially treated patients with non-severe haemophilia A receiving treatment over a 
two year period (1/1/11-31/12/12) were included.  
The primary objective was to audit compliance with inhibitor testing against published 
UKHCDO guidelines for the diagnosis of coagulation factor inhibitors 214. These guidelines 
recommend that patients with non-severe haemophilia A receive inhibitor screening in the 
following circumstances 214:  
 “Standard-risk” F8 mutation: Annual inhibitor testing in all patients who have 
received exposure to FVIII. Follow-up testing after intensi e e posure (≥ EDs) or 
surgery.  
 “High-risk” F8 mutation: Follow-up inhibitor testing is advised after all episodes of 
exposure to FVIII.  
No guidance however, is provided for the optimal time period in which testing should be 
performed following FVIII exposure (so called “con alescent inhibitor screening”) which is 
perceived as being “high-risk”, whether by F8 genotype or treatment exposure. For the 
purpose of this study, convalescent screening was defined as testing performed within six 
weeks (≤42 days) of the first treatment day.  
Secondary objectives were to assess compliance with F8 genotype testing, evaluate 
treatment patterns, bleeding patterns, timing of inhibitor screening and the incidence of new 
inhibitors. This study was developed as the first in a series of pan-London initiatives to audit 
and evaluate clinical and laboratory practices in the management of bleeding disorders. The 
study design and data to be collected were discussed with the Clinical Effectiveness Unit 
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(CEU) at The Royal London Hospital and Research Approvals Office (Joint Research 
Management Office). The study was registered locally at each centre as part of clinical audit 
and service evaluation by the lead treating physician. 
Diagnosis and Definitions of Non-Severe Haemophilia A 
All patients were diagnosed locally with baseline FVIII:C (bFVIII:C) levels based on those 
recorded within the centre’s patient registration records. Non-severe haemophilia A was 
defined as a FVIII:C of 1-50 IU/dL 64. Patients were then further sub-categorised by the 
investigator as having either, moderate (FVIII:C >  to ≤5 IU/dL) or mild (FVIII:C >  to ≤50 
IU/dL) haemophilia A 63;64;70.  
F8 Genotype Testing and Definitions of “High-Risk” F8 Genotypes 
Testing of personal F8 genotype was determined by any previous testing of a patient’s F8 
genotyping. In those, without previous personal F8 genotype testing, centres were asked if 
there was knowledge of the familial F8 mutation. In those in whom F8 genotyping had been 
performed, or was known these were categorised as having either “high” or “standard-risk” 
F8 mutations. Within recent national guidance, no clear summary of “high-risk” mutations is 
provided and this advises referring to published data 214. In this evaluation, F8 missense 
mutations published within the HIGS cohort were used to define “high-risk” F8 mutations 194. 
These were derived from mutations with an increased incidence of inhibitor formation within 
the HADB database 194;210. This included the following mutations, which are stated in legacy 
format, with the HGVS assignment given in parentheses: Arg593Cys (Arg612Cys), Tyr2105Cys 
(Ty2124Cys), Arg2150His (Arg2169His), Arg2163His (Arg2182His), Tyr2229Cys (Trp2248Cys), 
Asn2286Lys (Asn2305Lys) and Pro23000Leu (Pro2319Leu) 71;194;210.  
Data Collection 
The aim for data collection was to allow the majority of data to be directly retrieved from 
electronic patient records (EPR) of clinical and laboratory data. A standardised data-reporting 
tool was distributed to each of the haemophilia centres, following piloting of this tool at The 
Royal London Hospital. Examples (4 treatment episodes for 3 patients) of how to complete 
data entries were provided within this tool to help standardise data collected. Data collection 
took place by centres, between 4/4/13 and 18/6/13. All data provided to the lead investigator 
was anonymised, using sequential coding and returned using a secure email server (nhs.net). 
All data entries were checked manually for discrepancies or missing data, with these being 
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followed up by the lead investigator with the audit co-ordinator for each centre. Recoding 
and pooling of data was performed, with this being checked both manually and electronically 
with the source data on three occasions. 
Baseline demographic data, including age, bFVIII:C, inhibitor history, F8 genotype testing 
(“high-risk” or “standard-risk”) were collected for all patients. Information was collected on 
treatment modalities used by patients, including usage of DDAVP, FVIII concentrate or 
bypassing agents. In episodes treated with a FVIII concentrate centres were asked to provide 
information on the treatment indication and the timing and results (positive or negative) of 
all inhibitor tests performed following that episode. Treatment indications were categorised 
as home-treatment or on-demand (hospital based treatment). On-demand treatment was 
further sub-categorised as bleed/trauma, surgery, other or not-stated. Surgery was classified 
as any surgical or dental intervention/procedure requiring FVIII replacement therapy. No 
sub-classification of bleed data (location or spontaneous/traumatic) was performed. An 
exposure day (ED) was defined as a calendar date in which one or more FVIII infusions was 
used 99. In episodes treated with DDAVP or a bypassing agent, no additional information was 
retrieved. Analysis of inhibitor testing was performed for on-demand episodes as these 
episodes had clear documented evidence of FVIII being infused (i.e. bleeding or surgery). 
Home-treatment, was defined as an issue of FVIII concentrate that was supplied by the centre 
for the treatment or prevention of bleeding that was not administered within the centre. This 
could include treatment issues for prophylaxis, immune tolerance induction, on-demand 
home-treatment for bleeding or issue of concentrates prior to travel. Given the 
heterogeneity and lack of data on the indication and whether these issues had been 
administered no further evaluation was possible.    
Assessment of Timing of Inhibitor Testing 
All inhibitor testing was performed by local haemophilia centre laboratories. These 
laboratories are all accredited by the Clinical Pathological Accreditation (CPA) and triennial 
UKHCDO inspections. Centres were asked to provide the date and result of all inhibitor tests 
performed within the study period and following treatment episodes. Data from inhibitor 
testing was then manually paired by the investigator to the nearest chronological on-demand 
treatment episode, providing this occurred within one calendar year of the treatment 
episode.  
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For evaluation of annual inhibitor screening, treatment episodes were paired to the nearest 
inhibitor test, providing that it occurred within one year of the first treatment day. For 
patients who received multiple treatment episodes within a year period, a single inhibitor 
test could represent an annual inhibitor screen for multiple treatment episodes. For 
evaluation of paired inhibitor screening, tests were paired to the nearest treatment episode 
provided that this test occurred within one year of the first day of treatment and no 
treatment episode occurred in the intervening time. If no test was sent within that year or if 
another treatment episode occurred before an inhibitor screen within the same year, the 
treatment episode was judged as not having paired inhibitor screening. If more than one 
inhibitor test was sent, the treatment episode was paired to the first inhibitor screen sent 
with subsequent assays being excluded from the analysis. Consequently, for this analysis an 
inhibitor screen could only be paired with a single treatment episode. An assessment was 
also made to evaluate whether inhibitor testing occurred due to the patient receiving further 
treatment. Screening was assessed as having being sent due to treatment if the test was 
performed within (±) one day of the following treatment episode. Finally assessment of 
whether a paired inhibitor screen was performed as a true “con alescent screen”, was based 
on if this was performed within si  weeks (≤   days) of the first day of treatment.  
Statistical Analyses 
Analysis was performed of the pooled anonymised data of patients. Descriptive statistics, 
including mean, median, standard deviation, inter-quartile range (IQR) and frequency were 
performed. The annualised bleed rate (ABR) was calculated from the total number of 
bleeding episodes recorded in the 2 year data collection window, divided by two. 
Comparative statistics were performed using the Mann-Whitney U and Kruskall-Wallis H 
tests for continuous and the Chi-squared, Chi-squared goodness of fit or Fisher’s e act test 
for categorical variables. Adjustment for missing data, where stated was performed using 
multiple imputation (5 imputations). Assessment of association was performed using 
Spearman’s rank correlation. Graphical representation of annualised bleed rates was 
performed by local smooth polynomials as previously described 66.  
4.4 Results  
There were 853 patients with non-severe haemophilia A, registered at the 7 haemophilia 
centres within the London region. Of these patients, a treatment episode was recorded in 
377 (44%) over the two year study period. The mean age of patients treated was 35.7 years 
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(range 0.2-89.0 years). The mean bFVIII:C was 12.9IU/dL (range 1-44) with 102 (27.1%) 
patients having moderate and 275 (72.9%) mild haemophilia A. Seven patients had a bFVIII:C 
≥  IU/dL (mean bFVIII:C   .7IU/dL, range   . -44.0).  
4.4.1 Uptake of Testing of F8 Genotype 
There was a documented history of personal testing (and knowledge) of the F8 mutation in 
79% (297/377) of patients who received any form of treatment in the study period. 
Evaluating personal F8 testing by centre, all of the centres except one small HTC (19 patients 
treated) had performed personal F8 genotype testing in ≥7 % of patients. The haemophilia 
causative F8 mutation for the family was known in a further 34 patients (9%), who had not 
had their personal F8 genotype tested. As a result, there was knowledge of the causative F8 
mutation in 88% (331/377) patients treated in the study period. In patients in whom the F8 
mutation was known,  8% ( 8/   ) had a “high-risk” F8 mutation.  
4.4.2 Treatment Characteristics 
A large proportion (79%, 296/377) of patients were treated with a FVIII concentrate during 
the study period, with 259 patients only receiving treatment with FVIII (Figure 4.1). DDAVP 
was used as part of treatment for 110 patients (29%), with 76 (20%) only receiving DDAVP, 
33 (9%) FVIII & DDAVP and 1 (<1%) DDAVP and bypassing agents. DDAVP was used in the 
management of 10% (10/102) patients with moderate haemophilia A (DDAVP alone=4, FVIII 
& DDAVP=6) in comparison to 36% (100/275) patients with mild haemophilia A (DDAVP 
alone=72, FVIII & DDAVP=27 and DDAVP and bypassing agents=1). Three patients in whom 
DDAVP was used had an inhibitor history. 
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Figure 4.1: Treatment modalities used in the management of non-severe haemophilia A, 
representing the percentage of patients (total: 377) treated within the observation period.   
An evaluation of the demographics by treatment choices was performed for categories in 
which there were more than five individuals (FVIII alone, DDAVP alone and FVIII & DDAVP). 
Patients treated with FVIII alone were significantly older (35.8 years, IQR 16.6-57.2) than 
those treated with DDAVP alone (29.2 years, IQR 14.6-44.5, p=0.024). Although, a difference 
in age was seen between those treated with FVIII alone (35.8 years, IQR 16.6-57.2) and those 
treated with FVIII & DDAVP (25.3 years, IQR 12.6-48.2), this did not reach statistically 
significance (p=0.063). No significant difference in age was seen between patients treated 
with DDAVP alone (29.2 years, IQR 14.6-44.5) compared to those treated with FVIII & DDAVP 
(25.3 years, IQR 12.6-48.2, p=0.813). Patients treated with DDAVP alone had significantly 
higher median bFVIII:C (20.5IU/dL, IQR 11.3-29.0) than those treated with FVIII alone 
(8.0IU/dL, IQR 4.0-14.0, p<0.0005) or FVIII & DDAVP (10.0IU/dL, IQR 7.0-19.0, p=0.001). No 
difference in bFVIII:C was seen in those treated with FVIII alone (8.0IU/dL IQR 4.0-14.0) 
compared to those treated with FVIII & DDAVP (10.0IU/dL, IQR 7.0-19.0, p=0.0760. A whole 
case analysis of the frequency of “high-risk” F8 mutations in patients treated with FVIII alone 
(40/226, 17.7%), DDAVP alone (9/64, 14.1%), FVIII & DDAVP (4/32, 12.5%) did not differ from 
that expected by chance (p=0.642). Repeating this analysis using multiple imputation for the 
missing data points (n=46) also demonstrated no significant difference in the frequency of 
“high-risk” F8 mutations between these treatment categories (p=0.075).   
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4.4.3 On-Demand (Bleeding and Surgery) Treatment with FVIII Concentrate  
Over the study period, 236 patients received FVIII concentrate alone to cover 562 on-demand 
treatment episodes (surgery=211, bleeding=351). Patients who received treatment on-
demand with FVIII received a median of 4ED (range 1-159) of FVIII in the two year study 
period (Table 4.1). These on-demand episodes resulted in a cumulative of 2041ED 
(bleeding=887 and surgery=1154). 
In the treatment of bleed presentations, 157 patients received treatment with a FVIII 
concentrate to treat a median of 1 bleeding episode (range 1-15). Of these patients, 51 had 
moderate haemophilia A and 106 mild haemophilia A. A total of 130 patients received 
treatment with a FVIII concentrate to cover a median of 1 surgical episode (range 1-11). A 
high proportion of patient (n=96, 32.4%) were issued FVIII for home-treatment, with 50 
patients only having home-treatment episodes. A significant difference was seen in age and 
bFVIII:C, comparing patients treated on-demand with those on home-treatment alone or a 
combination of both. Patients receiving on-demand treatment alone were significantly older 
(39.9 years, IQR 17.6-59.4) than those treated with home-treatment alone (23.0 years, IQR 
13.3-39.2, p=0.011). No significant difference in age was seen comparing patients treated 
with both on-demand and home-treatment (38.7 years, IQR 18.8-54.0) compared to those 
treated on home-treatment alone (23.0 years, IQR 13.3-39.2, p=0.164) or on-demand 
treatment alone (39.9 years, IQR 17.6-59.4, p=0.488). Patients treated with on-demand 
treatment alone had significantly higher bFVIII:C (10.0IU/dL, IQR 6.0-15.8) than those treated 
on home-treatment alone (5.0IU/dL, IQR 3.0-9.3, p<0.0005) or on both home-treatment and 
on-demand treatment (6.6IU/dL, IQR 3.3-11.0, p=0.009). No significant difference for 
bFVIII:C, was observed comparing patients treated with home-treatment alone (5.0IU/dL, 
IQR 3.0-9.3) with those treated with both home-treatment and on-demand treatment 
(6.6IU/dL, IQR 3.3-11.0, p=0.223). Treatment indication were described as either being for 
other indications or not-stated in 56 episodes (37 patients). No further characterisation of 
treatment within these categories (home-treatment, not-stated and other) was possible.  
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 Bleeding Surgery Total 
Patients (episodes) 157 (351) 130 (211) 236 (562) 
Age (years) 
Mean±SD 
Median (range) 
 
34.9±22.8 
32.7 (0.2-89.0) 
 
46.6±23.0 
48.5 (2.1-89.0) 
 
39.1±24.1 
39.9 (0.2-89.0) 
bFVIII:C 
Mean±SD 
Median (range) 
 
10.0±7.6 
8.0 (1.0-42.0) 
 
13.0±9.5 
10.0 (1.5-43.8) 
 
12.2±9.1 
10.0 (1.0-43.8) 
Severity 
Moderate 
Mild 
 
56 
101 
 
28 
102 
 
67 
169 
F8 Mutation 
“High-risk” 
“Standard-risk” 
Not known 
 
27 (17.2%) 
109 (69.4%) 
21 (13.4%) 
 
24 (18.5%) 
88 (67.7%) 
18 (13.8%) 
 
42 (17.8%) 
162 (69.1%) 
31 (13.1%) 
Treatment Episode 
Mean±SD 
Median (range) 
 
2.2±2.2 
1 (1-15) 
 
1.6±1.4 
1 (1-11) 
 
2.38±2.2 
1 (1-15) 
Total ED / Patient 
Mean±SD 
Median (range) 
 
7.4±10.2 
4 (1-82) 
 
6.8±15.5 
2 (1-159) 
 
8.7±14.6 
4 (1-159) 
Table 4.1: Baseline demographics of patient with non-severe haemophilia A receiving on-
demand treatment with a FVIII concentrate  
 
4.4.4 Assessment of Bleeding in Non-Severe Haemophilia A 
An assessment of bleeding was performed in the subgroup of 193 patients (45 moderate and 
148 mild HA) without a history of inhibitor who only received on-demand FVIII treatment 
(bleeding or surgery). The median annualised bleed rate was 0.5 episodes/year (range 0-4.5) 
with the majority of patients ha ing an  BR ≤  (right/positive skewed distribution, Figure 
4.2). A weak, but statistically significant non-parametric correlation (r=-0.25, p=0.0005) was 
seen between bFVIII:C and ABR (Figure 4.3). No significant correlation (r=-015, p=0.105) was 
seen when this analysis was repeated in patients (n=120), treated for 1 or more bleeding 
events within the study period (i.e. excluding those who were treated only for surgery). 
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Figure 4.2: Frequency of bleeding in patients with non-severe haemophilia A. A right 
(positive) skew in distribution of bleeding episodes (annualised bleed rate) was seen for 
patients treated with on-demand FVIII (median 0.5 bleeds/year) 
 
Figure 4.3: Bleeding patterns in non-severe haemophilia A. A weak significant correlation 
(r=-0.25, p=0.0005) was seen between the baseline FVIII:C (bFVIII:C) and annualised 
bleeding rate (ABR) in patients treated with on-demand FVIII.   
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4.4.5 Inhibitor Screening: “Standard-Risk” F8 Mutation  
In patients with “standard-risk” F8 mutations, national guidance 214 advises inhibitor 
screening following e posure to FVIII for “high-risk” treatment episodes (bleed ≥ ED or 
surgery) and annually following any less intensive treatment with a FVIII concentrate.  
There were 194 patients with a “standard-risk” or unknown F8 mutations, treated with a FVIII 
concentrate for one or more on-demand treatment episode (n=474) over a cumulative of 
1753ED. The mean age was 37.7 years (range 0.2-89.1) and the mean baseline FVIII:C was 
11.6IU/dL (range 1.0-42.0), with 142 having mild and 52 moderate haemophilia A. Within this 
group of patients with a “standard-risk” or unknown F8 mutations, 58.7% (114/194) had an 
inhibitor screen sent at some point within the 2 year study period. Of these on-demand 
treatment episodes, 51.3% (243/474) were followed by an inhibitor screen within one year 
of treatment, at a median of 106 days (range 2-365). Of all on-demand treatment episodes, 
33.3% (158/474) received a directly paired annual inhibitor screen (i.e. inhibitor screen 
performed prior to subsequent FVIII exposure), with only 12.0% (57/474) having inhibitor 
screening within 6 weeks of treatment (Table 4.2). Therefore, 66.7% of treatment episodes 
were not screened prior to subsequent FVIII exposure. At a patient level this represented 
101/194 (52%) patients who received annual screening and 93/194 (48%) patients who were 
not screened annually following treatment with a FVIII concentrate.  
FVIII was used to provide haemostatic cover for 175 surgical episodes (106 patients), treated 
with a median of 1 day (range 1-157) of FVIII over a total of 773ED. Inhibitor screening was 
performed within one year of treatment for 40.6% (71/175) surgical episodes (Table 4.2). 
Paired inhibitor testing (i.e. screen before subsequent FVIII exposure) was recorded following 
27.4% (48/175) surgical episodes at a median of 67.0 days (range 2-329). Only 9.7% (17/175) 
surgical episodes had a true “con alescent inhibitor screen” performed within   weeks of 
treatment. Of the episodes that received inhibitor screening within 6 weeks, 41.2% (7/17) 
tests coincided with a subsequent treatment episode  
There were 299 bleeding episodes (130 patients) treated with a median of 2 days (range 1-
75) of FVIII over a cumulative of 980ED. Following usage of a FVIII concentrate for treatment 
of bleeding for ≥  days (n=  ),   .8% ( 8/  ) episodes had an inhibitor screen performed 
within one year of treatment (Table 4.2). Paired inhibitor testing was recorded in 40.3% 
(21/52) episodes at a median of 40.0 days (range 4-   ). True “con alescent inhibitor 
screening” within   weeks of treatment was performed following   . % (  /  ) of episodes. 
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Of the episodes that received inhibitor screening within 6 weeks, 21.2% (2/11) tests 
coincided with a subsequent treatment episode  
Taken together, the combined data for bleeding (≥ ED) and surgery demonstrated that 
although 30.4% (69/227) of episodes had paired inhibitor testing, only 12.3% (28/227) of 
these recei ed true “con alescent inhibitor screening” within   weeks of treatment as per 
national guidance (Table 4.2 and Figure 4.4). 
4.4.6 Inhibitor Screening: “High-Risk” F8 Mutation 
For “high-risk” F8 mutations, current national guidance 214 advises inhibitor screening 
following any exposure to a FVIII concentrate.  
There were  8 patients with a “high-risk” F8 mutation treated in the study period, with a 
mean age of 40.9 years (range 0.9-84.4). The mean bFVIII:C was 11.2IU/dL (range 1.9-43.8), 
with 19 (32%) having moderate and 39 (67%) mild haemophilia A. Of these patients, 46 (79%) 
received one or more treatment with a FVIII concentrate. This group of patients were mainly 
treated using on-demand treatment only (38/46). Two patients received home-treatment 
only, four on-demand and home-treatment and two treatment for other indications. This 
group of patients underwent treatment with a FVIII concentrate for 36 surgical episodes (114 
ED) and 52 bleeding episodes (174 ED), resulting in 88 on-demand episodes with a cumulative 
exposure of 288ED. Surgical episodes were treated with a median of 1 day (range 1-20) and 
bleeding episodes with a median of 2 days (range 1-19) of FVIII treatment. 
 f the    patients with “high-risk” F8 mutations treated within the study period, 69.0% 
(29/42) had an inhibitor screen performed at some point within the 2 year study period 
(Table 4.2). Of the 88 on-demand (surgery and bleeding) treatment episodes, 47.8% (42/88) 
had an inhibitor screen performed within one year of treatment at a median of 87.0 days 
(range 2-359). A paired inhibitor screen was performed following 33.0% (29/88) of episodes 
at a median of 93.5 days (range 2-365) after the first treatment day. Of these episodes, a true 
“con alescent inhibitor screen” was performed in only 13.6% (12/88) within six weeks of 
treatment (Table 4.2 and Figure 4.4). Of the episodes that received inhibitor screening within 
6 weeks, 16.7% (2/12) tests coincided with a subsequent treatment episode  
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   Tested Not Tested 
 Episodes Tested (%) Treatment screen 
(%) 
Not Tested (%) Episode <42 days 
(%) 
“High-Risk” F8 
Mutation 
Annual 88 42 (47.7%) 9 (21.4%) 46 (52.3%) - 
Pair 88 29 (33.0%) 9 (31.0%) 59 (67.0%) - 
<42 days 88 12 (13.6%) 2 (16.7%) 76 (86.4%) 15 (19.7%) 
“Standard-Risk” F8 
Mutation 
All Annual 474 243 (51.3%) 42 (17.3%) 231 (48.7%) - 
All Pair 474 158 (33.3%) 42 (26.6%) 316 (66.7%) - 
All <42 days 474 57 (12.0%) 21 (36.8%) 417 (88.0%) 75 (18.0%) 
Surgery Annual 175 71 (40.6%) 14 (19.7%) 104 (59.4%) - 
Surgery Pair 175 48 (27.4%) 14 (29.2%) 127 (72.6%) - 
Surgery <42 days 175 17 (9.7%) 7 (41.2%) 158 (90.3%) 22 (13.9%) 
≥ ED Bleed Annual 52 28 (53.8%) 2 (7.1%) 24 (46.2%) - 
≥ ED Bleed Pair 52 21 (40.4%) 2 (9.5%) 31 (59.6%) - 
≥ ED Bleed <42 
days 
52 11 (21.2%) 2 (18.2%) 41 (78.8%) 13 (31.7%) 
All Episodes 
Annual 562 285 (50.7%) 51 (17.9%) 277 (49.3%) - 
Pair 562 187 (33.3%) 51 (27.3%) 375 (66.7%) - 
<42 days 562 69 (12.3%) 23 (33.3%) 493 (87.7%) 90 (18.3%) 
Table 4.2: Frequency of inhibitor screening in non-severe haemophilia A.  Treatment screen=Inhibitor screen performed within (±) one day of the 
following treatment episode. Episode <42 days=Patient received another treatment episode in <42 days.
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Figure 4.4: Inhibitor screening in non-severe haemophilia A. Standard=“standard-risk” or F8 mutation not recorded. High Risk=“high-risk” F8 mutation.  
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4.4.7 Factor VIII Inhibitor Formation 
Thirteen patients had an inhibitor history, with a mean age of 53.6 years (7.5-80.5) and 
bFVIII:C of 7.6IU/dL (1.9-16.0). These patients were treated with FVIII alone (n=5, 38.5%), 
DDAVP alone (n=2, 15.4%), bypassing agents alone (n=4, 30.8%), FVIII and bypassing agents 
(n=1, 7.7%) and DDAVP and bypassing agents (n=1, 7.7%). Home-treatment was used for 3/5 
patients treated with FVIII alone.  
Of the patients treated with FVIII (n=290) at risk of inhibitor formation, three developed a 
new FVIII inhibitor within the study period. All of these cases were diagnosed in one centre, 
with these inhibitors being detected during treatment for bleeding (n=2) or on inhibitor 
screening (n=1). A change in the bleeding phenotype was seen in all three patients and fall in 
bFVIII:C<1% in two patients. One of these inhibitors was initially only detectable by the 
inhibitor assay (NBA) following pre-analytical heat treatment, discussed in more detail in 
Chapter 7. Two patients had “high-risk” and one a “standard-risk” F8 mutation.  
The inhibitor prevalence within patients treated within the study period was 4.2% (16/377). 
Patients with an inhibitor were significantly older (51.9 years, IQR 37.2-70.2) than those 
without an inhibitor at the start of the study (32.0 years, IQR 16.1-52.5, p=0.008). Patients 
with an inhibitor also had significantly lower bFVIII:C (6.5IU/dL, IQR 3.3-10.0) than those 
without an inhibitor (10.0IU/dL, IQR 5.0-18.0, p=0.014). F8 genotype testing was performed 
in all patients (16/16) with an inhibitor, compared to 281/361 patients without an inhibitor 
(77.8%, p=0.034). In patients in whom the F8 genotype was known (n=331), there was an 
increased frequency of patients with a “high-risk” F8 mutation (50.0%, 8/16) in those with an 
inhibitor compared to those without an inhibitor (15.9%, 50/315, p<0.0005). Although all 
three new inhibitors were detected in a single centre, the total inhibitor frequency for each 
centre did not differ significantly than that expected by chance (p=0.654). 
4.5 Discussion 
Within the London region, 44% (377/853) of patients with non-severe haemophilia A 
received haemostatic treatment over the two year study period. A large proportion (n=296, 
79%) of these patients received exposure to a FVIII concentrate to cover on-demand 
treatment episodes. Despite national guidance for inhibitor testing in patients with non-
severe haemophilia A, compliance with convalescent inhibitor screening was poor. In 
patients with a “standard-risk” F8 mutations, although around half (n=243, 51.3%) of the 
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treatment episodes were followed with an annual inhibitor screen, only 12.3% (28/227) were 
screened within six weeks of treatment when indicated for by higher intensity exposure or 
surgical inter ention. Similarly in patients with “high-risk” F8 genotypes only 13.6% (12/88) 
of episodes were screened with six weeks of treatment. All three inhibitors detected in this 
study were associated with a change in bleeding phenotype and no inhibitors were detected 
purely on inhibitor screening.  
4.5.1 Testing of F8 Genotype and “High-Risk” F8 mutations in Non-Severe Haemophilia A 
For unbiased assessment of genetic risk of inhibitor formation in non-severe haemophilia A, 
there is a need for high levels of uptake of F8 genotype testing. Within the London 
haemophilia centres, good compliance (88% F8 genotype known) with F8 genotype testing 
was observed, within all except one small HTC testing >70% of treated patients. Marked 
variation in F8 genotype testing practice have been described in an international survey (13 
centres) 309. In this survey, for sites outside of the USA, genetic testing had been performed 
in >75% of cases in 7/8 centres. In the USA, 4/5 had performed genetic testing in <50% of 
patients. The authors of this survey speculate that these differences in genetic screening 
practices in the USA, may relate to test funding and the need to demonstrate how these alter 
clinical management, for which there is no strong clinical data to support this at present. 
Generalisation of these findings is however limited due to the small number of centres 
surveyed. Similarly, in the INSIGHT study evaluation of inhibitor risk associated with F8 
genotype was performed only in centres that had genotyped ≥7 % of patients, resulting in 
inclusion of 41% (14/34) of centres 166. Given the high compliance with F8 testing and the 
authorship of the INSIGHT cohort, patients from 3-4 of the London haemophilia centres may 
have contributed substantially to this analysis 166. Risk evaluation of inhibitor formation and 
the response to inhibitor treatment in large observational studies such as the INSIGHT study 
is dependent on adequate laboratory detection of the primary endpoint. With poor 
compliance in “con alescent” inhibitor testing as seen in the London cohort, this will 
significantly impact on data quality within observational studies. This makes interpreting data 
on inhibitor risk associated with mutations 166 and whether patients with inhibitors respond 
to immunosuppression 169 difficult.  
When designing and piloting this evaluation, there was a paucity of data on inhibitor risk 
relating to specific F8 mutations. Within the UKHCDO guidance, no specific F8 mutations 
were identified, rather advising referral to the HADB and the awaited publication of the 
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I SIGHT study to identify “high-risk” F8 mutations 214. The “high-risk” F8 mutations selected, 
therefore were based on information available within a recently published international 
study 194 to represent mutations that clinicians may be aware of and could influence inhibitor 
screening practices.  f these “high-risk” F8 mutations, with reported inhibitor association 
assessed within the London cohort, 4/7: Arg593Cys, Tyr2105Cys, Arg2150His and 
Trp2229Cys, have subsequently been described as being associated with increased risk of 
inhibitor formation within the INSIGHT study 166. These four F8 mutations accounted for 16% 
(179/1112) patients within the INSIGHT study, with 57% (29/51) of patients who had an 
inhibitors having one of these F8 mutations. No inhibitors were seen in the remaining three 
“high-risk” F8 mutations in the INSIGHT study although the number of patients with these 
mutations was low, accounting for only 9 patients of the whole cohort 166. All three of these 
mutations (Arg2163His 64;310, Asn2286Lys311 and Pro2300Leu312) have been described to have 
been associated with inhibitor formation within the HADB 71. Data within the London cohort, 
appears to further support the idea of “high-risk” F8 mutations with these “high-risk” F8 
mutations being over-represented within the group of patient with an inhibitor.  
Further study into genetic risk factors of inhibitor formation in non-severe haemophilia A is 
required. Evaluation of risk is limited by difficulty in case-control matching, given some 
controls may develop inhibitors later in life with adequate FVIII exposure. Given the number 
of patients and length of follow-up required, construction of such prospective study would 
prove difficult even within an international study. In-silico approaches to prediction of 
inhibitor risk offers an interesting approach to address some of these difficulties. Work 
performed by investigators at the Institut national de la santé et de la recherche médicale 
(INSERM) 313 and by our research group 314 have attempted to identify prediction models 
based around peptide presentation for F8 mutations at the MHC Class II / TCR interface. 
These data suggest that risk of inhibitor formation in non-severe haemophilia A is more 
complex than simple knowledge of the F8 mutation. Addition of MHC Class II into these 
algorithms may improve risk prediction, but further work is required to establish risk based 
on context of FVIII exposure within these models.  
4.5.2 Timing and Methodology of Inhibitor Testing in Non-Severe Haemophilia A 
There is currently no available data to guide the optimal timing for performing inhibitor 
screening in non-severe haemophilia. A cut-off of ≤  weeks was selected as being 
representative of when a primary immunological response would be detectable and to 
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provide some certainty that testing was performed to screen for inhibitor formation 
following treatment. The FVIII subcommittee of the Scientific and Standardization 
Committee (SSC) of the International Society on Thrombosis and Haemostasis (ISTH) has 
proposed guidance suggesting that all patients with mild haemophilia A should have 
“con alescent” inhibitor screening performed by the Bethesda assay si  weeks after 
exposure to FVIII 315. This provides a pragmatic approach for inhibitor screening in mild 
haemophilia A in which there are still many unanswered questions as to what constitutes a 
high risk exposure. More widespread inhibitor screening will facilitate study of both genetic 
and environmental causes of antibody formation as well as allowing complete identification 
of the immune response to FVIII. Current inhibitor screening based on a subset of F8 
genotypes selected as being “high-risk” may skew toward detection of inhibitors in these 
groups, particularly where a founder effect is seen in some countries. For other F8 mutations 
where there is little data, this may lead to false reassurance that these patient are not at risk 
of antibody formation and could result in lack of detection if these are not screened following 
treatment. Despite earlier reports of what constitutes environmental risk within non-severe 
haemophilia, a preliminary report of data from the case-control study of the INSIGHT study 
suggest no strong predictors of risk 167. More widespread screening such as the approach 
suggested by the SSC may help in the detection of inhibitors in this group. Whether this 
approach will lead to increased detection of low-titre (or transient) inhibitors, as has been 
recently described in patients with severe haemophilia A215 is not clear. Finally, although 
increased screening from a scientific point of view allows clearer understanding of the 
immune response, this will be associated with substantial increases in cost. Of the whole 
London cohort, paired testing was performed in 33.3% (187/562) and 12.3% (69/562) of 
episodes were screened within six weeks of treatment (Table 4.2 and Figure 4.4). Meeting 
this screening target, however would have required an additional 375 tests being performed 
within this study period. Piloting of more intensive screening practice in a prospective study 
may help provide a health economic assessment of this approach to inhibitor screening.  
4.5.3 Laboratory Testing of FVIII Antibodies in Non-Severe Haemophilia A 
Within this cohort inhibitor testing was based on the usage of a functional inhibitor assay. 
This methodology has limitations in the detection of FVIII antibodies in non-severe 
haemophilia A due to many patients with mild haemophilia A having residual endogenous 
FVIII:C prior to testing. In this cohort over half of the patients (53%, 199/377) had a FVIII:C 
≥  IU/dL and   . % (8 / 77) a FVIII:C ≥  IU/dL. Some large haemophilia centre laboratories, 
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including one of the large CCCs included within this study have previously reported not 
testing samples in which FVIII:C ≥   IU/dL 290 when using a functional inhibitor assay. This 
approach would have resulted in 1 in 5 patients not being screened based on their bFVIII:C 
alone. In this setting a screening test with high specificity (i.e. correctly identifies negative 
results), which is insensitive to residual FVIII:C may facilitate inhibitor detection and result in 
increased understanding of the immune process in non-severe haemophilia A. Usage of an 
ELISA or modifications to the NBA, such as pre-analytical heat treatment could assist in the 
detection of inhibitors in this scenario which is evaluated further in Chapters 6 and 7.  
4.5.4 Classification of Mild Haemophilia A  
There is ongoing discussion about classification of patients with mild haemophilia A with a 
FVIII:C >40IU/dL 315. Within this cohort seven patients (4/7 centres) were registered as having 
FVIII:C ≥  IU/dL and   recei ed treatment with a FVIII concentrate (bleeding= , surgery= ). 
The mean age was 33.6 years (range 8.6-88.4) with three <18 years (8.6, 9.5 and 16.0 years). 
F8 genotype testing had been performed in  /7 of these patients and   had a “high-risk” F8 
mutation. Although, representing a small proportion of patients in clinical practice, this 
subset represents a clinical and laboratory challenge. Current international guidance 
classifies mild haemophilia A as FVIII:C 5-40IU/dL 70, although previous reports from the UK 
have used a higher threshold of <50IU/dL 64. The FVIII Subcommittee of the SSC of the ISTH 
has proposed individuals with FVIII:C >40IU/dL, on repeat testing could be classified as having 
haemophilia if: the F8 mutation is associated with haemophilia within one of the databases; 
a family member with the same F8 mutation has a FVIII:C <40IU/dL; or in the presence of the 
same mutation or a database record listing the F8 mutation is associated with FVIII:C 
<40IU/dL in other individuals 315. This group of patients offer an interesting area for further 
study through application of in-silico and in-vitro assessment of effect of these missense 
mutations on FVIII structure and function.   
4.5.5 Annualised Bleed Rates in Non-Severe Haemophilia A 
A negative correlation between FVIII:C and ABR was seen, similar to that described within 
other reports 66. A Dutch survey of 433 patients with non-severe haemophilia A (119 mild, 
314 moderate) of self-reported ABR (preceding year), demonstrated a mean of 1 bleed/year 
with right (positive) skew, similar to the data described within this chapter (Figure 4.2). 
Within this cohort patients with moderate haemophilia A (bFVIII:C <5%) had the highest risk 
for joint bleeds with no expected joint bleeds seen in patients with a bFVIII:C ≥  %. Statistical 
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modelling, using a multivariate regression analysis (negative binomial distribution) 
demonstrated an 18% reduction in bleed frequency for every 1% increase in FVIII:C 316. The 
correlation between ABR and bFVIII:C in patients treated in London was however weak, 
which may relate in part to the methodology of patient selection, analysis (post-hoc) and 
reliance on registration data for bFVIII:C.   
4.5.6 Treatment of Non-Severe Haemophilia A with DDAVP 
The number of patients managed with DDAVP within this cohort was lower than expected. 
DDAVP offers a cheap and safe (no inhibitor risk) method of treating responsive patients for 
minor bleeding or surgery 67. There has been varying reports in the literature on factors 
affecting response to DDAVP which include age, bFVIII:C and F8 mutation 317. Within the 
London cohort, patients treated with DDAVP had a higher bFVIII:C than those patients 
treated with FVIII alone. This is in keeping, with data from small studies suggesting increased 
DDAVP response associated with bFVIII:C, with lower responses in patients with moderate 
haemophilia A. The frequency of “high-risk” F8 mutations was similar in patients treated with 
FVIII alone, DDAVP and DDAVP and FVIII within the London cohort. Usage of DDAVP could 
minimise or avoid exposure to treatment with FVIII in responsi e patients with “high-risk” F8 
mutations.  f the “high-risk” F8 mutations within the London cohort three have previously 
published data on DDAVP responsiveness (Arg593Cys, Tyr2015Cys and Arg2169His) albeit in 
small numbers of patients 317. Further research is ongoing in this area within the RISE 
(Response to DDAVP In mild hemophilia A patients, in Search for dEterminants) study, a 
satellite study of the INSIGHT study.  
4.6 Limitations  
The main limitation from this study stems from the retrospective design which provided 
limited information on patient demographics and the treatment episodes. As such, it is not 
possible to confirm whether patients received treatment or were registered at more than 
one centre, which may affect estimations of proportions of patients receiving FVIII and 
calculation of inhibitor prevalence. Usage of FVIII:C without additional genetic information 
to define severity could have resulted in some patients with severe haemophilia A being 
included. This likely represents a small number of patients as only 6/377 (1.6%) patients of 
the whole cohort had a FVIII:C <2IU/dL. With this methodology, further assessment of the 
nature of bleeding (spontaneous or traumatic) or type of surgery was also not possible, both 
which will constitute heterogeneous groups of treatment indications. This approach however 
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allowed unbiased assessment of screening associated with FVIII treatment, without making 
judgement of severity/complexity in subsequent post-hoc analyses. Another difficulties in 
this and similar data-sets is in the assessment of usage of home-treatment. A high proportion 
of patients (n=96, 32.4%) were issued FVIII for home-treatment, which could have included 
a number of treatment indications, including, regular/targeted prophylaxis, on-demand 
home-treatment, ITI as well as issues prior to travel (that may not have been administered). 
No further analysis was performed within this group, although it is recognised that the true 
rate of bleeding within the cohort may be higher than the figure reported. 
Within these data sets it is not possible to assess the reason for outlying data-points with 
high numbers of EDs, which could represent inpatient commencement of prophylaxis. 
Similarly, in patients treated with DDAVP it is not possible to make further assessment of 
treatment episodes or whether these usages were linked to subsequent FVIII usage within 
the same treatment episode (i.e. DDAVP treatment failure or pre-planned combined use to 
minimise FVIII exposure). It would be interesting to assess the uptake of assessment of 
DDAVP responsiveness in this cohort. DDAVP responsiveness should be evaluated where 
there is no contraindication, in any patient with mild haemophilia A. In those with moderate 
haemophilia A consideration of assessment of DDAVP response would seem appropriate 
especially in the context of family history of inhibitor formation, but the likelihood of 
developing adequate response may be lower. Use of DDAVP in such high risk individuals for 
minor incidental events that may be amenable to DDAVP and tranexamic acid, incrementally 
through a life time may however save a meaningful number of FVIII concentrate exposures. 
It is possible that in selection of FVIII over DDAVP, for treatment episodes that clinicians may 
not have been aware of the F8 genotype at the time of treatment, or baseline (or target) 
FVIII:C was such that DDAVP was not sufficient to allow DDAVP alone. Although, there is 
significant heterogeneity described with the haemophilia databases for bFVIII:C for different 
F8 mutations, groups of mutations may have lower FVIII:C (or lack of response) making these 
not amenable to DDAVP treatment. In the screening and treatment practices described, it is 
of note that these appear similar in those with “high-risk” and “standard-risk” F8 mutations, 
which could imply that at present this does not impact on clinical management. 
Another limitation in this approach to assessment of inhibitor screening practices, is follow-
up of events that occurred within the last six months of the study, which although, providing 
sufficient data to allow assessment of testing for “convalescent” screening, did not have a 
full year of follow-up for assessment of annual screening. This could mean that there is an 
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underestimation in the uptake of annual screening in those with “standard-risk” F8 
mutations. Interestingly, the frequency of annual inhibitor screening was similar for all four 
six month (Q) periods (Q1: 44.1%, Q2: 51.7%, Q3: 57.7% and Q4: 50.4%). Patients in whom 
the F8 genotype was unknown, were grouped within the assessment of inhibitor screening 
with patients with “standard-risk” F8 mutations. This group of patients may well have 
contained a number who had a “high-risk” F8 mutation if genotype testing had been 
performed, which may have a small effect on the proportion of episodes included within this 
assessment. Assessment of all episodes regardless of F8 genotype e aluating “con alescent 
inhibitor screening”, howe er allowed unbiased assessment of episodes based on this status.  
One of the strengths of this data set however, relates to this unbiased approach to the 
assessment of uptake of inhibitor screening, which is not possible within a prospective 
setting. This study provides an informative snapshot of current inhibitor screening practices 
in non-severe haemophilia A, which underpin the data provided within observational studies 
examining risk of inhibitor formation.  
4.7 Conclusions 
Within a large cohort of patient with non-severe haemophilia A, although there was good 
compliance with genetic testing, poor compliance with “convalescent” inhibitor screening 
following FVIII treatment was observed. Re-auditing of inhibitor testing practices presented 
is required to evaluate the impact of these data on clinical practices. Further study is required 
to assess optimal practice and methodology of inhibitor screening in non-severe haemophilia 
A. Improvement in laboratory detection and planning for routine screening, through more 
sensitive and/or batched screening tests may help in earlier identification of FVIII antibodies, 
which is discussed in Chapters 6 and 7. 
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Chapter Five: Immunosuppression for Acquired Haemophilia A: A National 
Survey of Clinical and Laboratory Practice 
5.1 Introduction 
Factor VIII antibodies occurring in haemostatically normal individuals although a very rare 
phenomenon result in significant morbidity and mortality 107;318. Previous survey data has 
suggested that even within the haemophilia CCC clinicians may manage only a small number 
of cases per year 110;114;115. As such, clinicians may have limited personal experience of 
treating AHA, which has been highlighted in previous studies. In an international survey of 
ISTH members and CCC clinicians from the early 1980s, 47% (55/118 respondents) reported 
having not seen a case of AHA in the previous 10 years. In those who had treated AHA, 75% 
(47/6 ) had seen ≤  cases,   % (  /  )  -10 cases, 8% (5/63) 11-20 cases and only one 
respondent reported treating >20 cases 110. In a more recent European survey (Germany, 
Austria and Switzerland), 44% of respondents, reported personal treatment experience of 1-
4 cases, 24% 5-10 cases and only 18% 11-20 cases. It is difficult however to compare these 
survey data due to changes in clinical and laboratory practices over time and within both 
survey methodologies it is not clear which types of clinicians were surveyed or responded. 
Nevertheless as a rare disorder management decisions will be likely be influenced by recent 
publication, guidance (local, national or international) or anecdotal experience.    
In contrast to severe haemophilia A, treatment aimed at auto-antibody eradication hinges 
around the use of immunosuppressive agents 119;319. Despite recent increased understanding 
of the natural history of this disorder (discussed in Chapter 1), the optimal approach to first 
line immunosuppression remains to be defined and there is a lack of consensus as to the 
optimal duration and approach to withdrawal of immunosuppressive therapy 119;319. As a 
result differences in the management of immunosuppression in observational studies could 
affect reported clinical outcomes and predictors of risk. One of the greatest current challenge 
in the management of AHA is the high rates of morbidity and mortality that relate to the 
treatment of this disorder 117;118;318. Historically, the major concern in the management of 
AHA was mortality resulting from haemorrhage which historically occurred in 15-22% of 
cases 110;320. With improvements in early recognition and haemostatic management, 
mortality directly attributable to bleeding has reduced to around 3% 107. Within the EACH2 
study however, the same number of patients died as a result of immunosuppression (3%, 
16/331) as from bleeding (3%, 16/331) 107. Alongside this, one or more adverse event was 
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associated with immunosuppression in 25% and 44% of patients treated with steroids or 
steroids and cyclophosphamide respectively 318. Given these high rates of toxicities it would 
be desirable to risk stratify patients at commencement or early into immunosuppressive 
treatment to minimise the risk of toxicity in those more likely to achieve remission. Despite 
the existence of national guidance for the management of AHA in the UK 319 there has been 
no previous national study looking into how haematologists report their implementation of 
immunosuppression in AHA. 
5.2 Hypothesis and Aims 
The hypothesis for this chapter is that there is significant heterogeneity in the management 
of immunosuppression and its withdrawal in the treatment of AHA. It is hypothesised that 
differences in approaches to management may affect responses to treatment and 
occurrence of treatment related morbidity in clinical trials. The specific aims are as follows:   
1) To evaluate national treatment practices in the first line management 
(immunosuppressive and haemostatic agent) of AHA. 
2) To evaluate laboratory approaches to weaning and monitoring of weaning of 
immunosuppression. 
3) To evaluate clinical approaches to weaning of immunosuppression assessing: timing, 
speed and variables affecting speed of immunosuppressive weaning.  
4) To assess clinical case volumes managed by haemophilia treaters within the UK and 
provide pilot data to inform study design and protocol acceptability for a national, 
prospective, interventional study in AHA. 
5.3 Materials and Methods 
Survey Design and Distribution 
An assessment of clinical and laboratory practices of haematologists treating AHA in the UK 
was performed using a national, anonymised, electronic short survey (10 questions). This 
survey was constructed using the online SurveyMonkey® (SurveyMonkey Inc., Palo Alto, 
California, USA; https://www.surveymonkey.com/) survey tool on behalf of the UKHCDO 
Inhibitor Working Party. The members of which reviewed and approved the survey topics 
and questions prior to distribution.  
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This process of survey distribution was centrally co-ordinated by the UKHCDO, allowing 
additional blinding/anonymity of potential respondents to the investigator. E-mail invitations 
were sent to all haemophilia centre directors/co-directors (n=82), at the 78 haemophilia 
centres (CCC=28 and 50 HTC=50) in the UK. This invitation email contained a hyperlink to the 
survey (https://www.surveymonkey.com/s/QDFCFVV), which allowed direct access for 
online survey completion viewable as a single webpage. Questions were presented 
sequentially with no question randomisation. This survey platform was chosen as this was 
identified as a platform that physicians had previous experience of completion of web 
sur eys. The sur ey was an “open” sur ey allowing access and completion of the online 
questionnaire without registration and no financial incentive was offered. Each survey 
response was assigned a unique sequential response number by the web-server, with no 
identifiable respondent or centre data collected. Survey responses could be edited by 
respondents up until the last section of the survey had been completed, with no 
completeness check performed prior to survey submission. A maximum of one response per 
computer was allowed, through cookie placement following survey completion to prevent 
repeated access from the same web-browser from the same device. The survey was 
conducted via a secure encrypted SSL (Secure Sockets Layer) connection with responses 
stored on the SurveyMonkey® servers located in Luxembourg and the United States. The date 
and time taken to complete the survey were recorded for each participant. At the time of 
answering, the SurveyMonkey® web-server logs the internet provider (IP) address as part of 
standard survey recording. No demographic (personal or centre) or contact information was 
requested and no geo-positional data was electronically obtained. No paper or e-mail 
response options were provided to standardise the survey format and to help ensure 
anonymity for respondents. A reminder email was sent one month later, to all centre 
directors/co-directors, with the survey being open for four months (9/12-12/12).  
Data Entry and Statistical Analyses 
Individual survey responses were collated and coded electronically to allow more detailed 
analysis of respondent data. These processes were checked manually and electronically using 
the summary data provided by the SurveyMonkey® website. Categorical data were used to 
calculate response rates (n) and frequencies (%), with statistical analyses performed using 
the chi-squared, chi-squared goodness-of-fit and binomial probability tests. Analysis of 
survey data was performed within each question, based on the number of complete 
responses. No mathematical correction (imputation) was made for missing data, as it was 
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felt that these data points may be missing not at random. Inter-rater agreement was assessed 
using the Fleiss kappa. Agreement was rated as being either poor (<0), slight (0.0-0.20), fair 
(0.21-0.40), moderate (0.41-0.60), substantial (0.61-0.80) or almost perfect (0.81-1.00).  
5.4 Results 
The online survey was completed by 36 respondents, representing haemophilia centre and 
centre director/co-director response rates of 46.2% (36/78) and 43.9% (36/82), respectively. 
There were 26 survey responses received following the first survey email with an additional 
10 responses obtained following a reminder email being sent one month later. 44.4% (16/36) 
of responses were completed on the same day that the first survey email was distributed. 
The median time taken to complete the survey was 3 minutes and 4 seconds (range 20 
seconds-30 minutes and 30 seconds).  
The majority of clinicians (n=30, 83.3%) responding to the survey reported treating less than 
five (0-5) new cases of AHA per year. All of the remaining respondents (n=6, 16.7%) 
responding reported treating between five and ten new cases per year. No respondent 
reported treating more than ten new cases of AHA per year.  
5.4.1 Selection of First Line Haemostatic Agent 
Assessment of first line haemostatic agents used in the treatment of bleeding demonstrated 
that 61.8% (n=21) of respondents use Factor Eight Inhibitor Bypassing Activity (FEIBA®), 
35.3% (n=12) recombinant activated factor VII (rFVIIa, NovoSeven®) and 2.9% (n=1) high dose 
factor VIII. Despite a higher number of treaters opting to use FEIBA® in comparison to 
NovoSeven®, this did not reach statistical significance (p=0.117). 
5.4.2 Selection of First Line Immunosuppression 
An assessment of favoured first line immunosuppressive agent(s) was evaluated in three 
representative clinical groups (Figure 5.1). These consisted of: (A) patients <65 years or with 
minimal medical co-morbidity; (B) patients >65 years or with significant medical co-morbidity 
and (C) pregnancy associated AHA. The majority of respondents chose steroids alone or 
steroids and a cytotoxic agent (Group A 91.1%, B 82.4%, C 96.9%) as first line 
immunosuppression regardless of the clinical group (Figure 5.1). The remaining respondents 
mainly used rituximab based regimens either alone, or in combination with steroids. No 
respondent reported using a ciclosporin or a FVIII (ITI) based regimen as first line treatment.  
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A comparison was then made of usage of steroids alone versus steroids in combination with 
a cytotoxic agent for these three clinical groups. Data for other immunosuppressive choices, 
which contained ≤3 respondents were excluded to allow comparison with consensus 
guidance 119;319. In the treatment of pregnancy associated AHA (Group C), significantly more 
respondents reported using steroids in isolation (83.9%, 26/31) compared with steroids and 
cyclophosphamide (16.1%, 5/31; p<0.0005). In patients <65 years (Group A), although the 
percentage of respondents using steroids alone (64.5%, 20/31) was higher than for steroids 
plus cyclophosphamide (35.5%, 11/31), this did not reach statistical significance (p=0.106). 
Similarly, in patients >65 years (Group B), although a higher proportion of respondents 
reported using steroids alone (64.3%, 18/28) compared to steroids and cyclophosphamide 
(35.7%, 10/28), this did not reach statistically significant (p=0.131). 
 
Figure 5.1: First line immunosuppressive agent choices for the management of acquired 
haemophilia A, in three clinical scenarios. (Group A) <65 years or with minimal medical co-
morbidity; (Group B) >65 years or with significant medical co-morbidity and (Group C) 
pregnancy related AHA. Based on a figure in Batty et al 321, reproduced with the permission 
of the publisher.   
5.4.3 Laboratory Monitoring of Treatment and Immunosuppressive Weaning 
Next an evaluation of the laboratory tests performed to monitor treatment response and 
immunosuppressive weaning was performed. All participants reported using a FVIII:C assay  
in combination with an inhibitor assay (Bethesda assay or equivalent) to monitor treatment 
response. For guiding of weaning of immunosuppression the majority (85.3%) used the 
FVIII:C in combination with an inhibitor assay and 14.7% used the FVIII:C alone. Only one 
respondent reported using pre-analytical heat treatment to denature residual FVIII:C prior to 
0
5
10
15
20
25
30
Steroid Alone Cytotoxic
Alone
Steroid and
Cytotoxic
Anti-CD20
mAb
Steroid and
Anti-CD20
mAb
Ciclosporin
Based
Regimen
FVIII (ITI)
Based
Regimen
N
u
m
b
er
 o
f 
re
sp
o
n
se
s 
(n
)
Group A (< 65 years) Group B (> 65 years) Group C (pregnancy associated)
 109 
 
inhibitor testing. No respondents reported using either an ELISA (immunological testing) or 
global haemostatic assays to monitor treatment or guide weaning.  
5.4.4 Factors Affecting Timing of Commencement of Weaning of Immunosuppression 
Next an assessment of timing of commencement of weaning of immunosuppression was 
performed based on the results of laboratory results (6 potential options). There was marked 
variation in the reported timing of the weaning of immunosuppression (Table 5.1). The 
commonest strategies seen were to start weaning after the FVIII:C had normalised and the 
inhibitor assay had become negative (n=11, 33%), a time-point, equivalent to complete 
remission in recent studies 117;118. The second commonest timing to commence weaning was 
after the FVIII:C, had started to rise, but had not yet normalised (n=8, 24%). Analysis of the 
distribution of responses for timing of weaning, did not differ significantly from that expected 
by chance (p=0.073). A secondary analysis was performed grouping responses into two 
categories to compare commencement of weaning prior to (responses 1-4) or following 
(responses 5-6) obtaining complete remission (Table 5.1). This demonstrated no significant 
difference in the proportion of respondents who commence weaning prior to (51.5%, 17/33), 
or upon achieving (48.5%, 16/33) complete remission (p=0.862).  
 Laboratory Variables Response % (n) Response 
1 As soon as inhibitor assay* negative 9.1% (3) NR 
2 Once FVIII:C starts to rise but not yet normal 24.2% (8) NR 
3 After a period of maintained inhibitor assay* 
negativity 
9.1% (3) NR 
4 As soon as FVIII:C within the normal range, 
regardless of low level inhibitor assay* 
positivity 
9.1% (3) PR 
5 Once FVIII:C is within the normal range and 
inhibitor assay* is negative 
33.3% (11) CR 
6 After a period of FVIII:C being within the 
normal range and inhibitor assay* negativity 
15.2% (5) CR 
Table 5.1: Timing of commencement of weaning of immunosuppression based on 
laboratory variables in acquired haemophilia A.*Bethesda assay (or equivalent). NR=No 
response, PR=Partial remission, CR=Complete remission. Categories 1-4 indicate scenarios 
of patients not in complete remission, categories 5-6 represent scenarios of patients within 
complete remission. Based on a table in Batty et al 321, reproduced with the permission of 
the publisher.   
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5.4.5 Factors Affecting Speed of Weaning of Immunosuppression 
Next approaches to speed of weaning of immunosuppression, were evaluated in a scenario 
of an uncomplicated patient in complete remission following treatment with steroids alone. 
Respondents could choose one of three speed of weaning options: gradual (e.g. 60mg-50-
40-35-30-25-20-15-10-5-2.5-stop); intermediate (e.g. 60mg-40-30-20-10-5-stop) or rapid 
(e.g. 60mg-30-15-7.5-5-stop). Fifty percent (n=17) opted for a gradual, 44% (n=15) an 
intermediate and 6% (n=2) a rapid approach to weaning of immunosuppression 
 Speed Up No Change Slow Down p 
Bleeding at diagnosis 
(requiring bypassing 
agents) 
2.9% (1) 58.8% (20) 38.2% (13) 0.392 
Supra-normal FVIII:C 
 (e.g. >200IU/dL) 
55.9% (19) 41.2% (14) 2.9% (1) 0.392 
Steroid side effects 82.4% (28) 14.7% (5) 2.9% (1) <0.0005 
Cytotoxic side effects 90.9% (30) 3.0% (1) 6.1% (2) <0.0005 
Only achieving low 
normal FVIII:C (e.g. 50-
60IU/dL) 
2.9% (1) 70.6% (24) 26.5% (9) 0.0243 
Pregnancy associated 
AHA 
29.0% (9) 71.0% (22) 0.0% (0) 0.0294 
Table 5.2: Factors affecting weaning of immunosuppression in acquired haemophilia A. 
Numbers in brackets represent number of respondents. P refers to a two-tailed binomial 
probability test, with the null hypothesis that p=0.5 for the selection of no change. Based 
on a table in Batty et al 321, reproduced with the permission of the publisher. 
Finally, respondents were asked to rate whether a number of clinical and laboratory factors 
might influence their speed of weaning of immunosuppression (Table 5.2). For each scenario, 
an option of speed up, no change or slow down weaning of immunosuppression was 
provided. There was fair overall inter-rater agreement (κ=0.335) for factors influencing 
weaning of immunosuppression. Looking at each category, there was moderate agreement 
for factors relating to shortening of the weaning period (κ=0.490), with only fair and slight 
agreement to factors leading to no change (κ= .   ) or prolongation (κ=0.158) of the 
weaning period. Toxicity, either from steroids or cytotoxic agents was significantly associated 
with a change in weaning speed, with 82.4% (n=28, p<0.0005) and 90.9% (n=30, p<0.0005) 
of respondents reporting shortening of the weaning period. Achievement of only a low 
normal FVIII:C e.g. 50-60IU/dL (n=24, 70.6%, p=0.0243) and pregnancy associated AHA (n=22, 
71.0%, p=0.0294), were significantly associated with no change in weaning strategies. 
Although, a number of respondents reported shortening weaning for supra-normal FVIII:C 
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e.g. >200IU/dL (n=19, 55.9%, p=0.392) and prolonging for bleeding at diagnosis (n=13, 38.2%, 
p=0.392), these changes were not statistically significant.  
5.5 Discussion 
This is the first nationally co-ordinated survey in the UK of treatment and immunosuppressive 
weaning practices amongst treaters of AHA. These survey data, demonstrate that within a 
group of haematologists from a country with published consensus guidelines for the 
management of AHA, there is heterogeneity at all stages of treatment choices. This starts 
from the initial selection of immunosuppression, but is even more notable in the approaches 
seen to weaning of immunosuppression.  
5.5.1 Choice of Haemostatic Agents to Treat Bleeding 
In the treatment of bleeding in AHA, there are a number of options including, aPCC, rFVIIa 
and high dose FVIII. Of these, bleeding control has been demonstrated to be significantly 
higher for the usage of bypassing agents over FVIII (93.3% v 68.3%, p=0.003) 220. In keeping 
with these data, all except for one respondent selected using a bypassing agent for first line 
management of bleeding. In the selection of bypassing agents, although there has been no 
direct comparison of efficacy for these agents in AHA, a retrospective analysis of the data 
from the EACH2 cohort has suggested these to have similar efficacy and safety profiles 220. In 
this survey there was a trend (non-significant) towards selection of an APCC over rFVIIa (61.8 
v 35.3%) for treatment of bleeding. This finding, is similar to data observed within the 
UKHCDO annual reports over many years (Hay C.R., Professor in Haematology, Manchester 
Royal Infirmary, personal communication) 321. Similar data has also recently been reported in 
a cohort of patients (n=65) treated within the London CCCs and HTCs (1/2009-12/2012) 322. 
In this, aPCC alone were used to treat 33/65 patients in comparison to 5/65 patients who 
were treated with rFVIIa alone. These findings however, are in contrast to bypassing agent 
use previously reported in a national UK AHA surveillance study 106, the EACH2 220 and 
Surveillance des Auto anti-Corps au cours de L’Hémophilie  cquise (SACHA) studies 117. 
Within the reported national surveillance study, similar proportions of patients were treated 
with both agent (APCC alone=25%; rFVIIa alone=21%) and in the EACH2 study, rFVIIa was 
used in twice as many patients as aPCC (56.7 v 20.5%) 323. Similarly in the SACHA study, rFVIIa 
alone, was used to treat 28/37 patients and aPCC alone 6/37 patients 117. These recent data 
may represent a change in practice in the UK, since the previously published two year (1/5/01 
and 30/4/03) surveillance study 106. 
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5.5.2 Choice of First Line Immunosuppression  
In the treatment of AHA unrelated to pregnancy, there was a divide in respondents favouring 
steroids in isolation to steroids in combination with a cytotoxic agent. Forty one percent of 
respondents (n=13) reported only using steroids in isolation regardless of the clinical scenario 
(Group A, B or C). This variability, reflects the lack of clear data to provide treatment guidance 
for first line immunosuppression within the published literature 119;319. Within the EACH2 
study, although the combination of steroids and cyclophosphamide was associated with 
higher rates of stable complete remission (70% v 48%) compared to steroids alone, this did 
not translate into a survival benefit at final assessment and was associated with a higher rate 
of treatment related toxicity (25% v 41%) 318. To date, there has been only one small 
prospective interventional study (n=31) investigating first line immunosuppression 324. This 
study showed no difference with the addition of an alkylating agent to steroid treatment in 
patients with residual FVIII auto-antibody following treatment with steroids alone for 3 
weeks. The study was underpowered to identify differences between the treatment arms 
and only managed to recruit 31 patients (of a target of 100) over 5 years. 
A small proportion of respondents (Group A, n=3; Group B, n=5 and Group C, n=1), opt to use 
an anti-CD20 monoclonal antibody (rituximab) as part of first line therapy. Although, a 
number of recent reports have described high response rates for the use of first line 
rituximab 325;326, there are no data yet to suggest this approach is superior to conventional 
first-line immunosuppression 318. No respondent reported using ciclosporin or a FVIII (ITI) 
based regimen as first line treatment. There has been one case series describing the use of 
calcineurin inhibitors in 11 patients (8 ciclosporin and 3 tacrolimus) in combination with 
steroids (pulsed intravenous methylprednisolone day 1-3, followed by oral prednisolone), 
which demonstrated sustained response in 10 patients, at a median of 3 weeks (2-8 weeks), 
with no relapse at 14 months of follow-up. In this series, there was one serious adverse event 
(hypertensive posterior progressive encephalopathy) and the 5 year survival rate was 54.5%, 
with the cause of mortality being the underlying disorder or senescence in all 5 cases 327. 
Within the EACH2 study, although 5 patients received treatment that included cyclosporin 
no response data was presented due to the small number of cases included. There have also 
been two single centre descriptions of the use of ITI for the treatment of AHA 328-330. The first, 
used a three week protocol of intravenous methylprednisolone (100mg; one week tapering 
for week 2-3), cyclophosphamide (200mg; 10-15 days) and daily FVIII (30IU/kg week 1, 
20IU/kg week 2 and 15IU/kg week 3) 328. Inhibitor eradication was seen in 13/14 patients 
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treated with ITI at a mean of 4.6 weeks, compared to 4/6 patients at 28.3 weeks in a historical 
control group. There was no bleed related mortality in the ITI group, with 2 deaths (33%) 
related to bleeding in the control group. Interpretation of this study is limited by poor 
selection of historical controls, which are unmatched in all baseline characteristics. It is also 
not clear, how much of this response was a result of more intensive immunosuppression in 
the ITI group, especially in view of relatively low FVIII dosing in patients who will have normal 
endogenous FVIII production. Finally usage of the Bonn protocol (immunoadsorption days 1-
5; IVIg days 5-7; cyclophosphamide and prednisolone from day 1 until remission; high dose 
FVIII (100IU/kg) every 6 hours), has been described over a period of 19 years 329;330. This group 
treated    “high-risk” patients, which was were defined as one acute bleeding episode, with 
a fall in haemoglobin to <8.0 mg/dl and the presence of multiple hematomas. Using this 
protocol, 63 patients completed treatment, with complete remission seen in 54/63 and 
partial remission in 5/63 (overall response rate 93%). The median time until the inhibitor 
became undetectable was 3 days, with a median of 17 days FVIII treatment and 16 days 
immunoadsorption. Although both studies demonstrated fast responses to treatment with 
no bleed related mortality, lack of adequate control groups make interpretation of these 
response rates difficult and require confirmation in larger studies.  
In the management of AHA associated with pregnancy, the majority of respondents (n=26, 
81%), chose steroids alone as their preferred first line immunosuppressive agent(s).  This is 
in keeping with the treatment options seen in the EACH2 study, in which data is presented 
on 39 cases received immunosuppression (total 42 cases, 3 cases no data available). Of these 
the majority (n=27) were treated with steroids alone, with 6 patients receiving steroids and 
cytotoxic, 4 steroids and IVIg and 2 steroids and rituximab 109. A total of 29 patients (79%), 
went in to complete remission with first line treatment and at final follow-up, 86% of the 
total cohort (36/42) were in complete remission. All 40 of the patients, in which data was 
available were alive at final follow-up.    
5.5.3 Weaning of Immunosuppression and Treatment Related Toxicity 
Toxicity relating to treatment is currently one of the main difficulties in the management of 
AHA as highlighted in recent studies 106;117;118;318.  In keeping with these trial data toxicity from 
immunosuppression (steroids or cytotoxic agents) was reported in this survey to significantly 
impact on weaning of immunosuppression, with the majority of respondents shortening the 
weaning period on this basis. One potential way to limit the toxicity of immunosuppression 
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would be to wean earlier. The GTH-AH 01/2010 study is the only multicentre studied 
published to date in which there was clear guidance on weaning of immunosuppression. 
Tapering of immunosuppression was commenced at achievement of partial remission (FVIII:C 
>50IU/dL; no active bleeding after stopping haemostatic drugs for >24 hours), with cessation 
of cyclophosphamide/rituximab and then tapering of steroids over 6 weeks (descending 
doses of 50, 25, 20, 15, 10, 5mg, for 1 week each). With this rapid weaning schedule, of those 
achieving partial remission 19 (22%) had a fall in FVIII:C <50% requiring an increase in steroid 
dose and a more prolonged tapering, with 11 (95%) of these patients going on to obtain a 
complete remission. Data from this UK survey, demonstrated a more cautious approach to 
weaning immunosuppression, with only 9.1% (3/33) commencing weaning of 
immunosuppression at a timing which would be similar to partial remission in the GTH-AH 
01/2010 study (Category 4). In looking at approaches to weaning speed, 44% (n=15) 
respondents, took an intermediate approach to weaning, similar to the weaning protocol in 
the GTH-AH 01/2010 study, although without a proscriptive timing over which weaning is 
performed within this survey this is difficult to compare directly. This weaning schedule in 
the GTH-AH 01/2010 study may be appropriate for some patients with a lower risk of relapse 
to prevent additional toxicity, although requires further assessment in prospective study.   
5.5.4 Laboratory Monitoring of Treatment Response in Acquired Haemophilia A 
Monitoring of response and weaning was almost entirely based on the results of the FVIII:C 
and inhibitor assay. This is in keeping with published international consensus 
recommendations for the management of AHA 119. It is interesting to note that only one 
respondent reported using pre-analytical heat treatment to denature residual FVIII:C prior to 
testing. At the time this survey was conducted, this was routine practice in our centre 
(discussed in more detail in Chapter 7), but appears not to have been as widely used in the 
rest of the UK. One year after this survey was conducted, following the presentation of a 
number of reports by our group and others on usage of pre-analytical heat treatment, there 
appears to have been a change in practice within the UK with increased usage in a NEQAS 
exercise from November 2013 331. Usage of pre-analytical heat treatment as part of FVIII 
antibody testing in AHA is discussed in more detail in Chapter 7.  
5.5.5 Limitations and Use of Web Based Questionnaires in Healthcare Research 
With the increased routine use of the internet in healthcare environments and user friendly 
interface of online survey platforms, online surveys provides an attractive platform for 
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researchers in rare disorders. These provides a rapid, cheap and standardised methodology 
for collecting information on current practice, attitudes of physicians and the impact of 
recent research on their clinical practice 332;333. Understanding of these areas can help define 
healthcare policy, identify areas of required research and inform potential future study 
design. However, when using this approach it is important that the group that are sampled 
form a representative population of clinicians in whom findings will be generalised. The 
response rate (44-46%) seen in this survey is comparable to other online (single media) 
surveys conducted without provision of financial incentive 334-336. Within the centres surveyed 
there were paediatric centres (n=7) and centres which subsequently became inactive (n=10) 
in the year following the survey. If only active adult haemophilia centres were assumed to 
have participated, it is possible that the response rates could have been in the region of 
59.0% (36/61). It is however not possible to confirm the exact proportions of individual and 
centre response or the split between haemophilia centres and comprehensive care centres 
consequent on maintaining anonymity for respondents. Previous international and European 
surveys, carried out in AHA demonstrated response rates of 59% (118/200) and 16% (81/522) 
respectively 110;115. Despite technological advances to facilitate conducting surveys there are 
concerns that there may be a decline in the response to surveys by physicians. A review of 
response rates to physician surveys, demonstrated a small, but significant difference in 
response rates in surveys conducted between 1989 and 1995 (61.2%, 257 studies) and those 
between 1996 and 2005 (57.5%, 237 studies, p=0.02) 337;338. A Canadian study carried out in 
general practitioners and gynaecologist investigating reasons for lack of survey response, 
found reasons included inaccurate central listings (17.3%), physicians being away (2.6%), 
ineligibility due to practice type (18.5%) and office policy not to participate in surveys (36.3%) 
339. There are conflicting data from previous research as to factors that may affect response 
rates to surveys based on their methodology and design. Specific methods applied within this 
survey to maximise response rates 336;340 were usage of a short survey format (median 
response time 3 minutes and 4 seconds), UKHCDO centralised study, follow-up contact 
(repeat email after 1 month) and an interesting questionnaire topic (following recent 
publication or the EACH2 study). Given the design of the study it was not possible to allow 
personalised contact of non-responders or to provide incentives to survey. Methods that may 
have provided greater response rate would have been to allow respondents to reply via 
different modalities (e.g. post or internet) and through additional reminder emails, being 
sent to the target population.   
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One of the main advantages of using this methodology, was that it ensured anonymity for 
survey respondents, which could potentially reduce selection and response biases. It is likely 
that responses may be influenced by respondents’ anecdotal e perience of managing this 
rare condition in addition to awareness of recent data 318;323;341-344. The usage of 
anonymisation may have limitations as it is not possible to confirm that the survey was 
answered by the intended audience of the original email. For example, the email invitation 
could have been forwarded on to other interested members of the treatment team in one 
centre. An internet option was chosen to allow ease/speed of response and anonymity, 
despite recognition that this may potentially result in lower response rates. Although usage 
of a centralised method of disseminating the email link for this survey, allowed complete 
blinding to the clinicians in whom the survey was directed this has a number of potential 
problems, including difficulty in calculation of the precise number recipients for of the 
denominator. It is also not possible to assess how many individuals either did not open 
original emails or accessed the survey site and did not proceed with survey.  
5.5.6 Aging Population in the United Kingdom 
Similar to other areas of medicine, we are faced with an aging population. In 2010, the 
percentage of the population aged >65 years was 17%, with this projected to rise to 23% by 
2035 345. In the management of AHA this potentially poses two difficulties. Although, the 
overall incidence of AHA is reported at 1.48 million/year, this has been reported as increasing 
with age. In patients aged 16-64, there is an incidence of 0.3 million/year, which increases 
from 9 million/year to 15 million/year in patients aged 65-8  and ≥8  years old, respecti ely 
106;113. Given the projected rise in patients over 65 in the next decade, one would expect to 
see an increased incidence of AHA, assuming that the primary immunological mechanism is 
loss of tolerance to FVIII, resulting from the aging immune system (immunosenescence). 
Secondly, there is a well reported increase in multi-morbidity (presence of two or more co-
existing medical conditions) associated with age. In a large cross sectional study of the 
Scottish population (1.75 million individuals), 64.9% of patients aged 64-84 had multi-
morbidity, with this number rising to 8 . % in those aged ≥8  years 346. With the prevalence 
of multi-morbidity in the elderly, it is perhaps unsurprising there have been a large number 
of adverse events reported in previous studies of AHA relating to steroids and 
myelosuppressive drugs. Although there is requirement for more intensive 
immunosuppression in some patients with AHA, there is a need for further study of risk 
stratification based on clinical data and biomarkers. Development of such prognostic models, 
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given the rarity, heterogeneous aetiologies, limitations of diagnostic testing, and incomplete 
understandings of the underlying immunological mechanism may be difficult even in the 
context of an international study. 
5.6 Conclusions 
Conducting prospective interventional studies in very rare diseases such as AHA is challenging 
on account of the acute nature of presentation, significant multi-morbidity and statistical 
power considerations. Understanding trends in treatment practices, which have been 
obtained through these survey data are helpful for the design of protocols and gauging 
acceptable to physicians and patients. There are many unanswered questions in the 
management of AHA, which limit the development of clinical prediction tools to stratify risk. 
Although this survey is underpowered to make conclusions to guide clinical practice, I feel it 
offers a representati e impression of treaters’ preferences within one country, confirming 
the clinical equipoise that existing in the management of AHA. Despite commonly cited, peer-
reviewed guidelines in the UK, immunosuppression choice remains at the physician’s 
discretion and there is no proscriptive guidance on immunosuppression weaning 347. One of 
the aims of this survey was to describe current treatment practice in the United Kingdom in 
AHA, in advance of the development of a prospective interventional study in the 
management of AHA (Collins P., Professor in Haematology, Arthur Bloom Haemophilia 
Centre, Cardiff, personal communication). The heterogeneity highlighted in this survey, 
reflects the lack of clarity in published guidance, itself a function of a paucity of data and 
need for an appropriately designed prospective randomised study.   
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Chapter 6: Diagnostic Accuracy Study of a Factor VIII ELISA Kit for Detection 
of Inhibitory Antibodies in Congenital and Acquired Haemophilia A 
6.1 Introduction 
Antibodies to FVIII may arise at any stage of life in a person with any severity of haemophilia 
A 166;174;199. The urgency of testing for these antibodies will vary depending on the clinical 
context. In severe haemophilia A, laboratories are required to provide urgent inhibitor 
surveillance assay results during the early treatment of previously untreated patients (PUPs) 
149;214 or where there is impaired treatment efficacy or pharmacokinetic parameters 
(recovery or half-life) following an infusion of a FVIII concentrate. Urgent testing is important 
in these circumstances to allow provision of adequate haemostatic therapy for treatment of 
acute bleeding or prevention in the peri-operative period. Early detection may be associated 
with an improved outcomes through early commencement of ITI 348. There is similar urgency 
to confirm the presence of auto-antibodies to FVIII in AHA 119;319, to allow early 
commencement of haemostatic and immunosuppressive therapy. Aside from these two 
scenarios, comprising a minority of tests in most centres, most FVIII antibody assays 
performed within the CCC haemostasis laboratory are for the purpose of routine surveillance 
or screening. This may however, differ between centres depending on the age range of 
patients treated within that centre.  
The optimal test for FVIII antibody screening would be one that could be performed simply 
with both high specificity and negative predictive value. This would also ideally provide 
information to the clinician about the functional capacity of the FVIII antibody to influence 
treatment decisions. The most widely used assay for the detection of antibodies to FVIII is 
the NBA 273;276, which is associated with well documented inter-laboratory variability 278;298;299 
and affected by numerous pre-analytical variables 288;289 as discussed earlier in Chapter 1. 
Despite these limitations the NBA is considered the “gold standard” assay for detection of 
FVIII antibodies 214;270.    
  number of “immunological” assays, have been described for the detection of FVIII 
antibodies in research settings (discussed in Chapter 1), which include enzyme linked 
immunosorbent assays (ELISA) 262;300-303;349, fluorescence based immunoassays 259-261 and 
immunoprecipitation 265;266. A FVIII ELISA offers a simple approach to detect FVIII antibodies 
and is potentially less susceptible to the pre-analytical variables affecting functional inhibitor 
assays. Despite descriptions of usage of both commercial and in-house ELISAs in research 
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settings, this approach is not currently part of routine laboratory practice. A FVIII ELISA kit 
was introduced into routine laboratory practice in 2009-2010 in two London haemophilia 
CCCs. In this chapter the performance of this FVIII ELISA kit will objectively reviewed following 
implementation into routine laboratory practice.  
6.2 Hypothesis and Aims 
The hypothesis for this chapter is that a FVIII ELISA kit offers a simple approach for batch 
screening for FVIII antibodies in congenital and acquired haemophilia A in routine laboratory 
practice. The role of this assay as a screening test in routine haemostasis laboratory practice 
test has not previously been described. This is also the first formal comparison of the 
performance of a new assay compared to the NBA following the Standards for the Reporting 
of Diagnostic Accuracy Studies (STARD) criteria 271  for the reporting of diagnostic accuracy 
studies. This ELISA kit could allow early detection of FVIII antibodies that may provide a 
biomarker to predict the development of an immune response. It is hypothesised that the 
semi-quantitative results of this assay is directly associated with inhibitory capacity when 
measured using a functional inhibitor assay. The specific aims for this chapter are as follows: 
1) Compare the diagnostic accuracy of a FVIII ELISA kit to the NBA for detection of FVIII 
antibodies in patients with congenital and acquired haemophilia A. 
2) To model the effect of inter-individual clustering of data on the primary estimates 
within the diagnostic accuracy assessment.  
3) To describe the utility of the FVIII ELISA in testing of clinical samples for FVIII 
antibodies based on the results of the diagnostic accuracy assessment. 
4) To evaluate association between the results of the NBA and FVIII ELISA and to assess 
whether there is correlation between the results of these two assays. 
6.3 Materials and Methods 
Sample Selection and Inclusion/Exclusion Criteria 
All samples sent for routine FVIII inhibitor testing from patients with congenital and acquired 
haemophilia A were tested in parallel using the Nijmegen-Bethesda assay and a FVIII ELISA 
as part of routine clinical care. At centre 1 (The Royal London Hospital, London, UK), samples 
were tested between 9/9/2010-  / /     and at centre   (St Thomas’ Hospital, London, UK) 
between 11/12/2009-28/09/2011. Testing was performed within the specialist haemostasis 
laboratories of both centres. The results of both assays were made available on the electronic 
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reporting systems to the treating haematologist, with neither laboratory nor clinical staff 
being blinded to results of these tests. Samples were tested only once in the laboratory of 
the haemophilia centre in which the patient was being managed and no repeat testing was 
performed. 
A retrospective assessment of the performance of the ELISA was made based on the results 
of anonymised samples (discussed below), with a sub-group analysis performed using 
diagnostic labels provided at the time of venepuncture. No additional demographic or clinical 
data were retrieved to maintain patient anonymity. Samples were included, if they had a 
diagnostic label of either congenital (severe or non-severe) or acquired haemophilia A and 
where results from both assays were available. Samples were excluded, if the diagnostic label 
indicated a non-haemophilia A (congenital or acquired) diagnosis or if one (or more) of the 
assays had not been performed. All diagnoses were made by the local laboratory, with severe 
haemophilia A defined as a baseline FVIII:C <1IU/dL and non-severe haemophilia A 1-40 IU/dL 
63;70. Acquired haemophilia A, was defined as the presence of bleeding (acute or recent onset) 
with an unexplained prolongation of the activated partial thromboplastin time (aPTT) that 
does not correct on appropriately incubated mixing studies, associated with a low FVIII:C 
119;319. Local approval was granted at both centres for the evaluation of the efficacy (service 
evaluation) of the introduction of the ELISA in routine laboratory practice.   
Nijmegen-Bethesda Assay 
Inhibitor testing was performed following local protocols using the Nijmegen-Bethesda assay 
as described earlier (Chapter 3). At centre 1, assessment of residual FVIII:C was performed 
using a one stage FVIII:C assay with a cut-off for positi ity ≥ . BU/mL based on consensus 
recommendations 270. At centre 2, 4%BSA was used in the place of FVIII deficient plasma in 
the control sample and for test dilutions, with measurement of residual FVIII:C using a 
chromogenic FVIII assay. The cut-off for centre   was ≥ .7BU/mL, defined by in-house by 
dilution studies of a commercially available lyophilised FVIII inhibitor plasma 350. Inhibitors at 
both centres were defined as being of low-titre if the B  was ≤5BU/mL and high-titre if the 
NBA was >5BU/mL 63;70.  
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Factor VIII Indirect ELISA Kit  
A FVIII ELISA was performed as part of routine testing of samples sent for inhibitor screening 
at both centres as described in Chapter 3. Samples were defined as being positive if the ELISA 
optical density (OD) was greater than that of the kit control (KC). 
Statistical Analyses 
A diagnostic accuracy evaluation was performed for the results of samples tested in parallel 
by the FVIII ELISA (index test) and NBA (reference test) as a post-hoc analysis on an 
anonymised grouped database. Sub-group analyses, were performed based on diagnostic 
headers provided at the time of venepuncture. A whole case analysis was performed, as it is 
likely that missing data was missing not at random (MNAR); for example a test may not have 
been performed due to high or low clinical suspicion on the basis of previous 
clinical/laboratory information. The performance of the index test (ELISA) was summarised 
using sensitivity, specificity and predictive values (negative and positive). Confidence 
intervals (binomial exact) were calculated from the standard error taking these values as 
proportions 351. In view of multiple assays being performed in some patients, adjustments 
were made to these calculations to account for inter-individual clustering. This was modelled 
using logistic regression with sandwich estimator, logistic random-effects model (random 
effect across clusters) and generalised estimating equations (exchangeable correlation 
matrix) as described previously 352.  
An additional post-hoc analysis of the unadjusted data is presented in the form of likelihood 
ratios (negative and positive) and diagnostic odds ratios 353. Confidence intervals were 
calculated from the standard error (SE) for the likelihood ratio as previously described 354 and 
for the diagnostic odds ratio using the formula log DOR ± 1.96SE(log DOR) 353. Assessments 
of association of the results of both assays was performed utilising correlation (Pearson) and 
linear regression using the log-adjusted results of the NBA in comparison to the ELISA OD. To 
account for inter-individual clustering of data within these analyses the first recorded 
positive database entry was used. Statistical analysis of continuous variables was performed 
using a one-way ANOVA, with post-hoc comparison of groups using the post-hoc Turkey test 
355.  
The findings of this study are presented, following the recommendations of the Standards 
for the Reporting of Diagnostic Accuracy Studies (STARD) Statement 271. The STARD initiative 
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reported in 2002, with an aim of improving the quality of reporting of diagnostic accuracy 
studies, which includes a 25 item checklist and study flow chart template. The aim of this was 
to increase transparency of reporting and ensure all relevant study details are present which 
facilitates inclusion of data within meta-analysis and interpretation of potential bias. The 
STARD flow chart is presented in Figure 6.1 and the checklist in Appendix 1, respectively.  
6.4 Results 
6.4.1 Cohort Demographics 
During the observation period 569 samples (273 patients) were sent for inhibitor testing, 
with a mean number of 2.8 samples tested per week. Of these samples, 17 (14 patients) were 
excluded due to a non-haemophilia A diagnosis and 55 (45 patients) due to incomplete 
testing (Figure 6.1). In samples excluded due to incomplete testing, the reasons for these 
exclusion were the absence of NBA (n=51), lack of ELISA testing (n=2) or neither test being 
performed (n=2). Following exclusions, data were evaluable for 497 samples (239 patients). 
Of these samples, 59% (n=291, 140 patients) were from patients with severe haemophilia A, 
26% (n=129, 86 patients) from patients with non-severe haemophilia A and 15% (n=77, 14 
patients) from patients with acquired haemophilia A (Figure 6.1). Although, similar numbers 
of samples were tested at each centre; 113 (47.3%) for centre 1 and 126 (52.7%) for centre 
2, there was a difference in the clinical case load. At centre 1, more samples were tested from 
patients with non-severe haemophilia (54 v 31 patients) or AHA (10 v 4 patients) and at 
centre 2 more samples were tested from patients with severe haemophilia A (91 v 49 
patients). The mean number of samples tested per patient was 2.1 (range 1-20), with a single 
sample tested in 145 patients (60.7%) and more than one sample in 94 (39.3%). Patients with 
AHA, had significantly more samples (mean 5.5±SD 6.0) tested during the observation period 
than those with severe (mean 2.1±SD 2.0, p<0.005) or non-severe HA (mean 1.5±SD 1.9, 
p<0.005).  
  
 
1
2
3
 
 
Figure 6.1: STARD diagnostic accuracy study flow chart. Flow chart shows samples included and excluded within this analysis, with classification by test 
result and diagnostic header.
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6.4.2 Samples Positive by the Nijmegen-Bethesda Assay (Reference Test) 
There were 63 samples, that tested positive by the NBA from 28 patients (severe=17, non-
severe=6, acquired=5), resulting in an inhibitor sample and patient prevalence of 12.7% and 
11.8%, respectively. The median inhibitor titre of NBA positive samples was 1.2BU/mL (range 
0.7-978.0) with 49 being low-titre (median 1.1BU/mL, range 0.7-4.8) and 14 high-titre 
(median 63.7BU/mL, range 11.8-978.0). Of these 63 NBA positive samples, 49 (18 patients) 
were also positive by ELISA and 14 (13 patients) negative by ELISA (Figure 6.1). In samples 
classified as low-titre by the NBA and ELISA positive (n=35), the mean ELISA OD was 0.82 
(range 0.25-1.98). The ELISA OD was ≤ . , in 29/35 (82.9%) of these samples. An ELISA OD of 
>1 and <2 was seen in 5/35 samples and an OD of 2.0 in a single sample. For samples classified 
as high-titre (n=14), the mean ELISA OD was 2.03 (range 0.59-3.36). Within this group, the 
majority (85.7%, 12/14) of these samples, had an D ≥ .  and  /   (  . %) had an  D ≥ . . 
Two samples, from one patient with high-titre antibodies by the NBA, were recorded as 
ha ing an  D ≤ . .  
All samples that tested negative by the ELISA and positive by NBA (n=14) were of low-
inhibitory titre with a mean inhibitor titre of 0.8BU/mL (range 0.7-1.0). The mean ELISA OD 
for these samples was 0.23 (range 0.04-0.58), with the mean ELISA KC for these samples 
being similar (mean=0.44, range 0.22-0.62) to the cut-off seen for all samples. All of these 
patients had congenital haemophilia A (severe=9, non-severe=4) and the majority (13/14) 
were tested in centre 2. A further review of all samples sent in this group of patients was 
then performed. An additional sample was tested at some point within the observation 
period in 84.6% (11/13). All other tests recorded were negative by both assays in 8/11 (73%) 
patients, with only 3/11 (27%) patients demonstrating positivity by either the ELISA and/or 
the NBA in an additional sample (Table 6.1; Groups X and Y). 
6.4.3 Samples Negative by the Nijmegen-Bethesda Assay (Reference Test) 
There were 434 samples (226 patients) that tested negative by the NBA, of which 26 (15 
patients) tested positive by the ELISA and 408 (218 patients) negative by the ELISA. For 
samples that tested negative (n=408) by both assays the mean ELISA OD was 0.12 (range 
0.03-0.59) with a mean KC OD of 0.36 (range 0.16-0.67). The diagnostic header on these 
samples was severe HA=130, non-severe HA=78, AHA=10.  
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Of the samples that tested negative by the NBA and positive by the ELISA (n=26) the mean 
ELISA OD was 0.63 (range 0.20-1.59) with a mean KC OD of 0.34 (range 0.16-0.67). The mean 
sample FVIII:C was 62.4IU/dL (range <1-362.4), with 18 samples (69%) having a FVIII:C 
≥ IU/dL. Of these 26 samples (15 patients) positive by the ELISA, but negative by the NBA, 14 
(5 patients) were tested by centre 1 (non-severe HA=3, AHA=1) and 12 (10 patients) by centre 
2 (severe HA=6, non-severe HA=3 and AHA=1). Additional samples were tested in 8/15 
patients at another point within the observation period. A positive result was seen on 
another sample by the NBA and or the ELISA in 75% (6/8) of these cases (Table 6.1, Groups X 
and Z), in contrast to patients with samples that were NBA positive and ELISA negative (Group 
Y). In the remaining two patients all other samples tested were negative by both assays.   
Patient Samples B+E- B-E+ B+E+ B-E- Group 
1 14 1 1 6 6 X 
2 10 1 2 1 6 
3 8 2 0 3 3 Y 
4 5 1 0 0 4 
5 4 1 0 0 3 
6 3 1 0 0 2 
7 3 1 0 0 2 
8 3 1 0 0 2 
9 2 1 0 0 1 
10 2 1 0 0 1 
11 2 1 0 0 1 
12 1 1 0 0 0 
13 1 1 0 0 0 
14 16 0 1 6 9 Z 
15 12 0 1 0 11 
16 10 0 7 0 3 
17 7 0 4 1 2 
18 2 0 2 0 0 
19 2 0 1 0 1 
20 1 0 1 0 0 
21 1 0 1 0 0 
22 1 0 1 0 0 
23 1 0 1 0 0 
24 1 0 1 0 0 
25 1 0 1 0 0 
26 1 0 1 0 0 
Total 114 14 26 17 57  
Table 6.1: Assessment of sample discrepancy of the Nijmegen-Bethesda assay and FVIII 
ELISA at a patient level. B=Nijmegen-Bethesda assay. E=ELISA. Grouping of patients; 
X=Samples discrepant by both ELISA (E+B-) and Bethesda status (B+E-); Y=Samples 
discrepant by the Bethesda status only (B+E-); Z=Samples discrepant by the ELISA status 
only (E+B-). 
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6.4.4 Diagnostic Accuracy Assessment 
An assessment of the performance of the FVIII ELISA (index test) compared to the NBA 
(reference test) was made for all samples. This demonstrated a specificity 94.0% (95%CI 91.3-
96.0), sensitivity 77.8% (95%CI 65.5-87.3), negative predictive value (NPV) 96.7% (95%CI 
94.5-98.2) and positive predictive value (PPV) 65.3% (95%CI 53.5-76.0). Further post-hoc 
assessment based on these primary calculations (unaffected by prevalence) demonstrated a 
positive likelihood ratio (LR+) 13.0 (95%CI 8.7-19.3) and negative likelihood ratio (LR-) 0.2 
(95%CI 0.1-0.4). Global evaluation of the performance of the ELISA, demonstrated a 
diagnostic odds ratio (DOR) of 54.9 (95%CI 27.0-112.0) (Table 6.2).  
 Severe 
HA 
Non-
Severe 
HA 
Acquired 
HA 
Total Centre 1 Centre 2 
Samples 291 129 77 497 237 260 
Patients 140 85 14 239 113 126 
Prevalence 15.1% 
(11.0-
19.8) 
9.3% 
(4.9-15.7) 
9.1% 
(3.7-17.8) 
12.7% 
(9.9-15.9) 
7.2% 
(4.2-
11.2%) 
17.7% 
(13.3-
22.9) 
Sensitivity 
 
77.3% 
(62.2-
88.5) 
66.7% 
(34.9-
90.1) 
100.0% 
(59.0-
100.0) 
77.8% 
(65.5-
87.3) 
94.1% 
(71.3-
99.9) 
71.7% 
(56.5-
84.0) 
Specificity 96.8% 
(93.7-
98.6) 
94.9% 
(89.2-
98.1) 
82.9% 
(72.0-90.8) 
94.0% 
(91.3-
96.0) 
93.6% 
(89.6-
96.5) 
94.4% 
(90.4-
97.1) 
PPV  81.0% 
(65.9-
91.4) 
57.1% 
(28.9-
82.3) 
36.8% 
(16.3-61.6) 
65.3% 
(53.5-
76.0) 
53.3% 
(34.3-
71.7) 
73.3% 
(58.1-
89.9) 
NPV  96.0% 
(92.7-
98.1) 
96.5% 
(91.3-
99.0) 
100.0% 
(93.8-
100.0) 
96.7% 
(94.5-
98.2) 
 
99.5% 
(97.3-
100.0) 
94.0% 
(89.9-
96.7) 
LR+  23.9 
(11.8-
48.1) 
13.0 
(5.4-31.2) 
5.8 
(3.5-9.8) 
13.0 
(8.7-19.3) 
14.8 
(8.8-24.9) 
12.8 
(7.17-
22.8) 
LR-  0.2 
(0.1-0.4) 
0.4 
(0.2-0.8) 
0.0* 0.2 
(0.1-0.4) 
0.1 
(0.0-0.4) 
0.3 
(0.2-0.5) 
Diagnostic 
OR  
102.0 
(37.9-
272.0) 
37.0 (9.1-
152.0) 
* 54.9  
(27.0-
112.0) 
235.4 
(29-#) 
42.7  
(18.0-
101.7) 
Table 6.2: Diagnostic Accuracy Evaluation of the FVIII ELISA (index test) in comparison to 
the Nijmegen Bethesda assay (reference test). Figures in parenthesis, represent 95% 
confidence intervals (95%CI). PPV=Positive predictive value, NPV=Negative predictive 
value, LR= Likelihood ratio. OR=Odds ratio. # >1000. *Calculation not possible due to no 
false negative results.  
 
 127 
 
A subgroup analysis was performed based on diagnostic headers at the time of 
venepuncture. Similar findings were seen (Table 6.2), with high specificity, negative 
predictive values and positive likelihood ratios in patients with congenital (severe and non-
severe) HA. In patients with AHA, a high sensitivity (100.0%, 95%CI 59.0-100.0%) was also 
noted. This estimate may however, be skewed by the smaller sample size (n=77, 14 patients) 
and no “false-negati e” results seen for the ELISA in this group (Table 6.2). Of the samples 
from patients with AHA, 12 (56%) tested positive by ELISA, but were negative by the NBA, 
accounting for 46% (12/26) of the E+B- discrepant samples. This resulted in a lower PPV 
(36.8%, 95% CI 16.3-61.6%) than was seen for samples from patients with congenital HA. 
The diagnostic accuracy assessment was then repeated to compare testing at both centres 
(Table 6.2). Although, similar findings were seen in both centres for specificity and NPV, a 
higher sensitivity was seen for centre 1 (94.1% v 71.7%) and higher PPV for centre 2 (73.3 v 
53.3%). Differences in these estimates may relate to a lower number of “false negati e” 
results seen at centre   and lower number of “false positi e” results seen at centre 2. An 
increased inhibitor prevalence for samples tested at centre 2 (18.0%) compared to centre 1 
(7.2%) may have skewed these primary estimates, which is supported by similar likelihood 
ratios (unaffected by prevalence) being seen for both centres. 
6.4.5 Adjustment for Clustering within the Diagnostic Accuracy  
In view of multiple samples from some patients being tested within the diagnostic accuracy 
assessment, the primary estimates (sensitivity, specificity, NPV and PPV) were re-calculated 
using modelling to account for inter-individual clustering. This was performed using three 
different methodologies (Table 6.3) as previously described 352.  
Ignoring Clustering Sensitivity Specificity PPV NPV 
Binomial proportion 
(exact CI) 
77.8%  
(65.5-87.3) 
94.0%  
(91.3-96.0) 
65.3%  
(53.5-76.0) 
96.7%  
(94.5-98.2) 
Variance Adjusted Sensitivity Specificity PPV NPV 
Logistic regression 
with sandwich 
estimator 
77.8%  
(63.0-87.8) 
94.0%  
(88.8-96.9) 
65.3%  
(44.6-81.5) 
96.7%  
(94.4-98.1) 
Logistic random 
effects model 
80.5%  
(44.8-95.4) 
100.0%  
(96.0-100.0) 
71.3%  
(28.8-93.8) 
97.5%  
(92.3-99.2) 
GEE (exchangeable 
correlation matrix) 
69.4%  
(52.8-82.2) 
95.3%  
(92.0-97.3) 
58.4%  
(41.0-74.0) 
96.7%  
(94.4-98.0) 
Table 6.3: Modelled effects of inter-individual clustering on the estimates of diagnostic 
accuracy. Figures in parenthesis, represent 95%CI. GEE=Generalised estimating equations, 
PPV=positive predictive value, NPV=negative predictive value, CI=confidence interval. 
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All three methodologies, demonstrated similar results to the non-adjusted diagnostic 
accuracy assessment for the specificity and negative predictive values (Table 6.2 and 6.3, 
binomial proportion). Greatest variation was however, seen for the adjusted sensitivity (69.4-
80.5%) and PPV (58.4-71.3%). Taking the most conservative model (generalised estimating 
equations), this gave a specificity of 95.3%, sensitivity 69.4%, NPV 96.7% and a PPV 65.3% 
(Table 6.3). Due to the small number of patients with AHA (n=14) further sub-group analysis 
was not possible using these approaches. 
6.4.6 Assessment of Association of ELISA Optical Density with Nijmegen-Bethesda Assay 
An assessment of association was performed for all samples (63 samples, 27 patients) 
positive by the NBA (regardless of ELISA status), to further evaluate the observation of higher 
ELISA ODs being seen in patients with high-titre inhibitors. Assessment of the Q-Q plot and 
histograms for the results of the NBA titres (data not shown) demonstrated a non-parametric 
distribution with multiple outliers. The results of the NBA titre were normalised using log 
transformation. There was strong positive correlation (r=0.790, p<0.0005) between the 
results of the NBA (log-transformed) and ELISA OD. 
To account for inter-individual clustering this analysis was then repeated using the first 
recorded database entry for each patient, resulting in 28 samples (severe=17, non-severe=6 
and acquired=5). The median NBA titre was 1.1BU/mL (range 0.7-488.2) and ELISA OD 0.71 
(range 0.04-2.59). There was again strong correlation (r=0.774, p<0.0005) between the log-
transformed result of the NBA and the ELISA OD. The effect of variability in methodology 
between centres on measures of association was also assessed, repeating this analysis by 
centre (centre 1=7 samples, centre 2=21 samples). Comparison of correlation by centre 
demonstrated r values of 0.670 (p=0.10) and 0.894 (p<0.0005) for centres 1 and 2 
respectively.  
Finally assessment of association (linear regression) was performed to test the hypothesis 
that the result obtained by the ELISA OD could predict the inhibitor titre by the NBA (Figure 
6.2). This was performed on the subset of samples in the correlation analysis, positive by 
both assays (n=18). There was a significant association (R2 =0.475, p=0.002) with data fitting 
to the regression equation, logBU = (0.9512 x OD) – 0.4590; where OD=ELISA OD. The inverse 
equation for calculating the ELISA OD is, OD = (logBU + 0.495)/0.9512. Using this equation a 
high-titre inhibitor ≥ . BU/mL would be expected to have an ELIS  D ≥1.217. 
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Figure 6.2: Association between the Nijmegen-Bethesda assay and ELISA OD. Plotted line 
indicates the linear regression line: logBU = (0.9512 x OD) – 0.4590, with dotted lines 
representing the 95% confidence interval. 
6.5 Discussion 
This is the largest retrospective diagnostic accuracy study comparing the performance of a 
commercially available FVIII ELISA with the NBA in routine laboratory practice in patients with 
congenital and acquired haemophilia A. This is also the first study reported in the 
haemophilia setting, following the recommendations of the STARD initiative for reporting of 
these findings 271. This methodology of reporting standardises presentation and 
interpretation, facilitating comparison of these assay in future meta-analysis. The FVIII ELISA 
kit demonstrated high specificity, negative predictive value and diagnostic odds ratio in both 
laboratories, suggesting a role for the FVIII ELISA as a screening test for FVIII antibody 
detection. The ELISA OD demonstrated a semi-quantitate measure for assessment of 
inhibitory capacity in keeping with the findings of other studies 300;303.  
6.5.1 Application of ELISA in FVIII Antibody Testing 
Two previously published studies 300;303 and six conference abstracts 356-361 have investigated 
usage of this commercially available FVIII ELISA kit in comparison to a functional inhibitor 
assay, from which diagnostic accuracy estimates are calculated or can be derived from 
presented data (Table 6.4). Within these studies, estimates of sensitivity and specificity range 
form 77.8-100.0% and 60.0-100.0% respectively. A High NPV, as seen in this study is similar 
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to that seen in previous studies (90.6-100.0%) 300;358;360;361. Data reported in this study 
however, demonstrated a greater specificity (94.0% v 78.4%) 300, albeit with a lower 
sensitivity (77.8% v 97.7% v 95.5%) 300;303 for the ELISA kit. This may relate to differences in 
sample selection methodology in previously published studies, which used samples either 
known to be positive 303 or “at risk of inhibitor de elopment” 300, rather than as a screening 
tool in routine laboratory practice. These differences will affect the prevalence and pre-test 
probability of sample positivity, which could in turn influence the primary diagnostic accuracy 
estimates.  
Samples 
(Patients) 
 Sens Spec PPV NPV R Cal Reference 
131  
(93) 
CHA 
AHA 97.7% 78.4% 68.9% 98.6% 0.68 Y 
Martin et 
al. 
A 300 
246 
(176) 
CHA 
AHA 
95.5% 
 
- - - 0.82 N 
Sahud et 
al. 
A 303 
497  
(239) 
CHA 
AHA 77.8% 94.0% 65.3% 96.7% 0.77 Y 
Batty et 
al. 
A 362 
NS 
(30) 
CHA 
AHA - - - - 0.97 N 
Bowyer et 
al. 
B 356 
200 
(200) 
CHA 
- - 74.3% - - N 
Srivasta 
et al. 
B 357 
42 
(42) 
CHA 
100.0% 60.0% 33.3% 100.0% - N 
Riddell et 
al. 
B 358 
71  
(43) 
CHA 
AHA 93.0% 95.0% - - - Y 
Nougier 
et al. 
B 359 
28  
(28) 
CHA 
88.9% 100% 100% 94.4% 0.94 Y 
Needham 
et al. 
B 360 
160* 
NS 
CHA 
AHA 82.5% 93.2% 87.0% 90.6% - N 
Riddell et 
al. 
B 361 
Table 6.4: Comparison of studies using the FVIII ELISA and NBA in congenital and acquired 
haemophilia A. HA=Congenital haemophilia A; AHA=Acquired haemophilia A. r=Correlation 
co-efficient. Cal=Diagnostic accuracy evaluation calculated by the study authors (yes/no). 
A=Published article, B=Conference abstract (poster/oral communication). *Comparison is 
between a NBA with pre-analytical heat treatment and the FVIII ELISA. 
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6.5.2 FVIII ELISA Specificity  
Since the previous publications of the usage of the FVIII ELISA by Martin et al 300 and Sahud 
et al.303 there has been a change in rFVIII plate antigen and methodology used for 
determining positivity for this ELISA. The data presented in this chapter, is the first study 
comparing this newer version of the ELISA kit with the NBA. In earlier studies, the plate 
antigen used was Recombinate® (Baxter Healthcare Corp, Deerfield, IL, USA), an H2 
haplotype rFL-FVIII 179;307, with positivity defined by an absorbance value (OD), twice the 
mean of the negative control 300;303. In this newer version of the ELISA, the plate antigen used 
is Kogenate®, an H1 haplotype rFL-FVIII, with positivity defined by an absorbance value (OD) 
greater than the kit control (human serum containing FVIII antibodies in bovine albumin and 
0.1% NaN3) 179. The difference in primary sequence between H1 and H2 haplotype FVIII, is a 
single nucleotide polymorphism within the B domain, encoding either aspartic acid or 
glutamic acid at position 1241, respectively 179. There will also be differences in post-
translation modifications, between these two recombinant products, with Recombinate®, 
being produced from a baby hamster kidney cell line and Kogenate® from a Chinese hamster 
ovary cell line. Whether this change in plate antigen may affect the results obtained is not 
known, although differences in the reactivity of inhibitors to different FVIII concentrates has 
been previously reported (discussed below). Good correlation has however been 
demonstrated between the results of the two FVIII ELISAs in an evaluation of the effect of 
antiphospholipid antibodies 307.  
6.5.3 Discrepant Samples and Residual FVIII:C using the FVIII ELISA  
The presence of FVIII:C in samples, when using a functional inhibitor assay such as NBA, may 
impair detection of potentially clinically relevant FVIII antibodies 291, which is discussed in 
more detail in the following chapter. Given the difficulties in the diagnosis and accurate 
quantification of FVIII inhibitors in patients with type II antibodies (complex kinetics), who 
often have residual FVIII:C, the ELISA technique offers an attractive platform for inhibitor 
surveillance. Within this analysis, discrepancy between the results of the two assays was seen 
in 40 samples. Due to the methodology of this analysis no further evaluation of clinical 
parameters in these samples, or reproducibility of these results, was possible. The relevance 
of antibodies with discrepancy between assays requires further study. In congenital 
haemophilia, non-neutralising antibodies, may constitute one of these discrepant groups, 
which have been reported in approximately 18% of patients with congenital haemophilia 261. 
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The clinical significance of this group of non-neutralising antibodies remains unclear, with 
conflicting reports in the published literature 262. Further study of non-neutralising antibodies 
using parallel assays to evaluate binding affinity (e.g. surface plasmon resonance, biolayer 
interferometry or competition ELISA), epitope profiles (discussed in Chapter 8) or global 
haemostatic effects (e.g. thromboelastography or thrombin generation assays) may provide 
further insight into this class of antibodies.   
In the sub-group analysis of samples from patients with AHA, a substantial proportion (n=12, 
15.6%, 3 patients) were positive by the ELISA (mean OD 0.58, range 0.25-1.59) but negative 
by the NBA. In these the degree of positivity was significant, to a le el of ≥  fold the KC in 
58.3% (7/12) samples. All of these discrepant samples, had substantial FVIII:C measurable 
(mean 122.8IU/dL, range 40.8-362.4) prior to testing. Despite anecdotal reports of the 
significance of FVIII antibody detected using immunological methodology, with a negative 
functional inhibitor, the relevance of these findings are not clear. The first of these reports, 
compared the FVIII ELISA, with the Bethesda assay demonstrating prolonged ELISA positivity 
in 2 patients, with a negative Bethesda assay, although there was insufficient details provided 
to calculate assay performance, from the data presented within the abstract 363. In a recently 
published study, evaluating FVIII antibody subclasses and binding affinity, longitudinal follow-
up of a patient with AHA (days 10, 31 and 57) demonstrated, persistent IgG1 and IgG4 
antibodies throughout the observation period. At day 31, the inhibitor assay became 
negative and the patient was weaned off immunosuppression by day 42. He then relapsed at 
day 57 (2.8BU/mL) 269. Further prospective study, is required to evaluate if this may represent 
a biomarker for prediction of response to treatment or relapse in AHA. 
6.5.4 Role of New Assays in FVIII Antibody Testing  
There are a number of difficulties, in assessing new diagnostic tests for detection of FVIII 
antibodies. Firstly, there is a lack of consensus, as to what represents an important positive 
result for clinical practice. Although data supports the clinical rele ance of “high-titre” FVIII 
antibodies, this is less clear for antibodies with weak or no inhibitory capacity. The next 
problem, relates to the intended role that a new test would play in laboratory practice, which 
could either be for screening, replacement or as an add-on test 364. The ideal test from an 
immunological perspective would be an assay allowing detection of both inhibitory and non-
neutralising antibodies. Clinically however, it would be desirable that this test gave a 
reproducible quantitative result correlating with inhibitory capacity using simple 
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methodology and is insensitive to the pre-analytical variables affecting current laboratory 
methods. It is unclear however, whether there is a clinical desire for a new test to act as a 
triage/screening test, replace or as an add-on test to the NBA. Each approach would 
subsequently require different methodology to validate such an assay. The second limitation 
is where there is an imperfect reference standard or where the true relevance of the 
spectrum of pathological findings is unknown, which is the current situation in testing for 
FVIII antibodies. In the evaluation of new tests, given the limitations of the NBA, this assay 
forms an imperfect reference standard. Methodology for assessment of diagnostic tests is 
limited in the situation where a new assay may detect potentially relevant findings that are 
not detected on current assays, as may be the case for apparent “non-neutralising” 
antibodies. Using the NBA as a reference test in statistical comparison of a new assay with 
high sensitivity for the detection of non-neutralising antibodies, will result in a low PPV, which 
is seen in this and other studies (Table 6.4) using immunological assays. Despite recent 
advances in the understanding of non-neutralising antibodies, the long-term relevance of 
these remains uncertain and it is not known whether these have prognostic significance in 
predicting inhibitor formation (epitope spreading) or relapse from immunosuppression or ITI.  
6.5.5 Association between NBA Titre and ELISA OD 
Despite the limitations of the NBA in the detection of FVIII antibodies, one of the great 
strengths of this assay is that the quantitative results has been used to guide management 
of patients with bleeding episodes. For an alternative assay, it would be desirable to give a 
qualitative read-out that may differentiate, high and low-titre inhibitors. Within this study 
strong correlation was seen between the results of the ELISA OD when compared to an 
adjusted (log) Bethesda value, which are similar to the findings of other investigators (Table 
6.4).  
6.6 Limitations 
One of the major limitations of this study relates to the retrospective design, evaluating the 
performance of the FVIII ELISA with reliance on the diagnosis assigned when samples were 
collected. Using anonymised samples, could have resulted in patients being mis-categorised 
and does not take into account other important clinical variables present at the time of 
testing. To minimise mis-categorisation, data from patients with mild and moderate 
haemophilia A were grouped into a non-severe haemophilia A category. Retrospective 
analysis of these data does also not allow assessment of assay reproducibility or to further 
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investigate discrepancies seen between the results of the two assay. This study similar to 
other diagnostic accuracy studies contains multiple sample results from the same patient, 
which results  in the formation of clustered data 365. Without adjustment, due to lack of 
statistical independence in these clusters, this could skew the size of one of the diagnostic 
accuracy estimates or result in inappropriately narrow confidence intervals. For example, a 
patient may always test positive by one assay and negative by the other assay, which will 
result in false elevation of the rate of false positives or negatives, directly affecting 
subsequent calculations. Within my analysis, adjustment for this is presented both for 
diagnostic accuracy and correlation, although even using the most conservative model (GEE) 
to adjusting for clustering this clustering only had a minor effect on the estimates of 
diagnostic accuracy. Although significant correlation was seen between the results of the 
ELISA OD, this is limited by the number of samples included within this analysis and further 
study of this is required within a larger cohort. 
A further limitation to these data is that there were differences in the NBA testing 
methodology used at the two centres, although both approaches have been well described 
within the literature 279;280;366. Usage of 4%BSA in place of FVIII deficient plasma has been 
described in two studies, which has been discussed previously (Chapter 1) 279;280, with this 
modification being recently validated and demonstrating good agreement between the 
results of the two assays, especially samples with low-inhibitory capacity (<2BU/mL) 280. A 
comparison between the one stage and chromogenic FVIII assay as part of the NBA has also 
been recently presented in 1005 samples (702 patients) 366. In this study, 880/883 samples 
negative by the NBA, were also negative by Chromogenic Bethesda assay (ChBA). For 
inhibitor titres <2BU/mL, 43/80 specimens (53.8%) positive by the NBA were also positive by 
the ChBA. In samples positive by the NBA, with an inhibitor titre ≥ . BU/mL,   /   were 
positive by ChBA with excellent correlation (r=0.98, p<0.0001) between the two assay results. 
Variation in inhibitor testing methodology, is a common limitation in any study using local 
inhibitor testing to define positivity rather than centralised testing. To assess the impact of 
these differences, both the diagnostic accuracy analysis and correlation assessment were 
repeated to compare the results obtained in both centres. A differences in the correlation 
was seen, which most likely relates to the smaller number of NBA positive samples included 
in the analysis from centre 1 (n=7). An alternative explanation may relate to a higher 
proportion of samples from centre 1, being from patients with acquired or non-severe 
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haemophilia (centre 1: 4/7, 57.1%; centre 2: 7/21, 33.3%) which could display more complex 
inactivation kinetics 250. 
Finally, a potential limitation to this commercially available ELISA is the use of a single plate 
antigen (Kogenate®). Differences in specificity to different recombinant antigens have been 
described for both functional inhibitor assays 286 and in validated research-laboratory ELISAs 
258;367;368. These findings are of interest clinically given such small differences in primary 
sequence between different rFL-FVIII concentrates. Within samples tested by the ELISA, it is 
possible that some samples may have tested negative, due to the presence of antibody 
specificity to a different FVIII antigen or presence of non-IgG FVIII antibodies, although 
further evaluation of these samples was not possible within this work aimed at assessing the 
role for this ELISA in routine laboratory practice.  
6.7 Conclusions 
In summary, a commercially available FVIII ELISA kit in comparison to the NBA demonstrated 
good specificity and negative predictive value for FVIII antibody detection in samples from 
patients with congenital and acquired haemophilia A. The ELISA displays a semi-quantitative 
result which provides good correlation between the log-adjusted inhibitor titre and ELISA OD. 
With ELISA being a routinely available assay platform in most hospital laboratories, this offers 
the potential for efficient batching of FVIII antibody surveillance for non-urgent routine 
clinical samples.  
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Chapter 7: Pre-Analytical Heat Treatment Improves FVIII Antibody 
Detection by the Nijmegen-Bethesda Assay and Factor VIII ELISA 
7.1 Introduction 
The presence of residual FVIII:C in samples limits detection of inhibitors when using a 
functional inhibitor assay such as the NBA. There are however, multiple situations where 
inhibitor testing is required despite presence of residual FVIII:C, where it is not practical (or 
possible) to await a sample where FVIII:C is absent. One approach taken previously by some 
laboratories was to not test samples where there was substantial residual FVIII:C  290. In the 
assessment of patients with non-severe haemophilia A treated within London, presented in 
Chapter 4, 22. % (8 / 77) patients had a FVIII:C ≥  IU/dL and in the pre ious chapter 
e aluating the application of a FVIII ELIS  a FVIII:C ≥  IU/dL was seen in   % (   /  7) of 
samples tested. In these circumstances it would be desirable to have an assay insensitive to 
residual FVIII:C (e.g. FVIII ELISA) or to use a standardised modification to adjust for this. 
Although usage of a FVIII ELISA as a screening test forms one option this does not form part 
of current routine testing practice in the UK, at least in the setting of AHA as seen in Chapter 
5. Given current reliance on functional inhibitor assays, a more feasible option would be to 
use a modification (in-vitro) or correction (mathematical) to these assays to account for pre-
analytical FVIII:C. Perhaps, the simplest of these modification for the busy CCC laboratory is 
to use pre-analytical heat treatment (PHT) to denature FVIII:C, allowing standardisation of 
sample preparation prior to inhibitor testing 291. Although PHT has received a degree of 
interest within the recent literature 283;291;294;297;369, there are a number of questions 
surrounding usage of this modification that should be addressed prior to use in routine 
clinical practice. This modification is based on observations of differences in thermostability 
between FVIII:C and FVIII inhibitors from small studies performed in the 1960s 370 and 1970s 
292;371. In the study that is likely to have resulted in the recent use of this modification, sample 
incubation at 56°C for 30 minutes resulted in 95±3% of FVIII:C being inactivated with no effect 
on FVIII inhibitor neutralising activity 292. PHT resulted also in loss of reactivity of denatured 
FVIII in a neutralisation assay, suggested structural changes disrupting the B-cell epitopes on 
the FVIII surface, a finding which been confirmed in more recent experiments 147. These 
earlier experiments used a functional inhibitor assay similar to, although not the same as the 
CBA 292, with a limited range of incubation conditions. There is a lack of controlled data to 
supporting optimal PHT incubation conditions (temperature and time) for use with current 
inhibitor assays (NBA and FVIII ELISA). Although the most commonly used incubation 
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conditions described in clinical studies range from 56°C to 58°C 283;294;296;297, transition in 
FVIII:C stability has been seen between 46 and 66°C 147. The effect of using either higher or 
lower PHT temperatures or incubation times is not known. Another consideration for using 
this modification is that different sources of FVIII:C found in samples (exogenous or 
endogenous) could exhibit differences in thermostability. Finally, all studies using this 
modification have investigated usage as part of testing with a functional inhibitor assay and 
the effects of PHT on FVIII antibody detection using a FVIII ELISA is not known.  
7.2 Hypothesis and Aims 
In the first part of this chapter, the effect of the introduction of PHT in patients with AHA as 
part of routine clinical laboratory practice will be evaluated and discussed. Within the 
haemostasis laboratory of our CCC (The Royal London Hospital), a switch was made to using 
PHT for all samples requiring inhibitor testing from 2012 onwards. Following this change in 
practice, I evaluated the effect of using PHT during routine practice for samples from patient 
with AHA, where a high residual FVIII:C would be expected either at diagnosis or following 
response to treatment. The hypothesis for this first part, is that PHT improves the detection 
of FVIII antibodies through denaturation of FVIII:C in samples.  
In the second part of this chapter the effect of different PHT incubation conditions 
(time/temperature) will be systematically evaluated to assess the effect on residual FVIII:C 
and inhibitory activity seen in samples. PHT has not been evaluated using current laboratory 
methodologies, to assess FVIII:C and inhibitor presence using a functional (NBA) and an 
immunological (FVIII ELISA) assay. The hypothesis for this second part, is that different PHT 
incubation conditions will have different effects on the proportion of FVIII and inhibitor 
denatured. The specific aims of this chapter are as follows:   
1) To describe the effect of PHT in a pilot study at the introduction of this methodology 
as part of routine laboratory practice in patients with acquired haemophilia A. 
2) To assess the effect of different PHT incubation conditions on FVIII:C from 
endogenous and exogenous sources.  
3) To assess the effect of different PHT incubation conditions on FVIII inhibitor 
detection using the NBA and a FVIII ELISA. 
4) To provide guidance of the optimal conditions for the usage of PHT for inhibitor 
testing within the laboratory of The Royal London Hospital Haemophilia Centre.  
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7.3 Materials and Methods 
Study Samples and Approvals 
An assessment of the effect of PHT on inhibitor detection was made in routine inhibitor 
samples tested from patients with AHA (8/11-2/12). De-identified samples were tested in 
parallel using both the NBA and FVIII ELISA assays, before and after heat treatment at 58°C 
for 90 minutes 291. Study approval was granted by the Clinical Effectiveness Unit (CEU) Barts 
Health, as part of assay development and service evaluation at The Royal London Hospital 
(part 1 and 2). The assessment and optimisation of the PHT conditions, presented in part 2 
were discussed with the research approvals department at Queen Mary University London 
(QMUL) and these experiments did not represent material ethics. 
One Stage FVIII:C and Nijmegen Bethesda Assay  
These assays were performed as described previously in the materials and methods section 
(Chapter 3). Samples within part 1, were tested as part of routine care within the central 
laboratory of The Royal London Hospital. In the second part evaluating optimal PHT 
incubation conditions I performed all assays although due to limitations in available sample 
volumes and inhibitor titres the FVIII:C and NBA assays were performed undiluted.  
Factor VIII ELISA  
A commercially available, solid phase indirect FVIII ELISA (Lifecodes/Immucor, Norcross, USA) 
was performed as described within Chapter 3. 
Part 1: Pre-Analytical Heat Treatment: Evaluation of the Effects of Switching to Usage of 
PHT in Testing for FVIII antibodies in Acquired Haemophilia A 
Samples were tested in the presence or absence of heat treatment (58°C for 90 minutes), 
with samples left to cool to room temperature (RT) for 20 minutes following PHT. No 
precipitant was seen following heat treatment. FVIII:C was measured prior to and following 
heat treatment. 
Part 2: Effects of Pre-Analytical Heat Treatment on FVIII:C and FVIII Inhibitor Detection 
Preparation of Pooled Platelet Poor Plasma (Endogenous FVIII Source) 
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Discarded platelet-poor plasma, collected in 3.2% sodium citrate from 43 anonymous 
consecutive, routinely tested, non-haemophilia samples was collected and pooled. Following 
pool preparation, 200µL samples were aliquoted into cryovials and frozen at -80°C prior to 
testing.  
Preparation of FVIII Concentrates (Exogenous FVIII Source) 
The effect of pre-analytical heat treatment on FVIII from an exogenous source was evaluated 
using a rFVIII (Advate®, Baxter, Deerfield, USA) and a pdFVIII concentrate (Wilate®, 
Octapharma AG, Lachen, Switzerland). This was evaluated for the most commonly described 
temperatures used in previous studies (56 and 58°C). Pools were prepared for each 
concentrate in Factor VIII deficient plasma (F8DP). Lyophilised Advate® (500 IU) and Wilate® 
(500 IU) were reconstituted as per the manufacturers’ recommendations using sterile water 
(2mL) or sterile water/0.1% polysorbate-80 (5mL) respectively. These were then both diluted 
separately in 250mL of sterile water aiming to give a similar FVIII:C as seen for the pooled 
FVIII plasma (c. 200IU/dL). The diluted FVIII concentrates were allowed to sit on the bench 
for 10-15 minutes and mixed gently. Vials of lyophilised FVIII deficient plasma were then 
reconstituted using 1mL of the FVIII concentrate in sterile saline. These were allowed to stand 
on the laboratory bench for    minutes, prior to gentle mi ing as per the manufacturer’s 
recommendations. The vials of FVIII concentrate diluted in FVIII deficient plasma were then 
combined to give two separate pools and mixed by gentle inversion. These were then 
aliquoted into 200µL samples and directly frozen at -80°C prior to testing. 
Evaluation of the Effect of Pre-Analytical Heat Treatment on FVIII:C  
A sequential evaluation was performed of the effect of PHT on endogenous and exogenous 
FVIII:C. Assessment of the effect of PHT on FVIII:C activity was made across six temperature 
points (37, 47, 52, 56, 58 and 64°C), until FVIII:C was completely denatured within five 
minutes of PHT. The effect of PHT was evaluated over seven incubation times (control, 5, 15, 
30, 60, 90 and 120 minutes). All incubation temperatures and times were assessed in 
triplicate. This evaluation of PHT was made using methodology as available in a routine 
haemostasis laboratory using a water-bath for sample incubation. Prior to assessment, the 
water-bath being used for PHT was heated to the selected temperature for 30-60 minutes. 
The water-bath temperature was then monitored prior to commencement of sample 
incubation to ensure that the desired temperature had been obtained and this was not 
fluctuant for 10-15 minutes. Throughout each experiment, the water-bath temperature was 
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monitored, using a traceable digital thermometer (accuracy ±0.5°C) with temperature 
recordings performed every second, with a record of minimum and maximum temperatures. 
Frozen samples were rapidly thawed in a water-bath at 37°C for 5 minutes and all samples 
(except the control samples) were then immediately transferred for pre-analytical heat 
treatment into the second water-bath. Following PHT, samples were removed from the 
water-bath, the external surface was dried and allowed to cool at RT for 20 minutes and then 
directly tested using a one stage FVIII:C assay.  
Evaluation of the Effect of Pre-Analytical Heat Treatment on Inhibitor Plasma 
An assessment of the effect of PHT on inhibitor activity and detection was performed using 
a commercially available FVIII inhibitor plasma (George King Bio-Medical Inc., Kansas, USA). 
This inhibitor plasma was a commercially available FVIII inhibitor (48 BU/mL) sample 
obtained from a single donor by apheresis frozen directly at -<80°C without undergoing 
lyophilisation. This was diluted 1 in 21 in FVIII deficient plasma, then directly aliquoted into 
250µL samples and frozen at -80°C prior to testing. Due to small sample volumes being used 
two test sample were thawed and evaluated using the Nijmegen-Bethesda assay to assess 
the dilutions required within the Nijmegen-Bethesda assay and to compare the predicted to 
actual inhibitor titre. On testing these thawed sample gave an inhibitor titre of 1.1 BU/mL 
which was only just detectable on the 1 in 2 dilution (67% residual FVIII:C), as such all 
subsequent sample were tested undiluted. Inhibitor samples were incubated using PHT in a 
similar manner to the previous experiments over four temperature points (56°C, 58°C, 64°C 
and 72°C), with all samples being tested in duplicate. This temperature range was chosen 
based on temperatures at which Ig disruption would be expected to occur. Following sample 
incubation, the external surface was dried and samples were allowed to cool for 20 minutes 
at RT. Each sample was divided into a sample for use in the Nijmegen-Bethesda assay (160µL) 
and the remainder for the FVIII ELISA. These were then refrozen at -80°C prior to batch testing 
by the NBA and ELISA. 
Data Interpretation and Statistical Analyses 
Descriptive data, including raw data, mean, SD and co-efficient of variation (CV) of these 
experiments are presented. Co-efficient of variation, was calculated by dividing the standard 
deviation by the mean. Given lack of independence, between the datasets no further 
comparative statistics were performed. For the experiments looking at FVIII:C, these data 
were reported as mean raw FVIII:C and a normalised mean percentage FVIII:C. Normalisation 
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was performed relative to the mean FVIII:C of control samples to allow inter-experimental 
comparison of residual FVIII:C following PHT.  
7.4 Results 
7.4.1 Pre-Analytical Heat Treatment Improves Detection of FVIII Antibody Formation in 
Acquired Haemophilia A 
Thirty nine samples (8 patients) were tested using the FVIII ELISA and NBA before and after 
heat treatment. Prior to PHT all samples had detectable FVIII:C (median 75IU/dL, range 24.1-
362.4) which became undetectable in all samples following PHT.  
7.4.1.1 Nijmegen-Bethesda Assay  
Prior to PHT, only 2/39 samples (1 patient) were positive by NBA which increased to 20 
samples (6 patients) positive by the NBA following PHT (Table 7.1). All inhibitors, detected by 
 B  following heat treatment were “low-titre” (median  . BU/mL, range  . -2.0). Both 
samples that were positive by the NBA prior to PHT remained positive following PHT.  
 NBA ELISA Parallel Testing 
Untreated 
 
2 (5%) 
 
11 (28%) 12 (31%) 
Pre-Analytical Heat 
Treatment 
 
20 (51%) 
 
16 (41%) 24 (62%) 
Table 7.1: Factor VIII antibody detection by NBA and FVIII ELISA pre and post heat 
treatment. Figures shown represent the number of positive samples (%). Parallel testing, 
corresponds to positivity by one or more assay. Table reproduced from Batty et al. 296, 
with the permission of the publisher.  
7.4.1.2 FVIII ELISA 
Using the FVIII ELISA, 11/39 samples (3 patients) were antibody positive prior to PHT, which 
increased to 16/39 positive samples (5 patients) following PHT (Table 7.1). In samples positive 
by ELISA prior to PHT, parallel PHT NBA assays were positive in 7, equivocally positive (0.5 
BU/mL) in 2 and negative in 2. Interestingly, 5 samples (2 patients) positive by the ELISA prior  
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Figure 7.1: Effect of PHT and ELISA on FVIII antibody detection in acquired haemophilia A. 
Plotted curves show FVIII:C and PHT NBA titre. U=Untreated; H=Pre-analytical heat 
treatment. A: Undetectable FVIII antibody with NBA(U), transition to positive by ELISA (H) 
and NBA (H), with fall in FVIII:C. B: Undetectable FVIII antibody by the NBA (U), detectable 
by ELISA (U & H) and NBA (H); transition to negative on NBA (H) with rising FVIII:C. C: 
Undetectable FVIII antibody by NBA (U) and ELISA (U & H); Transition from low-titre 
positive by NBA (H) to negative with rise in FVIII:C. Based on a Figure in Batty et al 296, 
reproduced with the permission of the publisher. 
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to PHT, became negative following heat treatment. Of these samples 2 were positive, 2 
equivocally positive and 1 negative by the NBA following PHT.  
7.4.1.3 Parallel testing (NBA and FVIII ELISA) 
The number of samples with detectable antibody increased from 5% (2/39) identified using 
a conventional NBA without heat treatment to 62% (24/39) identified using parallel testing 
by heat-treated NBA and ELIS . Si  patients (7 %) had ≥  sample negati e using a 
conventional NBA without heat-treatment that became positive following PHT by the NBA 
and/or ELISA. In the remaining 2 patients, all 5 samples tested were negative by both assays, 
before and after PHT. In a longitudinal assessment of samples tested, PHT appears to improve 
detection of low-titre FVIII antibodies by NBA. The results for samples tested in three 
patients, are shown in Figures 7.1A-C.   
7.4.2 Optimisation of Pre-Analytical Heat Treatment Conditions for the Detection of FVIII 
Antibodies 
Within the clinical data, a tenfold change from negative to positive was seen comparing the 
results of samples tested by the NBA prior to and following PHT. Within these observations 
an unexpected finding was that 5 samples tested by the ELISA became negative following 
PHT. This raises the possibility that the incubation using PHT may have a detrimental effect 
on antibody activity. To investigate the optimal conditions for routine laboratory usage the 
effect of varying PHT incubation conditions were tested to assess effects on FVIII:C and 
inhibitor detection (NBA and ELISA). 
7.4.2.1 Assessment of the Effect of Pre-Analytical Heat Treatment on Endogenous FVIII:C  
Pooled, non-haemophilia plasma samples were sequentially incubated in triplicate over a 
range of six temperatures for up to 120 minutes. Within all experiments some denaturation 
of endogenous FVIII:C was seen following PHT for 120 minutes. PHT of endogenous FVIII at 
36, 47, and 52°, resulted in an incremental decline in FVIII:C up to 120 minutes, with adjusted 
residual FVIII percentages of 68.9%, 57.4% and 13.5% respectively. Of the commonly used 
temperatures for PHT, differences were seen in the time taken to reach FVIII:C ≤ IU/dL. PHT 
at   ,  8 and   °C resulted in a fall in mean FVIII:C to ≤ IU/dL (>  % reduction in adjusted 
residual FVIII%) after incubation for 60, 30 and 5 minutes respectively (Figure 7.2 and Table 
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7.2). Finally the experiments using commonly cited (56°C and 58°C) temperatures for PHT 
were repeated, the results of which are plotted as a control in the following set of 
experiments (Table 7.2 and Figure 7.3).  
 
Figure 7.2: Effect of Pre-Analytical Heat Treatment on Endogenous (pooled plasma) FVIII:C. 
Data-points represent the mean inter-experiment normalised values (%), with samples 
tested in triplicate. Measures of error within these samples are shown for raw values 
within Table 7.2  
7.4.2.2 Assessment of the Effect of Pre-Analytical Heat Treatment on Exogenous FVIII:C  
The effect of PHT was compared between FVIII of endogenous (pooled, non-haemophilia 
plasma) and exogenous sources (rFVIII and pdFVIII). The effect of PHT using commonly cited 
incubation conditions (56°C and 58°C) was evaluated with samples incubated for up to two 
hours, in triplicate as per the previous experiments. Within these experiments a further set 
of endogenous FVIII:C samples were incubated to act as a control and to confirm the findings 
within the first dataset. With these experiments differences were seen both in the rate of 
decline of FVIII:C and time to reach a normalised residual FVIII:C ≤ %, comparing FVIII from 
endogenous and exogenous sources (Figure 7.3). With incubation at 56°C, FVIII:C became 
undetectable (FVIII:C ≤ IU/dL) after    minutes for endogenous FVIII and after     minutes 
for rFVIII. Even after PHT at 56°C for 120 minutes, FVIII:C remained detectable (3.1IU/dL, 
normalised residual FVIII 2.6%) for the pdFVIII concentrate. For incubation at 58°C, a 
reduction in FVIII:C to ≤ IU/dL was seen at between 15-30 minutes PHT for endogenous FVIII 
and following 60 minutes of PHT for both the rFVIII and pdFVIII concentrates. 
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Figure 7.3: Comparison of the effect of Pre-Analytical Heat Treatment on Endogenous 
(pooled plasma) and Exogenous (FVIII concentrates) FVIII:C. PHT was performed at 56 and 
58°C. Data-points represent the mean inter-experiment normalised values (%), with 
samples tested in triplicate. Measures of error within these samples are shown for raw 
data within Table 7.2. F8DP=Factor VIII deficient plasma. rFVIII=recombinant FVIII 
concentrate (Advate®). pdFVIII=plasma derived FVIII concentrate (Wilate®) 
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Temperature Range Control 5 min 15 min 30 min 60 min 90 min 120 min 
37°C 
 
37.5-37.7 233±11 
(100) 
226±6 
(97) 
228±20 
(98) 
221±4 
(95) 
209±12 
(90) 
204±5 
(88) 
160±20 
(69) 
47°C 46.6-47.2 261±2 
(100) 
257±6 
(98) 
208±11 
(80) 
172±12 
(66) 
152±4 
(58) 
139±3 
(53) 
150±12 
(57) 
52°C 51.9-52.5 197±24 
(100) 
202±4 
(103) 
138±22 
(70) 
95±8 
(48) 
61±6 
(31) 
41±6 
(21) 
27±3 
(13) 
56°C A 
 
56°C B 
 
56°C rFVIII 
 
56°C pdFVIII 
55.9-56.7 
 
55.9-56.8 
 
55.9-56.8 
 
55.9-56.5 
232±24 
(100) 
188±13 
(100) 
173±3 
(100) 
118±1 
(100) 
110±14 
(48) 
88±4 
(47) 
130±4 
(75) 
100±4 
(85) 
35±1 
(15) 
20±3 
(11) 
52±5 
(30) 
60±1 
(51) 
8±2 
(3) 
5±1 
(3) 
23±2 
(14) 
33±3 
(28) 
1±0 
(1) 
<1±0 
(0) 
6±0 
(4) 
14±1 
(12) 
1±0 
(0) 
<1±0 
(0) 
3±0 
(2) 
8±1 
(7) 
1±0 
(0) 
<1±0 
(0) 
<1±1 
(1) 
3±0 
(3) 
58°C A 
 
58°C B 
 
58°C rFVIII 
 
58°C pdFVIII 
57.4-58.2 
 
57.8-58.7 
 
57.8-58.7 
 
57.7-58.3 
196±6 
(100) 
192±7 
(100) 
170±8 
(100) 
123±5 
(100) 
53±3 
(27) 
24±4 
(13) 
57±3 
(34) 
68±2 
(55) 
6±2 
(3) 
<1±1 
(0) 
7±0 
(4) 
17±5 
(14) 
1±0 
(1) 
<1±0 
(0) 
1±0 
(1) 
7±0 
(6) 
<1±0 
(0) 
<1±0 
(0) 
<1±0 
(0) 
<1±1 
(1) 
<1±0 
(0) 
<1±0 
(0) 
<1±0 
(0) 
<1±0 
(0) 
<1±0 
(0) 
<1±0 
(0) 
<1±0 
(0) 
<1±0 
(0) 
64°C 63.7-64.6 207±9 
(100) 
<1±0 
(0) 
<1±0 
(0) 
<1±0 
(0) 
<1±0 
(0) 
<1±0 
(0) 
<1±1 
(0) 
Table 7.2: Effect of Pre-Analytical Heat Treatment of Endogenous and Exogenous FVIII:C. Figures represent mean raw FVIII:C±SD (IU/dL). Figures in 
parenthesis represent the normalised FVIII percentage. A=1st experiment; B=2nd experiment. rFVIII=recombinant FVIII concentrate. pdFVIII=plasma derived 
FVIII concentrate. 
  
 
1
4
7
 
Temperature Cut-Off Control 5 min 15 min 30 min 60 min 90 min 120 min 
56°C (56.0-56.6) 
NBA (BU/mL) 
 
ELISA OD (1) 
 
ELISA OD (2) 
 
≥ .  
 
≥ .  7 
 
≥ .    
 
1.4±0.0 
 
0.44±0.14* 
 
0.54±0.25* 
 
1.3±0.0 
 
0.60±0.18* 
 
0.66±0.00 
 
1.5±0.1 
 
0.67±0.06 
 
0.66±0.06 
 
1.5±0.0 
 
0.46±0.20* 
 
0.63±0.01 
 
1.5±0.0 
 
0.62±0.05 
 
0.50±0.08 
 
1.5±0.0 
 
0.68±0.33* 
 
0.54±0.04 
 
1.5±0.0 
 
0.67±0.33* 
 
0.61±0.01 
58°C (57.8-59.1) 
NBA 
 
ELISA OD (1) 
 
ELISA OD (2) 
 
≥ .  
 
≥ .   
 
≥ .   
 
1.3±0.0 
 
0.50±0.26* 
 
0.44±0.04 
 
1.4±0.0 
 
0.70±0.26* 
 
0.63±0.03 
 
1.5±0.1 
 
0.70±0.28* 
 
0.42±0.15* 
 
1.4±0.1 
 
0.79±0.16* 
 
0.81±0.37* 
 
1.4±0.0 
 
0.67±0.44* 
 
0.52±0.01 
 
1.7±0.2 
 
0.67±0.25* 
 
0.57±0.00 
 
1.6±0.0 
 
0.63±0.16* 
 
0.53±0.04 
64°C (63.8-65.0) 
NBA 
 
ELISA OD (1) 
 
ELISA OD (2) 
 
≥ .  
 
≥ .   
 
≥ .   
 
1.4±0.1 
 
0.61±0.21* 
 
0.27±0.01 
 
1.5±0.1 
 
0.77±0.47* 
 
0.34±0.02 
 
1.5±0.1 
 
0.75±0.20* 
 
0.42±0.05 
 
1.7±0.3 
 
0.67±0.14* 
 
0.38±0.08*  
 
1.3±0.2 
 
0.66±0.15* 
 
0.29±0.01 
 
1.1±0.3 
 
0.62±0.13* 
 
0.41±0.00 
 
0.4±0.2 
 
0.72±0.02 
 
0.45±0.01 
Table 7.3: Effect of Pre-Analytical Heat Treatment on Inhibitor Detection. Cut-Off=Assay cut-off. Values shown represent mean values for samples tested 
in duplicate.*  V≥20%.  
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Figure 7.4: Effect of Pre-Analytical Heat Treatment on FVIII inhibitor detection at 56°C (A), 
58°C (B) and 64°C (C) evaluated using a FVIII ELISA and the Nijmegen Bethesda Assay (NBA). 
Data plotted for the NBA is the mean±SD for sample evaluation performed in duplicate and 
the data from the second ELISA experiment with OD±SD.  
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7.4.2.3 Assessment of the Effect of Pre-Analytical Heat Treatment on FVIII Inhibitor 
Detection 
Finally, an assessment of the effect of PHT was performed on pooled FVIII deficient plasma 
spiked with a low-titre FVIII inhibitor (1.4BU/mL) from a single donor. The effect of PHT on 
inhibitor detection by the FVIII ELISA and NBA was evaluated over four temperatures (56, 58, 
64 and 72°C) to assess whether this resulted in loss of inhibitor detection. A higher 
temperature range was used in these experiments to the previous experiments to assess a 
temperature range which resulted in impaired antibody activity. PHT at 56 and 58°C did not 
result in any change in inhibitor detection by the NBA and FVIII ELISA for up to 120 minutes 
of sample incubation (Table 7.3 and Figure 7.4). PHT at 64°C resulted in a loss of antibody 
detection by the NBA after 120 minutes of sample incubation, with the suggestion of a 
decline in inhibitor titre with increasing incubation time (Figure 7.4). PHT at 64°C, did not 
affect inhibitor detection by the FVIII ELISA even after 120 minutes of incubation. PHT at 72°C 
resulted in plasma gelation within 15 minutes of heating. This process was irreversible and it 
was not possible to obtain sufficient sample volumes for inhibitor testing by the NBA or FVIII 
ELISA.   
7.5 Discussion 
The data presented for clinical usage of PHT, demonstrated improvement (10 fold) in the 
detection of FVIII auto-antibodies, using a functional inhibitor assay (NBA) in parallel with the 
FVIII ELISA. A change from negative to positive was seen in samples from 6/8 patients, which 
could have had implications for clinical management. Evaluating the longitudinal time lines 
(Figure 7.1 A-C), PHT using a functional inhibitor assay (NBA) and/or a FVIII ELISA, allowed 
earlier detection of FVIII auto-antibodies, allowing unmasking of otherwise undetectable 
low-titre FVIII antibodies 292. Improving the sensitivity of antibody detection using PHT, 
described in this chapter and by other investigators (Table 7.4) could have application as a 
biomarker for early detection of relapse or as a more sensitive marker of remission in AHA. 
Evaluation of commonly used PHT incubation conditions (56 and 58°C), demonstrated 
differences in denaturation of FVIII dependent on the incubation time, without affecting 
inhibitor detection by the NBA or FVIII ELISA.  
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7.5.1 Pre-Analytical Heat Treatment in Congenital and Acquired Haemophilia A 
There has been increased research interest in the usage of PHT, as part of inhibitor testing in 
both congenital and acquired haemophilia A. The key features of these previously described 
studies are summarised in Table 7.4. All of these used PHT incubation temperatures between 
56 and 58°C, although there were some difference in incubation times and use of 
centrifugation. The largest of these studies (1353 samples, 710 patients), was carried out as 
part of a national inhibitor surveillance study from the US 283. In samples from patients with 
severe haemophilia A, 55% (126/228) contained measurable FVIII:C. A total of 202 samples 
(159 negative inhibitor history, 43 positive inhibitor history and 30 controls) were tested 
using the NBA before and after PHT. Of these, six became positive following heat treatment 
with only one from a patient with no inhibitor history (pre: 0BU/mL to post: 0.7BU/mL) and 
the remainder from patients with a previous inhibitor history 283. A more recent publication 
has systematically evaluated the effect of PHT in patients with severe haemophilia A, with no 
inhibitor history (group I, n=20); inhibitor history with no recent FVIII exposure (group II, 
n=21) and patients on ITI (group III, n=5, 68 samples). Although no samples from patients 
without an inhibitor history became positive post PHT, samples in both other groups with an 
inhibitor history had a change in inhibitor status post PHT (group II=6 and group III=5). It is 
interesting to note that all of these samples that became positive had very low amounts of 
FVIII:C (range 0.1-1.8IU/dL) prior to PHT, although there was demonstrable FVIII:Ag in all 
samples. This change in positivity in these samples could support previous findings  292 that 
an additional mechanism of PHT in increasing inhibitor testing sensitivity is through 
disassociation of bound FVIII antibodies.  
Data for usage of PHT in AHA is more limited with three small unpublished studies (not 
including the data presented in this chapter) being presented to date in abstract format. The 
first of these, presented in 2005, represents one of the first recent descriptions of routine 
use of this modification 293 (Sahud M., Senior Academic Associate, Quest Diagnostics, 
personal communication). This study looked at 120 samples from patients with FVIII 
antibodies; auto-antibodies (n=84) and allo-antibodies (n=9) 293. Following PHT (56°C for 60 
minutes), FVIII:C became undetectable in all samples. There was an increase in auto-antibody 
inhibitor titre in 86% (66/77) samples (mean increase 28.3±71BU/mL), although all of these 
samples appear to have detectable antibody present prior to PHT (i.e. no negative samples). 
Relatively little change was seen in inhibitor titre following PHT in a small number (n=9) of 
samples containing allo-antibodies. Similar findings to the data presented in this chapter  
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PHT Cent Samples 
(pt) 
Diag Findings Ref 
56°C 
60mins 
No 120 
(NS) 
AHA 
CHA 
+PHT at 56°C for 1 hour, FVIII:C <1%, no 
effect on inhibitor activity 
+66/77 positive AHA samples mean increase 
in Bethesda titre 28.3±71 
Sahud et 
al 
B 293 
58°C 
90mins 
Yes 
Dual 
20 
(7) 
CHA +Low-titre assay cut-off >0.03BU/mL 
+6/7 patients post ITI, low-titre NBA+, with 
impaired FVIII pharmacokinetics (PK) 
+3 patients, normalisation of PK with 
negative low-titre NBA.  
+2 patients continued impaired PK with 
ongoing low-titre NBA+ 
Dardikh et 
al 
A 294 
56°C 
30mins 
Yes 
5000rpm 
5mins 
202 
(NS) 
CHA 
 
+ PHT resulted in undetectable FVIII:C & 
FVIII:Ag in severe (n=15) and non-severe 
(n=7) haemophilia A 
+ No inhibitor history: 1/159 became NBA+ 
+ Inhibitor history: 5/30 became NBA+ 
Miller et al 
A 283 
58°C 
90mins 
Yes 
Dual 
38 
(15) 
AHA + 7 patients (FVIII <70IU/dL and BU 
≤ BU/mL).  /7 patients had ≥  BA+ sample 
following PHT,  
+8/14 samples BA- with FVIII <70IU/dL pre-
PHT were positive post PHT.  
+All BA+ samples remained positive post 
PHT.  
+No samples BA+ post PHT if FVIII >70IU/dL 
(n=24) 
Bodo et al 
B 295 
58°C 
90mins 
No 39 
(8) 
AHA + Pre PHT: 2/39 samples NBA+ and 11/39 
ELISA+.  
+ Post PHT: 20/39 NBA+ and 16/39 ELISA+ 
+  /8 patients, ≥  sample NBA+ post  PHT 
Batty et al 
A 296;372 
56°C 
60mins 
Yes 
2700g 
5mins 
1092 
(NS) 
CHA 
AHA 
+Increased sample testing, post PHT 
(95v72%) 
+ 0/31 samples with severe HA NBA+ with 
FVIII:C>20IU/dL.  
+3/14 samples NBA+ with non-severe HA 
with FVIII:C >20 IU/dL. 
+ 91/140 samples NBA+ with AHA, were 
NBA+ with FVIII:C >20 IU/dL 
Gandhi et 
al 
B 290 
56°C 
30mins 
Yes 
2500g 
5mins 
109 
(46) 
CHA + No inhibitor history (n=20): PHT no change 
+ Inhibitor history, no recent FVIII (n=21): 6 
samples became positive with PHT. 
Increased mean inhibitor titre (p<0.05) 
+ ITI patients (n=5, 68 samples): 5 samples 
became positive with PHT. 3 fold mean 
increase in inhibitor titre in positive samples. 
de Lima 
Montalvão 
et al 
A 297 
Table 7.4: Clinical usage of Pre-Analytical Heat Treatment in Congenital and Acquired 
Haemophilia A. NS=Not-stated. Cent=Centrifugation. Dual=Two step centrifugation, with 
initial short centrifugation at 18,000g for 5 minutes, followed by centrifugation of 
supernatant plasma at 4200g for 45 minutes at room temperature in a Ultra-Free-4 
centrifugal filter with a nominal molecular weight limit of 100kD. Concentrates were 
collected from the filter unit and mixed in a ratio of 3:1 with 0.1mol/L imidazole buffered 
normal plasma (pH 7.4). AHA=acquired haemophilia A, CHA=congenital haemophilia A. 
A=Published article, B=Poster or conference presentation. 
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have been described in a cohort of patients (n=15), which was presented in abstract form in 
2013 295, alongside my data 296;372.  
7.5.2 Laboratory Monitoring of Treatment Response in Acquired Haemophilia A 
Interestingly, five clinical samples positive by ELISA prior to PHT became negative by ELISA 
following PHT. Although, one could suspect, these represented false positives on the initial 
ELISA, this seems unlikely given that there was some detectable inhibitory capacity using the 
NBA in four of these following PHT. An alternative explanation could be that PHT has a 
greater effect on the immunoglobulin structure than previously suggested 292;370;373. 
Experimental data, in another setting has shown heating results in alterations in 
immunoglobulin secondary structure affecting the Fab region at 61°C, followed by the Fc 
region at 71°C 374. One could hypothesise that some antibodies’ binding kinetics, for e ample 
those with low binding affinity may be more sensitive to temperature induced disruption of 
Ig structure. This would in turn lead to a lack of detection when using a FVIII ELISA. In contrast, 
immunoglobulins might still be able to exert inhibitory effect through steric hindrance 
resulting in detectable inhibitory capacity even with lower binding affinity. In my subsequent 
experiments following on from these observations, PHT at 56°C and 58°C did not affect 
antibody detection by ether the NBA or ELISA, even when incubated at 64°C for 120 minutes, 
despite loss of detection by the NBA.   
Finally, the clinical and function relevance of antibodies detectable following PHT remains 
unknown. Whether these represent truly pathogenic antibodies, or are similar to “natural” 
FVIII antibodies seen following heat treatment of samples from normal individuals and 
patients with congenital haemophilia A is not clear 375. In my view, introduction of PHT in the 
absence of prospective clinical trial data of clinical significance may adversely influence 
clinical treatment decisions in AHA. For example, in the weaning of immunosuppression this 
could result in patients with persistently detectable antibody following PHT, being exposed 
to protracted immunosuppression, with associated risk of morbidity. The approaches 
described in this and the previous chapter (PHT and ELISA) could provide biomarkers to allow 
more personalised management of immunosuppression in AHA. To date there has been no 
description of the usage of ELISA or similar technology to provide long term monitoring in 
AHA. As such, it is not known if some patients develop a long term (chronic) immune 
response to FVIII, even following normalisation of FVIII:C, that remains detectable using a 
more sensitive assays. On the other hand, some patients who achieve antibody negativity by 
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all assays/modifications, as seen for two patients in this study, might form a distinct subgroup 
of patients in whom immunosuppression could be de-escalated more rapidly and toxicity 
minimised. Whether the first of these scenarios represents an analogous status to the 
concept of minimal residual disease, used for in leukaemia risk stratification in haemato-
oncology studies of treatment response, is not clear. Further prospective study would be 
required to determine whether differences exist in relapse rates in patients with persistent 
detectable low level antibody, compared to those whose antibodies become undetectable 
by all assays. This would optimally be performed in a multicentre study with centralised 
laboratory testing and would by a difficult study to conduct even within the setting of a 
national or international cohort study.  
7.5.3 Usage of Pre-Analytical Heat Treatment in the United Kingdom 
Within the UK there appears to have been an increased uptake in usage of PHT as part of 
inhibitor testing. Survey data presented in Chapter 5, demonstrated that only one 
respondent used PHT as part of their inhibitor testing in AHA 321. Since this survey, a NEQAS 
exercise (November 2013), reported 21% (23/110) of centres surveyed reported using PHT 
to inactivate residual FVIII:C as part of their inhibitor testing 331. There was variation in 
incubation temperature (56-58°C), incubation time (15-120 minutes) and centrifugation use 
(none, or 3000-15,000 x g), reflecting a lack of previous data comparing these conditions. 
This change in laboratory practice may have resulted from recently presented data on usage 
of PHT (Table 7.4). An alternative explanation may be that clinicians surveyed regarding 
management of AHA were unaware of the specifics surrounding inhibitor testing within their 
centre’s laboratory. 
The data from my experiments assessing different PHT conditions has demonstrated 
differences between the commonly cited PHT (temperature and incubation time) conditions. 
Although, incubation at 56°C resulted in a FVIII:C <1IU/dL for endogenous pooled plasma and 
rFVIII after 60 and 120 minutes respectively, there was detectable FVIII:C for the pdFVIII 
concentrate following 120 minutes of incubation. PHT at 58°C, as used in our laboratory 
practice, had a clearer pattern of denaturation for both endogenous and exogenous FVIII:C, 
which resulted in FVIII:C <1IU/dL after 60 minutes. Within these temperatures there was no 
significant denaturation of FVIII antibodies seen. Data from the usage of a higher 
temperature (64°C) for heat treatment appear to suggest a modification that may be 
associated with significant time saving for laboratory staff, in that endogenous FVIII:C was 
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completely denatured within 5 minutes of PHT, although there was a trend for loss of 
inhibitory potential with increased incubation time. The findings of incomplete FVIII:C 
inactivation with usage of an incubation of 56°C, although in keeping with the earlier 
experimental data 292;371, differ from recent studies that found undetectable FVIII:C following 
30 293 and 60 283 minutes of PHT. Whether these differences relate to the high levels of FVIII:C 
present in my experiments, relative to those seen in these recent studies, is not clear and 
requires further study. 
7.6 Limitations 
Within the sample testing used within this work, there are a number of limitations due to the 
protocols used. Within testing of the FVIII:C for the endogenous and exogenous plasma, with 
these samples having baseline FVIII:C >100IU/dL, the precision in testing at this point will be 
lower, which is seen through the wide SD for these data-points (Table 7.2). In reporting of 
the effect of PHT on FVIII:C, both the normalised and raw data were reported to provide 
transparency of reporting, with the absolute cut-off of a FVIII:C of ≤ IU/dL being used. In this 
it is recognised that the level of effect of PHT might be affected by the starting proportion of 
FVIII:C. Additional limitations exist in the precision of reporting of the inhibitor titres and 
FVIII:C, in which only testing of undiluted samples were performed due to cost limitations 
and the low-titre of inhibitor present. Although this may have resulted in lower precision 
being insensitive to subtle changes following PHT, the primary outcome being evaluated was 
loss of FVIII:C (<1IU/dL) or loss of inhibitor detection, which demonstrated consistent results 
on repeat testing.  
Finally it should be noted that as there is increased usage of PHT in routine laboratory 
practice, greater care is required in the calibration and validation of laboratory equipment 
used for these purposes. Even within these controlled experiments, variability in the water-
bath temperatures were seen for each temperature point. In the usage of water-baths for 
sample incubation, centres should not assume temperature settings of the water-bath will 
provide accurate measures of water temperature, highlighting the importance of usage of 
calibrated devices (as required by ISO 15189:2012) and temperature monitoring during the 
process of PHT. Secondly in the usage of the ELISA, within these experiments, although no 
detectable change in signal was seen, even with duplicate testing there was a greater than 
desired CV (>20%) for some samples tested, although this was improved with the addition of 
a gentle vortexing step between stages within the ELISA protocol. As no further ELISA plates 
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were available for usage in these experiments, it was unfortunately not possible to repeat 
the tests in which the CV was >20%.  
Finally, a significant limitation in the review of the clinical data was that the ELISA results 
were only available for analysis in a binary format (positive or negative). This did not allow 
comparison of the ELISA OD pre and post PHT, or evaluation of the testing QC (KC and CV). A 
variation in CV seen in the ELISA could potentially impact on the results of this assay, although 
it was not possible to repeat testing on these samples due to the study design. Measures of 
imprecision should ideally be reported alongside results if they are to be used in clinical 
decision making processes.  
7.7 Conclusions 
PHT improves detection of FVIII antibodies in congenital and acquired haemophilia A. The 
proposed mechanism for this is through denaturation of residual FVIII:C within samples prior 
to analysis and/or release of bound FVIII antibodies. Commonly cited PHT protocols could 
yield different results in their effect of denaturing FVIII:C, especially when exogenous FVIII:C 
is present in samples. PHT at 58°C for 60 minutes yielded consistent results for denaturation 
of both endogenous and exogenous FVIII without affecting inhibitory capacity. The rapid 
denaturation of FVIII:C, seen using PHT at 64°C without impacting on inhibitor detection, 
could result in time and cost savings for use of this modification, requires further study.  
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Chapter 8: Amino Acid Sequence Epitope Mapping of Factor VIII Antibodies 
in Severe Haemophilia A 
8.1 Introduction 
Polyclonal FVIII antibodies have been reported to interact with multiple domains on both the 
heavy and light chain of FVIII in congenital and acquired haemophilia A. Although 
modifications to FVIII antibody testing described in the previous chapters improved detection 
of FVIII antibodies, these do not provide a mechanism of inhibitory action for FVIII antibodies. 
Understanding where these antibodies interact (B-cell epitope) with FVIII may provide 
further information for understanding of the immune response to FVIII. Improved 
characterisation of antibody interaction sites may identify regions of increased 
immunogenicity (immunodominant epitopes) and allow greater understanding of 
differences in antibody classes (inhibitory/non-neutralising) and kinetics. This could in turn 
allow development of modified FVIII products with reduced immunogenicity as 
demonstrated in a murine haemophilia A model 376 by mutagenesis at residues within an 
immunodominant epitope in the A2 domain (R484-I508) 377 . In this model, an 
R484A/R489A/P492A mutated B domain deleted (BDD) FVIII had reduced immunogenicity 
compared to a control wild type BDD FVIII  376. Certain epitope profiles may be predictive of 
ITI response (or failure) which could provide a biomarker for further stratification of patients 
towards different treatment approaches. In keeping with this, small studies of patients 
undergoing ITI have suggested that the FVIII antibody domain epitope may predict likelihood 
of ITI success 378-380. In the most recent of these studies (15 patients), the presence of FVIII 
antibodies to the A1 and A2 domain prior to ITI initiation demonstrated significant 
discriminatory ability (AUC >0.875) for prediction of ITI failure 380. Similar findings of poor 
response to ITI in patients with A2 domain binding antibodies has been reported 378;379. These 
data support a hypothesis that differences in B-cell epitopes of FVIII antibodies may influence 
outcomes, although this requires further study in larger cohorts. There has been substantial 
research interest over the last three decades attempting to characterise the B-cell epitopes 
of FVIII antibodies 239;247;381, via a number of different approaches at high (amino acid 
sequence) and low (domain or sequence region) resolutions, which are summarised in Table 
8.1 382.  
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 Domain Seq 
 
Linear Conformational Time Ref 
Luminex® + / - - + + + 246;247;261;380 
IB / IP + LRes + - ++ 135;383-385 
MS + LRes/HRes + + ++ 386;387 
Recombinant 
hybrid 
porcine/human 
FVIII 
+ LRes/HRes + + ++ 133;377;388;389 
Alanine 
scanning 
mutagenesis  
+ HRes + + +++ 390 
Phage display + HRes + + +++ 391-393 
Peptide array + HRes + + / - + 394-398 
SPR + HRes + + ++ 399 
X-Ray 
crystallography 
+ HRes + + ++++ 400 
Table 8.1: Comparison of assays used in detection and description of FVIII antibodies in 
congenital and acquired haemophilia A. Time=Time taken to perform epitope mapping. 
LRes=Low-resolution (region of amino acids), HRes=High-resolution (amino acid sequence). 
IB=Immunoblotting. IP=Immunoprecipitation. MS=Mass spectrometry. SPR=Surface 
plasmon resonance. 
Prior to consideration of the optimal approach for epitope mapping in the setting of 
haemophilia, it is useful to consider some of the core determinants of B-cell epitopes in a 
broader context 401-405. Although the majority of epitopes described form conformational or 
discontinuous epitopes 401, 85% of epitopes contain linear stretches of 5 or more residues 
403;405.  The positioning of epitopes protrude from the antigen surface 406 and are more 
exposed than the remaining antigen 405. Within these regions, the secondary structure is 
depleted of strands/helices and enriched in loops 401;407, with paired amino acids (Y:Y, C:P, 
N:Y, G:Y, D:P, T:Y, R:Y, H:Y and H:M) 135;383;384 represented more frequently in the epitope than 
the remaining antigenic surface 401;403. As such, the optimal epitope mapping platform should 
allow characterisation of continuous and discontinuous epitopes at an amino acid level. This 
would allow high-throughput assessment within an integrated bioinformatics algorithm to 
provide epitope data for clinicians and translational researchers. This would also ideally allow 
evaluation using low sample volumes without complex sample preparation. Previous 
techniques used for epitope mapping in haemophilia (Table 8.1), all have specific advantages 
and limitations, but none have provided an approach amenable for high-throughput, high 
resolution epitope profiling of continuous and discontinuous B-cell epitopes. Of these 
multiple methodologies, peptide arrays consisting of synthesised peptides of variable lengths 
on a solid phase medium provide an attractive approach due to relatively low costs and 
potential to allow high-throughput testing 404. A number of groups have used linear peptide 
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arrays to provide a low-throughput approach to epitope profiling of FVIII inhibitors 394-398. 
These studies have applied different sequence lengths of synthesised peptides and have only 
provided a mimic of the primary FVIII structure (linear sequence). As a result, this could lead 
to conformational differences between a region represented in the array and the 
corresponding region within the intact protein 408;409 and bias towards the detection of linear 
epitope sequences 404.  
A novel, commercially available peptide microarray (Pepscan), offers a high-throughput 
reusable approach for high-resolution mapping of antibody-protein interactions to an amino 
acid sequence level 410. This uses customised chemically synthesised overlapping peptide 
sequences, in a 455 well micro-card format, for any protein in which the amino acid sequence 
is known. This platform offers a variety of different arrays providing in-vitro representation 
of linear (primary sequence) or a conformation (primary and secondary structure) through 
constrained scaffolded peptide sequences. This approach has been used in a number of other 
settings describing the B-cell epitopes for a number of monoclonal (e.g. FSH-β, CD  , CC-
chemokine receptor CCR5) 410 and polyclonal (e.g. wheat allergy: α-, γ, ω , and ω -gliadin) 
411;412 antibodies. This technique has also notably been used to describe the binding epitope 
of two anti-CD20 monoclonal antibodies (rituximab and obinutuzumab) 413;414, delineating 
discrete binding profiles for each with potential mechanistic implications. A reusable high-
throughput peptide microarray, providing a conformational mimic, has not previously been 
described for epitope mapping of FVIII antibodies, which potentially offers a novel approach 
for characterising the binding of FVIII antibodies within clinical studies. Within this chapter I 
have evaluated the application of this platform in the characterisation of B-cell epitopes of 
monoclonal and polyclonal FVIII antibodies.   
8.2 Hypothesis and Aims 
The hypothesis is that a novel, high-throughput peptide microarray provides a feasible 
platform for epitope mapping of FVIII antibodies, which will allow high-throughput analysis 
of oligo-/poly-clonal B-cell epitopes. This technique will allow high-resolution epitope 
mapping of clinical samples containing FVIII antibodies and identify recurrent 
immunodominant sequence epitopes. The specific aims from these experiments are as 
follows:  
1) To evaluate a novel, high-throughput microarray for the description of B-cell 
epitopes recognised by a panel of FVIII monoclonal antibodies (mAbs). 
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2) To define the array cut-off for positivity and validate the re-usability to allow 
interpretation of clinical samples. 
3) To describe the B-cell epitopes of inhibitory antibodies in a cohort of patients with 
severe haemophilia A.  
4) To assess whether inhibitory antibodies have common FVIII (immunodominant) B-
cell epitopes and to correlate these with FVIII structure and function. 
8.3 Materials and Methods 
Monoclonal Antibodies 
GMA-012 (R8B12) and GMA-8011 (2A9) were purchased from Green Mountain Antibodies 
(Burlington, Vermont, USA). The remaining monoclonal antibodies were kind gifts from the 
following: C5, Prof. Z.M. Ruggeri (The Scripps Research Institute, La Jolla, CA, USA), 58.12 & 
2D2, Dr L. Regan (Bayer HealthCare, Berkeley, CA, USA). The known characteristics of these 
monoclonal antibodies are summarised in Table 8.2. 
Monoclonal 
Antibody 
Domain Sequence Epitope Technique Reference 
C5 A1 338-362 
 
351-365 
L 
 
L 
Phage 
 
C.ELISA 
Ware et al. 415 
 
Foster et al. 383 
58-12 A1 N/A N/A N/A 
 
Nil 
GMA-8012 
(R8B12) 
A2 563-740 
 
497-510; 584-593 
L 
 
D 
IB 
 
MS 
Fay et al. 416 
 
Ansong et al. 417 
2D2 A3 N/A N/A N/A 
 
Nil 
GMA-8011 
(2A9) 
C1 N/A C ELISA Summers el al. 
418 
Table 8.2: Factor VIII murine monoclonal antibodies previously characterised epitopes. 
L=Linear, D=Discontinuous, C=Conformational. C.ELISA=Competition ELISA. 
IB=Immunoblotting. MS=Mass spectrometry.  
Pepscan Epitope Mapping Platform  
Epitope mapping of FVIII monoclonal and polyclonal antibodies was performed using peptide 
micro-arrays produced by a commercially available precision epitope mapping service 
(Pepscan, Lelystad, Netherlands). These microarrays allow high-throughput epitope mapping 
of any protein in which the sequence is known, using low  olumes of antibody (   μg) or 
untreated plasma (   μL). These micro-arrays consist of a proprietary re-usable ‘mini-card’ 
with overlapping solid-bound peptide sequence of up to 40-mer in length, offering varying 
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degrees of protein scaffolding, from “un-scaffolded” (linear T ) to “scaffolded” (looped, T ). 
Plate design was based on FASTA sequence for the mature FVIII protein (P00451). Selection 
of peptide sequence lengths for the array wells was made based on previous data of epitopes’ 
characteristics as discussed earlier (majority of epitopes containing 15 residues with linear 
stretches of 5 or more residues within these regions) 404;405. Two arrays were created to mimic 
linear and conformation structures of FVIII. The linear (T1) array consisted of 20-mer peptide 
sequences within each well, with a 5-mer sequence overlap between adjacent wells (Figure 
8.1). The looped (T2) array consisted of 15-mer sequences with a 5-mer overlap between 
each microwell, with a conformational mimic created through the addition of cysteine 
residues at the  ’ and  ’ ends of the peptide sequence resulting in a  7-mer amino acid in 
each microwell (Figure 8.1). Peptides were robotically synthesised using a syro-synthesiser 
onto 455 well micro-cards for both the linear (T1) and looped (T2) arrays, by Pepscan 
(Lelystad, Netherlands). Solid-phase synthesis was performed using standard 
Fluorenylmethyloxycarbonyl (FMOC) chemistry onto polypropylene supports containing 
carboxylic acid groups, with peptides sequences being covalently bonded at the C-terminal 
peptide to each well 410;419. Residues were then de-protected using trifluoric acid (TFA) with 
scavengers. For the creation of peptide sequences within the looped array (T2), each peptide 
sequence was capped with a cysteine residue at the C- and N-terminus. Within the T2 array, 
where a cysteine occurred within the primary protein sequence, an alanine substitution was 
made. There are 23 cysteine (22 represented in assay) residues in FVIII, which occur in the 
following domains: A1=5; a1=0; A2=4; a2=1; B=4; a3=0; A3=5; C1=2; C2=2 (1 C2 domain 
cysteine represented in the array). An alanine substitution was made in 61/455 wells on the 
looped array to allow provision of conformational mimics for these regions. These plates 
were designed within our group prior to the commencement of these experiments and 
analyses. The sequence coverage for the T1 and T2 arrays, was 98.2% (1-2290): A1/a1 (100%), 
A2/a2 (100%), B (100%), a3/A3 (100%), C1 (100%), C2 (73.8%). Formation of scaffolds was 
performed using Chemical Linkage of Peptides onto Scaffolds (CLIPS™) technology in 100% 
H20 at room temperature at pH 7.8-8.0 410. This process involves the chemical reaction 
between the cysteine residues and a template (T) containing a benzyl bromide group, a 
reaction which is selective to the nucleophilic (SH) group of cysteine 410;419. Following micro-
card construction and between each e periment, plates were “cleaned” by sonication in 
“disrupt buffer” at 70°C for 30 minutes followed by sonication in millipore H20 for 45 minutes.  
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Samples were transported to Pepscan using the recommended sample transportation 
conditions and frozen at -80°C prior to testing. Samples were prepared for analysis by 
Pepscan staff and robotically applied to the array within the Pepscan laboratories. Samples 
were incubated (diluted 1 in 1000 in buffer) overnight at 4°C. After washing, the wells were 
incubated with either an anti-human or murine peroxidase conjugated secondary antibody 
for 1 hour at 25°C. After washing, the peroxidase substrate 2,2′-azino-di-3-
ethylbenzthiazoline sulfonate and 3% H2O2 were added for 1 hour and colour development 
was measured using a charge-coupled device camera 420;421. The results of all experiments 
were reported to the investigator as raw optical densities (ODs) for each well of the 
microarray. No cut-off or bioinformatics interpretation was performed at the point of testing 
within Pepscan.  
 
Figure 8.1: Pepscan Linear (T1) and Loop (T2) arrays demonstrating first four wells on these 
plates. These arrays consist of 20 (T1) and 15 (T2) mer peptide sequences, overlapping by 
5 amino acids between each wells.  
Clinical Samples 
Samples were obtained (non-sequentially) from patients with severe haemophilia A patients 
with a current inhibitor at the Angelo Bianchi Bonomi, Hemophilia and Thrombosis Center, 
IRCCS Maggiore Hospital, University of Milan, Italy. Local institutional approval was obtained 
and informed written consent was obtained from all patients with the study being performed 
in line with the Declaration of Helsinki.  
Demonstration of Pepscan Assay Cut-Off 
To evaluate feasibility of assay use for characterising the B-cell epitope of FVIII antibodies, 
five FVIII mAbs with known domain or sequence epitopes (Table 8.2) (positive controls) and 
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eight negative controls (buffer media) were tested. These samples were tested sequentially 
with a negative controls tested prior to and following each mAb to evaluate assay reusability 
by identifying potential signal carry-over between experiments.  Assessment of the data from 
all experiments, including the mAbs (n=5), negative controls (n=8) and clinical samples (n=13) 
was performed to establish a cut-off for positivity.  
On examination of the raw OD data for these experiments, clear binding peaks were seen for 
4/5 mAbs and 12/13 clinical samples. The raw assay OD data from the three sets of samples 
(negative controls, FVIII mAbs and clinical samples) were initially examined to determine 
whether this could provide an absolute cut-off for positivity for both arrays. For the linear 
(T1) array, the mean (range) OD for the negative controls, mAbs and clinical samples were 
37.9 (0-126), 112.2 (0-2860) and 239.0 (2-2552) respectively. Similarly, for the looped (T2) 
array the mean (range) OD for the negative controls, mAbs and clinical samples were 37.3 (0-
140), 94.0 (0-2857) and 265.6 (41-2661). Given the range of OD seen for the negative controls 
compared to the clinical samples (Figure 8.2), it was not possible to define a cut-off based on 
OD alone. In the clinical samples 72.7% (4303/5915) and 71.0% (4200/5915) of wells on the 
linear and looped arrays had optical density values greater than the maximum values seen 
using buffer media. 
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Figure 8.2: Scatterplot of optical density data for monoclonal antibody, negative controls 
and inhibitor samples from patients with severe haemophilia A. 
Examination of the distribution of pooled data points for each group of experiments 
demonstrated a normal distribution for the negative controls and the appearances of a 
bimodal distribution curve for the mAbs and clinical samples. Further assessment of assay 
cut-off was then performed based on variance of results from the experimental mean. For 
the FVIII mAbs, the second peak was seen at appro imately ≥ SD from the e perimental 
mean (Figure 8.3) on both the linear and looped arrays. Taking this cut-off of ≥5SD, the 
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binding peaks in 17 (linear) and 12 (loop) array wells for the mAbs all coincided with clear 
binding peaks seen on examination of the experimental raw data. Using a cut-off of ≥ SD, 
only 8 (linear) and 1 (looped) array wells for the negative controls were positive (Figure 8.3). 
This threshold was used as an absolute cut-off to describe antibody binding similar to that 
seen for the mAbs. Applying this threshold alone to clinical samples was too restrictive giving 
positivity in only 32/5915 (linear) and 26/5915 (loop) of the array wells, despite additional 
peaks being evident on examination of the raw data. An evaluation of a “relative cut-off”, 
was performed based around the repetition of 5-mer sequences in subsequent wells on the 
linear (n= ) and looped (n= ) arrays. Gi en most epitopes contain linear stretches of ≥  
residues 403;405 this could allow identification of these regions. An assessment of a relative 
threshold based around binding in the sequential well containing the same 5-mers sequence 
was performed. Manual filtering was performed for all array wells in which the D was ≥ SD 
from the e perimental mean. Positi e wells with a ≥ SD were then grouped into “epitopes” 
falling within sequential or semi-sequential wells of the array (see Epitope characterisation 
and description). With the repetition of 5-mer sequences in subsequent wells, it would be 
expected to see binding in two or more continuous or discontinuous wells on the array if this 
sequence formed part of the B-cell epitope. Evaluation of the characteristics of all potential 
epitopes, based on binding data (SD and binding in subsequent wells), suggested that using 
such a filtering strategy with a relative cut-off of ≥ SD and binding in ≥  sequential/semi-
sequential wells would allow inclusion of more of the binding peaks seen in clinical samples 
and a reduction in non-specific binding seen in the negative controls (Appendix 2). An 
absolute cut-off of ≥ SD and relati e cut-off of ≥ SD was therefore set for these e periments. 
This approximates to a raw well specificity of 98.9% and 99.3% for the negative controls on 
the linear and looped arrays respectively. 
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Figure 8.3A: Linear (T1) array, 
distribution (SD) of epitope 
binding data, from the 
experimental mean. Data 
shown represents the combined 
normalised results for all array 
wells for each group of 
experiments. Distribution of 
binding data has a peak 
occurring around the mean 
(±0.5SD, normal distribution), 
with bimodal distribution of 
monoclonal antibody and 
clinical (haemophilia A) data.   
m b’s=monoclonal antibodies. 
SD=standard deviations. 
Negative Controls 
FVIII m b’s 
Haemophilia A 
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Figure 8.3B: Looped (T2) array, 
distribution (SD) of epitope 
binding data, from the 
experimental mean. Data 
shown represents the combined 
normalised results for all array 
wells for each group of 
experiments. Distribution of 
binding data has a peak 
occurring around the mean 
(±0.5SD, normal distribution), 
with bimodal distribution of 
monoclonal antibody and 
clinical (haemophilia A) data.   
m b’s=monoclonal antibodies. 
SD=standard deviations. 
Negative Controls  
FVIII m b’s 
Haemophilia A 
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Demonstration of Re-usability of the Pepscan epitope mapping array 
Evaluation for carryover of binding between experiments was performed, comparing the OD 
seen for the mAb peaks, with the OD within the same well prior to and following that 
experiment. This was performed for experiments in which all three data points (pre, mAb 
peak and post) were available (R8B12, GMA-8011, 2D2 and 58-12). No significant difference 
was seen for the mean negative control OD before and after mAb binding peaks for both the 
linear (pre 37.7±14.4 v post 37.2±19.8, p=1.0) and looped arrays (pre 39.6±11.7 v post 
34.6±15.8, p=1.0). The mean peak mAb OD, was significantly higher than the preceding 
negative control OD, for both the linear (pre 37.7±14.4, post 1483.9±1086.5, p<0.0005) and 
looped arrays (pre 39.6±11.7 v post 1327.3±1231.7, p=0.001). When positivity for the 
negative controls was defined based on the experimental SD (absolute cut-off SD≥  and 
relative cut-off SD≥  in ≥  wells containing the same  -mer sequence) none of the wells in 
the negative controls following the mAb peaks were positive.  
Epitope Characterisation and Description 
Low-resolution (LRes) epitopes described represent the total sequence length in which 
positivity was seen. For example, if binding was seen in first three array wells of the linear 
plate, well 1 (1-20), well 2 (well 6-25), well 3 (11-30), the low-resolution epitope would 
represent the first aa to last aa in which positive binding seen, which in this example would 
be 1-30. The high-resolution epitopes (HRes) presented represent a putative epitope based 
on the recurrence of 5-mer sequences in subsequent wells on the array. Using the same 
example as above, the sequence that is represented in all three of these wells on the linear 
array is the region 11-20. A similar approach was also taken if a discontinuous signal was 
seen, for example if binding was seen in wells 1, 3 and 4. Using this approach, the low-
resolution epitope would correspond to positions 1-35 and the high-resolution epitope 
positions 16-20, based on this 5-mer sequence being represented in all three of these wells. 
Within the summary of epitope data, these are also described based on the array in which 
positi ity was demonstrated, with a “shared epitope” being positi ity seen within the same 
sequence region on both the linear and looped arrays. 
Bioinformatic Resources, Structural Analysis and Epitope Representation 
The FVIII amino acid sequences was obtained from the Universal Protein Resource 
(www.uniprot.org) for human coagulation factor VIII (P00451-FA8_HUMAN) 419. The 3.7Å B 
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domain deleted FVIII crystalline structure (PDB ID: 2R7E) 7 was obtained from the Research 
Collaboratory for Structural Bioinformatics (RCSB) Protein Databank (www.rcsb.org)420. As 
discussed in Chapter 1, this crystalline structure has disordered regions not represented 
within the crystalline structure. For the purpose of visual presentation of the sequence 
epitopes, prediction for these regions were performed using pGenTHREADER 421 (accessed 
9/6/15) part of the PSIPRED v3.3 protein sequence analysis workbench 
(www.bioinf.cs.ucl.ac.uk/psipred) 422. Predictions were made for the heavy chain of Factor 
VIII based on the primary sequence (P0451) for the mature FVIII heavy chain (legacy positions 
1-740). This resulted in 31 statistically significant (p<0.05) predictions for the heavy chain, 
with 3 predictions with a net GenTHREADER score >200. The 2R7EA0 prediction was used 
based on the basis of sequence length coverage (735aa) and visual similarity of the heavy 
chain to that modelled in the original crystalline structure (2R7E). The heavy chain prediction 
was aligned electronically to the structure of 2R7E within PYMOL. This resulted in additional 
representation of the following regions within the heavy chain: 215-221, 335-359, 726-735 
within the heavy chain for demonstration of epitope positions.  
Assessment of solvent accessibility (accessible surface area, ASA) was performed for areas 
with positive binding (epitopes) to evaluate whether these regions were likely antibody 
interaction sites. ASA assesses the surface area of a protein that is accessible to a solvent 
giving a representation of surface exposed residues. Within an antigenic region, residues 
involved within the B-cell epitope are more surface expose than the remaining antigen 401.  
The absolute ASA represents the ratio between the solvent ASA of a residue within a three-
dimensional structure and that in an extended tripeptide (A-X-A) conformation. Absolute 
solvent accessible surface area for all residues represented (i.e. not predicted) within the 
FVIII crystalline structure were obtained using the Dictionary of protein secondary structure 
(DSSP) 423. Relative accessible surface area was then calculated using previously published 
scaling values (AASF) 424 using the following formula: Relative ASA = (Absolute ASA/AASF) x 
100. These AASF values are : A (110.2), D (144.1), C (140.4), E (174.7), F (200.7), G (78.7), H 
(181.9), I (185.0), K (205.7), L (183.1), M (200.1), N (146.4), P (141.9), Q (178.6), R (229.0), S 
(117.2), T (138.7), V (153.7), W (240.5) and Y (213.7) 424;425. This gives estimates of relative 
ASA ranging from 0% (completely buried) to 100% (completely accessible). A relative ASA 
≥  % was used to classify residues as being e posed and <  % as being buried 426. Secondary 
structure assignments were obtained using DSSP 423;427 from the RCSB Protein Databank, for 
the 2R7E FVIII crystal structure (last accessed 7/7/15) 420. Secondary structure assignments 
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are: H=α-heli , B=residue in isolated β-bridge, E=e tended strand, participates in β ladder, 
G=310 helix, I=5-heli  (π-helix), T=hydrogen bonded turn and S=bend. Blank entries, 
represent either a loop, irregular or no reported output 423. Assessment of potential 
discontinuous epitopes was made through calculation of pythagorean distance between the 
co-ordinates (X,Y,Z) of the α-carbons of residues obtained using DSSP 423;428. A cut-off of ≤  Å 
was used to assess potential proximity of residues likely to form part of a discontinuous 
epitope 429. Analysis of sequence similarity was performed using the local sequence 
alignment server Emboss Matcher based on the LALIGN application prediction server 430. 
Representation of epitopes was performed using PYMOL (The PYMOL Molecular Graphics 
System, Version 1.3, Schrödinger, LLC).  
Data Analysis and Statistical Analysis 
Sequence epitopes described are based on the numerical sequence position within the 
mature protein, i.e. legacy format. Data is presented as mean, range and standard deviation. 
Assessment of the data distribution was performed using scatterplots and histograms of the 
grouped data. Comparison of the mean optical density was performed using a one-way 
repeated measures ANOVA (pre, peak, post) for positively defined peaks from the 
monoclonal antibody experiments. Within the one-way repeated measures ANOVA 
sphericity was assessed using Mauchly’s test431 and where significant (i.e. sphericity violated) 
corrections to degrees of freedom were made using the Greenhouse-Geisser correction 432 
with post-hoc comparison being made using the Bonferroni test.  
8.4 Results 
8.4.1 Amino Acid Sequence Epitope Mapping of Factor VIII Monoclonal Antibodies 
Five anti-FVIII monoclonal antibodies with known sequence or domain epitopes (Table 8.2) 
to the heavy (n=3) and light (n=2) chain were tested on both the linear and looped peptide 
microarrays. Clear binding signals (Figure 8.4) were seen for 4 of these monoclonal antibodies 
(C5, R8B12, 2D2 and 58-12).  
A shared epitope for the a1 domain binding mAb (C5) is characterised between positions 341-
370 (HRes 351-360, TDSEMDVVRF), as shown in Figure 8.4A. This acidic terminal region of 
the A1 domain (a1), which includes the HRes epitope, lies within a disordered region of the 
FVIII crystal structure 7, although all amino acids represented (360-370) within the remainder 
of the LRes epitope are highly solvent accessible (Figure 8.5). Importantly, the HRes epitope 
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seen in these experiments is identical to the previous reported linear epitope for this mAb 
383;415. Significant binding was also seen within the B domain, with a shared epitope at 
positions 1091-1120 (HRes 1101-1110, FLPESARWIQ). These two regions showing significant 
similarity (underlined) at 7/16 (43.8%) and are identical (bold and underlined) at 5/16 (31.2%) 
residues (LTDSEMDVVRFDDDNS and LPESARWIQRTHGKNS), including three residues within 
the C5 HRes epitope (D352, S353, V357 and R359). 
A second A1 domain mAb (58-12), demonstrates a discontinuous epitope (Figure 8.4B). This 
has a shared epitope at positions 1-25 (HRes 6-15, YLGAVELSWD), with further binding at 
positions 36-50 (HRes 36-50, KSFPFNTSVVYKKTL) and 161-190 (HRes 171-190, GLIGALLVCR) 
on the looped and linear arrays respectively. The high-resolution linear epitope of the third 
region (171-190) is solvent inaccessible within the first 9 amino acids of this sequence 
(GLIGALLVC), with the terminal 10 amino acids being located distant from the putative 
discontinuous epitope described above. Analysis of relative spatial positioning of the alpha 
carbons of residues for these three regions demonstrates the following regions lie within 
pro imity (≤  Å): 7-18 and 43-50; 170-172 and 9, 11, 14; 46-50 and 167-174. Taking into 
account the relative solvent accessibility (>20%) of these regions, this results in a putative 11 
residue discontinuous epitope (shown in white in Figure 8.4B) with the co-ordinates: 11-
13(ELS), 17-18 (MQ), 43-47 (SVVYK) and 50 (L). Further binding was seen on the linear array 
within the B domain (841-870, HRes 851-865, PESGLQLRLNEKLGT) and A3 domain (1841-
1870, HRes 1851-1860, LIGPLLVCHT). The first of these regions demonstrates sequence 
similarity (similarity 60%, identical 50%) over a stretch of 10 amino acids (DLVKDLNSGL and 
DMVFTPESGL) in regions 163-172 and 846-855, respectively. The second of these also 
demonstrates a high degree of sequence similarity (similarity 78.3%, identical 65.2%) over a 
stretch of 23aa (VDLVKDLNSGLIGALLVCREGSL and VDLEKDVHSGLIGPLLVCHTNTL), in regions 
162-184 and 1841-1863, respectively. These regions share a common 5 amino acid motif of 
SGL and D-X-V where X represents any amino acid.   
The third monoclonal antibody (R8B12) demonstrates a shared epitope in the a2 domain 
between positions 716-745 (HRes 726-735, ISAYLLSKNN) (Figure 8.4C). This peak was 
reproducible on both linear and looped arrays on repeat testing. The high-resolution epitope 
falls within a disordered region of the crystalline structure, although the peptides within the 
low-resolution epitope (719-725) demonstrates solvent accessibility (Figure 8.5). This 
epitope falls within the region described previously (Table 8.2), but differs from a more 
recently reported discontinuous epitope for this monoclonal antibody between positions  
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Figure 8.4: Sequence Epitope Mapping of FVIII Monoclonal Antibodies. Low-resolution 
(LRes) and high-resolution (HRes) epitopes are represented in yellow and red respectively. 
Normalised data for binding is shown on the curves with the linear and looped arrays 
plotted in blue and red, respectively. A: C5 mAB (a1 domain): 341-370 (HRes 351-360, 
TDSEMDVVRF). B: 58-12 mAb (A1 domain): 1-25 (HRes 6-15, YLGAVELSWD), 36-50 (HRes 
36-50, KSFPFNTSVVYKKTL) and 161-190 (HRes 171-190, GLIGALLVCR). 58-12 dis-continuous 
epitope (shown in white): 7-18 and 43-50; 170-172 and 9, 11, 14; 46-50 and 167-174. C: 
R8B12 mAb (A2 domain) 716-745 (HRes 726-735, ISAYLLSKNN). D: 2D2 mAb (A3 domain): 
1786-1820, (HRes 1801-1805, EPRKN). E: GMA-8011 mAb (C1 domain): LRes: 491-510, 736-
760, 1701-1730 (HRes: MSSSPHVLRN, 1711-1720) and 1791-1805.
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Figure 8.5: Solvent Accessibility of FVIII Monoclonal Antibody Epitopes. Regions denoted 
(.) represent areas not represented within the FVIII crystalline structure for which 
estimation of ASA was not possible.  
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497-510 and 584-593. No significant binding was observed within these two regions on either 
the linear or looped arrays. The epitope characterised in my data and the previously 
characterised discontinuous epitope share sequence similarity (75% identical) over a region 
of four amino acids: SAYL (727-730) and SWYL (584-587).  
The fourth monoclonal antibody (2D2) demonstrates a shared epitope within the A3 domain 
at positions 1786-1820, (HRes 1801-1805, EPRKN) which is solvent accessibility in the 
residues 1802-1805 (Figure 8.4D and 8.5) Binding for the mAb falls within the domain 
previously characterised (Regan L., Bayer Healthcare, Berkley, USA) although there is no 
published experimental data of the sequence epitope. Additional binding is seen on the linear 
array within the B domain at positions 1216-1240 (HRes 1221-1235, KNFMKNLFLLSTRQN). 
These two sequence regions on pairwise comparison, have 100% similarity (80% identical) 
for a linear section of five amino acid residues KNFVK (1804-1809) and KNFMK (1221-1225), 
which includes two of the residues of the high-resolutions epitope (K1804 and N1805).  
No clear dominant epitopes were demonstrable for GMA-8011, a commercially available 
mAb previously described to bind to the C1 domain by ELISA 418. There were 10 regions 
(Figure 8. E) in which positi e binding was seen, with no “shared” epitopes seen. Within this 
experiment the raw optical density for these peaks was lower than seen for the other 
monoclonal antibodies. Outside the B domain, binding was seen in the following regions 491-
510 (A2), 736-760 (a2), 1701-1730 (A3) and 1791-1805 (A3). Although no significant binding 
was seen within the C1 domain, the binding seen within the A3 domain (1701-1730) is in a 
region directly adjacent to the C1 domain.  
8.4.2 Amino Acid Sequence Epitope Mapping of Factor VIII Antibodies in Severe 
Haemophilia A 
Samples from 13 patients with severe haemophilia A with a current inhibitor were analysed 
on both the linear and looped arrays. The median inhibitor titre for these samples was 26.0 
BU/mL (range 0.8-750.0), with 10 having high-titre and 3 low-titre inhibitors (Table 8.3). The 
F8 genotype was known for 9/13 patients which included intron 22 inversion (n=4), nonsense 
mutations (n=3), large deletions (n=1) and a small deletion (n=1). The F8 genotype was not 
known for four patients, with no mutation being found in three and the result not being 
available for the fourth patient.  
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 Titre (BU/mL) F8 mutation Domain epitopes Low resolution sequence epitopes High resolution sequence epitopes 
1 22 Not found A1, a1, A2, a2, B, a3 11-30; 96-125; 321-365; 381-400; 706-725; 
801-860; 896-920; 1226-1250; 1646-1670 
11-30; 106-115; 336-360; 386-395; 711-720; 
806-820; 841-845; 901-915; 1231-1245; 
1651-1665 
2 19 Not found A1, a1, B, a3 106-130; 316-370; 931-950; 1261-1280; 
1651-1665 
111-125; 331-355; 936-945; 1266-1275; 
1651-1665 
3 193 i22 inv A1, a1, A2, a2, B, a3 96-125; 316-365; 426-450; 586-610; 701-
725; 896-945; 1646-1670 
106-115; 331-335; 341-360; 431-445; 591-
605; 705-720; 901-915; 926-940; 1651-1665 
4 0.8 i22 inv A1, a1, A3 231-255; 331-355; 1916-1940 236-250; 336-350; 1921-1935 
5 80 Nonsense (Ex15) A1, a1, B, a3 96-125; 326-355; 1261-1280; 1651-1665 106-115; 336-345; 1266-1275; 1651-1665 
6 26 i22 inv A1, A2, a2, B, A3 11-35; 231-255; 706-730; 841-870; 896-920; 
1231-1255; 1911-1945 
16-30; 236-250; 711-725; 851-860; 901-915; 
1236-1250; 1916-1935 
7 96 i22 inv A1, a1, A2, a2, B 331-355; 701-725; 1151-1175 336-350; 706-720; 1156-1170 
8 4 Nonsense (Ex14) B 861-880; 1001-1020; 1056-1085; 1101-1130; 
1211-1235; 1421-1435; 1466-1505; 1556-
1575; 1581-1605 
866-875; 1001-1020; 1066-1075; 1111-1120; 
1216-1230; 1421-1435; 1476-1500; 1556-
1575; 1586-1600 
9 75 Large Del A1, a1, B, A3 231-255; 326-350; 1051-1070; 1281-1305; 
1921-1945 
236-250; 331-345; 1056-1065; 1286-1300; 
1926-1940 
10 80 Not available A1, a1, A2, a2, A3 191-205; 231-255; 326-355; 381-400; 701-
725; 1916-1940 
191-205; 236-250; 336-345; 386-395; 706-
720; 1921-1935 
11 13 Small Del (Ex18) A1, a1, A2, B, A3 186-205; 231-255; 326-355; 451-465; 1001-
1025; 1871-1885 
186-205; 236-250; 331-345; 451-465; 1006-
1020, 1871-1885 
12 750 Not found A1, a1, B, A3, C2 231-255; 341-365; 1001-1025 
1916-1940; 2266-2285 
236-250; 346-360; 1006-1020; 1921-1935; 
2271-2280 
14 4 Nonsense (Ex10) A1, a1, A2, a2#, A3 191-205; 231-255; 331-355;  381-400; 451-
465; 711-730; 1851-1885; 1916-1945 
191-205; 236-250; 336-350; 386-395; 451-
465; 716-725; 1866-1880; 1926-1935 
Table 8.3: Summary of domain and sequence epitope of patients with severe haemophilia A, with inhibitory antibodies using linear and looped peptide 
arrays.  Colour coding refers to recurrent sequence epitopes and is the same as represented within Figure 8.6, demonstrating position of these sequences. 
Del=deletion. Ex=exon. # = A single amino acid of the a2 domain at position 730 is covered within this epitope. 
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Code Array Epitope (HRes) Domain Frequency Functional regions Previously Described 
A LIN 11-30 (16-30) A1 2 - Sugihara et al. 395 
B SHARED 96-125 (106-125) A1 4 Calcium K107, E110, D116, E122, D125, D126 
A1/A3C1C2 interaction site 
Palmer et al. 394, Sugihara et al. 395 
C LOOP 191-205 (191-205) A1 3 - Griffiths et al. 386 
D LIN 231-255 (236-250) 
 
A1 6 Disulphide bond C248-C329 
N-linked glycosylation N239 
Sugihara et al. 395 
 
E SHARED 316-365 (331-360) A1/a1 11 FX interaction site M337-R372 
A1-A2 interaction site  
FVIIIa inactivation (APC/Xa) R336 
Sulphated Y346 
Disulphide bond C248-C329 
Foster et al. 383, Ware et al. 415, 
Huang et al. 433, Griffiths et al. 386, 
Sugihara et al. 395 
F LOOP 381-400 (386-395) A2 3 A2-A1/A3C1C2 interaction Ser373-Trp393 
 
Kopecky et al. 396, Gharagozlou et al. 
398, Ware et al 434 
G LOOP 451-465 (451-465) A2 2 - Palmer et al.394 
Gharagozlou et al. 398 
H SHARED 701-730 (706-725) A2/a2 6 FIXa interaction site K707-N714 
Sulphated Y718, Y718 and Y723 
van den Brink et al. 133, Huang et al. 
433, Gharagozlou et al. 398 
I LIN 841-860 (N/A) B 2 - - 
J LIN 896-920 (901-915) B 4 N-linked glycosylation N900 Palmer et al. 394 
K LIN/LOOP 931-945 (936-940) B 2 N-linked glycosylation N943 Palmer et al. 394 
L LIN 1001-1025 (1006-1020) B 3 N-linked glycosylation N1001 and N1005 Huang et al. 433 
M LOOP 1061-1070 (1066-1070) B 3 N-linked glycosylation N1066 Huang et al. 433 
N LIN 1216-1250 (1236-1245) B 3 FVIII haplotype SNP D1241  - 
O LOOP 1261-1280 (1266-1275) B 2 - - 
P SHARED 1646-1670 (1651-1665) B/a3 4 VWF interaction E1649-R1689  
Sulphated Y1664 
Tiarks et al. 244 
Huang et al. 433 
Q LOOP 1871-1885 (1871-1880) A3 2 VWF interaction E1875 Griffiths et al. 386 
R SHARED 1916-1945 (1921-1935) A3 5 - Sugihara et al.  395 
Table 8.4: Summary of recurrent inhibitor epitopes seen in clinical samples, with functional correlation to binding regions. LIN=Linear array, LOOP=Looped 
array. HRes=High-resolution. 
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Clear binding peaks were seen for 12/13 patients, although there was, predictably, more 
background signal with samples being polyclonal than for the mAb samples. There were 77 
regions of positive binding (linear and looped), with a median of 6 epitopes per patient (range 
3-9). Binding was seen to both the heavy and light chain in 11/13 patients and to the heavy 
chain alone in 2/13 patients. At a domain level, binding was seen to the A1 (12/13), a1 
(11/13), A2 (7/13), a2 (6/13), B (10/13), a3 (4/13), A3 (7/13) and C2 (1/13) domains. No 
patients demonstrated positive binding within the C1 domain and one patient with a low-
titre inhibitor (4BU/mL) demonstrated binding to the B domain alone. The sequence and 
domain epitopes are summarised in Table 8.3. 
On analysis of the epitopes from each patient, it became apparent that some epitopes 
recurred in more than one patient (immunodominant). Summarising all of the positive 
binding epitopes (linear and looped) by 5-mer sequence demonstrated 18 candidate 
immunodominant epitopes which were seen in ≥  patients (Table 8.4 and Figure 8.6). There 
were ≥  sol ent accessible residues for antibody interaction in all of these epitopes which 
are represented within the FVIII crystalline structure (n=10) (Figure 8.7). Binding within these 
characterised epitopes has previously been described in one of more patient in previous 
studies in 83% (15/18) of these regions. Of the epitopes which were seen outside of the B 
domain (n=11), binding was seen in 7 regions with structural or functional importance (Table 
8.4).  
The most frequently seen epitope (11/13) was a recurrent shared epitope between positions 
316-365 (HRes 331-360) in the A1/a1 domains (Table 8.3 and Figure 8.6). The majority of the 
high-resolution epitope falls within a disordered region which is only partially represented 
within the FVIII crystalline structure (disordered 335-359). Residues surrounding this 
disordered region demonstrate substantial solvent accessibility (Figure 8.7). This epitope 
contains a paired C:P residues (C329:P330). This region of FVIII contains the FX interaction 
site (337-372) 45;435, a sulphated tyrosine residue (Y346) important for FVIII activation 39 and 
the APC inactivation site (R336)48. This region also contains one of the interaction site 
between the A1 and A2 domains involved in maintaining FVIII stability. Epitopes within this 
region have previously been described by a number of different methodologies in clinical 
samples 386;395;433. A second shared epitope was seen in 5/13 patients in the a2 domain 701-
730 (HRes 706-725, Figure 8.6). This region demonstrates solvent accessibility and paired 
tyrosine residue (Y718:Y719). This region contains one of the FIXa interaction sites (707-714) 
43, 3 key sulphated tyrosine residues (Y718, Y719 and Y723)39 and is in a region of previously 
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characterised inhibitor binding (Table 8.4). Binding to either/both of these two regions 
involved in tenase complex formation was observed in 12/13 patient.  
A third shared epitope was seen at positions 96-125 (HRes 106-125) in the A1 domain in 5/13 
patients. The region formed by the HRes epitope predominantly consists of bends within the 
secondary structure. Functionally, this region contains a predicted calcium ion site 6;7 and 
specific residues (R121, E122) are involved in maintenance of FVIII structure through 
interaction with the A1 and C2 domain (residues Q2266, L2302, K2239) 6;436 (Figure 8.6). A 
looped epitope was also seen in 3 patients in the A2 domain at positions 381-400 (HRes 386-
395), a region containing paired H:Y residues (H384:Y385) forming a continuous beta-strand 
within the secondary structure. This region is involved in interaction between the A2 domain 
and A1/A3C1C2 dimer at positions 373-393 437 (Figure 8.6).  
Analysis of binding to the FVIII light chain identified recurrent epitopes in areas involved in 
the interaction between FVIII and VWF. The first of these was a shared epitope seen in 4/13 
patients regions within the a3 domain between positions 1646-1670 (HRes 1651-1665). This 
region falls within a disordered region of the FVIII crystalline structure. The region between 
positions 1649-1689 has been described as being involved in maintenance of optimal 
conformation (for maximal binding) of FVIII to the VWF high-affinity binding site (1673-1689) 
29.  The second of these epitopes was seen in 2/15 patients on the looped (T2) array between 
positions 1871-1885 (1871-1880). Interestingly, this region demonstrates solvent 
accessibility at only three residues, which likely form the key determinants of antibody 
interaction at positions V1871, T1872 and D1884. This region contains both bends (T1872, 
V1873) and a region consisting of a beta strand Q1874-A1877 within which the VWF 
interaction residue (E1875) is observed.  
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Figure 8.6: Sequence Epitope Mapping of FVIII Inhibitory Antibodies in Severe Haemophilia A. Epitopes shown represent the low resolution epitopes. 
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Figure 8.7 Solvent accessibility of severe haemophilia A inhibitor epitopes. Epitopes shown, 
correspond to the epitopes, within Table 8.4, with epitopes A-H, located in the heavy chain 
and Q-R in the light chain of FVIII. Regions denoted (.) represent areas not represented 
within the FVIII crystalline structure for which estimation of ASA was not possible.
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8.5 Discussion 
These high-throughput peptide microarray experiments have demonstrated amino acid 
sequence epitopes for both monoclonal and polyclonal FVIII antibodies. Assays were possible 
using small volumes of patient plasma or monoclonal antibody without requiring purification 
and demonstrated re-usability without antibody carryover. In patients with severe 
haemophilia A with inhibitors, recurrent regions (clusters) of binding on the FVIII surface 
were identified, consistent with immunodominant B-cell epitopes, which were located in 
regions of functional (tenase and VWF interaction sites) or structural importance (e.g. inter-
domain interaction sites). Where structural information was available, all of these regions 
contained sol ent accessible residues (≥ aa) for antibody interaction. In keeping with 
previous studies, seven of the epitopes contained paired aa, previously shown to occur with 
increased frequency within B-cell epitopes. Functional and structural correlation between 
the epitope sequences and previously described in-vitro data has provided putative in-silico 
mechanism of FVIII inhibition in these samples. 
8.5.1 Epitope Characterisation of Factor VIII Monoclonal Antibodies 
Within my experiments characterising the B-cell epitopes of FVIII mAbs, binding was seen 
within the previously described domains for 4/5 antibodies. Of these, the C5 mAb 
demonstrated identical binding to that which has previously been described 383. Within these 
experiments, application of the raw data in combination with positional information has 
given a putative discontinuous epitope for a monoclonal antibody within the A1 domain (58-
12) that has so far only been characterised at a domain level. Binding for the A2 domain mAb 
R8B12, although falling within the same region as previously described by immunoblotting 
(563-740), differed from the discontinuous epitope described by affinity directed mass 
spectrometry (497-510 and 584-593) 417 with a lack of binding seen in these regions on my 
experiments performed in duplicate. Whether this represents a limitation of this peptide 
microarray approach compared to this study using affinity directed mass spectrometry is not 
clear. Comparison of these data is however confounded by differences in coverage of the A2 
domain between my experiments (100%) compared to those using affinity directed mass 
spectrometry (70%) which did not have complete representation of the C-terminal region of 
the A2/a2 domain.  
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8.5.2 Factor VIII Immunogenicity and B-Cell Epitopes 
I have detected immunodominant epitope profiles in 12/13 patients in regions associated 
with tenase complex formation (FX or FIXa interaction sites). The predominant B-cell epitope 
(11/13 patients) was within the a1 domain between positions 316 and 365, which includes 
the FX interaction site and sites involved in FVIII activation/ inactivation. A second recurrent 
epitope was seen in around half (6/13) of these patients within one of the sites of the FIXa 
interaction sites within the a2 domain (707-714)43. Binding within these regions in the a1 (FX) 
383;386;395;415;433 and a2 (FIXa) 391;433;438 domains, involved within the tenase complex formation, 
have been described previously and my data provides further supportive information 
regarding this being an important mechanism of inhibitor action in severe haemophilia A 
(Table 8.4). A further recurrent epitope was seen in the A1 domain  (96-125), within a calcium 
ion containing region involved in interaction between the A1 and light chain (A3C1C2) 436 
which has again been characterised in small numbers of patients previously 394;395. Although 
antibody binding to the A1/a1 domain is seen less frequently than other domains (A2 and 
C2), binding within the a1 domain between positions 351-365 383 and 338-362 415 has been 
previously characterised. Although the precise crystal structure of the a1 domain has not 
been characterised 7, given the functional roles of this region involving protein-protein 
interactions, it is likely that this would be solvent accessible. Although binding to the A1 
domain is less common, a study by Palmer et al., demonstrated epitopes in 3/6 patients with 
congenital haemophilia A with binding occurring in  one region that was also seen within my 
experiments (96-125) 394. Studies of FVIII antibody epitope profiles towards the heavy chain 
of FVIII have demonstrated that a large proportion of patients contain epitopes towards the 
A2 domain. A recently published study investigating the diversity of the immune response to 
the A2 domain has shown overlapping epitopes covered the majority of the surface of the A2 
domain for 29 anti-human A2 domain mAbs produced in a murine haemophilia A model 438. 
Most of these murine antihuman mAbs, recognised a previously described epitope bounded 
by R484-I508 and resulted in non-competitive inhibition of the tenase complex. Other 
epitope regions identified involved in inhibition of FVIII activation by thrombin or were non-
neutralising. Similar to these experiments, one of the first epitopes characterised in the A2 
domain as being immunodominant by homolog scanning mutagenesis with a hybrid 
human/porcine FVIII molecules was found between positions 484-508 using the murine 
monoclonal antibody (mAb 413) 377. This interfered with FX binding and non-competitively 
inhibit the tenase complex. More recent work investigating epitope profiles in patients with 
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severe haemophilia A has not demonstrated consistent binding within this region 398, in 
keeping with the results seen in my experiments. A second immuno-dominant epitope has 
been described in the terminal acidic region of the A2 domain (a2) between positions 712-
736 391, a region in which binding was seen in more than half of the inhibitor samples tested 
within my experiments. 
Within my experiments, the predominant area of binding to the light chain of FVIII (3 
recurrent epitopes) was in the a3/A3 domain. Two of these epitopes fall within regions that 
are involved with VWF interaction (Table 8.4). Significant binding in the C2 domain was only 
seen for one patient (2266-2285), which is in contrast to previous studies 384. The C2 domain 
has previously been described to contain immunodominant epitopes at the N (2181-2243) 
and C (2248-2312) terminal regions of this domain. FVIII antibodies binding to the C2 domain 
have been previously been described as either classical (inhibit tenase complex formation on 
phospholipid membranes) or non-classical (inhibit FVIII activation by thrombin and/or FXa). 
Whether this lack of binding to the C2 domain in my experiments represents an assay 
limitation or differences in the characteristics of these C2 domain binding antibodies is not 
clear, which is discussed in more detail in the following section. It is interesting to note that 
other groups using peptide arrays have also only identified small numbers of epitopes within 
the C2 domain relative to those seen in the A2 domain 398.  
It was interesting to note that five of the epitopes seen in the B domain occurred in regions 
containing N-linked glycosylation sites. It is possible these represent areas of increased 
immunogenicity in patients treated with rFVIII concentrates due to differences in 
glycosylation seen at these sites from non-human cells lines (CHO and BHK) 104. Within 
previously described epitope mapping platforms, only two studies have included 
representation of the B domain either in large fragments 433 or partial coverage (760-960 and 
1411-1667) 394, with binding being characterised within all of these regions.  Unfortunately, 
no details of treatments received by the patients included in my analysis were available to 
further assess this hypothesis and due to lack of N-linked glycosylation as part of this assay 
the relevance of these findings is not clear.  
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8.6 Limitations 
There are a number of limitations with the epitope mapping platform used within these 
experiments. Although providing clear descriptions of epitopes within the heavy chain and 
N-terminal region of the light chain (a3/A3 domains), there was a lack of binding in other light 
chain regions. In the clinical samples tested, only one patient demonstrated significant 
binding within the C2 domain and no clear binding epitopes were seen for a C1 domain mAb 
(GMA8011). These findings are in contrast to previously characterised B-cell epitopes in 
patients with severe haemophilia A. Due to an error which occurred in the final design and 
manufacture stage at Pepscan, prior to my commencement of these experiments, the arrays 
utilised gave incomplete coverage of the C-terminal region of C2 domain (2291-2332). This 
error, unfortunately, only became apparent during data analysis after the maximum number 
of samples that could be tested had been reached. Given the costs and time associated with 
plate redesign to provide full FVIII coverage, it was not possible to repeat testing to further 
investigate this lack of C2 domain binding. Nevertheless, in view of clear epitope peaks being 
seen, an analysis was performed acknowledging that this limitation is present which may 
have excluded B-cell epitopes within the C2 domain. An alternative explanation for lack of 
binding seen within the light chain could relate to structural (secondary/tertiary) differences 
between the heavy and light chain. Antibodies binding to the light chain could potentially 
display more complex epitopes, as has been previously described from the crystal structure 
of a human monoclonal antibody (Bo2C11) in complex with the C2 domain 400. Although this 
represents the epitope for a single mAb which may not be representative for other C2 domain 
antibodies’ binding, in-silico predictions of epitopes in the C2 domain support the complexity 
of epitope profiles seen within this domain of the FVIII structure 439. Similar difficulties in 
characterisation of light chain antibody epitopes have also been reported by other 
investigators (Shannon Meeks, Associate Professor, Emory University, Atlanta, personal 
communication).  
There are limitations to all currently available epitope mapping platforms in the evaluation 
of a polyclonal immune response. In the use of synthesised peptide sequences, this may 
favour towards identification of linear epitopes and subsequently not allow detection of 
conformational or discontinuous B-cell epitopes. Using this type of peptide array, with 
conformational mimics, although helping proving closer representation of native protein 
structures could in some parts, artificially disrupt relevant epitopes. Other approaches such 
as mass spectroscopy may be limited in their representation of regions of interest, due to 
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relying on FVIII cleavage (e.g. thrombin), which could result in difference in 
secondary/tertiary structure once antigenic regions are not constrained within the full 
protein conformation. A further limitation of this (and similar) approaches, is that it is more 
likely to identify antibodies with higher binding affinities and cut-offs assume similar binding 
kinetics across the surface of FVIII. One difficulty in defining thresholds for epitope mapping 
studies at the time these experiments were conducted was a lack of positive controls (mAb) 
with known amino acid sequence epitopes. The absolute and relative cut-offs applied were 
pragmatic cut-offs based around evaluation of binding across the whole dataset. Usage of 
these thresholds, however, allowed systematic assessment of data between experiments, 
which were likely to represent significant FVIII antibody binding. This assay and similar 
peptide arrays lack in-assay positive and negative controls, which would be of use in 
discriminating between lack of binding or assay failure. Inclusion of such modifications within 
future plate design may allow more precise definition of cut-off, standardised for each array 
plate. This could include negative (e.g. poly-A tails or a lack of plate antigen) and a positive 
control (e.g. sequence epitope for testing a strongly positive mAb) wells being included 
within the plate design. In plate redesign, this would include all regions of the FVIII to allow 
coverage of the C-terminal region of the C2 domain, although changes in sequence length or 
regions represented would be required to allow this to fit with the 455 available microwells. 
Finally, due to the commercial nature of this platform there is limited information available 
in the public domain regarding methodology to allow comparison with other peptide arrays. 
8.7 Conclusions 
A high-throughput epitope mapping platform has allowed characterisation of B-cell epitope 
profiles of monoclonal and polyclonal FVIII antibodies, using low sample volumes and 
demonstrating re-usability. Within clinical samples tested, immunodominant epitopes were 
seen in regions of functional and structural significance. Usage of constrained peptides within 
a looped (T2) array, provided an in-vitro mimic of primary and secondary structure. This T2 
array demonstrated higher specificity for epitope representation, with a reduction in non-
specific binding attributable to regions of sequence similarity that was seen in the linear (T1) 
array. This approach offers a high throughput methodology for epitope mapping of clinical 
samples which may provide greater insights into the immune response to FVIII in larger 
cohort studies. 
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Chapter 9: Next Generation Sequencing (RNA-Seq) to Identify Prognostic 
Variables for Inhibitor Formation in Severe Haemophilia A 
9.1 Introduction 
Previous observational studies in severe haemophilia A have demonstrated a strong genetic 
component to inhibitor formation. A family history of inhibitor formation gave a three-fold 
(RR=3.2; 95%CI 2.1-4.9) increased risk of inhibitor formation within the Malmö International 
Brother Study (MIBS) 178. Of the genetic factors investigated to date the underlying class of 
F8 gene mutation appears to be one of the most significant risk factors. A meta-analysis of 
30 published studies (5383 patients, including 1029 inhibitor patients), demonstrated that 
the risk of high-titre inhibitor formation (comparator intron 22 inversion) was greatest in 
patients with large deletions (OR=5.18; 95%CI 3.35-7.99), with this risk being greatest when 
these deletions involved multiple exons (OR=14.79; 95%CI 7.79-28.11) 177. Alongside the 
underlying F8 mutation there is an increased incidence of inhibitor formation associated with 
black or Hispanic ethnicity, although the biological mechanisms for this are not clear 
(discussed in Chapter 1). Variable risk has been described in single nucleotide polymorphisms 
in the genes involved in the immune response (CTLA-4, TNF-α, IL-10) 188-191;440-443 and some 
HLA Class II alleles 186-188. A more detailed assessment of genetic risk has been presented in a 
large study of 833 subjects from 3 independent cohorts, investigating 1081 genes involved in 
the immune response or immune modifier genes (13,331 SNPs). This identified 13 SNPs, 
associated with either increased (n=5) or reduced risk (n=8) of inhibitor formation risk, 
including SNPs within the following genes: CD44, CSF1R, DOCK2, MAPK9, and IQGAP2.194.  
Recently advances in sequencing technology and a reduction of costs has made this 
technology more accessible for usage within clinical studies. These approaches allow detailed 
evaluation at a DNA (genome wide or exome mapping), RNA (transcriptome / gene 
expression), proteomic and epigenetic level. Alongside investigator lead studies, population 
based genomics projects such as the 100,000 (100k) Genome Project will create vast open-
access repositories of genomic/transcriptomic data to increase the understanding of the 
pathogenesis of disease processes. It is hoped that these studies will herald an era of genomic 
diagnostics and personalised medicine. Within the haemophilia setting, it is hoped these 
approaches may allow prediction of patients who will develop inhibitors and allow 
identification of patients in whom ITI is unlikely to be successful. These approaches may allow 
personalised management of patients at high (or low) risk of inhibitor formation to modify 
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replacement therapy and potentially justify novel interventions (e.g. selective or targeted 
immunomodulation) in particular high risk individuals.  
Although studies have described the epidemiology of inhibitor formation in severe 
haemophilia A in some detail, there is still an incomplete understanding of this process. 
Clinical studies at the initiation of FVIII treatment offer a unique opportunity to further 
develop an understanding of the allo-immune response. Analysis of changes occurring in the 
gene expression (transcriptome) will allow assessment of dynamic change occurring on 
exposure to a novel stimulus. Usage of Next-Generation Sequencing (NGS), by RNA-Seq 
allows quantitative assessment of the whole transcriptome including both coding 
(messenger RNA, mRNA) and non-coding/regulatory (including micro RNA, miRNA). Within 
such studies, patients are treated with a single protein therapeutic with regular laboratory 
testing for antibody formation and recording of relevant clinical data occurring at the time of 
treatment. In the design of such studies in severe haemophilia A there are however, a 
number of sampling considerations. Due to the early age of commencement of FVIII 
treatment (median 9.8 months) 149 and the blood sample requirements for evaluation of 
safety and efficacy, the blood volume available for additional studies is limited. Alongside this 
when collecting samples for transcriptome analysis, pre-analytical variables may artificially 
induce changes in mRNA expression without adequate consideration. Following 
venepuncture blood cells are exposed to a change in environment and new stimuli, which 
results in changes in the cellular activation status and/or ex-vivo change in mRNA expression 
(induction or downregulation). Speed of blood sampling 444, sample tube surfaces 445 , 
activation of coagulation 446, endotoxins 447, contents of lysed cells (e.g. haemoglobin) 448;449 
and endogenous nucleases 450 have all been shown to affect mRNA expression previously.  
Routinely available anticoagulated sample tubes, which do not contain RNA stabilisation 
media, could potentially affect cytokine expression in whole blood samples. Whole blood 
collected into EDTA sample tubes and incubated at room temperature (7 days), resulted in 
increases in IL-6 and TNF-α e pression and an initial decrease in IL-1-β expression (6 hours) 
with subsequent increases between 1-3 days. In comparison whole blood in a sample tube 
containing an RNA stabilisation media (PAXgene, PG) did not demonstrate significant 
differences in mRNA expression for these cytokines up to 7 days 451. This supports the 
observation that ex-vivo changes in gene expression following blood sampling can be blunted 
either, by the addition of a transcription factor inhibitor such as actinomycin-D 452 or usage 
of RNA stabilising media containing tubes as in the aforementioned PG tube 451-453. There are 
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two commercially available storage solutions for RNA collection from whole blood, the 
P Xgene and Tempus™ R   systems, which require 2.5mL and 3mL of blood respectively.  
Although in an adult study the blood volume required for RNA storage tubes is of no 
significant concern, this may not be the case in paediatric studies, especially where there is 
requirements for multiple blood tests for efficacy and safety. For investigators looking to 
reduce blood volume requirements, this either means allowing under (and variable) filling of 
commercially available sample tubes or the development of modifications to currently 
available sample tubes. Usage of under-filled Tempus™ R   tubes has resulted in suboptimal 
values for RNA yield, integrity and purity (260/280 and 260/230 ratios) 454. Usage of a 
modification allowing maintenance of the ratio of storage reagent media to whole blood has 
been described previously. The first study collected small blood volumes (50-   μL) from 
mice, using maintained ratios of blood to PG media 455. Even using sample  olumes of   μL 
the mRNA obtained was of sufficient quantity (average 2.3μg) and quality to allow multiple 
gene expression determinations. The second study was carried out to investigate invasive 
pneumococcal disease in children in Malawi (n=87, median age 3.25 years, range 0.17-13 
years) 456. This study firstly, evaluated using smaller blood volumes (maintaining the blood to 
PG media ratio) of 2.5ml, 1ml and 0.3ml, demonstrated total RNA yields of 4.5-  . μg,  . -
8. μg and  . - . μg respecti ely, with high R   integrity (RI  8. -9.6) and purity (260/280 
ratios 1.97-2.14). Although the lowest blood volume (0.3mL) gave sufficient mRNA for 
multiple RT-PCR experiments this did not consistently produce sufficient mRNA for 
application on a microarray 456. 
Changes in gene expression have been described at first exposure to a novel stimulus and 
have provided novel biomarkers for the prediction of risk in another clinical setting, such as 
response to influenza vaccination 457. There is only one case-control small (n=20) study 
comparing gene expression profiles in severe haemophilia A 195. This study demonstrated 
downregulation of CCL3L1, CCL3L3, CXCL7 and IL8, with upregulation of CXCL9 and CXCL11 
in inhibitor patients. This study took a cross-sectional (rather than longitudinal) approach and 
it is not clear from the methodology how samples were collected. This approach may mean 
that gene expression may be affected either by environmental factors occurring at the time 
of blood sampling or from sample collection methodology. To allow a more structured 
dynamic evaluation of changes in transcriptome profiling prospective clinical study is 
required. To this end I have developed a protocol and initiated sample collection, 
longitudinally evaluating changes in gene expression profiles at first exposure to FVIII or 
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during ITI in severe haemophilia A. This forms part of an international collaboration as a 
satellite study within the trial of a new human cell line rFVIII concentrate (Nuwiq®) in 
previously untreated patients (PUPs) with severe haemophilia A. 
9.2 Hypothesis and Aims  
As part of an investigator lead collaboration, I have developed a protocol (Appendix 3) for 
the prospective sampling of total and miRNA (RNA-Seq) at first exposure to FVIII and during 
ITI in severe haemophilia A. This is being performed within an international study (GENA-05 
/ NuProtect study) of previously untreated patients (PUPs) treated with a new human cell 
line (HEK293) rFVIII concentrate (Nuwiq®). To minimise sample volume requirements for this 
paediatric study, I have tested the application of a modified PG RNA storage tube, created 
within our laboratory. Within this chapter, the application of this low volume sampling for 
application in genomic studies will be evaluated in healthy volunteers and boys with severe 
haemophilia A. I hypothesise that this modified sample tube will allow blood sampling using 
a reduced blood volume (1mL) providing RNA (total and miRNA) of sufficient quantity and 
quality for use in transcriptome analysis by next generation sequencing (NGS). This 
methodology for sample collection and storage will be acceptable to paediatricians and allow 
evaluation of changes in gene expression at first exposure to FVIII and during ITI in patients 
with severe haemophilia A. This will allow high-throughput global assessment of changes 
occurring in patients who are at risk (or no risk) of inhibitor formation in severe haemophilia 
and identification of novel biomarkers of inhibitor risk. The specific aims are as follow: 
1) To validate usage of a modified RNA storage tube for collection of peripheral blood 
samples for transcriptome (mRNA and miRNA) analysis in healthy volunteers. 
2) To evaluate the effect of pre-analytical (clinical and laboratory) variables on quantity 
and quality of RNA collected using this modified tube.  
3)  To demonstrate validity of using this modified RNA storage tube for transcriptome 
analysis in patients with severe haemophilia A at first exposure to FVIII and to 
demonstrate acceptability for use in paediatric clinical studies.  
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9.3 Materials and Methods 
Modified Sample Tube Production Protocol 
Modified PG blood tubes were prepared in RNase free conditions within a positive pressure 
tissue culture hood as described earlier (Chapter 3).  
9.3.1 NGS Pilot Study Materials and Methods (Part 1) 
Recruitment of Study Participants and Blood Sampling (NGS Pilot Study)  
Normal healthy volunteers were recruited from staff and students at Barts and The London 
School of Medicine and Dentistry (Whitechapel Campus) and The Royal London Hospital. The 
inclusion criteria were: staff or student; age ≥18 and ≤65 years and the ability to give 
informed written consent. Participants not meeting these criteria, or who were currently 
taking immunosuppressive or chemotherapeutic agents were excluded. No NHS patients or 
vulnerable groups were recruited. Anonymised demographic data on age and gender of 
participants was collected. The study was approval by proportionate review by the Joint 
Research Management Office (Barts Health NHS Trust and Queen Mary University of 
London), ReDA Reference: 008864. All sample tubes were kept at RT (18-25°C) prior to 
sampling. Blood was collected into the modified PG tube using the same protocol as in the 
GENA-05 study (Appendix 3). Blood collected into the standard, unmodified PG tube was 
collected as per the manufacturer’s recommendation. Following collection of blood into 
sample tubes these were gently inverted 8-10 times to allow mixing of blood with PG media 
and sample tubes were incubated at room temperature and frozen directly to <-80°C until 
extracted.    
Phase 1: Investigation of Pre-Analytical Sampling Variables 
Within the first phase of this study blood was collected from 10 healthy volunteers. The aim 
of this phase was to evaluate the performance of the modified sample tube in comparison to 
the standard PG tube and the effect of simulated pre-analytical sampling variables. Within 
this the internal control for comparison were 2.5mL (standard PG) and 1mL (modified PG) 
samples incubated for 4 hours and frozen at -80°C for 2 months. Pre-analytical variables 
evaluated were sample freezing duration (no freezing/immediate extraction, 2 months, 4 
months), sample incubation time (<60 minutes, 4 hours and 24 hours) and sample fill volume 
(0.5, 1 and 1.5mL). 
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Phase 2: Assessment of Inter-Batch Variability  
The second phase of this pilot study was performed to evaluate whether differences in 
batches of PG media or extraction kits affected RNA quality and quantity. A secondary aim of 
this phase was to evaluate lower than expected RNA integrity (RIN) values obtained in the 
first phase of the pilot study. Samples were collected from 5 further healthy volunteers, into 
1mL modified PG tubes (total 4) containing PG media from 2 separate batches (i.e. different 
lot numbers and expiry dates). These samples were incubated at room temperature for 4 
hours prior to freezing at -80°C for 2 months. Following thawing of samples these were 
extracted using one of two extraction kits, consisting of the same kit used in the previous 
phase and a second kit used by another group within our laboratory.    
Phase 3: Investigation of Feasibility of miRNA Extraction and Protocol Comparison 
In the third phase of this pilot study, feasibility of usage of the modified (1mL) PG tube for 
extraction of miRNA was assessed, in comparison to the standard (2.5mL) PG tubes. Blood 
samples were collected from 5 further healthy volunteers into modified and standard PG 
tubes. A comparison was also made of two different miRNA extraction protocols, which were 
based on extraction of all RNA, including miRNA into one tube (extraction protocol B) or a 
protocol in which miRNA and mRNA were collected into two separate sample tubes 
(extraction protocol C). Finally a further comparison was made to provide additional 
assessment of the standard and modified PG tubes for quality and quantity of total RNA, to 
assess the effect of these extractions over time. 
Extraction of Total RNA and miRNA  
Manual purification of total RNA and miRNA were performed within the Genome Centre 
QMUL Core Facility, following the manufacturers’ protocols for whole blood RNA extraction 
as described earlier (Chapter 3).  
Measurement of RNA Quality Control 
Quantification of total RNA extracted was performed by spectrophotometry using the 
NanoDrop 8000 spectrophotometer (Fisher Scientific, Wilmington, DE, United States). This 
gives a report of the total RNA concentration with the eluate (ng/µL), with the total RNA yield 
in µg being equal to the RNA concentration x 40 x 0.01. For the purpose of downstream 
analysis, a minimum R   yield of ≥ µg was targeted. Estimation of RNA quality was 
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performed through assessment of RNA integrity and purity using the Agilent 2100 
Bioanalyser (Agilent Technologies, Santa Clara, CA, United States). RNA Integrity numbers 
(RIN) was calculated using the Agilent 2100 software 458. This methodology provides a high-
throughput standardised approach for the reporting of RNA integrity, which is reported on 
an ordinal scale ranging from 0 (poor quality) to 10 (highest quality). A RIN value of >5 is 
thought to be adequate and >8 optimal for downstream analysis 459. Purity of extracted RNA 
was evaluated using the 260/280 and 260/230 ratios. These two ratios measure the 
absorbance by RNA at 260nm and contamination at 280nm (protein) and 230nm (salts, 
including guanidine thiocyanate and organic contaminants such as phenol or aromatic 
compounds). For the primary measure of RNA purity (260/280) a ratio of >1.8 is assumed to 
represent pure RNA suitable for downstream analysis 460;461. For the secondary RNA purity 
measure (260/230) pure RNA should demonstrate a 260/230 ratio of approximately 2.0, 
although there is no consensus internationally as to what represents the lower limit of 
acceptability for this ratio.  
9.3.2 GENA-05 (NuProtect) Gene Expression Sub-Study (Part 2) 
An assessment of changes in gene expression occurring at first exposure to FVIII and during 
ITI patients is currently underway using this modified PG sample tube, within the GENA-05 
(NuProtect) study. This is an international phase 3 study (ClinicalTrials.gov identifier: 
NCT01712438) of a human cell line (HEK293) rFVIII concentrate (Nuwiq®, Octapharma AG, 
Lachen, Switzerland). This study aims to assess immunogenicity of this product in the first 
100ED, in previously untreated patients with severe haemophilia A. As part of this study, we 
are co-ordinating an investigator led study of changes in gene expression with an aim of 
identifying those changes that indicate potential inhibitor formation / failure of ITI and to 
provide mechanistic insight into these poorly understood process. Samples are being 
collected in this study for all patients enrolled in this sub-study at the following time-points: 
at first exposure to FVIII and after every 3-4 ED up until 20ED or inhibitor formation. In 
patients diagnosed with an inhibitor undergoing immune tolerance induction samples were 
collected prior to commencement of ITI and then at 2, 4, 8, 12, 16, 20 and 24 weeks. Modified 
PG sample tubes used for the GENA-05 sub-study were prepared as described in Chapter 3. 
These were shipped overnight in sealed cryoboxes at ambient temperature to a centralised 
Clinical Trials management / logistics facility (AdminOps, LabCorp, Marken, Hamburg, 
Germany) for sample tube pack production for distribution to study sites. 
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Statistical Analyses 
Analysis of the pooled anonymised data for these experiments was made. Descriptive 
statistics (mean, median, standard deviation and 95% confidence intervals) are displayed for 
continuous variables. Exploratory parametric statistical comparisons were made for these 
experimental data. For continuous data, these were performed using the paired T-test or 
repeated measures ANOVA (one or two way). Assessment of sphericity within these repeated 
measures    V s was performed using Mauchly’s test 431 and where significant (i.e. 
sphericity violated) corrections to the degrees of freedom were made using the Greenhouse-
Geisser correction 432. Where significant difference was found on univariate testing (ANOVA), 
multiple comparisons were performed using the post-hoc Turkey (one-way ANOVA) and 
Bonferroni (two way ANOVA) tests.  
9.4 Results 
9.4.1 Gene Expression (RNA-Seq) Pilot Study 
A total of 20 healthy volunteers (8 male and 12 females), with a median age of 35 years (range 
26-63) were recruited to the three phases of this pilot study. This resulted in a total of 150 
samples being collected into standard (n=25) or modified (n=125) PG blood tubes. RNA 
extraction was possible in all samples, including one which demonstrated excessive 
coagulation.  
9.4.1.1 Quantitative and Qualitative Effect of Modification to the Standard PAXgene Tube 
Assessment of the modification to the PG tube was made in samples from 15 individuals in 
two phases of recruitment (phase 1 and 3). Significantly lower mean total RNA yields were 
obtained from the modified PG tube (2.66±1.23µg) compared to the standard PG tube 
(6.12±3.55µg, p=0.0002). The mean RNA yield was 2.3 times lower than for the modified RNA 
tube, closely matching the 2.5 fold reduction in sample volume. A small, but statistically 
significant difference was seen for the mean RNA integrity (RIN) for samples collected into 
the modified PG tube (6.8±1.7) compared to the standard PG tube (7.8±0.9, p=0.02). All 
samples demonstrated high R   purity (   / 8 ), with  alues ≥ . . Samples collected into 
the modified PG tube (2.24±0.13) demonstrated a small but statistically significant difference 
in 260/280 ratio in comparison to the standard PG tubes (2.15±0.05, p=0.017). There was no 
significant difference in 260/230 ratios comparing samples collected into the standard PG 
(1.18±0.55) and modified PG tube (1.02±0.72, p=0.191) 
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Figure 9.1: Quantitative and Qualitative Effect of Modification to the Standard PAXgene 
Tube. ns=Not significant. *=Significant p<0.05. 
 9.4.1.2 Quantitative and Qualitative Effect of Clinical Variable on Whole Blood RNA in 
Healthy Volunteers (Phase 1) 
In the first study phase an assessment was made of pre-analytical variables that might have 
quantitative of qualitative effects on RNA obtained in 10 healthy volunteers.  
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9.4.1.3 Quantitative and Qualitative Assessment of Freeze Duration  
An assessment of the effect of sample freezing was made comparing samples collected into 
the modified PG tube with RNA extraction being performed either immediately (control) or 
after freezing at <-80°C for either 2 or 4 months (Figure 9.2). All samples was made incubated 
at RT for 4-6 hours following venepuncture. A significant difference was seen for total RNA  
 
Figure 9.2: Quantitative and Qualitative Assessment of Freeze Duration. ns=Not significant. 
*=Significant p<0.05. 
yield and freeze duration (p=0.009). Surprisingly, higher RNA yields were seen for samples 
frozen for 4 compared to 2 months (4.21±1.63µg v 2.98±1.21µg, p=0.008), although theses 
difference may represent variance in extraction yields between extraction batches. No 
significant difference in RNA yield was seen comparing sample extracted immediately 
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(3.27±1.42µg) or after freezing for either 2 (2.98±1.21µg, p=1.000) or 4 months (4.21±1.63µg, 
p=0.232). There was no significant difference in the RNA integrity (RIN) of samples extracted 
immediately (6.8±1.1) or after 2 (5.9±1.1) or 4 months (6.7±1.2) of freezing (p=0.188). 
Similarly, no significant difference was seen in the 260/280 ratio, comparing sample 
extracted immediately (2.28±0.14) or after 2 (2.24±0.13) or 4 (2.20±0.05) months of freezing 
(p=0.416). There was also no significant difference in the 260/230 ratio comparing sample 
extracted immediately (0.74±0.51), after 2 (0.80±0.68) or 4 (0.81±0.49) months of freezing 
(p=0.886). 
 
Figure 9.3 Quantitative and Qualitative Effect of Sample Fill Volume. ns=Not significant. 
*=Significant p<0.05. 
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9.4.1.4 Quantitative and Qualitative Effect of Sample Fill Volume 
An assessment of the effect of sample fill volume was performed comparing under (0.5mL), 
or over-filling (1.5mL) of the modified PG tube, with a control sample (1mL) (Figure 9.3). 
Samples were incubated at room temperature for 4-6 hours following venepuncture and 
subsequently frozen at <-80°C for 2 months. There was a significant difference in mean total 
RNA yield obtained in relation to fill volume (p=0.001). Significantly lower mean total RNA 
yield were seen in under-filled samples (1.12±0.75µg) compared to control (2.98±1.21µg, 
p=0.002) and over-filled samples (4.50±2.36µg, p<0.0005). Although a difference was seen in 
total RNA yield for over-filled samples (4.50±2.36µg) compared to controls (2.98±1.21µg), 
this did not reach statistical significance (p=0.156). No significant difference was seen for RNA 
integrity (RIN) obtained under these conditions (RIN 5.9±1.3, 5.1±1.1 and 5.5±1.4, p=0.775). 
Similarly, no significant difference was seen in the 260/280 ratio, comparing these conditions 
(2.18±0.24, 2.24±0.13 and 2.18±0.08, p=0.496), under-fill, control and overfill respectively.  A 
significant difference in 260/230 ratio was seen comparing the fill volumes (p=0.019), with 
higher 260/230 ratios seen for over-filled (1.22±0.38) compared to under-filled samples 
(0.60±0.41, p=0.002). No difference in 260/230 ratio was seen comparing control tubes 
(0.81±0.68) to either under-filled (0.60±0.41, p=1.0) or over-filled tubes (1.22±0.38, p=0.274).   
9.4.1.5 Quantitative and Qualitative Effect of Sample Incubation Time 
Assessment was made of the effect of sample incubation time (<1 hour, 4-6 hours (control) 
or >24 hours) at RT prior to freezing at <-80°C for 2 months (Figure 9.4). There was a 
significant difference in the mean total RNA yield obtained comparing the different sample 
incubation conditions (p=0.008). Significantly higher total RNA yields were obtained for 
samples incubated for 4 hours (2.98±1.21µg) compared to those frozen within 1 hour 
(2.14±1.26µg) of venepuncture (p=0.049). No significant difference was observed for total 
RNA yields comparing samples incubated for 24 hours (3.51±1.77µg) and those incubated for 
either <1 hour (2.14±1.26µg, p=0.07) or 4 hours (2.98±1.21µg, p=0.455). No significant 
difference in RNA integrity (RIN) in relation to sample incubation time was seen for samples 
incubated for <1 hour (5.9±1.1), 4 hours (6.6±0.6) or 24 hours (6.0±1.2) (p=0.263). A small, 
but significant difference in the 260/280 ratio was seen comparing the three incubation 
conditions (<1 hour: 2.33±0.18, 4 hours: 2.24±0.13, 24 hours: 2.20±0.078, p=0.043), but this 
lost statistical significance on pair-wise comparison. Similarly a small, but statistically 
significant difference was seen for the 260/230 ratio comparing the three incubation 
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conditions (<1 hour: 0.60±0.53, 4 hours: 0.81±0.68, 24 hours: 0.97±0.80, p=0.043), which 
again lost significance on pair-wise comparison. 
 
Figure 9.4: Quantitative and Qualitative Effect of Sample Incubation Time. ns=Not 
significant. *=Significant p<0.05. #=Significant on univariate analysis, but not significant on 
pair-wise comparison. 
9.4.1.6 Quantitative and Qualitative Effect of Laboratory Variables on Whole Blood RNA in 
Healthy Volunteers (Phase 2) 
In the second phase of this study, an assessment was made to firstly to investigate, lower 
than anticipated RNA integrities (RIN) seen within the first study phase and to evaluate 
variability in RNA yield and quality from different PG media and extraction kits. A cross-over 
comparison was performed in five additional healthy volunteers, using two separate PG 
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media and extraction kits. Significantly higher mean RNA integrity (RIN) were seen for 
samples extracted in this second study phase compared to those extracted in phase 1 (RIN 
phase 1: 5.9±1.1 v phase 2: 7.5±0.3, p=0.007), with only one sample having a RIN value of <7 
(RIN 6.6) in this phase. There was a trend towards higher total RNA yields (phase 1: 2.98±1.21 
v phase 2: 5.43±3.72, p=0.07). No significant difference was observed on comparison of 
different PG media and extraction kits, for total RNA yield (PG media p=0.478, extraction kit 
p=0.466), RIN (PG media p=0.615, extraction kit p=0.552) and 260/280 ratio (PG media 
p=0.292, extraction kit p=0.958). A small, but statistically significant difference was observed 
in the 260/230 ratio, between the two PG medias (media 1 0.45±0.10 v media 2 0.55±0.08, 
p=0.026).  
9.4.1.7 Assessment of Feasibility of miRNA Collection and Optimal Extraction Method 
(Phase 3) 
The aim of the third phase of this study was to evaluate whether the modified PG tube could 
allow extraction of miRNA for downstream application and to ascertain the optimal 
laboratory method for extraction. There are two available miRNA extraction which either 
extract RNA (total and miRNA) into a single (Protocol B) or two tubes (Protocol C). A cross-
over comparison was made for samples taken from 5 further healthy volunteers into 
modified and standard BD PG tubes. to allow comparison of the kits as well as between the 
standard and modified PG tubes.  
Similar to data presented in the previous sections, there was a significant difference in the 
mean total RNA obtained using the modified PG (2.47 µg, 95%CI 0.964-3.966) compared to 
the standard (4.12 µg, 95%CI 2.766-5.482) PG tube (p=0.007). There was also a difference 
observed in comparing the Protocol B (3.94 µg, 95%CI 2.559-5.318) to the Protocol C (2.65 
µg, 95%CI 1.287-4.014) kit for total RNA yield. On cross-over analysis, there was however no 
significant difference seen for the two variables. No significant difference was seen 
comparing the RIN, 260/280 and 260/230 ratio between the two PG tubes or extraction kits.  
Comparison of the miRNA concentration obtained using the standard (2266.4pg/µL, 95%CI 
529.4-4003.4) and modified (1837.4pg/µL, 95%CI 707.6-2967.3) PG tube demonstrated no 
significant difference (p=0.640), Although a slightly lower miRNA concentration was seen for 
Protocol B (883.6pg/µL, 95%CI -1.628-1768.9) in comparison to Protocol C (3220pg/µL, 95%CI 
1128.7-5311.8) this did not reach statistical significance (p=0.074).  
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Figure 9.5: Quantitative and Qualitative Evaluation of RNA Obtained Across the Different 
Study Phases. ns=Not significant. *=Significant p<0.05. 
9.4.1.8 Evaluation of Quantity and Quality of RNA Obtained in Different Study Phases 
Finally an assessment of the quality and quantity of RNA obtained across the three phases of 
this pilot study was performed (Figure 9.5). A significant difference was seen for total RNA 
yields obtained across the different phases of the study (p=0.047). A lower total RNA yields 
was seen in the third phase (2.03±1.11µg) compared to the second (5.43±3.72µg, p=0.048) 
phase of the study. No significant difference was seen in RNA yields between those obtained 
in the first (2.98±1.21 µg) compared to the second (5.43±3.72 µg, p=0.108), or third study 
(2.03±1.11µg, p=0.688) phases. A significant difference was seen in the mean RNA Integrity 
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(RIN) across the three phases of the study (p<0.0005). Significantly higher RIN values were 
seen in the second (7.5±0.3) and third (8.7±0.3, p<0.005) phases of this pilot study compared 
to the first phase (5.9±1.1, p=0.006). No significant difference was seen in the mean 260/280 
ratio across all three phases of the study (p=0.923). There was a trend towards difference in 
the 260/230 ratios obtained across the three study phases (p=0.051), with samples extracted 
in the third (1.43±0.68) phase of the study having a higher 260/230 ratio compared to those 
extracted in the second phase (0.42±0.20, p=0.044).  
9.4.2 GENA-05 RNA-Seq Sub-Study  
As of June 2015, 79 patients have been screened and enrolled from 11 countries into the 
GENA-05 (NuProtect) study. There are 28 active study sites internationally and 42 sites 
initiated. It is anticipated that 45 sites in 17 countries will participate in this study, with an 
aim to recruit 100 patients. To date, 68 patients have initiated treatment and of these 51 are 
receiving regular prophylaxis with 36 patients having received treatment for >20 EDs (25 
patients ≥   ED). A large proportion of patients (68%, 54/79) have enrolled and have been 
recruited onto the gene-expression (RNA-Seq) sub-study from 18 centres (3 continents). To 
date, 195 RNA samples have been received in our laboratory for analysis, with a median of 4 
samples per patients (range 1-7). There are ≥  samples available for analysis in 19 patients.  
RNA (total) extraction was performed on samples obtained from the GENA-05 study to assess 
feasibility and proof of principle that the modified RNA sample tube is suitable methodology 
for RNA collection in a paediatric population. RNA was extracted from study participants with 
≥  samples sent for gene e pression analysis and in whom a screening sample was recorded 
at study registration. This included 63 samples from 11 patients, with a median of 6 samples 
per patient. The mean RNA yield obtained was 7.08±3.11µg, with all samples having a total 
RNA yield of >1.00µg. The mean RNA Integrity (RIN) obtained was 8.6±1.2, with 62/63 (96.8%) 
ha ing a RI  ≥  and   /   (8 . %) a RI  ≥8. Two samples had sub-optimal RNA integrity (RIN 
2.8 and 5.0) for downstream analysis, although good total RNA quantity was seen for both 
samples (4.55µg and 6.41µg respectively). The mean RNA purity (260/280) was 2.12±0.04, 
with all samples ha ing a    / 8  ratio ≥ . .  In these samples the mean    /    ratio was 
1.47±0.47, which is higher than was seen within the pilot study.   
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9.5 Discussion 
The modified PG RNA sample tube demonstrated a feasible and valid approach for the 
collection of RNA (total and miRNA) for downstream analysis in healthy adult volunteers and 
in an international paediatric clinical study. High uptake of recruitment into the GENA-05 sub-
study demonstrates that this forms an acceptable methodology for RNA sampling from young 
children within an international study. Predictable difference in total RNA yields were seen 
as a result of reduced sample volume being collected into this modified PG tube, but these 
sample tubes provided RNA of sufficient quantity and quality for downstream sequencing. 
Within the initial phase of this pilot study lower than expected RNA integrity was seen for 
samples collected into both the modified and standard PG tubes. With increased experience 
with sample handling, improvements were seen in the RNA integrity and purity of samples 
throughout these experiments. It was interesting to note that RNA quantity and integrity 
obtained in the samples from the NuProtect study were higher than those seen in the pilot 
study, where sampling may have been performed in a more controlled environment. 
9.5.1 Effect of Pre-Analytical Variables on Usage of a Modified PAXgene RNA Blood Tube 
Within the first phase of evaluation of this sample tube in healthy volunteers, although good 
RNA yields and purity were obtained, lower than anticipated RNA integrity was seen in 
comparison to similar studies in this area 456. The mean RIN values seen for the standard PG 
and modified PG tubes in the first phase were 7.4 and 5.9, respectively. Previous reports of 
usage of the modified PG tube has given RIN values, in the range of 7-8, with very few samples 
having a RIN <7 (Carrol E, Professor in Clinical Infection, University of Liverpool, personal 
communication). Although higher RNA integrity was expected using the standard PG tube 
from previous experience within our laboratory, the mean RIN values seen are in keeping 
with those seen in previous studies of healthy volunteers (mean RIN 7.4-8.1) 454;459. A second 
phase was performed to further evaluate these finding of sub-optimal RNA integrity 
demonstrating higher RNA integrity for all samples. Given these findings, the most likely 
mechanism for suboptimal RNA integrity within the first phase was RNase contamination 
within one of the extraction kit reagents that was not present in future extractions. Although 
RNase contamination within the modified PG tubes could provide and alternative 
explanation, this seems unlikely given higher RIN values seen for samples collected into this 
same batch of modified PG tubes, in the second study phase and GENA-05 study. Within this 
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assessment of pre-analytical variables RNA integrity was not effected by sample incubation 
time, freezing or fill-volume.  
9.5.2 Transcriptome Analysis in Haemophilia 
The GENA-05 (NuProtect) study, will create a vast database of RNA-Seq data from patients 
with severe haemophilia A at first treatment and during ITI. One of the problems with such 
hypothesis generating datasets is the careful construction of subsequent analyses to 
interpret changes that are seen in gene expression. Within this study, the first analyses that 
will be constructed will consist of case-control analysis of changes in gene expression in 
patients with and without inhibitor looking at prior to FVIII exposure and early within 
treatment with FVIII. The hypothesis of this analysis is that there will be changes in gene 
expression early in treatment with FVIII that may predict onset of inhibitor formation. 
Changes in gene expression within these patients would then be validated by quantitative 
polymerase chain reaction (qPCR) that could provide biomarkers that could be included 
within prediction algorithms. Alongside this study looking at the usage of whole blood for 
transcriptome analysis in patients at first exposure to FVIII, there is a similar study the 
Hemophilia Inhibitor Previously Untreated Patients Study (HIPS, ClinicalTrials.gov Identifier: 
NCT01652027), which is utilising buffy coat-separated RNA extraction 462. Although 
potentially offering a more difficult approach for sample collection at study sites this will 
provide a complementary dataset for increasing understanding of the development of an 
immune response to FVIII.  
9.6 Limitations  
One of the main limitations of the data described in healthy volunteers relates to the small 
sample size for describing differences between the pre-analytical samples conditions 
analysed. This may mean that there is over, or underestimation of the size of effect of one or 
more of these variable investigated. Although allowing exploratory comparison of the effect 
of different variables, but due to a lack of power these data will be insensitive to the discovery 
of small effects and may be more likely to be affected by chance findings. Nevertheless, one 
of principle aims of these pilot data was to demonstrate validity of usage of this approach in 
healthy volunteers to allow ethical sample collection within this paediatric study. Finally, 
although the GENA-05 study will create a vast repository of transcriptome data to help 
unravel the immune processes, this study is limited by the use of a functional inhibitor assay 
as the primary outcome measure for assessing FVIII antibody formation. Further study is 
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required to evaluate changes occur with onset of different classes of antibody (inhibitory and 
non-neutralising). 
9.7 Conclusions 
A modified PG sample tube provides a feasible and acceptable methodology for 
transcriptome (total RNA and miRNA) analysis using whole blood in paediatric studies prior 
to the availability of commercially manufactured sampling tubes. Samples collected from the 
GENA-05 (NuProtect) RNA-Seq sub-study will create a vast dataset of RNA-Seq information 
for the haemophilia community, which will hopefully provide greater insights into the 
immunological mechanism of antibody formation and provide biomarkers for risk 
stratification for patients with severe haemophilia A.   
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Chapter 10: Summary and Conclusions 
10.1 Summary 
There is a lack of understanding of the total immune response to FVIII, resulting from reliance 
on functional inhibitor assays for the detection of FVIII antibodies in clinical studies. Although 
standardisation of these inhibitor assays in the 1970s resulted in improvements in diagnosis 
and inter-study comparison, there remains questions into the optimal approaches for FVIII 
antibody testing (laboratory assay and timing). This is particularly the case where FVIII 
antibody formation is a rare event, such as in non-severe haemophilia A and acquired 
haemophilia A. Within my work, significant heterogeneity was described in approaches to 
inhibitor testing and clinical management in both of these settings. Reviewing inhibitor 
testing practices in a large cohort of patients with non-severe haemophilia A, demonstrated 
poor compliance with targeted inhibitor testing following “high-risk” treatment. This could 
result in underestimation of the humoral response to FVIII and skew towards detection of 
antibodies that result in a change in clinical phenotype (cross reactive antibodies to 
endogenous FVIII). In acquired haemophilia A, there was significant heterogeneity at all levels 
of the management of immunosuppression. Selection of immunosuppression in both non-
severe haemophilia A and acquired haemophilia A appears to be influenced by clinical and 
laboratory factors 169;233. These “stratifications” made by clinicians in their approaches to 
management 169;233, however, lack in an evidence base. This introduces systematic bias in 
observational studies, limiting interpretation and generalisability of clinical outcomes. There 
is a need for prospective study in both setting following standardised treatment protocols 
with centralised testing to improve understanding of the natural history of FVIII antibodies. 
Usage of a modification (PHT) to current inhibitor assays and/or a FVIII ELISA improves 
detection of FVIII antibodies. Evaluation of B-cell epitope profiles in patients with severe 
haemophilia A, using a novel re-usable peptide microarray demonstrated immunodominant 
epitopes in regions of functional (tenase complex) and structural importance, giving further 
insight into the mechanism of action of inhibitors. Advances and reduction in costs for high-
throughput genomic techniques (NGS), allows evaluation of the immune response to a 
protein therapeutic, such as FVIII. Modifications to sampling methodology described in this 
work, demonstrate feasibility of this approach in young boys with severe haemophilia A and 
samples collected within this study will provide a vast repository of data for unravelling the 
immune response to FVIII.   
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10.2 FVIII Antibody Testing in Congenital and Acquired Haemophilia A 
The classical Bethesda assay which was first proposed in the 1970s was developed for 
quantification of type 1 inhibitors in patients with severe haemophilia A.  Since introduction 
of this assay, usage has been extrapolated for detection and quantification of FVIII antibodies 
in non-severe and acquired haemophilia A; two settings where antibodies may display more 
complex inactivation kinetics and samples may contain substantial residual FVIII:C. It has not 
been until more recently that there has been interest in the usage of assay modifications to 
adjust for residual FVIII:C in samples. Within this thesis, modifications and additional testing 
approaches have demonstrated improvements in FVIII antibody detection in both congenital 
and acquired haemophilia A. There appears to be recent changes in laboratory testing 
practices, with a recent NEQAS exercise reporting increased usage of pre-analytical heat 
treatment in routine laboratory practice 331. Alongside this, at a local level at The Royal 
London Hospital, it is interesting to note a recent increase in the number of FVIII inhibitor 
tests being performed. In the last year (10/14-11/15) a total of 331 inhibitor samples were 
tested, representing an increase from an average of 2.8 to 6.4 samples per week. Whether 
this has resulted in increases in the inhibitor detection requires further evaluation. 
The usage of a FVIII ELISA either alone or in parallel to a FVIII inhibitor assay may allow 
improvements in antibody detection, giving further understanding of the immune response 
to FVIII. From an immunological perspective, there is a need for further prospective studies, 
using parallel approaches to testing (immunological and functional) to gain further 
understanding of the natural history of FVIII antibodies. A large monitoring study has recently 
been presented from the USA, over a 6 year period with prospective central monitoring for 
FVIII antibodies using three different testing platforms (Nijmegen-Bethesda, Chromogenic 
Bethesda and a fluorescence immunoassay) with PHT (56°C for 30 minutes) 366;463-465. Within 
the study protocol there were recommended times for monitoring, including at entry, 
annually, before product switching and where there was a clinical indication 465. Despite the 
scale of such project, which included 824 patients with all severities of haemophilia A 
(severe=498, non-severe=326), only 23 inhibitors were detected (9 high-titre and 14 low-
titre), highlighting the difficulties in conducting such studies. This study is however an 
important advance in the conceptualisation of FVIII antibody detection in haemophilia A 
moving away from simple testing using a functional assay and allows confirmation of FVIII 
specificity.  
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Approaches for inhibitor testing using parallel testing will be associated with substantial cost 
increases for centres if performed within local laboratories. To allow further economic 
justification for these approaches, collaborative studies are required to provide further data 
on timing and optimal assays for screening. With increased screening, there is the likelihood 
that there will be increased detection of FVIII antibodies in which the long-term physiological 
relevance is not clear, such as low-titre and non-neutralising antibodies. Awareness of this is 
of importance, in future comparisons of inhibitor incidence both at a local clinical level, but 
also at a registry level. Reported inhibitor occurrence rates are heavily politicised in 
haemophilia care due to the commercial interest of pharmaceutical companies. This 
increases the imperative to understand more fully the basis of inhibitor occurrence in the 
various scenarios discussed in my thesis. Other approaches such as the usage of thrombin 
generation assays, offer novel approaches that may allow global assessment of inhibitory 
capacity 466. These techniques have been used successfully by laboratories to help guide 
treatment in patients with inhibitors. Previous lack of standardisation and quality control has 
mainly limited usage to research settings and does not provide a technique amenable to 
screening for FVIII antibodies. Thrombin generation in parallel to an immunoassay could 
provide additional data of the functional capacity of FVIII inhibitors allowing personalised of 
management for bleeding and surgery 219;467.   
10.3 Future Developments in Haemophilia Treatment 
A number of novel approaches are undergoing clinical trials for improvement of treatment 
for patients with haemophilia A. These include both modified FVIII concentrates and non-
FVIII based approaches 468-473. In approaches using modified FVIII concentrates, these have 
either attempted to improve pharmacokinetic profiles of FVIII or reduce immunogenicity, 
which include fusion to the immunoglobulin Fc domain, pegylation, modified (covalently 
bonded heavy-light chain) single chain FVIII and rFVIII produced from a human recombinant 
cell line (HEK293). Similar approaches in FIX deficiency, using a Fc fusion protein to FIX, in a 
phase 3 study produced an increase in half-life from 33.8 to 82.1 hours, with low annualised 
bleeding rates, in patients treated once every 1-2 weeks with this product 474. There were 
initial hopes similar strategies for FVIII would result in a significant reduction to the number 
of infusions required per week on prophylaxis. Unfortunately, similar increases in half-life 
have not been seen for the extended half-life FVIII concentrates, with an average of a 1.4-1.6 
fold half-life extension (13-19 hours). These small extensions in half-life are thought to relates 
to requirement of molecular chaperoning of FVIII to VWF 472;473.   However, the potential for 
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these modifications to reduce the immunogenicity of factor FVIII concentrates are yet to be 
fully assessed. The studies of usage in haemophilia A PUPs and post marketing surveillance 
will provide important data to inform decisions of immunogenicity of these new products. 
A number of approaches using modified FVIII structures either to reduce immunogenicity, 
through introduction of mutations within immunodominant epitopes (T or B cell) or to 
provide increased FVIII hetero-trimer 475, or domain 476 stability have been investigated in-
vitro and in murine haemophilia A models. From the work presented in this thesis, 
modification of immunodominant B-cell epitopes, may not provide an easy mechanisms for 
reduction in immunogenicity given the majority that were characterised fell within key 
functional regions of the FVIII structure. Modifications of residues could result in changes in 
the functional capacity of FVIII and/or neo-epitope formation. With modification to FVIII 
sequence there is an importance for pharmacovigilance projects to evaluate increased rates 
of immunogenicity. This was highlighted firstly through an outbreak of inhibitor formation 
following usage of a pasteurised FVIII concentrate in the early 1990s 477-479 and more recently 
through concerns of increased immunogenicity of a B domain deleted FVIII concentrate with 
the presence of a non-native linker sequence 480. Given the heterogeneity of the human 
immune system and F8 causative mutations, one would expect differences in the 
immunodominant epitopes (T and B cell) seen between individuals. As such, development of 
“personalised” FVIII concentrates based on risk profiles may prove difficult given regulatory 
requirements and lack of financial viability for such projects 481.  
There are a number of novel non-FVIII approaches to management of patients with 
congenital and acquired haemophilia A. Agents that are currently undergoing clinical trials 
are a bispecific monoclonal antibody, which binds FX and FIX (ACE 910) 482;483, inhibitors of 
TFPI (e.g. concizumab) 484 and a small interfering RNA (siRNA) to anti-thrombin (ALN-AT3) 485. 
The results of ongoing trials in these novel agents are encouraging and may provide a non-
FVIII based therapy that could personalise management of haemophilia A in patients at high 
risk of inhibitor formation. There are continued hopes that gene therapy could revolutionise 
the care of patients with haemophilia A, following the impressive results seen in the first 
studies of gene therapy in haemophilia B 486-488. Further study of gene therapy using an 
Adenovirus-Associated Viral vector (BMN 270) is ongoing in haemophilia A (ClinicalTrials.gov 
Identifier: NCT02576795), which may provide an additional option for the long-term 
management of haemophilia A.  
 210 
 
10.4 Further Studies 
10.4.1 Laboratory Testing of FVIII Antibodies 
Although the evaluation of pre-analytical heat treatment has provided clearer data to guide 
use of this modification in laboratory practice, there is a need for further study of this 
modification. This would ideally be performed as part of centralised laboratory testing within 
a prospective clinical study. Clinical data suggested loss of inhibitor activity by a FVIII ELISA 
following PHT in some samples from patients with AHA, after incubating for 90 minutes at 
58°C, which was not reproducible on more systematic evaluation. Whether some antibodies 
with weaker affinity or different epitope profiles are more susceptible to the effects of PHT 
is not clear. Within these experiments, usage of higher temperatures for PHT (58-64°C), could 
offer time and cost saving approaches to the use of this modification in laboratory practice 
and further evaluation of this is required. Finally, there is variable reports of usage of 
centrifugation as part of this modification which warrants further study, given differences 
seen in this and previous work for FVIII inactivation at 56°C 283. 
10.4.2 B-Cell Epitope Mapping of FVIII Antibodies 
The approach (Pepscan) described in this thesis, provides a novel high throughput approach 
for epitope mapping of FVIII antibodies using  in-vitro scaffolded mimics of secondary 
structure. This approach given reusability, lack of complex sample preparation is particularly 
amenable to the evaluation within clinical trials. In the further development of this platform 
validation of epitope profiles for the clinical samples is planned using an alternative platform 
393  as part of a collaboration with the University of Frankfurt (Königs C., Head of Molecular 
Haemostasis, University Hospital Frankfurt am Main, personal communication). Redesigning 
of this array is also required to allow completion of coverage of the C2 domain. This approach 
offers epitope mapping methodology that could be applied within a larger international 
cohort, to further evaluate the immunodominant epitope profiles seen. This methodology 
may also allow further investigation of differences between individuals with inhibitory and 
non-neutralising antibodies to further evaluate differences in epitope profiles and whether 
epitope spreading occurs in time in both groups. Finally, although this approach offered high-
throughput methodology for testing of FVIII antibodies, this lacked high-throughput data 
analysis, with all data being analysed manually. Interrogation of this dataset has provided the 
early framework for development of an algorithm for automated interpretation of such 
datasets, which could allow development of a server for usage with other protein-antibody 
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interactions. This methodology could allow assessment using variable cut-offs for positivity 
and give clinicians a summary of B-cell epitopes as well as structural and functional data on 
these regions.  
10.4.3 Transcriptome Analysis in Severe Haemophilia A 
Sample collection of RNA within the GENA-05 (NuProtect) study has allowed the 
development of a vast repository of gene expression data at first exposure to FVIII and during 
ITI in patients with severe haemophilia A. Work in this thesis demonstrated clinical 
acceptability and sample viability, but is the first stage in this hypothesis generating project 
to improve immune response to FVIII and identify biomarkers of risk. The first approach to 
analysis within this study will be to evaluate changes in gene expression profiles seen at 
registration compared to an early sample point (3-6ED) in patients developing inhibitors 
compared to those that remained inhibitor free (case-control study). This approach allows 
sequencing of both coding and non-coding RNA, with a high sequencing read-depth to 
identify changes (or lack of change) seen early in treatment in patients with inhibitors. 
Following on from this, interrogation of the antibody repertoire (Ab-Seq) 489 will be 
performed to evaluate the diversity of the immune response to FVIII to determine whether 
particular germlines (clonal diversity) are highly represented and the timing of isotype 
switching.  
10.5 Conclusions 
With the ever expanding use of such high-throughput platforms in clinical studies, there is a 
growing need for increasing collaboration between clinical, genomic and bioinformatic 
researchers to provide meaningful translational data. With these advances a paradigm shift 
is required in approaches to FVIII antibody testing as reliance on imperfect laboratory 
methodology such as a functional inhibitor assays may undermine the relevance of these 
future findings. Advances in treatment options and understanding of immune processes 
underlying inhibitor formation will allow more personalised care for persons with 
haemophilia in the third millennium. Finally, although these advances may have substantial 
benefits for boys born with haemophilia in developed nations, there is an ongoing need for 
consideration of the global implications of haemophilia 490 . 
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Appendix 1: STARD checklist for reporting of studies of diagnostic accuracy  
Section and 
Topic 
Item  Pages 
Title/abstract/ 
Keywords 
1 Identify the article as a study of diagnostic 
accuracy (recommend MeSH heading 'sensitivity 
and specificity'). 
118 
Introduction 2 State the research questions or study aims, such 
as estimating diagnostic accuracy or comparing 
accuracy between tests or across participant 
groups. 
118-119 
Methods    
Participants 3 The study population: The inclusion and exclusion 
criteria, setting and locations where data were 
collected. 
119-120 
 4 Participant recruitment: Was recruitment based 
on presenting symptoms, results from previous 
tests, or the fact that the participants had 
received the index tests or the reference 
standard? 
119-120 
 5 Participant sampling: Was the study population a 
consecutive series of participants defined by the 
selection criteria in item 3 and 4? If not, specify 
how participants were further selected. 
119-120 
 6 Data collection: Was data collection planned 
before the index test and reference standard 
were performed (prospective study) or after 
(retrospective study)? 
121 
Test methods 7 The reference standard and its rationale. 60-67 
120 
 8 Technical specifications of material and methods 
involved including how and when measurements 
were taken, and/or cite references for index tests 
and reference standard. 
60-68 
72-75 
120-121 
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 9 Definition of and rationale for the units, cut-offs 
and/or categories of the results of the index tests 
and the reference standard. 
72-7 
120-121 
 10 The number, training and expertise of the 
persons executing and reading the index tests 
and the reference standard. 
119-121 
 11 Whether or not the readers of the index tests and 
reference standard were blind (masked) to the 
results of the other test and describe any other 
clinical information available to the readers. 
119-120 
Statistical 
methods 
12 Methods for calculating or comparing measures 
of diagnostic accuracy, and the statistical 
methods used to quantify uncertainty (e.g. 95% 
confidence intervals). 
121 
 13 Methods for calculating test reproducibility, if 
done. 
N/A 
Results    
Participants 14 When study was performed, including beginning 
and end dates of recruitment. 
119 
 15 Clinical and demographic characteristics of the 
study population (at least information on age, 
gender, spectrum of presenting symptoms). 
122 
Figure 6.1 
 
 16 The number of participants satisfying the criteria 
for inclusion who did or did not undergo the 
index tests and/or the reference standard; 
describe why participants failed to undergo 
either test (a flow diagram is strongly 
recommended). 
122 
Figure 6.1 
Test results 17 Time-interval between the index tests and the 
reference standard, and any treatment 
administered in between. 
119-121 
 18 Distribution of severity of disease (define criteria) 
in those with the target condition; other 
122 
Figure 6.1 
Table 6.2 
 248 
 
diagnoses in participants without the target 
condition.  
 
 19 A cross tabulation of the results of the index tests 
(including indeterminate and missing results) by 
the results of the reference standard; for 
continuous results, the distribution of the test 
results by the results of the reference standard. 
Figure 6.1 
Table 6.2 
 20 Any adverse events from performing the index 
tests or the reference standard. 
N/A 
Estimates 21 Estimates of diagnostic accuracy and measures of 
statistical uncertainty (e.g. 95% confidence 
intervals). 
121 
Table 6.2 
Table 6.3 
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Appendix 2: Filtering of B-Cell Epitopes Using FVIII Pepscan Arrays 
An evaluation of a “relative cut-off”, was performed based around the repetition of 5-mer 
sequences in subsequent wells on the linear (n=4) and looped (n=3). Manual filtering of 
positive binding was performed in all array wells for in which the OD was ≥ SD from the 
e perimental mean. Positi e wells with a ≥ SD were then grouped into “epitopes” falling 
within sequential or semi-sequential wells of the array. With the repetition of 5-mer 
sequences in subsequent wells, it would be expected to see binding in two or more 
continuous or discontinuous wells on the array if this sequence formed part of the B-cell 
epitope. Figures shown in this section show the effect of application of this strategy and the 
loss of non-specific binding. 
Within these figures each column represents a single epitope for the negative controls, 
mAbs and polyclonal FVIII antibodies. The shading in these bars as shown in the keys 
represents the number of sequential or semi-sequential wells in which the result based on 
the SD would remain positive if this threshold were to be used. This allows assessment of 
the effect of using a variable cut-off based on either the SD from the experimental mean or 
number of consecutive wells in which binding was seen. For example, if binding was seen in 
a single well on the linear array, 3.2SD from the mean, this would result in a column up to 
level 3SD (i.e. this would not be positive if a cut-off of 3.5SD were used) on the y-axis 
without shading. If binding is seen in 3 consecutive wells on the linear array with these 
results being 2.3, 2.4 and 5.1SD from the experimental mean, this would result in the 
column would being black (n=3) up to a level of 2SD as all 3 results would be positive with 
this cut-off and then a clear column up to the level of 5SD.     
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Looped (T2) Arrays 
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Appendix 3 GENA-05 / NuProtect RNA-Seq Sub-Study Protocol 
Inhibitory antibody formation remains the greatest challenge in the management of severe 
haemophilia A. The focus of genetics studies of inhibitor risk has been on variations / 
mutations in the inherited DNA sequences of the factor VIII (FVIII) gene (causative 
haemophilia mutation or FVIII wild type haplotype) and genes involved in the immune 
response (e.g. IL-10, TNF-α and CTL -4).  However, such DNA based technology only gives 
the baseline gene profile of the individual without taking into account the dynamic changes 
that will occur in actual gene expression around the time of exposure to a novel immunogenic 
stimulus. Quantitative assessment of transcribed messenger Ribonucleic Acid (mRNA) offers 
a way of measuring differential changes in gene activity in these circumstances. Although 
technology for assessment of mRNA expression has been available for some years, the arrival 
of next generation sequencing (RNA-Seq) offers the ability to perform high throughput 
analysis of gene transcript activity on small volumes of venous blood in the setting of an 
international clinical study. This technology offers the ability to sequence the gene transcript 
products of millions of genes from each clinical sample. This enables an unbiased assessment 
of the genes involved in the immune response as well as other potential novel biological 
pathways that may prove to be of key importance in the process of inhibitor formation.  
This is the first clinical study to prospectively evaluate changes in gene expression around the 
time of exposure to exogenous FVIII and during immune tolerance induction. Measurement 
of real-time changes in mRNA expression may give further insight into the complex dynamic 
processes and pathways in ol ed with the aim of  identifying “bio-signatures” that can 
predict those at greatest risk of inhibitor formation or failure of immune tolerance induction. 
Sampling of mRNA is feasible in a paediatric study as it only requires small volumes of venous 
whole blood.  Due to instability in mRNA and changes in gene expression following 
phlebotomy, stabilisation is required at the point of collection (1,2,3). Modifications of 
commercially available stabilisation systems have been successfully trialled in both paediatric 
and animal studies demonstrating satisfactory mRNA yields whilst minimising required blood 
volumes (4,5). 
RNA Expression Analysis Sampling Schedule 
Formal written consent should be obtained at study entry for storage of whole blood (mRNA) 
samples for research purposes to investigate the mechanisms of inhibitor formation / 
immune tolerance.   
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For a patient enrolled on this optional sub-study, peripheral venous blood samples will be 
collected on commencement of Human-cl rhFVIII treatment at the time points shown in table 
1. 
A screening sample (pre-fVIII exposure) is necessary to proceed with follow up samples. If 
the screening sample is missed, do not collect subsequent follow up samples. However, these 
patients could still be enrolled in the ITI RNA-Seq study (see Table 2), with a new pre-ITI 
baseline sample and subsequent follow up samples. 
 Pre-1st exposure 
(Screening) 
Every 3 – 4 ED 
(with routine 
inhibitor screen) 
20 ED or at inhibitor 
formation 
RNA expression 
analysis 
1mL 1mL 1mL 
Table 1: RNA expression analysis sampling schedule: First 20 Exposure Days (20ED) 
 
For patients diagnosed with an inhibitor (commencing on ITI), enrolled on this optional ITI 
RNA expression analysis sub-study, peripheral venous blood samples will be taken at the time 
points shown in table 2. 
 Pre-ITI 
Initiation 
Week 
2 
Week 
4 
Week 
8 
Week 
12 
Week 
16 
Week 
20 
Week 
24 
RNA 
expression 
analysis 
1mL 
 
1mL 1mL 1mL 1mL 1mL 1mL 1mL 
Table 2: RNA expression analysis sampling schedule: Immune Tolerance Induction (ITI) 
RNA Expression Study Materials  
Investigation centres will be provided with centrally prepared customized PAXgene mRNA 
sampling tubes. The materials required for this study are as follows:  
1) Customized PAXgene mRNA sampling tube: sterile(RNAse / DNAse free) cryovial (4.5 
mL volume) containing 2.76mL PAXgene reagent (ratio 1mL blood : 2.76mL reagent)  
(provided)   
2) Sterile butterfly / winged infusion kit (not provided) 
3) Sterile 1mL syringe (not provided) 
4) Sterile gloves (not provided) 
5) Skin surface wipe (not provided) 
 
 256 
 
RNA Expression Sampling Protocol 
1) Keep RNA expression sample tube at room temperature (18 – 25°C) prior to 
sampling. Do not re-use once opened. 
2) Collect 1mL venous blood into a 1mL sterile syringe using the local centre’s protocol 
for venepuncture, wearing sterile gloves. 
3) Open PAXgene sample tube and directly transfer 1mL of venous blood following 
venepuncture into the PAXgene tube.   
4) Close sample tube. 
5) Gently invert the customized PAXgene tube 8 to 10 times.  
6) Label sample with patient identifiable information / study number / and study time-
point. 
RNA Expression Transportation and Storage Protocol 
1) Keep sample upright for 4-6 hours at room temperature (18 – 25°C) following blood 
sampling, prior to freezing. Early freezing of samples will substantially decrease the 
RNA yield. 
2) Freeze sample at –70°C in a wire rack (not a stryofoam tray as this may lead to sample 
tubes cracking). 
3) Transport frozen PAXgene stabilised RNA study samples to LabCorp (LabCorp Clinical 
Trials, Laboratory Services, 8490 Upland Dr, Ste. 100, Englewood, CO 80112, USA) on 
dry ice. 
4) RNA Samples kept at -70°C will be stable for a period of up to 60 months (6). 
RNA Extraction and Transcriptosome Analysis 
All extraction, purification of RNA and next generation sequencing (RNA-Seq) will be 
performed at The Genome Centre, John Vane Science Centre, United Kingdom. 
Interpretation of results will be performed by Dr Paul Batty / Dr Daniel Hart in collaboration 
with the Bioinformatics Department at The Genome Centre, John Vane Science Centre, 
United Kingdom. 
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